GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: October 18, 2005, 09:39:17 ; Search time 0.001 Seconds
(without alignments)
41.256 Million cell updates/sec

Title: US-10-605-498-91-COPY
Perfect score: 764
Sequence: 1 ggcacgaggagcagagtcag.....aagttcaaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 2 seqs, 27 residues

Total number of hits satisfying chosen parameters: 4

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 2 summaries

EST

Database : estdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
c 1	11.4	1.5	13	1	BM394028	ACCESSION:BM394028
2	11.4	1.5	14	1	BQ584787	ACCESSION:BQ584787

ALIGNMENTS

RESULT 1
BM394028/c
LOCUS BM394028 13 bp mRNA linear EST 17-JAN-2002
DEFINITION 50072-2-12-E02.r.1 Chilcoat/Turkewitz cDNA (large fraction) Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION BM394028
VERSION BM394028.1 GI:18194066
KEYWORDS EST.
SOURCE Tetrahymena thermophila
ORGANISM Tetrahymena thermophila
Eukaryota; Alveolata; Ciliophora; Oligohymenophorea; Hymenostomatida; Tetrahymenina; Tetrahymenidae; Tetrahymena.
REFERENCE 1 (bases 1 to 13)
AUTHORS Turkewitz,A.P., Karrer,K.M., Jahn,C., Orias,E., Kirk,K.E., Frankel,J. and Klobutcher,L.
TITLE EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL Unpublished (2002)
COMMENT Contact: Turkewitz AP
Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.
FEATURES Location/Qualifiers
source 1. .13
/organism="Tetrahymena thermophila"
/mol_type="mRNA"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/note="Vector: BlueScript2 SK+; Details on library preparation can be found in Chilcoat and Turkewitz (2001) Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match 1.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        597 TTGGGGGCCCAGA 609
              | ||||||||||||
Db         13 TAGGGGGCCCAGA 1
```

RESULT 2
BQ584787
LOCUS BQ584787 14 bp mRNA linear EST 06-DEC-2002
DEFINITION E011673-024-002-K09-SP6R MPIZ-ADIS-024-inflorescence Beta vulgaris cDNA clone 024-002-K09 5-PRIME, mRNA sequence.
ACCESSION BQ584787
VERSION BQ584787.1 GI:26114364
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 14)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
MEDLINE 22362189
PUBMED 12472698
COMMENT Contact: Weisshaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaa@mpiz-koeln.mpg.de
Insert Length: 14 Std Error: 0.00
Plate: 2 row: K column: 09
Seq primer: SP6r; ATTTAGGTGACACTATAGAAGA.
FEATURES Location/Qualifiers
source 1. .14
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:181901"
/db_xref="taxon:161934"
/clone="024-002-K09"
/tissue_type="inflorescence"
/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-inflorescence"
/note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI; cDNA library from sugar beet, library provided by KWS Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match 1.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        724 ATCTTCTGTTTTT 736
              ||||||| ||||
Db          2 ATCTTCTGATTTT 14
```

Search completed: October 18, 2005, 09:39:17
Job time : 0.001 secs

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: October 18, 2005, 09:40:46 ; Search time 2 Seconds
(without alignments)
2.828 Million cell updates/sec

Title: US-10-605-498-91-COPY
Perfect score: 764
Sequence: 1 ggcacgaggagcagagtcag.....aagttcaaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 200 seqs, 3702 residues

Total number of hits satisfying chosen parameters: 400

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 201 summaries

GenBank / EMBL

Database : gedb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	25	3.3	25	1	AR091050	ACCESSION:AR091050
c	2	25	3.3	25	1	AR198085	ACCESSION:AR198085
c	3	25	3.3	25	1	AR260239	ACCESSION:AR260239
	4	24	3.1	24	1	AR091049	ACCESSION:AR091049
	5	24	3.1	24	1	AR198084	ACCESSION:AR198084
	6	24	3.1	24	1	AR260238	ACCESSION:AR260238
	7	21.4	2.8	23	1	AX454996	ACCESSION:AX454996
c	8	21	2.7	21	1	CQ799903	ACCESSION:CQ799903
c	9	21	2.7	21	1	CQ799904	ACCESSION:CQ799904
c	10	21	2.7	21	1	CQ799905	ACCESSION:CQ799905
c	11	21	2.7	21	1	CQ799906	ACCESSION:CQ799906
c	12	21	2.7	21	1	CQ799907	ACCESSION:CQ799907
c	13	21	2.7	21	1	CQ799908	ACCESSION:CQ799908
c	14	21	2.7	21	1	CQ799909	ACCESSION:CQ799909
c	15	21	2.7	21	1	CQ799910	ACCESSION:CQ799910
c	16	21	2.7	21	1	CQ799911	ACCESSION:CQ799911
c	17	21	2.7	21	1	CQ799912	ACCESSION:CQ799912
c	18	21	2.7	21	1	CQ799913	ACCESSION:CQ799913
c	19	21	2.7	21	1	CQ799914	ACCESSION:CQ799914
c	20	21	2.7	21	1	CQ799915	ACCESSION:CQ799915
c	21	21	2.7	21	1	CQ799916	ACCESSION:CQ799916
c	22	21	2.7	21	1	CQ799917	ACCESSION:CQ799917
c	23	21	2.7	21	1	CQ799918	ACCESSION:CQ799918
c	24	21	2.7	21	1	CQ799919	ACCESSION:CQ799919
c	25	21	2.7	21	1	CQ799920	ACCESSION:CQ799920
c	26	21	2.7	21	1	CQ799921	ACCESSION:CQ799921
c	27	21	2.7	21	1	CQ799922	ACCESSION:CQ799922
c	28	21	2.7	21	1	CQ799923	ACCESSION:CQ799923
c	29	21	2.7	21	1	CQ799924	ACCESSION:CQ799924
c	30	21	2.7	21	1	CQ799925	ACCESSION:CQ799925
c	31	21	2.7	21	1	CQ799926	ACCESSION:CQ799926
c	32	21	2.7	21	1	CQ799927	ACCESSION:CQ799927
c	33	21	2.7	21	1	CQ799928	ACCESSION:CQ799928
c	34	21	2.7	21	1	CQ799929	ACCESSION:CQ799929
c	35	21	2.7	21	1	CQ799930	ACCESSION:CQ799930
c	36	21	2.7	21	1	CQ799931	ACCESSION:CQ799931
c	37	21	2.7	21	1	CQ799932	ACCESSION:CQ799932
c	38	21	2.7	21	1	CQ799933	ACCESSION:CQ799933
c	39	21	2.7	21	1	CQ799934	ACCESSION:CQ799934
c	40	21	2.7	21	1	CQ799935	ACCESSION:CQ799935
c	41	21	2.7	21	1	CQ799936	ACCESSION:CQ799936
c	42	21	2.7	21	1	CQ799937	ACCESSION:CQ799937
c	43	21	2.7	21	1	CQ799938	ACCESSION:CQ799938
c	44	21	2.7	21	1	CQ799939	ACCESSION:CQ799939
c	45	21	2.7	21	1	CQ799940	ACCESSION:CQ799940
c	46	21	2.7	21	1	CQ799941	ACCESSION:CQ799941
c	47	21	2.7	21	1	CQ799942	ACCESSION:CQ799942
c	48	21	2.7	21	1	CQ799943	ACCESSION:CQ799943
c	49	21	2.7	21	1	CQ799944	ACCESSION:CQ799944
c	50	21	2.7	21	1	CQ799945	ACCESSION:CQ799945
c	51	21	2.7	21	1	CQ799946	ACCESSION:CQ799946
c	52	21	2.7	21	1	CQ799947	ACCESSION:CQ799947
c	53	21	2.7	21	1	CQ799948	ACCESSION:CQ799948
c	54	21	2.7	21	1	CQ799949	ACCESSION:CQ799949
c	55	21	2.7	21	1	CQ799950	ACCESSION:CQ799950
c	56	21	2.7	21	1	CQ799951	ACCESSION:CQ799951
c	57	21	2.7	21	1	CQ799952	ACCESSION:CQ799952
c	58	21	2.7	21	1	CQ799953	ACCESSION:CQ799953
c	59	21	2.7	21	1	CQ799954	ACCESSION:CQ799954
c	60	21	2.7	21	1	CQ799955	ACCESSION:CQ799955
c	61	21	2.7	21	1	CQ799956	ACCESSION:CQ799956
c	62	21	2.7	21	1	CQ799957	ACCESSION:CQ799957
c	63	21	2.7	21	1	CQ799958	ACCESSION:CQ799958
c	64	21	2.7	21	1	CQ799959	ACCESSION:CQ799959
c	65	21	2.7	21	1	CQ799960	ACCESSION:CQ799960
c	66	21	2.7	21	1	CQ799961	ACCESSION:CQ799961
c	67	21	2.7	21	1	CQ799962	ACCESSION:CQ799962
c	68	21	2.7	21	1	CQ799963	ACCESSION:CQ799963
c	69	21	2.7	21	1	CQ799964	ACCESSION:CQ799964
c	70	21	2.7	21	1	CQ799965	ACCESSION:CQ799965
c	71	21	2.7	21	1	CQ799966	ACCESSION:CQ799966
c	72	21	2.7	21	1	CQ799967	ACCESSION:CQ799967
c	73	21	2.7	21	1	CQ799968	ACCESSION:CQ799968
c	74	21	2.7	21	1	CQ799969	ACCESSION:CQ799969
c	75	21	2.7	21	1	CQ799970	ACCESSION:CQ799970
c	76	21	2.7	21	1	CQ799971	ACCESSION:CQ799971
c	77	21	2.7	21	1	CQ799972	ACCESSION:CQ799972
c	78	21	2.7	21	1	CQ799973	ACCESSION:CQ799973
c	79	21	2.7	21	1	CQ799974	ACCESSION:CQ799974
c	80	21	2.7	21	1	CQ799975	ACCESSION:CQ799975
c	81	21	2.7	21	1	CQ799976	ACCESSION:CQ799976
c	82	21	2.7	21	1	CQ799977	ACCESSION:CQ799977
c	83	21	2.7	21	1	CQ799978	ACCESSION:CQ799978
c	84	21	2.7	21	1	CQ799980	ACCESSION:CQ799980
c	85	21	2.7	21	1	CQ799981	ACCESSION:CQ799981
c	86	21	2.7	21	1	CQ799982	ACCESSION:CQ799982
c	87	21	2.7	21	1	CQ799983	ACCESSION:CQ799983
c	88	20	2.6	20	1	CQ799984	ACCESSION:CQ799984
	89	19	2.5	19	1	CQ799989	ACCESSION:CQ799989
	90	19	2.5	19	1	CQ799992	ACCESSION:CQ799992
	91	18.4	2.4	21	1	BD178972	ACCESSION:BD178972
c	92	18	2.4	18	1	CQ799979	ACCESSION:CQ799979
	93	17.8	2.3	21	1	CQ799991	ACCESSION:CQ799991
c	94	17.8	2.3	22	1	BD178973	ACCESSION:BD178973
	95	17.4	2.3	20	1	BD230260	ACCESSION:BD230260
	96	17	2.2	17	1	AX671859	ACCESSION:AX671859
	97	17	2.2	17	1	AX728678	ACCESSION:AX728678
	98	17	2.2	17	1	AX738957	ACCESSION:AX738957
	99	17	2.2	17	1	AX762937	ACCESSION:AX762937
	100	15.8	2.1	19	1	CQ799985	ACCESSION:CQ799985
	101	15.8	2.1	21	1	CQ799909	ACCESSION:CQ799909
	102	15.4	2.0	17	1	CQ625927	ACCESSION:CQ625927
	103	15.4	2.0	17	1	AR466990	ACCESSION:AR466990
	104	15.4	2.0	17	1	AX735327	ACCESSION:AX735327
	105	15.4	2.0	17	1	AX762926	ACCESSION:AX762926
	106	15	2.0	15	1	AR180537	ACCESSION:AR180537

c 107	14.8	1.9	18	1	AR072210	ACCESSION:AR072210
108	14.8	1.9	18	1	CQ786325	ACCESSION:CQ786325
c 109	14.8	1.9	18	1	I26321	ACCESSION:I26321
c 110	14.8	1.9	18	1	AR392122	ACCESSION:AR392122
c 111	14.8	1.9	18	1	AX480662	ACCESSION:AX480662
c 112	14.4	1.9	16	1	I69196	ACCESSION:I69196
c 113	14.4	1.9	16	1	AR253794	ACCESSION:AR253794
c 114	14.4	1.9	16	1	AX696849	ACCESSION:AX696849
115	14.4	1.9	17	1	CQ625926	ACCESSION:CQ625926
116	14.4	1.9	17	1	CQ625928	ACCESSION:CQ625928
117	14.4	1.9	17	1	AR466989	ACCESSION:AR466989
118	14.4	1.9	17	1	AR466991	ACCESSION:AR466991
c 119	14.4	1.9	17	1	AX615411	ACCESSION:AX615411
c 120	14.4	1.9	17	1	AX615412	ACCESSION:AX615412
121	14.4	1.9	17	1	AX783872	ACCESSION:AX783872
122	14.4	1.9	17	1	AX783873	ACCESSION:AX783873
123	14.4	1.9	18	1	AR096356	ACCESSION:AR096356
124	14.4	1.9	18	1	AR109825	ACCESSION:AR109825
125	14.4	1.9	18	1	BD217404	ACCESSION:BD217404
c 126	14.4	1.9	18	1	AR294360	ACCESSION:AR294360
127	14	1.8	17	1	AX215323	ACCESSION:AX215323
128	14	1.8	17	1	AX216349	ACCESSION:AX216349
c 129	14	1.8	17	1	AX266839	ACCESSION:AX266839
130	14	1.8	17	1	AX266840	ACCESSION:AX266840
c 131	13.8	1.8	17	1	AR164573	ACCESSION:AR164573
132	13.8	1.8	17	1	BD197647	ACCESSION:BD197647
c 133	13.8	1.8	17	1	BD241652	ACCESSION:BD241652
c 134	13.8	1.8	17	1	CQ617589	ACCESSION:CQ617589
c 135	13.8	1.8	17	1	CQ617590	ACCESSION:CQ617590
c 136	13.8	1.8	17	1	CQ617591	ACCESSION:CQ617591
137	13.8	1.8	17	1	CQ625929	ACCESSION:CQ625929
138	13.8	1.8	17	1	CQ625930	ACCESSION:CQ625930
139	13.8	1.8	17	1	AR286401	ACCESSION:AR286401
140	13.8	1.8	17	1	AR398391	ACCESSION:AR398391
c 141	13.8	1.8	17	1	AR458652	ACCESSION:AR458652
c 142	13.8	1.8	17	1	AR458653	ACCESSION:AR458653
c 143	13.8	1.8	17	1	AR458654	ACCESSION:AR458654
144	13.8	1.8	17	1	AR466992	ACCESSION:AR466992
145	13.8	1.8	17	1	AR466993	ACCESSION:AR466993
c 146	13.8	1.8	17	1	AR483153	ACCESSION:AR483153
147	13.8	1.8	17	1	AX216972	ACCESSION:AX216972
c 148	13.8	1.8	17	1	AX498863	ACCESSION:AX498863
149	13.8	1.8	17	1	AX531714	ACCESSION:AX531714
150	13.8	1.8	17	1	AX579468	ACCESSION:AX579468
c 151	13.8	1.8	17	1	AX580066	ACCESSION:AX580066
c 152	13.8	1.8	17	1	AX580067	ACCESSION:AX580067
c 153	13.8	1.8	17	1	AX725108	ACCESSION:AX725108
154	13.8	1.8	17	1	AX725434	ACCESSION:AX725434
c 155	13.8	1.8	17	1	AX735751	ACCESSION:AX735751
156	13.8	1.8	17	1	AX736224	ACCESSION:AX736224
157	13.8	1.8	17	1	AX753978	ACCESSION:AX753978
c 158	13.8	1.8	17	1	AX783428	ACCESSION:AX783428
c 159	13.8	1.8	17	1	AX783429	ACCESSION:AX783429
160	13	1.7	21	1	CQ799952	ACCESSION:CQ799952
161	12.8	1.7	16	1	AR110507	ACCESSION:AR110507
162	12.8	1.7	16	1	AR137060	ACCESSION:AR137060
c 163	12.8	1.7	16	1	BD266330	ACCESSION:BD266330
c 164	12.8	1.7	16	1	CQ858645	ACCESSION:CQ858645
c 165	12.8	1.7	16	1	I69269	ACCESSION:I69269
c 166	12.8	1.7	16	1	AR253867	ACCESSION:AR253867
167	12.8	1.7	16	1	AR391398	ACCESSION:AR391398
168	12.8	1.7	16	1	AR391498	ACCESSION:AR391498
169	12.8	1.7	16	1	AR435928	ACCESSION:AR435928
170	12.8	1.7	16	1	AR451605	ACCESSION:AR451605
171	12.8	1.7	16	1	AR451617	ACCESSION:AR451617
c 172	12.8	1.7	16	1	AX073744	ACCESSION:AX073744
c 173	12.8	1.7	16	1	AX073745	ACCESSION:AX073745
174	12.8	1.7	16	1	AX132924	ACCESSION:AX132924
175	12.8	1.7	16	1	AX281878	ACCESSION:AX281878
176	12.8	1.7	16	1	AX281978	ACCESSION:AX281978
c 177	12.8	1.7	16	1	AX696922	ACCESSION:AX696922
178	12.6	1.6	21	1	CQ799962	ACCESSION:CQ799962
c 179	12.4	1.6	15	1	AR097225	ACCESSION:AR097225
180	12.4	1.6	15	1	E05651	ACCESSION:E05651
181	12.4	1.6	15	1	I77111	ACCESSION:I77111
182	12.4	1.6	15	1	AR180586	ACCESSION:AR180586
183	12.4	1.6	15	1	AR432576	ACCESSION:AR432576
184	12.4	1.6	15	1	AX269347	ACCESSION:AX269347
c 185	12	1.6	12	1	AX097953	ACCESSION:AX097953
c 186	12	1.6	12	1	AX138529	ACCESSION:AX138529
187	12	1.6	14	1	AX525366	ACCESSION:AX525366
c 188	12	1.6	15	1	AR180644	ACCESSION:AR180644
c 189	12	1.6	15	1	AR180645	ACCESSION:AR180645
190	12	1.6	21	1	CQ799917	ACCESSION:CQ799917
191	11.6	1.5	21	1	CQ799916	ACCESSION:CQ799916
192	11.6	1.5	21	1	CQ799930	ACCESSION:CQ799930
c 193	11.4	1.5	13	1	BD263080	ACCESSION:BD263080
c 194	11.4	1.5	13	1	AX025026	ACCESSION:AX025026
195	11.4	1.5	13	1	AX556272	ACCESSION:AX556272
c 196	11.4	1.5	14	1	A89531	ACCESSION:A89531
197	11.4	1.5	14	1	BD209296	ACCESSION:BD209296
c 198	11.4	1.5	14	1	BD209297	ACCESSION:BD209297
c 199	11.4	1.5	14	1	AX025606	ACCESSION:AX025606
c 200	11.4	1.5	14	1	BD067044	ACCESSION:BD067044
c 201	11.4	1.5	14	1	ATH523733	ACCESSION:AJ523733

ALIGNMENTS

```
RESULT 1
AR091050/c
LOCUS       AR091050                  25 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 1170 from patent US 5994076.
ACCESSION   AR091050
VERSION     AR091050.1  GI:10017805
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 5994076-A 1170 30-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 3.4;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 2
AR198085/c
LOCUS       AR198085                  25 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 1170 from patent US 6352829.
ACCESSION   AR198085
VERSION     AR198085.1  GI:20247934
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6352829-A 1170 05-MAR-2002;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"
```

```
  Query Match             3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 3.4;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 3
AR260239/c
LOCUS       AR260239                  25 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 1170 from patent US 6489455.
ACCESSION   AR260239
VERSION     AR260239.1  GI:27310750
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6489455-A 1170 03-DEC-2002;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 3.4;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 4
AR091049
LOCUS       AR091049                  24 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 1169 from patent US 5994076.
ACCESSION   AR091049
VERSION     AR091049.1  GI:10017804
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 5994076-A 1169 30-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 4.5;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 5
AR198084
LOCUS       AR198084                  24 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 1169 from patent US 6352829.
ACCESSION   AR198084
VERSION     AR198084.1  GI:20247933
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6352829-A 1169 05-MAR-2002;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 4.5;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 6
AR260238
LOCUS       AR260238                  24 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 1169 from patent US 6489455.
ACCESSION   AR260238
VERSION     AR260238.1  GI:27310749
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6489455-A 1169 03-DEC-2002;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 4.5;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 7
AX454996
LOCUS       AX454996                  23 bp    DNA     linear   PAT 06-JUL-2002
DEFINITION  Sequence 63 from Patent WO0208453.
ACCESSION   AX454996
VERSION     AX454996.1  GI:21714181
KEYWORDS    .
SOURCE      Canis familiaris (dog)
  ORGANISM  Canis familiaris
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE   1
  AUTHORS   Farr,S.B., Pickett,G.G., Neft,R.E. and Dunn,R.T.
  TITLE     Canine toxicity genes
  JOURNAL   Patent: WO 0208453-A 63 31-JAN-2002;
            Phase-1 Molecular Toxicology (US)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Canis familiaris"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9615"

  Query Match             2.8%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 11;
```

```
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         73 GGACCCCTTCCGCGACTGGTACC 95
              |||||| ||||||||||||||||
Db          1 GGACCCTTTCCGCGACTGGTACC 23


RESULT 8
CQ799903/c
LOCUS       CQ799903                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 1 from Patent WO2004030660.
ACCESSION   CQ799903
VERSION     CQ799903.1  GI:46848850
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 1 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 GGCACGAGGAGCAGAGTCAGC 21
              |||||||||||||||||||||
Db         21 GGCACGAGGAGCAGAGTCAGC 1


RESULT 9
CQ799904/c
LOCUS       CQ799904                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 2 from Patent WO2004030660.
ACCESSION   CQ799904
VERSION     CQ799904.1  GI:46848851
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 2 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         11 GCAGAGTCAGCCAGCATGACC 31
              |||||||||||||||||||||
Db         21 GCAGAGTCAGCCAGCATGACC 1


RESULT 10
CQ799905/c
LOCUS       CQ799905                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 3 from Patent WO2004030660.
ACCESSION   CQ799905
VERSION     CQ799905.1  GI:46848852
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 3 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         21 CCAGCATGACCGAGCGCCGCG 41
              |||||||||||||||||||||
Db         21 CCAGCATGACCGAGCGCCGCG 1


RESULT 11
CQ799906/c
LOCUS       CQ799906                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 4 from Patent WO2004030660.
ACCESSION   CQ799906
VERSION     CQ799906.1  GI:46848853
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 4 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         31 CGAGCGCCGCGTCCCCTTCTC 51
              |||||||||||||||||||||
Db         21 CGAGCGCCGCGTCCCCTTCTC 1


RESULT 12
CQ799907/c
LOCUS       CQ799907                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 5 from Patent WO2004030660.
ACCESSION   CQ799907
VERSION     CQ799907.1  GI:46848854
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 5 15-APR-2004;
```

```
          The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         41 GTCCCCTTCTCGCTCCTGCGG 61
              |||||||||||||||||||||
Db         21 GTCCCCTTCTCGCTCCTGCGG 1


RESULT 13
CQ799908/c
LOCUS       CQ799908                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 6 from Patent WO2004030660.
ACCESSION   CQ799908
VERSION     CQ799908.1  GI:46848855
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 6 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 CGCTCCTGCGGGGCCCCAGCT 71
              |||||||||||||||||||||
Db         21 CGCTCCTGCGGGGCCCCAGCT 1


RESULT 14
CQ799909/c
LOCUS       CQ799909                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 7 from Patent WO2004030660.
ACCESSION   CQ799909
VERSION     CQ799909.1  GI:46848856
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 7 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         61 GGGCCCCAGCTGGGACCCCTT 81
              |||||||||||||||||||||
Db         21 GGGCCCCAGCTGGGACCCCTT 1


RESULT 15
CQ799910/c
LOCUS       CQ799910                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 8 from Patent WO2004030660.
ACCESSION   CQ799910
VERSION     CQ799910.1  GI:46848857
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 8 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         71 TGGGACCCCTTCCGCGACTGG 91
              |||||||||||||||||||||
Db         21 TGGGACCCCTTCCGCGACTGG 1


RESULT 16
CQ799911/c
LOCUS       CQ799911                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 9 from Patent WO2004030660.
ACCESSION   CQ799911
VERSION     CQ799911.1  GI:46848858
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 9 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         81 TCCGCGACTGGTACCCGCATA 101
              |||||||||||||||||||||
Db         21 TCCGCGACTGGTACCCGCATA 1


RESULT 17
CQ799912/c
LOCUS       CQ799912                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 10 from Patent WO2004030660.
ACCESSION   CQ799912
VERSION     CQ799912.1  GI:46848859
```

```
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 10 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         91 GTACCCGCATAGCCGCCTCTT 111
              |||||||||||||||||||||
Db         21 GTACCCGCATAGCCGCCTCTT 1


RESULT 18
CQ799913/c
LOCUS       CQ799913                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 11 from Patent WO2004030660.
ACCESSION   CQ799913
VERSION     CQ799913.1  GI:46848860
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 11 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        101 AGCCGCCTCTTCGACCAGGCC 121
              |||||||||||||||||||||
Db         21 AGCCGCCTCTTCGACCAGGCC 1


RESULT 19
CQ799914/c
LOCUS       CQ799914                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 12 from Patent WO2004030660.
ACCESSION   CQ799914
VERSION     CQ799914.1  GI:46848861
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 12 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        111 TCGACCAGGCCTTCGGGCTGC 131
              |||||||||||||||||||||
Db         21 TCGACCAGGCCTTCGGGCTGC 1


RESULT 20
CQ799915/c
LOCUS       CQ799915                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 13 from Patent WO2004030660.
ACCESSION   CQ799915
VERSION     CQ799915.1  GI:46848862
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 13 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        121 CTTCGGGCTGCCCCGGCTGCC 141
              |||||||||||||||||||||
Db         21 CTTCGGGCTGCCCCGGCTGCC 1


RESULT 21
CQ799916/c
LOCUS       CQ799916                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 14 from Patent WO2004030660.
ACCESSION   CQ799916
VERSION     CQ799916.1  GI:46848863
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 14 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        131 CCCCGGCTGCCGGAGGAGTGG 151
              |||||||||||||||||||||
```

```
Db         21 CCCCGGCTGCCGGAGGAGTGG 1


RESULT 22
CQ799917/c
LOCUS       CQ799917                 21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 15 from Patent WO2004030660.
ACCESSION   CQ799917
VERSION     CQ799917.1  GI:46848864
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 15 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        141 CGGAGGAGTGGTCGCAGTGGT 161
              |||||||||||||||||||||
Db         21 CGGAGGAGTGGTCGCAGTGGT 1


RESULT 23
CQ799918/c
LOCUS       CQ799918                 21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 16 from Patent WO2004030660.
ACCESSION   CQ799918
VERSION     CQ799918.1  GI:46848865
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 16 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        151 GTCGCAGTGGTTAGGCGGCAG 171
              |||||||||||||||||||||
Db         21 GTCGCAGTGGTTAGGCGGCAG 1


RESULT 24
CQ799919/c
LOCUS       CQ799919                 21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 17 from Patent WO2004030660.
ACCESSION   CQ799919
VERSION     CQ799919.1  GI:46848866
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 17 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        161 TTAGGCGGCAGCAGCTGGCCA 181
              |||||||||||||||||||||
Db         21 TTAGGCGGCAGCAGCTGGCCA 1


RESULT 25
CQ799920/c
LOCUS       CQ799920                 21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 18 from Patent WO2004030660.
ACCESSION   CQ799920
VERSION     CQ799920.1  GI:46848867
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 18 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        171 GCAGCTGGCCAGGCTACGTGC 191
              |||||||||||||||||||||
Db         21 GCAGCTGGCCAGGCTACGTGC 1


RESULT 26
CQ799921/c
LOCUS       CQ799921                 21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 19 from Patent WO2004030660.
ACCESSION   CQ799921
VERSION     CQ799921.1  GI:46848868
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 19 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
```

```
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        181 AGGCTACGTGCGCCCCCTGCC 201
              |||||||||||||||||||||
Db         21 AGGCTACGTGCGCCCCCTGCC 1


RESULT 27
CQ799922/c
LOCUS       CQ799922                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 20 from Patent WO2004030660.
ACCESSION   CQ799922
VERSION     CQ799922.1  GI:46848869
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 20 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        191 CGCCCCCTGCCCCCCGCCGCC 211
              |||||||||||||||||||||
Db         21 CGCCCCCTGCCCCCCGCCGCC 1


RESULT 28
CQ799923/c
LOCUS       CQ799923                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 21 from Patent WO2004030660.
ACCESSION   CQ799923
VERSION     CQ799923.1  GI:46848870
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 21 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        201 CCCCCGCCGCCATCGAGAGCC 221
              |||||||||||||||||||||
Db         21 CCCCCGCCGCCATCGAGAGCC 1


RESULT 29
CQ799924/c
LOCUS       CQ799924                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 22 from Patent WO2004030660.
ACCESSION   CQ799924
VERSION     CQ799924.1  GI:46848871
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 22 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        211 CATCGAGAGCCCCGCAGTGGC 231
              |||||||||||||||||||||
Db         21 CATCGAGAGCCCCGCAGTGGC 1


RESULT 30
CQ799925/c
LOCUS       CQ799925                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 23 from Patent WO2004030660.
ACCESSION   CQ799925
VERSION     CQ799925.1  GI:46848872
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 23 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        221 CCCGCAGTGGCCGCGCCCGCC 241
              |||||||||||||||||||||
Db         21 CCCGCAGTGGCCGCGCCCGCC 1


RESULT 31
CQ799926/c
LOCUS       CQ799926                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 24 from Patent WO2004030660.
ACCESSION   CQ799926
VERSION     CQ799926.1  GI:46848873
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 24 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        231 CCGCGCCCGCCTACAGCCGCG 251
              |||||||||||||||||||||
Db         21 CCGCGCCCGCCTACAGCCGCG 1


RESULT 32
CQ799927/c
LOCUS       CQ799927                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 25 from Patent WO2004030660.
ACCESSION   CQ799927
VERSION     CQ799927.1  GI:46848874
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 25 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        241 CTACAGCCGCGCGCTCAGCCG 261
              |||||||||||||||||||||
Db         21 CTACAGCCGCGCGCTCAGCCG 1


RESULT 33
CQ799928/c
LOCUS       CQ799928                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 26 from Patent WO2004030660.
ACCESSION   CQ799928
VERSION     CQ799928.1  GI:46848875
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 26 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        251 GCGCTCAGCCGGCAACTCAGC 271
              |||||||||||||||||||||
Db         21 GCGCTCAGCCGGCAACTCAGC 1


RESULT 34
CQ799929/c
LOCUS       CQ799929                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 27 from Patent WO2004030660.
ACCESSION   CQ799929
VERSION     CQ799929.1  GI:46848876
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 27 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        261 GGCAACTCAGCAGCGGGGTCT 281
              |||||||||||||||||||||
Db         21 GGCAACTCAGCAGCGGGGTCT 1


RESULT 35
CQ799930/c
LOCUS       CQ799930                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 28 from Patent WO2004030660.
ACCESSION   CQ799930
VERSION     CQ799930.1  GI:46848877
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 28 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        271 CAGCGGGGTCTCGGAGATCCG 291
              |||||||||||||||||||||
Db         21 CAGCGGGGTCTCGGAGATCCG 1


RESULT 36
```

```
CQ799931/c
LOCUS       CQ799931                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 29 from Patent WO2004030660.
ACCESSION   CQ799931
VERSION     CQ799931.1  GI:46848878
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 29 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        281 TCGGAGATCCGGCACACTGCG 301
              |||||||||||||||||||||
Db         21 TCGGAGATCCGGCACACTGCG 1


RESULT 37
CQ799932/c
LOCUS       CQ799932                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 30 from Patent WO2004030660.
ACCESSION   CQ799932
VERSION     CQ799932.1  GI:46848879
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 30 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        291 GGCACACTGCGGACCGCTGGC 311
              |||||||||||||||||||||
Db         21 GGCACACTGCGGACCGCTGGC 1


RESULT 38
CQ799933/c
LOCUS       CQ799933                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 31 from Patent WO2004030660.
ACCESSION   CQ799933
VERSION     CQ799933.1  GI:46848880
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 31 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        301 GGACCGCTGGCGCGTGTCCCT 321
              |||||||||||||||||||||
Db         21 GGACCGCTGGCGCGTGTCCCT 1


RESULT 39
CQ799934/c
LOCUS       CQ799934                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 32 from Patent WO2004030660.
ACCESSION   CQ799934
VERSION     CQ799934.1  GI:46848881
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 32 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        311 CGCGTGTCCCTGGATGTCAAC 331
              |||||||||||||||||||||
Db         21 CGCGTGTCCCTGGATGTCAAC 1


RESULT 40
CQ799935/c
LOCUS       CQ799935                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 33 from Patent WO2004030660.
ACCESSION   CQ799935
VERSION     CQ799935.1  GI:46848882
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 33 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        321 TGGATGTCAACCACTTCGCCC 341
              |||||||||||||||||||||
Db         21 TGGATGTCAACCACTTCGCCC 1


RESULT 41
CQ799936/c
LOCUS       CQ799936                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 34 from Patent WO2004030660.
ACCESSION   CQ799936
VERSION     CQ799936.1  GI:46848883
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 34 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        331 CCACTTCGCCCCGGACGAGCT 351
              |||||||||||||||||||||
Db         21 CCACTTCGCCCCGGACGAGCT 1


RESULT 42
CQ799937/c
LOCUS       CQ799937                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 35 from Patent WO2004030660.
ACCESSION   CQ799937
VERSION     CQ799937.1  GI:46848884
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 35 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        341 CCGGACGAGCTGACGGTCAAG 361
              |||||||||||||||||||||
Db         21 CCGGACGAGCTGACGGTCAAG 1


RESULT 43
CQ799938/c
LOCUS       CQ799938                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 36 from Patent WO2004030660.
ACCESSION   CQ799938
VERSION     CQ799938.1  GI:46848885
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 36 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGACCAAGGATG 371
              |||||||||||||||||||||
Db         21 TGACGGTCAAGACCAAGGATG 1


RESULT 44
CQ799939/c
LOCUS       CQ799939                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 37 from Patent WO2004030660.
ACCESSION   CQ799939
VERSION     CQ799939.1  GI:46848886
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 37 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        361 GACCAAGGATGGCGTGGTGGA 381
              |||||||||||||||||||||
Db         21 GACCAAGGATGGCGTGGTGGA 1


RESULT 45
CQ799940/c
LOCUS       CQ799940                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 38 from Patent WO2004030660.
ACCESSION   CQ799940
VERSION     CQ799940.1  GI:46848887
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
```

```
  JOURNAL   Patent: WO 2004030660-A 38 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        371 GGCGTGGTGGAGATCACCGGC 391
              |||||||||||||||||||||
Db         21 GGCGTGGTGGAGATCACCGGC 1


RESULT 46
CQ799941/c
LOCUS       CQ799941                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 39 from Patent WO2004030660.
ACCESSION   CQ799941
VERSION     CQ799941.1  GI:46848888
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 39 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        381 AGATCACCGGCAAGCACGAGG 401
              |||||||||||||||||||||
Db         21 AGATCACCGGCAAGCACGAGG 1


RESULT 47
CQ799942/c
LOCUS       CQ799942                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 40 from Patent WO2004030660.
ACCESSION   CQ799942
VERSION     CQ799942.1  GI:46848889
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 40 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        391 CAAGCACGAGGAGCGGCAGGA 411
              |||||||||||||||||||||
Db         21 CAAGCACGAGGAGCGGCAGGA 1


RESULT 48
CQ799943/c
LOCUS       CQ799943                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 41 from Patent WO2004030660.
ACCESSION   CQ799943
VERSION     CQ799943.1  GI:46848890
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 41 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        401 GAGCGGCAGGACGAGCATGGC 421
              |||||||||||||||||||||
Db         21 GAGCGGCAGGACGAGCATGGC 1


RESULT 49
CQ799944/c
LOCUS       CQ799944                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 42 from Patent WO2004030660.
ACCESSION   CQ799944
VERSION     CQ799944.1  GI:46848891
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 42 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        411 ACGAGCATGGCTACATCTCCC 431
              |||||||||||||||||||||
Db         21 ACGAGCATGGCTACATCTCCC 1


RESULT 50
CQ799945/c
LOCUS       CQ799945                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 43 from Patent WO2004030660.
ACCESSION   CQ799945
```

```
VERSION     CQ799945.1  GI:46848892
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 43 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        421 CTACATCTCCCGGTGCTTCAC 441
              |||||||||||||||||||||
Db         21 CTACATCTCCCGGTGCTTCAC 1


RESULT 51
CQ799946/c
LOCUS       CQ799946                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 44 from Patent WO2004030660.
ACCESSION   CQ799946
VERSION     CQ799946.1  GI:46848893
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 44 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        431 CGGTGCTTCACGCGGAAATAC 451
              |||||||||||||||||||||
Db         21 CGGTGCTTCACGCGGAAATAC 1


RESULT 52
CQ799947/c
LOCUS       CQ799947                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 45 from Patent WO2004030660.
ACCESSION   CQ799947
VERSION     CQ799947.1  GI:46848894
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 45 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        441 CGCGGAAATACACGCTGCCCC 461
              |||||||||||||||||||||
Db         21 CGCGGAAATACACGCTGCCCC 1


RESULT 53
CQ799948/c
LOCUS       CQ799948                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 46 from Patent WO2004030660.
ACCESSION   CQ799948
VERSION     CQ799948.1  GI:46848895
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 46 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        451 CACGCTGCCCCCCGGTGTGGA 471
              |||||||||||||||||||||
Db         21 CACGCTGCCCCCCGGTGTGGA 1


RESULT 54
CQ799949/c
LOCUS       CQ799949                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 47 from Patent WO2004030660.
ACCESSION   CQ799949
VERSION     CQ799949.1  GI:46848896
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 47 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        461 CCCGGTGTGGACCCCACCCAA 481
```

```
                    ||||||||||||||||||||
Db         21 CCCGGTGTGGACCCCACCCAA 1


RESULT 55
CQ799950/c
LOCUS       CQ799950                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 48 from Patent WO2004030660.
ACCESSION   CQ799950
VERSION     CQ799950.1  GI:46848897
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 48 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        471 ACCCCACCCAAGTTTCCTCCT 491
                ||||||||||||||||||||
Db         21 ACCCCACCCAAGTTTCCTCCT 1


RESULT 56
CQ799951/c
LOCUS       CQ799951                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 49 from Patent WO2004030660.
ACCESSION   CQ799951
VERSION     CQ799951.1  GI:46848898
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 49 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        481 AGTTTCCTCCTCCCTGTCCCC 501
                ||||||||||||||||||||
Db         21 AGTTTCCTCCTCCCTGTCCCC 1


RESULT 57
CQ799952/c
LOCUS       CQ799952                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 50 from Patent WO2004030660.
ACCESSION   CQ799952
VERSION     CQ799952.1  GI:46848899
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 50 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        491 TCCCTGTCCCCTGAGGGCACA 511
                ||||||||||||||||||||
Db         21 TCCCTGTCCCCTGAGGGCACA 1


RESULT 58
CQ799953/c
LOCUS       CQ799953                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 51 from Patent WO2004030660.
ACCESSION   CQ799953
VERSION     CQ799953.1  GI:46848900
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 51 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        501 CTGAGGGCACACTGACCGTGG 521
                ||||||||||||||||||||
Db         21 CTGAGGGCACACTGACCGTGG 1


RESULT 59
CQ799954/c
LOCUS       CQ799954                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 52 from Patent WO2004030660.
ACCESSION   CQ799954
VERSION     CQ799954.1  GI:46848901
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 52 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
```

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 511 ACTGACCGTGGAGGCCCCCAT 531
||||||||||||||||||||
Db 21 ACTGACCGTGGAGGCCCCCAT 1

RESULT 60
CQ799955/c
LOCUS CQ799955 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 53 from Patent WO2004030660.
ACCESSION CQ799955
VERSION CQ799955.1 GI:46848902
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 53 15-APR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers
source 1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 521 GAGGCCCCCATGCCCAAGCTA 541
||||||||||||||||||||
Db 21 GAGGCCCCCATGCCCAAGCTA 1

RESULT 61
CQ799956/c
LOCUS CQ799956 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 54 from Patent WO2004030660.
ACCESSION CQ799956
VERSION CQ799956.1 GI:46848903
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 54 15-APR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers
source 1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 531 TGCCCAAGCTAGCCACGCAGT 551
||||||||||||||||||||
Db 21 TGCCCAAGCTAGCCACGCAGT 1

RESULT 62
CQ799957/c
LOCUS CQ799957 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 55 from Patent WO2004030660.
ACCESSION CQ799957
VERSION CQ799957.1 GI:46848904
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 55 15-APR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers
source 1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCAGTCCAACGAGAT 561
||||||||||||||||||||
Db 21 AGCCACGCAGTCCAACGAGAT 1

RESULT 63
CQ799958/c
LOCUS CQ799958 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 56 from Patent WO2004030660.
ACCESSION CQ799958
VERSION CQ799958.1 GI:46848905
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 56 15-APR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers
source 1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 551 TCCAACGAGATCACCATCCCA 571
||||||||||||||||||||
Db 21 TCCAACGAGATCACCATCCCA 1

RESULT 64
CQ799959/c
LOCUS CQ799959 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 57 from Patent WO2004030660.
ACCESSION CQ799959
VERSION CQ799959.1 GI:46848906
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

```
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
  AUTHORS  Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE    Compositions for treatment of prostate and other cancers
  JOURNAL  Patent: WO 2004030660-A 57 15-APR-2004;
           The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 TCACCATCCCAGTCACCTTCG 581
              |||||||||||||||||||||
Db         21 TCACCATCCCAGTCACCTTCG 1


RESULT 65
CQ799960/c
LOCUS       CQ799960                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 58 from Patent WO2004030660.
ACCESSION   CQ799960
VERSION     CQ799960.1  GI:46848907
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
  AUTHORS  Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE    Compositions for treatment of prostate and other cancers
  JOURNAL  Patent: WO 2004030660-A 58 15-APR-2004;
           The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        571 AGTCACCTTCGAGTCGCGGGC 591
              |||||||||||||||||||||
Db         21 AGTCACCTTCGAGTCGCGGGC 1


RESULT 66
CQ799961/c
LOCUS       CQ799961                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 59 from Patent WO2004030660.
ACCESSION   CQ799961
VERSION     CQ799961.1  GI:46848908
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
  AUTHORS  Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE    Compositions for treatment of prostate and other cancers
  JOURNAL  Patent: WO 2004030660-A 59 15-APR-2004;
           The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        581 GAGTCGCGGGCCCAGCTTGGG 601
              |||||||||||||||||||||
Db         21 GAGTCGCGGGCCCAGCTTGGG 1


RESULT 67
CQ799962/c
LOCUS       CQ799962                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 60 from Patent WO2004030660.
ACCESSION   CQ799962
VERSION     CQ799962.1  GI:46848909
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
  AUTHORS  Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE    Compositions for treatment of prostate and other cancers
  JOURNAL  Patent: WO 2004030660-A 60 15-APR-2004;
           The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        591 CCCAGCTTGGGGGCCCAGAAG 611
              |||||||||||||||||||||
Db         21 CCCAGCTTGGGGGCCCAGAAG 1


RESULT 68
CQ799963/c
LOCUS       CQ799963                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 61 from Patent WO2004030660.
ACCESSION   CQ799963
VERSION     CQ799963.1  GI:46848910
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
  AUTHORS  Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE    Compositions for treatment of prostate and other cancers
  JOURNAL  Patent: WO 2004030660-A 61 15-APR-2004;
           The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        601 GGGCCCAGAAGCTGCAAAATC 621
              |||||||||||||||||||||
Db         21 GGGCCCAGAAGCTGCAAAATC 1
```

```
RESULT 69
CQ799964/c
LOCUS       CQ799964                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 62 from Patent WO2004030660.
ACCESSION   CQ799964
VERSION     CQ799964.1  GI:46848911
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 62 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        611 GCTGCAAAATCCGATGAGACT 631
              |||||||||||||||||||||
Db         21 GCTGCAAAATCCGATGAGACT 1


RESULT 70
CQ799965/c
LOCUS       CQ799965                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 63 from Patent WO2004030660.
ACCESSION   CQ799965
VERSION     CQ799965.1  GI:46848912
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 63 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        621 CCGATGAGACTGCCGCCAAGT 641
              |||||||||||||||||||||
Db         21 CCGATGAGACTGCCGCCAAGT 1


RESULT 71
CQ799966/c
LOCUS       CQ799966                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 64 from Patent WO2004030660.
ACCESSION   CQ799966
VERSION     CQ799966.1  GI:46848913
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 64 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAG 651
              |||||||||||||||||||||
Db         21 TGCCGCCAAGTAAAGCCTTAG 1


RESULT 72
CQ799967/c
LOCUS       CQ799967                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 65 from Patent WO2004030660.
ACCESSION   CQ799967
VERSION     CQ799967.1  GI:46848914
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 65 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        641 TAAAGCCTTAGCCCGGATGCC 661
              |||||||||||||||||||||
Db         21 TAAAGCCTTAGCCCGGATGCC 1


RESULT 73
CQ799968/c
LOCUS       CQ799968                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 66 from Patent WO2004030660.
ACCESSION   CQ799968
VERSION     CQ799968.1  GI:46848915
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 66 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
```

```
  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        651 GCCCGGATGCCCACCCCTGCT 671
              |||||||||||||||||||||
Db         21 GCCCGGATGCCCACCCCTGCT 1


RESULT 74
CQ799969/c
LOCUS       CQ799969                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 67 from Patent WO2004030660.
ACCESSION   CQ799969
VERSION     CQ799969.1  GI:46848916
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 67 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        661 CCACCCCTGCTGCCGCCACTG 681
              |||||||||||||||||||||
Db         21 CCACCCCTGCTGCCGCCACTG 1


RESULT 75
CQ799970/c
LOCUS       CQ799970                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 68 from Patent WO2004030660.
ACCESSION   CQ799970
VERSION     CQ799970.1  GI:46848917
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 68 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        671 TGCCGCCACTGGCTGTGCCTC 691
              |||||||||||||||||||||
Db         21 TGCCGCCACTGGCTGTGCCTC 1


RESULT 76
CQ799971/c
LOCUS       CQ799971                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 69 from Patent WO2004030660.
ACCESSION   CQ799971
VERSION     CQ799971.1  GI:46848918
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 69 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        681 GGCTGTGCCTCCCCCGCCACC 701
              |||||||||||||||||||||
Db         21 GGCTGTGCCTCCCCCGCCACC 1


RESULT 77
CQ799972/c
LOCUS       CQ799972                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 70 from Patent WO2004030660.
ACCESSION   CQ799972
VERSION     CQ799972.1  GI:46848919
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 70 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        691 CCCCCGCCACCTGTGTGTTCT 711
              |||||||||||||||||||||
Db         21 CCCCCGCCACCTGTGTGTTCT 1


RESULT 78
CQ799973/c
LOCUS       CQ799973                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 71 from Patent WO2004030660.
ACCESSION   CQ799973
VERSION     CQ799973.1  GI:46848920
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
```

```
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 71 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGATACAT 721
              |||||||||||||||||||||
Db         21 CTGTGTGTTCTTTTGATACAT 1


RESULT 79
CQ799974/c
LOCUS       CQ799974                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 72 from Patent WO2004030660.
ACCESSION   CQ799974
VERSION     CQ799974.1  GI:46848921
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 72 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        711 TTTTGATACATTTATCTTCTG 731
              |||||||||||||||||||||
Db         21 TTTTGATACATTTATCTTCTG 1


RESULT 80
CQ799975/c
LOCUS       CQ799975                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 73 from Patent WO2004030660.
ACCESSION   CQ799975
VERSION     CQ799975.1  GI:46848922
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 73 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        721 TTTATCTTCTGTTTTTCTCAA 741
              |||||||||||||||||||||
Db         21 TTTATCTTCTGTTTTTCTCAA 1


RESULT 81
CQ799976/c
LOCUS       CQ799976                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 74 from Patent WO2004030660.
ACCESSION   CQ799976
VERSION     CQ799976.1  GI:46848923
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 74 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        731 GTTTTTCTCAAATAAAGTTCA 751
              |||||||||||||||||||||
Db         21 GTTTTTCTCAAATAAAGTTCA 1


RESULT 82
CQ799977/c
LOCUS       CQ799977                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 75 from Patent WO2004030660.
ACCESSION   CQ799977
VERSION     CQ799977.1  GI:46848924
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 75 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        741 AATAAAGTTCAAAGCAACCAC 761
              |||||||||||||||||||||
Db         21 AATAAAGTTCAAAGCAACCAC 1


RESULT 83
CQ799978/c
LOCUS       CQ799978                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 76 from Patent WO2004030660.
```

```
ACCESSION   CQ799978
VERSION     CQ799978.1  GI:46848925
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 76 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        744 AAAGTTCAAAGCAACCACCTG 764
              |||||||||||||||||||||
Db         21 AAAGTTCAAAGCAACCACCTG 1


RESULT 84
CQ799980/c
LOCUS       CQ799980                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 78 from Patent WO2004030660.
ACCESSION   CQ799980
VERSION     CQ799980.1  GI:46848927
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 78 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        365 AAGGATGGCGTGGTGGAGATC 385
              |||||||||||||||||||||
Db         21 AAGGATGGCGTGGTGGAGATC 1


RESULT 85
CQ799981/c
LOCUS       CQ799981                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 79 from Patent WO2004030660.
ACCESSION   CQ799981
VERSION     CQ799981.1  GI:46848928
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 79 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        265 ACTCAGCAGCGGGGTCTCGGA 285
              |||||||||||||||||||||
Db         21 ACTCAGCAGCGGGGTCTCGGA 1


RESULT 86
CQ799982/c
LOCUS       CQ799982                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 80 from Patent WO2004030660.
ACCESSION   CQ799982
VERSION     CQ799982.1  GI:46848929
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 80 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        264 AACTCAGCAGCGGGGTCTCGG 284
              |||||||||||||||||||||
Db         21 AACTCAGCAGCGGGGTCTCGG 1


RESULT 87
CQ799983/c
LOCUS       CQ799983                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 81 from Patent WO2004030660.
ACCESSION   CQ799983
VERSION     CQ799983.1  GI:46848930
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 81 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          26 ATGACCGAGCGCCGCGTCCCC 46
               |||||||||||||||||||||
Db          21 ATGACCGAGCGCCGCGTCCCC 1


RESULT 88
CQ799984/c
LOCUS       CQ799984                  20 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 82 from Patent WO2004030660.
ACCESSION   CQ799984
VERSION     CQ799984.1  GI:46848931
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 82 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          26 ATGACCGAGCGCCGCGTCCC 45
               ||||||||||||||||||||
Db          20 ATGACCGAGCGCCGCGTCCC 1


RESULT 89
CQ799989
LOCUS       CQ799989                  19 bp    RNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 87 from Patent WO2004030660.
ACCESSION   CQ799989
VERSION     CQ799989.1  GI:46848936
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 87 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         556 CGAGATCACCATCCCAGTC 574
               |||||||||||||||||||
Db          1 CGAGATCACCATCCCAGTC 19


RESULT 90
CQ799992
LOCUS       CQ799992                  19 bp    RNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 90 from Patent WO2004030660.
ACCESSION   CQ799992
VERSION     CQ799992.1  GI:46848939
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 90 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          26 ATGACCGAGCGCCGCGTCC 44
               |||||||||||||||||||
Db          1 ATGACCGAGCGCCGCGTCC 19


RESULT 91
BD178972
LOCUS       BD178972                  21 bp    DNA     linear   PAT 16-APR-2003
DEFINITION  HSP inducing agent.
ACCESSION   BD178972
VERSION     BD178972.1  GI:30016240
KEYWORDS    WO 02078705-A/1.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Terashita,Z., Naruo,K., Uchikawa,O. and Nakanishi,A.
  TITLE     HSP inducing agent
  JOURNAL   Patent: WO 02078705-A 1 10-OCT-2002;
            TAKEDA CHEMICAL INDUSTRIES LTD,ZENICHI TERASHITA,KENICHI NARUO,
            OSAMU UCHIKAWA,ATSUSHI NAKANISHI
COMMENT     OS   Artificial Sequence
            PN   WO 02078705-A/1
            PD   10-OCT-2002
            PF   27-MAR-2002 WO 2002JP002946
            PR   28-MAR-2001 JP 01P   092704
            PI   ZENICHI TERASHITA,KENICHI NARUO,OSAMU UCHIKAWA,ATSUSHI  PI
            NAKANISHI
            PC   A61K31/437,A61K45/00,A61K45/06,C07D471/04,A61P1/00,A61P1/04,
            PC   A61P1/08,
            PC
            A61P1/16,A61P3/04,A61P3/06,A61P3/10,A61P5/00,A61P7/02,A61P7/06, PC
             A61P9/04,
            PC
            A61P9/06,A61P9/08,A61P9/10,A61P9/12,A61P11/00,A61P11/04,A61P11/ PC
             06,
            PC   A61P13/08,A61P13/12,A61P19/02,A61P19/06,A61P19/10,A61P23/00,
            PC   A61P25/16,
            PC   A61P25/18,A61P25/22,A61P25/24,A61P25/28,A61P27/02,A61P29/00,
            PC   A61P31/00,
            PC   A61P35/00,A61P37/08,A61P43/00
            CC   PCR primer for amplifying HSP27 gene
            FH   Key             Location/Qualifiers
            FT   source          1. .21
            FT                   /organism='Artificial Sequence':
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 25;
```

```
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        359 AAGACCAAGGATGGCGTGGT 378
              ||||||||||| ||||||||
Db          2 AAGACCAAGGAAGGCGTGGT 21


RESULT 92
CQ799979/c
LOCUS       CQ799979                  18 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 77 from Patent WO2004030660.
ACCESSION   CQ799979
VERSION     CQ799979.1  GI:46848926
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 77 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        226 AGTGGCCGCGCCCGCCTA 243
              ||||||||||||||||||
Db         18 AGTGGCCGCGCCCGCCTA 1


RESULT 93
CQ799991
LOCUS       CQ799991                  21 bp    RNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 89 from Patent WO2004030660.
ACCESSION   CQ799991
VERSION     CQ799991.1  GI:46848938
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 89 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 31;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        576 CCTTCGAGTCGCGGGCCCAGC 596
              |||||| |||||||||| ||
Db          1 CCTTCGTGTCGCGGGCCCTGC 21


RESULT 94
BD178973/c
LOCUS       BD178973                  22 bp    DNA     linear   PAT 16-APR-2003
DEFINITION  HSP inducing agent.
ACCESSION   BD178973
VERSION     BD178973.1  GI:30016241
KEYWORDS    WO 02078705-A/2.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Terashita,Z., Naruo,K., Uchikawa,O. and Nakanishi,A.
  TITLE     HSP inducing agent
  JOURNAL   Patent: WO 02078705-A 2 10-OCT-2002;
            TAKEDA CHEMICAL INDUSTRIES LTD,ZENICHI TERASHITA,KENICHI NARUO,
            OSAMU UCHIKAWA,ATSUSHI NAKANISHI
COMMENT     OS   Artificial Sequence
            PN   WO 02078705-A/2
            PD   10-OCT-2002
            PF   27-MAR-2002 WO 2002JP002946
            PR   28-MAR-2001 JP 01P   092704
            PI   ZENICHI TERASHITA,KENICHI NARUO,OSAMU UCHIKAWA,ATSUSHI  PI
            NAKANISHI
            PC   A61K31/437,A61K45/00,A61K45/06,C07D471/04,A61P1/00,A61P1/04,
            PC   A61P1/08,
            PC
            A61P1/16,A61P3/04,A61P3/06,A61P3/10,A61P5/00,A61P7/02,A61P7/06, PC
             A61P9/04,
            PC
            A61P9/06,A61P9/08,A61P9/10,A61P9/12,A61P11/00,A61P11/04,A61P11/ PC
             06,
            PC   A61P13/08,A61P13/12,A61P19/02,A61P19/06,A61P19/10,A61P23/00,
            PC   A61P25/16,
            PC   A61P25/18,A61P25/22,A61P25/24,A61P25/28,A61P27/02,A61P29/00,
            PC   A61P31/00,
            PC   A61P35/00,A61P37/08,A61P43/00
            CC   PCR primer for amplifying HSP27 gene
            FH   Key             Location/Qualifiers
            FT   source          1. .22
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 35;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        413 GAGCATGGCTACATCTCCCGG 433
              || |||||||||||||| |||
Db         21 GAACATGGCTACATCTCTCGG 1


RESULT 95
BD230260
LOCUS       BD230260                  20 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Total genome radiation hybrid map of canine genome and its use for
            identification of interesting genes.
ACCESSION   BD230260
VERSION     BD230260.1  GI:33040030
KEYWORDS    JP 2002530091-A/129.
SOURCE      Canis familiaris (dog)
  ORGANISM  Canis familiaris
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Galibert,F. and Andre,C.
  TITLE     Total genome radiation hybrid map of canine genome and its use for
            identification of interesting genes
  JOURNAL   Patent: JP 2002530091-A 129 17-SEP-2002;
            CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
COMMENT     OS   Canis familiaris (dog)
            PN   JP 2002530091-A/129
            PD   17-SEP-2002
            PF   15-NOV-1999 JP 2000582596
```

```
            PR   13-NOV-1998 US    60/108193
            PI   FRANCIS GALIBERT,CATHERINE ANDRE
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC   A0086R
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Canis familiaris (dog)'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Canis familiaris"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9615"

  Query Match             2.3%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 33;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        495 TGTCCCCTGAGGGCACACT 513
              ||||||||||||||||| ||
Db          1 TGTCCCCTGAGGGCACTCT 19


RESULT 96
AX671859
LOCUS       AX671859                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 304 from Patent WO03004526.
ACCESSION   AX671859
VERSION     AX671859.1  GI:29330207
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 304 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 97
AX728678
LOCUS       AX728678                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 312 from Patent WO03025175.
ACCESSION   AX728678
VERSION     AX728678.1  GI:30508021
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 312 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 98
AX738957
LOCUS       AX738957                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4547 from Patent WO03025177.
ACCESSION   AX738957
VERSION     AX738957.1  GI:30518247
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 4547 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 99
AX762937
LOCUS       AX762937                 17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 6258 from Patent WO03040369.
ACCESSION   AX762937
VERSION     AX762937.1  GI:32257553
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 6258 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
```

```
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 100
CQ799985
LOCUS       CQ799985                  19 bp    RNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 83 from Patent WO2004030660.
ACCESSION   CQ799985
VERSION     CQ799985.1  GI:46848932
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 83 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        266 CTCAGCAGCGGGGTCTCGG 284
              ||| || ||||||||||||
Db          1 CTCTGCTGCGGGGTCTCGG 19


RESULT 101
CQ799909
LOCUS       CQ799909                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 7 from Patent WO2004030660.
ACCESSION   CQ799909
VERSION     CQ799909.1  GI:46848856
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 7 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 62;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         60 GGGGCCCCAGCTGGGACCC 78
              |||| |||||||||| |||
Db          3 GGGGTCCCAGCTGGGGCCC 21


RESULT 102
CQ625927
LOCUS       CQ625927                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10667 from Patent WO0192524.
ACCESSION   CQ625927
VERSION     CQ625927.1  GI:41676145
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10667 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 47;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 103
AR466990
LOCUS       AR466990                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10667 from patent US 6686188.
ACCESSION   AR466990
VERSION     AR466990.1  GI:42702047
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10667 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 47;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 104
AX735327
LOCUS       AX735327                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 917 from Patent WO03025177.
ACCESSION   AX735327
VERSION     AX735327.1  GI:30514604
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
```

```
           reversion, apoptosis and/or resistance to viruses and the use
           thereof as medicaments
  JOURNAL  Patent: WO 03025177-A 917 27-MAR-2003;
           Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 47;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||||||||| ||
Db          1 GATCACCATCCCAGCCA 17


RESULT 105
AX762926
LOCUS       AX762926                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 6247 from Patent WO03040369.
ACCESSION   AX762926
VERSION     AX762926.1  GI:32257542
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 6247 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 47;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||||||||| ||
Db          1 GATCACCATCCCAGCCA 17


RESULT 106
AR180537
LOCUS       AR180537                  15 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 605 from patent US 6333152.
ACCESSION   AR180537
VERSION     AR180537.1  GI:20222570
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
  TITLE     Gene expression profiles in normal and cancer cells
  JOURNAL   Patent: US 6333152-A 605 25-DEC-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        529 CATGCCCAAGCTAGC 543
              |||||||||||||||
Db          1 CATGCCCAAGCTAGC 15


RESULT 107
AR072210/c
LOCUS       AR072210                  18 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 13 from patent US 5948611.
ACCESSION   AR072210
VERSION     AR072210.1  GI:9998974
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Prockop,D.J., Ala-Kokko,L., Williams,C.J., Ritvaniemi,P.,
            Baldwin,C., Hopkinson,I. and Ahmad,N.Nina.
  TITLE     Primers and methods for detecting mutations in the procollagen II
            gene (COL2A1) that indicate a genetic predisposition for a
            COL2A1-associated disease
  JOURNAL   Patent: US 5948611-A 13 07-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 65;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        129 TGCCCCGGCTGCCGGAGG 146
              ||||| |||||| |||||
Db         18 TGCCCTGGCTGCAGGAGG 1


RESULT 108
CQ786325
LOCUS       CQ786325                  18 bp    DNA     linear   PAT 24-MAR-2004
DEFINITION  Sequence 133 from Patent WO2004020668.
ACCESSION   CQ786325
VERSION     CQ786325.1  GI:45721427
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Nakamura,Y. and Katagiri,T.
  TITLE     Method for treating synovial sarcoma
  JOURNAL   Patent: WO 2004020668-A 133 11-MAR-2004;
            Oncotherapy Science, Inc. (JP); The University of Tokyo (JP)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: synthetic
                     oligonucleotide"

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 65;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        100 TAGCCGCCTCTTCGACCA 117
              || | |||||||||||||
Db          1 TAACTGCCTCTTCGACCA 18


RESULT 109
I26321/c
LOCUS       I26321                    18 bp    DNA     linear   PAT 07-OCT-1996
```

```
DEFINITION  Sequence 13 from patent US 5558988.
ACCESSION   I26321
VERSION     I26321.1  GI:1606191
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Prockop,D.J., Ala-Kokko,L. and Ritvaniemi,P.
  TITLE     Primers and methods for detecting mutations in the procollagen II
            gene that indicate a genetic predisposition for osteoarthritis
  JOURNAL   Patent: US 5558988-A 13 24-SEP-1996;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 65;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        129 TGCCCCGGCTGCCGGAGG 146
              ||||| |||||| |||||
Db         18 TGCCCTGGCTGCAGGAGG 1


RESULT 110
AR392122/c
LOCUS       AR392122                  18 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 37 from patent US 6613567.
ACCESSION   AR392122
VERSION     AR392122.1  GI:40116012
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Bennett,C.F. and Cowsert,L.M.
  TITLE     Antisense inhibition of Her-2 expression
  JOURNAL   Patent: US 6613567-A 37 02-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 65;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTGC 140
              |||||||| | |||||||
Db         18 TCGGGCTGGCTCGGCTGC 1


RESULT 111
AX480662/c
LOCUS       AX480662                  18 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 50 from Patent WO0248189.
ACCESSION   AX480662
VERSION     AX480662.1  GI:22217411
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Etzerodt,M., Holtet,T.L., Graversen,N.J. and th Gersen,H.C.
  TITLE     Combinatorial libraries of proteins having the scaffold structure
            of c-type lectin-like domains
  JOURNAL   Patent: WO 0248189-A 50 20-JUN-2002;
            Borean Pharma A/S (DK)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="oligonucleotide"

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 65;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         86 GACTGGTACCCGCATAGC 103
              ||| |||||||||||| ||
Db         18 GACCGGTACCCGCATCGC 1


RESULT 112
I69196/c
LOCUS       I69196                    16 bp    DNA     linear   PAT 04-FEB-1998
DEFINITION  Sequence 466 from patent US 5677149.
ACCESSION   I69196
VERSION     I69196.1  GI:2831318
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Bauer,S.Christopher., Abrams,M.Allen., Braford-Goldberg,S.Ruth.,
            Caparon,M.Helena., Easton,A.Michael., Klein,B.Kure.,
            McKearn,J.Patrick., Olins,P., Paik,K., Polazzi,J. and
            Thomas,J.Warren.
  TITLE     Interleukin-3 (IL-3) mutant polypeptides and their recombinant
            production
  JOURNAL   Patent: US 5677149-A 466 14-OCT-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 113
AR253794/c
LOCUS       AR253794                  16 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 466 from patent US 6479261.
ACCESSION   AR253794
VERSION     AR253794.1  GI:27302222
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Bauer,S.C., Abrams,M.A., Braford-Goldberg,S.R., Caparon,M.H.,
            Easton,A.M., Klein,B.K., McKearn,J.P., Olins,P., Paik,K.,
            Polazzi,J. and Thomas,J.W.
  TITLE     Methods of using interleukin-3 (IL-3) mutant polypeptides for
            ex-vivo expansion of hematopoietic stem cells
  JOURNAL   Patent: US 6479261-A 466 12-NOV-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
```

```
Db         16 CATTCCAGTCACCTTC 1


RESULT 114
AX696849/c
LOCUS       AX696849                16 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 466 from Patent EP1283264.
ACCESSION   AX696849
VERSION     AX696849.1  GI:29419961
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Bauer,S.C., Abrams,M.A., Braford-Goldberg,S.R., Caparon,M.H.,
            Easton,A.M., Klein,B.K., Mckearn,J.P., Olins,P.O., Paik,K.,
            Polazzi,J.O. and Thomas,J.W.
  TITLE     Interleukin-3 (il-3) mutant polypeptides
  JOURNAL   Patent: EP 1283264-A 466 12-FEB-2003;
            G.D. SEARLE & CO. (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 115
CQ625926
LOCUS       CQ625926                17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10666 from Patent WO0192524.
ACCESSION   CQ625926
VERSION     CQ625926.1  GI:41676144
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10666 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 116
CQ625928
LOCUS       CQ625928                17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10668 from Patent WO0192524.
ACCESSION   CQ625928
VERSION     CQ625928.1  GI:41676146
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10668 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 117
AR466989
LOCUS       AR466989                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10666 from patent US 6686188.
ACCESSION   AR466989
VERSION     AR466989.1  GI:42702046
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10666 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 118
AR466991
LOCUS       AR466991                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10668 from patent US 6686188.
ACCESSION   AR466991
VERSION     AR466991.1  GI:42702048
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10668 03-FEB-2004;
FEATURES             Location/Qualifiers
```

```
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match              1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 119
AX615411/c
LOCUS       AX615411                  17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 218 from Patent EP1262488.
ACCESSION   AX615411
VERSION     AX615411.1  GI:28446457
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 218 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match              1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         11 GCAGAGTCAGCCAGCA 26
              |||||||||||| |||
Db         17 GCAGAGTCAGCCTGCA 2


RESULT 120
AX615412/c
LOCUS       AX615412                  17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 219 from Patent EP1262488.
ACCESSION   AX615412
VERSION     AX615412.1  GI:28446458
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 219 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match              1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         11 GCAGAGTCAGCCAGCA 26
              |||||||||||| |||
Db         16 GCAGAGTCAGCCTGCA 1


RESULT 121
AX783872
LOCUS       AX783872                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 2203 from Patent WO03050284.
ACCESSION   AX783872
VERSION     AX783872.1  GI:32951721
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 2203 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match              1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              ||| ||||||||||||
Db          2 CTGAGGGGCCCCAGCT 17


RESULT 122
AX783873
LOCUS       AX783873                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 2204 from Patent WO03050284.
ACCESSION   AX783873
VERSION     AX783873.1  GI:32951722
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 2204 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match              1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              ||| ||||||||||||
Db          1 CTGAGGGGCCCCAGCT 16


RESULT 123
AR096356
LOCUS       AR096356                  18 bp    DNA     linear   PAT 08-SEP-2000
DEFINITION  Sequence 27 from patent US 6007995.
ACCESSION   AR096356
VERSION     AR096356.1  GI:10025093
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
```

```
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Baker,B.F. and Cowsert,L.M.
  TITLE     Antisense inhibition of TNFR1 expression
  JOURNAL   Patent: US 6007995-A 27 28-DEC-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 74;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || |||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 124
AR109825
LOCUS       AR109825                  18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 249 from patent US 6114139.
ACCESSION   AR109825
VERSION     AR109825.1  GI:12826101
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Hinuma,S., Hosoya,M., Fujii,R., Ohtaki,T., Fukusumi,S. and Ohgi,K.
  TITLE     G-protein coupled receptor protein and a DNA encoding the receptor
  JOURNAL   Patent: US 6114139-A 249 05-SEP-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 74;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        218 AGCCCCGCAGTGGCCG 233
              |||| ||||||||||
Db          1 AGCCTCGCAGTGGCCG 16


RESULT 125
BD217404
LOCUS       BD217404                  18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Antisense modulation of TNFR1 expression.
ACCESSION   BD217404
VERSION     BD217404.1  GI:33027174
KEYWORDS    JP 2002519015-A/27.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Baker,B.F. and Cowsert,L.M.
  TITLE     Antisense modulation of TNFR1 expression
  JOURNAL   Patent: JP 2002519015-A 27 02-JUL-2002;
            ISIS PHARMACEUTICALS INC
COMMENT     OS   Unidentified
            PN   JP 2002519015-A/27
            PD   02-JUL-2002
            PF   17-JUN-1999 JP 2000557265
            PR   26-JUN-1998 US    09/106038
            PI   BRENDA F BAKER,LEX M COWSERT
            PC
            C12N15/09,A61K31/7105,A61K31/711,A61K48/00,A61P29/00,A61P43/00, PC
             C12Q1/68,
            PC   C12N15/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Antisense modulation of TNFR1 expression
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 74;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || |||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 126
AR294360/c
LOCUS       AR294360                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 6095 from patent US 6537751.
ACCESSION   AR294360
VERSION     AR294360.1  GI:31681644
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 6095 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 74;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGA 716
              |||||||||||| |||
Db         18 CTGTGTGTTCTTCTGA 3


RESULT 127
AX215323
LOCUS       AX215323                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 765 from Patent WO0159103.
ACCESSION   AX215323
VERSION     AX215323.1  GI:15525366
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 765 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"
```

```
  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        164 GGCGGCAGCAGCTG 177
              ||||||||||||||
Db          3 GGCGGCAGCAGCTG 16


RESULT 128
AX216349
LOCUS       AX216349                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1791 from Patent WO0159103.
ACCESSION   AX216349
VERSION     AX216349.1  GI:15526410
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1791 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        164 GGCGGCAGCAGCTG 177
              ||||||||||||||
Db          2 GGCGGCAGCAGCTG 15


RESULT 129
AX266839/c
LOCUS       AX266839                 17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 4230 from Patent WO0173002.
ACCESSION   AX266839
VERSION     AX266839.1  GI:16515640
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 4230 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         15 AGCCACGCAGTCCA 2


RESULT 130
AX266840
LOCUS       AX266840                 17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 4231 from Patent WO0173002.
ACCESSION   AX266840
VERSION     AX266840.1  GI:16515641
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 4231 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          3 AGCCACGCAGTCCA 16


RESULT 131
AR164573/c
LOCUS       AR164573                 17 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 6 from patent US 6274310.
ACCESSION   AR164573
VERSION     AR164573.1  GI:16237643
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Habener,J.F. and Stoffers,D.A.
  TITLE     Compositions and methods for detecting pancreatic disease
  JOURNAL   Patent: US 6274310-A 6 14-AUG-2001;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         38 CGCGTCCCCTTCTCGCT 54
              ||| |||||| ||||||
Db         17 CGCCTCCCCTGCTCGCT 1


RESULT 132
BD197647
LOCUS       BD197647                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD197647
VERSION     BD197647.1  GI:33007417
KEYWORDS    JP 2002509721-A/673.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
```

```
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 673 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/673
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="genomic RNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         64 CCCCAGCTGGGACCCCT 80
              ||||| || ||||||||
Db          1 CCCCAACTTGGACCCCT 17


RESULT 133
BD241652/c
LOCUS       BD241652                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Methods and products related to genotyping and DNA analysis.
ACCESSION   BD241652
VERSION     BD241652.1  GI:33051422
KEYWORDS    JP 2002525127-A/599.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: JP 2002525127-A 599 13-AUG-2002;
            MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002525127-A/599
            PD   13-AUG-2002
            PF   24-SEP-1999 JP 2000572407
            PR   25-SEP-1998 US    60/101757
            PI   JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
              C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
            G01N37/00,
            PC   C12N15/00
            CC   Methods and products related to genotyping and DNA analysis FH
              Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 AGTTCAAAGCAACCACC 762
              ||| |||||||| ||||
Db         17 AGTACAAAGCAAACACC 1


RESULT 134
CQ617589/c
LOCUS       CQ617589                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 2329 from Patent WO0192524.
ACCESSION   CQ617589
VERSION     CQ617589.1  GI:41667807
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 2329 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 135
CQ617590/c
LOCUS       CQ617590                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 2330 from Patent WO0192524.
ACCESSION   CQ617590
VERSION     CQ617590.1  GI:41667808
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 2330 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1
```

```
RESULT 136
CQ617591/c
LOCUS       CQ617591                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 2331 from Patent WO0192524.
ACCESSION   CQ617591
VERSION     CQ617591.1  GI:41667809
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 2331 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              |||||| ||| ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 137
CQ625929
LOCUS       CQ625929                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10669 from Patent WO0192524.
ACCESSION   CQ625929
VERSION     CQ625929.1  GI:41676147
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10669 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              ||| ||||||||||| |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 138
CQ625930
LOCUS       CQ625930                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10670 from Patent WO0192524.
ACCESSION   CQ625930
VERSION     CQ625930.1  GI:41676148
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10670 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||| ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 139
AR286401
LOCUS       AR286401                  17 bp    RNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 773 from patent US 6528640.
ACCESSION   AR286401
VERSION     AR286401.1  GI:29723997
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Synthetic ribonucleic acids with RNAse activity
  JOURNAL   Patent: US 6528640-A 773 04-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              |||||||| | ||||||
Db          1 TCGGGCTGGCTCGGCTG 17


RESULT 140
AR398391
LOCUS       AR398391                  17 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 772 from patent US 6617438.
ACCESSION   AR398391
VERSION     AR398391.1  GI:40136165
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Oligoribonucleotides with enzymatic activity
  JOURNAL   Patent: US 6617438-A 772 09-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"
```

```
  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              ||||||||  | ||||||
Db          1 TCGGGCTGGCTCGGCTG 17


RESULT 141
AR458652/c
LOCUS       AR458652                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 2329 from patent US 6686188.
ACCESSION   AR458652
VERSION     AR458652.1  GI:42693709
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 2329 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              ||||  |||  ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 142
AR458653/c
LOCUS       AR458653                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 2330 from patent US 6686188.
ACCESSION   AR458653
VERSION     AR458653.1  GI:42693710
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 2330 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              |||||  |||  |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 143
AR458654/c
LOCUS       AR458654                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 2331 from patent US 6686188.
ACCESSION   AR458654
VERSION     AR458654.1  GI:42693711
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 2331 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              ||||||  |||  ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 144
AR466992
LOCUS       AR466992                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10669 from patent US 6686188.
ACCESSION   AR466992
VERSION     AR466992.1  GI:42702049
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10669 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              |||  ||||||||||| |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 145
AR466993
LOCUS       AR466993                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10670 from patent US 6686188.
ACCESSION   AR466993
VERSION     AR466993.1  GI:42702050
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10670 03-FEB-2004;
FEATURES             Location/Qualifiers
```

```
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match              1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||||  ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 146
AR483153/c
LOCUS       AR483153                  17 bp    DNA     linear   PAT 14-MAY-2004
DEFINITION  Sequence 599 from patent US 6703228.
ACCESSION   AR483153
VERSION     AR483153.1  GI:47245676
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: US 6703228-A 599 09-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match              1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 AGTTCAAAGCAACCACC 762
              ||| ||||||||| ||||
Db         17 AGTACAAAGCAAACACC 1


RESULT 147
AX216972
LOCUS       AX216972                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2414 from Patent WO0159103.
ACCESSION   AX216972
VERSION     AX216972.1  GI:15527033
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2414 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match              1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        462 CCGGTGTGGACCCCACC 478
              || |||||||||||  ||
Db          1 CCCGTGTGGACCCCGCC 17


RESULT 148
AX498863/c
LOCUS       AX498863                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 170 from Patent EP1229046.
ACCESSION   AX498863
VERSION     AX498863.1  GI:23381156
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 170 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match              1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        295 CACTGCGGACCGCTGGC 311
              ||||||||  ||| ||||
Db         17 CACTGCGGCCCGGTGGC 1


RESULT 149
AX531714
LOCUS       AX531714                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 1223 from Patent EP1239051.
ACCESSION   AX531714
VERSION     AX531714.1  GI:25255211
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 1223 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match              1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        557 GAGATCACCATCCCAGT 573
              ||||||| ||  ||||||
Db          1 GAGATCAGCACCCCAGT 17


RESULT 150
AX579468
LOCUS       AX579468                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1306 from Patent WO0211674.
ACCESSION   AX579468
VERSION     AX579468.1  GI:27648670
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1306 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        506 GGCACACTGACCGTGGA 522
              |||||| ||| ||||||
Db          1 GGCACAGTGATCGTGGA 17


RESULT 151
AX580066/c
LOCUS       AX580066                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1904 from Patent WO0211674.
ACCESSION   AX580066
VERSION     AX580066.1  GI:27649268
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1904 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        423 ACATCTCCCGGTGCTTC 439
              ||||||||| ||| |||
Db         17 ACATCTCCCTGTGATTC 1


RESULT 152
AX580067/c
LOCUS       AX580067                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1905 from Patent WO0211674.
ACCESSION   AX580067
VERSION     AX580067.1  GI:27649269
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1905 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        422 TACATCTCCCGGTGCTT 438
              ||||||||| ||| ||
Db         17 TACATCTCCCTGTGATT 1


RESULT 153
AX725108/c
LOCUS       AX725108                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2795 from Patent WO03025176.
ACCESSION   AX725108
VERSION     AX725108.1  GI:30504451
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2795 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Mus musculus"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:10090"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        273 GCGGGGTCTCGGAGATC 289
              || ||||||| ||||||
Db         17 GCTGGGTCTCAGAGATC 1


RESULT 154
AX725434
LOCUS       AX725434                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3121 from Patent WO03025176.
ACCESSION   AX725434
VERSION     AX725434.1  GI:30504777
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 3121 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Mus musculus"
```

```
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:10090"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||  |||||||
Db          1 GATCACCAAACCAGTCA 17


RESULT 155
AX735751/c
LOCUS       AX735751                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1341 from Patent WO03025177.
ACCESSION   AX735751
VERSION     AX735751.1  GI:30515028
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 1341 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        734 TTTCTCAAATAAAGTTC 750
              ||||||||||||  | ||
Db         17 TTTCTCAAATAATGATC 1


RESULT 156
AX736224
LOCUS       AX736224                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1814 from Patent WO03025177.
ACCESSION   AX736224
VERSION     AX736224.1  GI:30515501
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 1814 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||  |||||||
Db          1 GATCACCAAACCAGTCA 17


RESULT 157
AX753978
LOCUS       AX753978                  17 bp    DNA     linear   PAT 23-JUN-2003
DEFINITION  Sequence 325 from Patent WO03037931.
ACCESSION   AX753978
VERSION     AX753978.1  GI:32166675
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M. and Phan,T.
  TITLE     Human angiomotin-like protein 1
  JOURNAL   Patent: WO 03037931-A 325 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        243 ACAGCCGCGCGCTCAGC 259
              ||| |||| ||||||||
Db          1 ACATCCGCTCGCTCAGC 17


RESULT 158
AX783428/c
LOCUS       AX783428                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 1759 from Patent WO03050284.
ACCESSION   AX783428
VERSION     AX783428.1  GI:32951277
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 1759 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        520 GGAGGCCCCCATGCCCA 536
              |||||| |||| |||||
Db         17 GGAGGCACCCAGGCCCA 1


RESULT 159
AX783429/c
LOCUS       AX783429                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 1760 from Patent WO03050284.
ACCESSION   AX783429
VERSION     AX783429.1  GI:32951278
```

```
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 1760 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 81;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        519 TGGAGGCCCCCATGCCC 535
              ||||||| |||| ||||
Db         17 TGGAGGCACCCAGGCCC 1


RESULT 160
CQ799952
LOCUS       CQ799952                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 50 from Patent WO2004030660.
ACCESSION   CQ799952
VERSION     CQ799952.1  GI:46848899
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 50 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.7%;  Score 13;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy        495 TGTCCCCTGAGGGCACACTGA 515
              ||| |||| |||| |||  ||
Db          1 TGTGCCCTCAGGGGACAGGGA 21


RESULT 161
AR110507
LOCUS       AR110507                  16 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 16 from patent US 6114598.
ACCESSION   AR110507
VERSION     AR110507.1  GI:12826783
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kucherlapati,R., Jakobovits,A., Kalpholz,S., Brenner,D.G. and
            Capon,D.J.
  TITLE     Generation of xenogeneic antibodies
  JOURNAL   Patent: US 6114598-A 16 05-SEP-2000;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 162
AR137060
LOCUS       AR137060                  16 bp    DNA     linear   PAT 16-JUN-2001
DEFINITION  Sequence 16 from patent US 6162963.
ACCESSION   AR137060
VERSION     AR137060.1  GI:14478310
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kucherlapati,R., Jakobovits,A., Klapholz,S., Brenner,D.G. and
            Capon,D.J.
  TITLE     Generation of Xenogenetic antibodies
  JOURNAL   Patent: US 6162963-A 16 19-DEC-2000;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 163
BD266330/c
LOCUS       BD266330                  16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Universal arrays.
ACCESSION   BD266330
VERSION     BD266330.1  GI:33076098
KEYWORDS    JP 2002539849-A/330.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
            Lockhart,D.J., Ryder,T. and Sklar,P.
  TITLE     Universal arrays
  JOURNAL   Patent: JP 2002539849-A 330 26-NOV-2002;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002539849-A/330
            PD   26-NOV-2002
            PF   27-MAR-2000 JP 2000608794
            PR   26-MAR-1999 US    60/126473,23-JUN-1999 US    60/140359 PI
            JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
            HUANG,PAUL KAPLAN,ERIC
            PI   S LANDER,
            PI   DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
            PC   C12Q1/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53, PC
             G01N33/566,
            PC   G01N37/00,C12N15/00,C12N15/00,C12N15/00
            CC   Primer
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Artificial Sequence'.
```

```
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        464 GGTGTGGACCCCACCC 479
              |||| |||||||| ||
Db         16 GGTGAGGACCCCAGCC 1


RESULT 164
CQ858645/c
LOCUS       CQ858645                  16 bp    DNA     linear   PAT 31-AUG-2004
DEFINITION  Sequence 107 from Patent WO2004069991.
ACCESSION   CQ858645
VERSION     CQ858645.1  GI:51852612
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Hansen,B., Thrue,C.A., Petersen,K.D., Westergaard,M. and
            Wissenbach,M.
  TITLE     Oligomeric compounds for the modulation of survivin expression
  JOURNAL   Patent: WO 2004069991-A 107 19-AUG-2004;
            Santaris Pharma A/S (DK)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        161 TTAGGCGGCAGCAGCT 176
              || || ||||||||||
Db         16 TTTGGAGGCAGCAGCT 1


RESULT 165
I69269/c
LOCUS       I69269                    16 bp    DNA     linear   PAT 04-FEB-1998
DEFINITION  Sequence 539 from patent US 5677149.
ACCESSION   I69269
VERSION     I69269.1  GI:2831391
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Bauer,S.Christopher., Abrams,M.Allen., Braford-Goldberg,S.Ruth.,
            Caparon,M.Helena., Easton,A.Michael., Klein,B.Kure.,
            McKearn,J.Patrick., Olins,P., Paik,K., Polazzi,J. and
            Thomas,J.Warren.
  TITLE     Interleukin-3 (IL-3) mutant polypeptides and their recombinant
            production
  JOURNAL   Patent: US 5677149-A 539 14-OCT-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||| ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 166
AR253867/c
LOCUS       AR253867                  16 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 539 from patent US 6479261.
ACCESSION   AR253867
VERSION     AR253867.1  GI:27302295
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Bauer,S.C., Abrams,M.A., Braford-Goldberg,S.R., Caparon,M.H.,
            Easton,A.M., Klein,B.K., McKearn,J.P., Olins,P., Paik,K.,
            Polazzi,J. and Thomas,J.W.
  TITLE     Methods of using interleukin-3 (IL-3) mutant polypeptides for
            ex-vivo expansion of hematopoietic stem cells
  JOURNAL   Patent: US 6479261-A 539 12-NOV-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||| ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 167
AR391398
LOCUS       AR391398                  16 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 10 from patent US 6613520.
ACCESSION   AR391398
VERSION     AR391398.1  GI:40114887
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ashby,M.
  TITLE     Methods for the survey and genetic analysis of populations
  JOURNAL   Patent: US 6613520-A 10 02-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        525 CCCCCATGCCCAAGCT 540
              ||||| |||| |||||
Db          1 CCCCCGTGCCGAAGCT 16


RESULT 168
AR391498
LOCUS       AR391498                  16 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 110 from patent US 6613520.
ACCESSION   AR391498
VERSION     AR391498.1  GI:40114996
KEYWORDS    .
SOURCE      Unknown.
```

```
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ashby,M.
  TITLE     Methods for the survey and genetic analysis of populations
  JOURNAL   Patent: US 6613520-A 110 02-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              |||||| ||| |||||
Db          1 CTGCGGTGCCGCAGCT 16


RESULT 169
AR435928
LOCUS       AR435928                 16 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 187 from patent US 6656731.
ACCESSION   AR435928
VERSION     AR435928.1  GI:40199012
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Eckstein,F., Ludwig,J. and Beigelman,L.
  TITLE     Nucleic acid catalysts with endonuclease activity
  JOURNAL   Patent: US 6656731-A 187 02-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 TTCTTTTGATACATTT 723
              | |||||||||| ||||
Db          1 TCCTTTTGATAAATTT 16


RESULT 170
AR451605
LOCUS       AR451605                 16 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 17 from patent US 6673986.
ACCESSION   AR451605
VERSION     AR451605.1  GI:42682638
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kucherlapati,R., Jakobovits,A., Klapholz,S., Brenner,D.G. and
            Capon,D.J.
  TITLE     Generation of xenogeneic antibodies
  JOURNAL   Patent: US 6673986-A 17 06-JAN-2004;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 171
AR451617
LOCUS       AR451617                 16 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 29 from patent US 6673986.
ACCESSION   AR451617
VERSION     AR451617.1  GI:42682650
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kucherlapati,R., Jakobovits,A., Klapholz,S., Brenner,D.G. and
            Capon,D.J.
  TITLE     Generation of xenogeneic antibodies
  JOURNAL   Patent: US 6673986-A 29 06-JAN-2004;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 172
AX073744/c
LOCUS       AX073744                 16 bp    DNA     linear   PAT 06-FEB-2001
DEFINITION  Sequence 4 from Patent WO0104290.
ACCESSION   AX073744
VERSION     AX073744.1  GI:12710156
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jin,Y.X. and Liu,J.S.
  TITLE     Triplex-forming oligonucleotides and their use in therapy
  JOURNAL   Patent: WO 0104290-A 4 18-JAN-2001;
            Shanghai Institute of Biochemistry Chinese Academy of Sciences (CN)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Single stranded TFO-p"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        483 TTTCCTCCTCCCTGTC 498
              ||||||| ||||| ||
Db         16 TTTCCTCTTCCCTCTC 1


RESULT 173
AX073745/c
LOCUS       AX073745                 16 bp    DNA     linear   PAT 06-FEB-2001
DEFINITION  Sequence 5 from Patent WO0104290.
ACCESSION   AX073745
VERSION     AX073745.1  GI:12710157
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jin,Y.X. and Liu,J.S.
  TITLE     Triplex-forming oligonucleotides and their use in therapy
  JOURNAL   Patent: WO 0104290-A 5 18-JAN-2001;
            Shanghai Institute of Biochemistry Chinese Academy of Sciences (CN)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Single stranded TFO1"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        483 TTTCCTCCTCCCTGTC 498
              ||||||| ||||| ||
Db         16 TTTCCTCTTCCCTCTC 1


RESULT 174
AX132924
LOCUS       AX132924                  16 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 4142 from Patent WO0130362.
ACCESSION   AX132924
VERSION     AX132924.1  GI:14139234
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 4142 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Hairpin ribozyme recognition site for cyclin B1"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGACCAA 366
              |||| ||||||| |||
Db          1 TGACTGTCAAGAACAA 16


RESULT 175
AX281878
LOCUS       AX281878                  16 bp    DNA     linear   PAT 02-NOV-2001
DEFINITION  Sequence 10 from Patent WO0177392.
ACCESSION   AX281878
VERSION     AX281878.1  GI:16609129
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Ashby,M.
  TITLE     Methods for the survey and genetic analysis of populations
  JOURNAL   Patent: WO 0177392-A 10 18-OCT-2001;
            Ashby, Matthew (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="unidentified soil organism"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        525 CCCCCATGCCCAAGCT 540
              ||||| |||| |||||
Db          1 CCCCCGTGCCGAAGCT 16


RESULT 176
AX281978
LOCUS       AX281978                  16 bp    DNA     linear   PAT 02-NOV-2001
DEFINITION  Sequence 110 from Patent WO0177392.
ACCESSION   AX281978
VERSION     AX281978.1  GI:16609229
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Ashby,M.
  TITLE     Methods for the survey and genetic analysis of populations
  JOURNAL   Patent: WO 0177392-A 110 18-OCT-2001;
            Ashby, Matthew (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="unidentified soil organism"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              |||||| ||| |||||
Db          1 CTGCGGTGCCGCAGCT 16


RESULT 177
AX696922/c
LOCUS       AX696922                  16 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 539 from Patent EP1283264.
ACCESSION   AX696922
VERSION     AX696922.1  GI:29420035
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Bauer,S.C., Abrams,M.A., Braford-Goldberg,S.R., Caparon,M.H.,
            Easton,A.M., Klein,B.K., Mckearn,J.P., Olins,P.O., Paik,K.,
            Polazzi,J.O. and Thomas,J.W.
  TITLE     Interleukin-3 (il-3) mutant polypeptides
  JOURNAL   Patent: EP 1283264-A 539 12-FEB-2003;
            G.D. SEARLE & CO. (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| |||||||||| ||
```

```
Db         16 CATTCCAGTCACCGTC 1


RESULT 178
CQ799962
LOCUS       CQ799962                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 60 from Patent WO2004030660.
ACCESSION   CQ799962
VERSION     CQ799962.1  GI:46848909
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 60 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.6%;  Score 12.6;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        596 CTTGGGGGCCCAGAAGCTG 614
              |||  ||||||  ||||||
Db          1 CTTCTGGGCCCCCAAGCTG 19


RESULT 179
AR097225/c
LOCUS       AR097225                  15 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 6 from patent US 6071695.
ACCESSION   AR097225
VERSION     AR097225.1  GI:12805955
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Ozkaynak,E. and Oppermann,H.
  TITLE     Methods and products for identification of modulators of osteogenic
            protein-1 gene expression
  JOURNAL   Patent: US 6071695-A 6 06-JUN-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        398 GAGGAGCGGCAGGA 411
              |||||||||  ||||
Db         14 GAGGAGCGGGAGGA 1


RESULT 180
E05651
LOCUS       E05651                    15 bp    DNA     linear   PAT 29-SEP-1997
DEFINITION  PCR primer.
ACCESSION   E05651
VERSION     E05651.1  GI:2173838
KEYWORDS    JP 1993268968-A/4.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Yonemura,H., Tajima,Y., Sugawara,K. and Masuda,K.
  TITLE     PRODUCTION OF HUMAN COAGULATION FACTOR VIII PROTEIN COMPLEX
  JOURNAL   Patent: JP 1993268968-A 4 19-OCT-1993;
            CHEMO SERO THERAPEUT RES INST, TEIJIN LTD
COMMENT     OS   Artificial gene
            OC   Artificial sequence; Genes.
            PN   JP 1993268968-A/4
            PD   19-OCT-1993
            PF   22-SEP-1992 JP 1992252688
            PR   24-SEP-1991 JP 91P   243262
            PI   YONEMURA HIROSHI, TAJIMA YOSHITAKA, SUGAWARA KEISHIN, PI
            MASUDA KENICHI
            PC   C12N15/12,C07K15/06,C12N5/10,C12P21/02//A61K37/465,(C12N5/10,
            PC   C12R1:91),
            PC   (C12P21/02,C12R1:91);
            CC   strandedness: Single;
            CC   topology: Linear.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        594 AGCTTGGGGGCCCA 607
              ||||| ||||||||
Db          1 AGCTTTGGGGCCCA 14


RESULT 181
I77111
LOCUS       I77111                    15 bp    DNA     linear   PAT 03-APR-1998
DEFINITION  Sequence 8 from patent US 5693499.
ACCESSION   I77111
VERSION     I77111.1  GI:3013265
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Yonemura,H., Tajima,Y., Sugawara,K. and Masuda,K.
  TITLE     Process for preparing human coagulation factor VIII protein complex
  JOURNAL   Patent: US 5693499-A 8 02-DEC-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        594 AGCTTGGGGGCCCA 607
              ||||| ||||||||
Db          1 AGCTTTGGGGCCCA 14


RESULT 182
AR180586
LOCUS       AR180586                  15 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 654 from patent US 6333152.
ACCESSION   AR180586
VERSION     AR180586.1  GI:20222619
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
```

```
  TITLE     Gene expression profiles in normal and cancer cells
  JOURNAL   Patent: US 6333152-A 654 25-DEC-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        369 ATGGCGTGGTGGAG 382
              |||||| |||||||
Db          2 ATGGCGGGGTGGAG 15


RESULT 183
AR432576
LOCUS       AR432576                  15 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 5 from patent US 6653448.
ACCESSION   AR432576
VERSION     AR432576.1  GI:40195078
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Vernet,C., Rastelli,L. and Herrmann,J.
  TITLE     Wnt-7B-like polypeptides and nucleic acids encoding same
  JOURNAL   Patent: US 6653448-A 5 25-NOV-2003;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        426 TCTCCCGGTGCTTC 439
              |||||||| |||||
Db          1 TCTCCCGGCGCTTC 14


RESULT 184
AX269347
LOCUS       AX269347                  15 bp    DNA     linear   PAT 29-OCT-2001
DEFINITION  Sequence 5 from Patent WO0174856.
ACCESSION   AX269347
VERSION     AX269347.1  GI:16542166
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Vernet,C.A., Rastelli,L. and Herrmann,J.L.
  TITLE     Wnt-7b-like polypeptides and nucleic acids encoding same
  JOURNAL   Patent: WO 0174856-A 5 11-OCT-2001;
            Curagen Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="SYNTHETIC PCR PRIMER"

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        426 TCTCCCGGTGCTTC 439
              |||||||| |||||
Db          1 TCTCCCGGCGCTTC 14


RESULT 185
AX097953/c
LOCUS       AX097953                  12 bp    DNA     linear   PAT 30-MAR-2001
DEFINITION  Sequence 21 from Patent WO0118048.
ACCESSION   AX097953
VERSION     AX097953.1  GI:13514648
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   van Eijs,G.J., Hateboer,G. and Havenga,M.J.
  TITLE     Smooth muscle cell promoter and uses thereof
  JOURNAL   Patent: WO 0118048-A 21 15-MAR-2001;
            Introgene B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="variant intron-exon splice recognition sequences"

  Query Match             1.6%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 75;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        606 CAGAAGCTGCAA 617
              ||||||||||||
Db         12 CAGAAGCTGCAA 1


RESULT 186
AX138529/c
LOCUS       AX138529                  12 bp    DNA     linear   PAT 30-MAY-2001
DEFINITION  Sequence 21 from Patent EP1083231.
ACCESSION   AX138529
VERSION     AX138529.1  GI:14274424
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   .
  TITLE     Smooth muscle cell promoter and uses thereof
  JOURNAL   Patent: EP 1083231-A 21 14-MAR-2001;
            Introgene B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="variant intron-exon splice recognition sequences"

  Query Match             1.6%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 75;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        606 CAGAAGCTGCAA 617
              ||||||||||||
Db         12 CAGAAGCTGCAA 1


RESULT 187
AX525366
LOCUS       AX525366                  14 bp    DNA     linear   PAT 21-NOV-2002
DEFINITION  Sequence 53 from Patent WO02066676.
ACCESSION   AX525366
VERSION     AX525366.1  GI:25170255
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
           other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Pugnere,D., Marti,J., Manchon,L. and Piquemal,D.
  TITLE     Method for qualitative and quantitative analysis of a population of
            nucleic acids contained in a sample
  JOURNAL   Patent: WO 02066676-A 53 29-AUG-2002;
            CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="TAG"

  Query Match             1.6%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        738 TCAAATAAAGTT 749
              ||||||||||||
Db          3 TCAAATAAAGTT 14


RESULT 188
AR180644/c
LOCUS       AR180644                  15 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 712 from patent US 6333152.
ACCESSION   AR180644
VERSION     AR180644.1  GI:20222677
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
  TITLE     Gene expression profiles in normal and cancer cells
  JOURNAL   Patent: US 6333152-A 712 25-DEC-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        500 CCTGAGGGCACA 511
              ||||||||||||
Db         14 CCTGAGGGCACA 3


RESULT 189
AR180645/c
LOCUS       AR180645                  15 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 713 from patent US 6333152.
ACCESSION   AR180645
VERSION     AR180645.1  GI:20222678
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
  TITLE     Gene expression profiles in normal and cancer cells
  JOURNAL   Patent: US 6333152-A 713 25-DEC-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        500 CCTGAGGGCACA 511
              ||||||||||||
Db         14 CCTGAGGGCACA 3


RESULT 190
CQ799917
LOCUS       CQ799917                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 15 from Patent WO2004030660.
ACCESSION   CQ799917
VERSION     CQ799917.1  GI:46848864
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 15 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.6%;  Score 12;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 1.9e+02;
  Matches   15;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy        106 CCTCTTCGACCAGGCCTTCG 125
              || || ||||||  ||| ||
Db          2 CCACTGCGACCACTCCTCCG 21


RESULT 191
CQ799916
LOCUS       CQ799916                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 14 from Patent WO2004030660.
ACCESSION   CQ799916
VERSION     CQ799916.1  GI:46848863
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 14 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 11.6;  DB 1;  Length 21;
  Best Local Similarity   77.8%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        128 CTGCCCCGGCTGCCGGAG 145
              || | ||||| ||||| |
Db          4 CTCCTCCGGCAGCCGGGG 21


RESULT 192
CQ799930
LOCUS       CQ799930                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 28 from Patent WO2004030660.
ACCESSION   CQ799930
```

```
VERSION     CQ799930.1  GI:46848877
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 28 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 11.6;  DB 1;  Length 21;
  Best Local Similarity   77.8%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        276 GGGTCTCGGAGATCCGGC 293
              || |||| |||| || ||
Db          2 GGATCTCCGAGACCCCGC 19


RESULT 193
BD263080/c
LOCUS       BD263080                  13 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Vector.
ACCESSION   BD263080
VERSION     BD263080.1  GI:33072848
KEYWORDS    JP 2002530115-A/12.
SOURCE      Rous sarcoma virus
  ORGANISM  Rous sarcoma virus
            Viruses; Retroid viruses; Retroviridae; Alpharetrovirus.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Mitrophanous,K., Uden,M., Rohll,J., Kingsman,S.M. and Kingsman,A.J.
  TITLE     Vector
  JOURNAL   Patent: JP 2002530115-A 12 17-SEP-2002;
            OXFORD BIOMEDICA LTD
COMMENT     OS   Rous sarcoma virus
            PN   JP 2002530115-A/12
            PD   17-SEP-2002
            PF   19-NOV-1999 JP 2000584089
            PR   20-NOV-1998 GB    9825524.3
            PI   KYRIACOS MITROPHANOUS,MARK UDEN,JONATHAN ROHLL,SUSAN MARY  PI
             KINGSMAN,
            PI   ALAN JOHN KINGSMAN
            PC   C12N15/09,A61K35/76,A61K48/00,A61P1/04,A61P9/00,A61P11/06, PC
             A61P17/00,
            PC   A61P25/00,A61P25/28,A61P27/02,A61P29/00,A61P31/12,A61P35/00,
            PC   A61P37/00,
            PC   C12N5/10,C12N7/00,C12N15/00,C12N5/00
            CC   Vector
            FH   Key             Location/Qualifiers
            FT   source          1. .13
            FT                   /organism='Rous sarcoma virus'.
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Rous sarcoma virus"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:11886"

  Query Match             1.5%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        483 TTTCCTCCTCCCT 495
              ||||| |||||||
Db         13 TTTCCCCCTCCCT 1


RESULT 194
AX025026/c
LOCUS       AX025026                  13 bp    DNA     linear   PAT 15-SEP-2000
DEFINITION  Sequence 12 from Patent WO0031280.
ACCESSION   AX025026
VERSION     AX025026.1  GI:10184946
KEYWORDS    .
SOURCE      Rous sarcoma virus
  ORGANISM  Rous sarcoma virus
            Viruses; Retroid viruses; Retroviridae; Alpharetrovirus.
REFERENCE   1
  AUTHORS   Kingsman,S.M., Mitrophanous,K., Uden,M., Rohll,J. and Kingsman,A.J.
  TITLE     Vector
  JOURNAL   Patent: WO 0031280-A 12 02-JUN-2000;
            KINGSMAN SUSAN MARY (GB) ; MITROPHANOUS KYRIACOS (GB) ; UDEN MARK
            (GB) ; ROHLL JONATHAN (GB) ; KINGSMAN ALAN JOHN (GB) ; OXFORD
            BIOMEDICA LTD (GB)
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Rous sarcoma virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:11886"

  Query Match             1.5%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        483 TTTCCTCCTCCCT 495
              ||||| |||||||
Db         13 TTTCCCCCTCCCT 1


RESULT 195
AX556272
LOCUS       AX556272                  13 bp    DNA     linear   PAT 27-NOV-2002
DEFINITION  Sequence 17 from Patent WO0242447.
ACCESSION   AX556272
VERSION     AX556272.1  GI:25899609
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Uhler,M.D.
  TITLE     Surface transfection and expression procedure
  JOURNAL   Patent: WO 0242447-A 17 30-MAY-2002;
            THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US)
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        202 CCCCGCCGCCATC 214
              |||||| ||||||
Db          1 CCCCGCTGCCATC 13


RESULT 196
A89531/c
LOCUS       A89531                    14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 1679 from Patent WO9833904.
ACCESSION   A89531
VERSION     A89531.1  GI:6738101
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
```

```
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 1679 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.5%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 GCCAGCATGACCG 32
              ||||||||| |||
Db         13 GCCAGCATGCCCG 1


RESULT 197
BD209296
LOCUS       BD209296                  14 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION   BD209296
VERSION     BD209296.1  GI:33019066
KEYWORDS    JP 2002512791-A/2886.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Blatt,L., Mcswiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
  JOURNAL   Patent: JP 2002512791-A 2886 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Hepatitis virus (hepatitis C virus)
            PN   JP 2002512791-A/2886
            PD   08-MAY-2002
            PF   26-APR-1999 JP 2000545991
            PR   27-APR-1998 US    60/083217,18-SEP-1998 US    60/100842 PR
            25-FEB-1999 US    09/257608,23-MAR-1999 US    09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A  PI
            PAVCO,
            PI   DENNIS MACEJAK
            PC   C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC   A61K37/66,
            PC   C12N15/00
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                 related to
            CC   hepatitis C virus infection.
            FH   Key             Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Hepatitis virus (hepatitis C  FT
                              virus)'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             1.5%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        651 GCCCGGATGCCCA 663
              | ||||||||||||
Db          1 GTCCGGATGCCCA 13


RESULT 198
BD209297/c
LOCUS       BD209297                  14 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION   BD209297
VERSION     BD209297.1  GI:33019067
KEYWORDS    JP 2002512791-A/2887.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Blatt,L., Mcswiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
  JOURNAL   Patent: JP 2002512791-A 2887 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Hepatitis virus (hepatitis C virus)
            PN   JP 2002512791-A/2887
            PD   08-MAY-2002
            PF   26-APR-1999 JP 2000545991
            PR   27-APR-1998 US    60/083217,18-SEP-1998 US    60/100842 PR
            25-FEB-1999 US    09/257608,23-MAR-1999 US    09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A  PI
            PAVCO,
            PI   DENNIS MACEJAK
            PC   C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC   A61K37/66,
            PC   C12N15/00
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                 related to
            CC   hepatitis C virus infection.
            FH   Key             Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Hepatitis virus (hepatitis C  FT
                              virus)'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             1.5%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        168 GCAGCAGCTGGCC 180
              || ||||||||||
Db         13 GCTGCAGCTGGCC 1


RESULT 199
AX025606/c
LOCUS       AX025606                  14 bp    DNA     linear   PAT 16-SEP-2000
DEFINITION  Sequence 6 from Patent WO0029592.
ACCESSION   AX025606
VERSION     AX025606.1  GI:10187274
KEYWORDS    .
SOURCE      Triticum aestivum (bread wheat)
  ORGANISM  Triticum aestivum
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Pooideae; Triticeae; Triticum.
REFERENCE   1
  AUTHORS   Logemann,E., Somssich,I., Hahlbrock,K., Kirsch,C. and Rushton,P.
  TITLE     Chimeric promoters capable of mediating gene expression in plants
            upon pathogen infection and uses thereof
  JOURNAL   Patent: WO 0029592-A 6 25-MAY-2000;
            MAX PLANCK GESELLSCHAFT (DE) ; LOGEMANN ELKE (DE) ; SOMSSICH IMRE
            (DE) ; HAHLBROCK KLAUS (DE) ; KIRSCH CHRISTOPH (DE) ; RUSHTON PAUL
            (GB)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="Triticum aestivum"
                     /mol_type="unassigned DNA"
```

```
                     /db_xref="taxon:4565"

  Query Match             1.5%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGAC 363
              ||||||||||| |
Db         14 TGACGGTCAAGTC 2


RESULT 200
BD067044/c
LOCUS       BD067044                  14 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD067044
VERSION     BD067044.1  GI:22612647
KEYWORDS    JP 2001511000-A/1679.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 1679 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/1679
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             1.5%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 GCCAGCATGACCG 32
              ||||||||| |||
Db         13 GCCAGCATGCCCG 1


RESULT 201
ATH523733/c
LOCUS       ATH523733                 14 bp    DNA     linear   PLN 29-MAR-2003
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
            060G05.
ACCESSION   AJ523733
VERSION     AJ523733.1  GI:26791969
KEYWORDS    left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
  TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
  JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
  MEDLINE   22363535
    PUBMED  12446565
REFERENCE   2  (bases 1 to 14)
  AUTHORS   Balzergue,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="060G05"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature    1. .14
                     /note="T-DNA flanking sequence
                     left border"

  Query Match             1.5%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        616 AAAATCCGATGAG 628
              |||| ||||||||
Db         13 AAAAACCGATGAG 1


Search completed: October 18, 2005, 09:40:49
Job time : 3 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: October 18, 2005, 09:41:56 ; Search time 1 Seconds
(without alignments)
1.623 Million cell updates/sec

Title: US-10-605-498-91-COPY
Perfect score: 764
Sequence: 1 ggcacgaggagcagagtcag.....aagttcaaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 62 seqs, 1062 residues

Total number of hits satisfying chosen parameters: 124

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Issued_Patents_NA

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 62 summaries

Database : issdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	25	3.3	25	1	US-08-859-998-1170	Sequence 1170, Ap
c	2	25	3.3	25	1	US-09-225-928-1170	Sequence 1170, Ap
c	3	25	3.3	25	1	US-09-225-201B-1170	Sequence 1170, Ap
	4	24	3.1	24	1	US-08-859-998-1169	Sequence 1169, Ap
	5	24	3.1	24	1	US-09-225-928-1169	Sequence 1169, Ap
	6	24	3.1	24	1	US-09-225-201B-1169	Sequence 1169, Ap
	7	20.8	2.7	25	1	US-09-396-196G-92419	Sequence 92419, A
	8	20.2	2.6	25	1	US-09-396-196G-92432	Sequence 92432, A
	9	15.8	2.1	19	1	US-09-990-613A-7	Sequence 7, Appli
	10	15.4	2.0	17	1	US-09-866-108A-10667	Sequence 10667, A
	11	15	2.0	15	1	US-09-081-646-605	Sequence 605, App
c	12	14.8	1.9	18	1	US-07-977-284A-13	Sequence 13, Appl
c	13	14.8	1.9	18	1	US-08-256-426B-13	Sequence 13, Appl
c	14	14.8	1.9	18	1	US-09-663-834A-37	Sequence 37, Appl
c	15	14.4	1.9	16	1	US-08-411-796-466	Sequence 466, App
c	16	14.4	1.9	16	1	US-08-471-039-466	Sequence 466, App
c	17	14.4	1.9	16	1	US-08-559-390-466	Sequence 466, App
c	18	14.4	1.9	16	1	PCT-US93-11198-466	Sequence 466, App
	19	14.4	1.9	17	1	US-09-866-108A-10666	Sequence 10666, A
	20	14.4	1.9	17	1	US-09-866-108A-10668	Sequence 10668, A
	21	14.4	1.9	18	1	US-09-106-038A-27	Sequence 27, Appl
	22	14.4	1.9	18	1	US-08-513-974B-249	Sequence 249, App
c	23	14.4	1.9	18	1	US-09-422-978-6095	Sequence 6095, Ap
	24	14	1.8	15	1	US-08-431-048F-150	Sequence 150, App
c	25	13.8	1.8	17	1	US-09-275-680-11	Sequence 11, Appl
c	26	13.8	1.8	17	1	US-08-881-450A-6	Sequence 6, Appli
	27	13.8	1.8	17	1	US-09-474-432B-773	Sequence 773, App
	28	13.8	1.8	17	1	US-09-476-387-772	Sequence 772, App
c	29	13.8	1.8	17	1	US-09-866-108A-2329	Sequence 2329, Ap
c	30	13.8	1.8	17	1	US-09-866-108A-2330	Sequence 2330, Ap
c	31	13.8	1.8	17	1	US-09-866-108A-2331	Sequence 2331, Ap
	32	13.8	1.8	17	1	US-09-866-108A-10669	Sequence 10669, A
	33	13.8	1.8	17	1	US-09-866-108A-10670	Sequence 10670, A
c	34	13.8	1.8	17	1	US-09-404-912-599	Sequence 599, App
	35	13.6	1.8	15	1	US-08-431-048F-151	Sequence 151, App
c	36	13.4	1.8	16	1	US-08-770-235A-24	Sequence 24, Appl
c	37	12.8	1.7	16	1	US-08-411-796-539	Sequence 539, App
c	38	12.8	1.7	16	1	US-08-471-039-539	Sequence 539, App
	39	12.8	1.7	16	1	US-08-464-582-16	Sequence 16, Appl
	40	12.8	1.7	16	1	US-08-462-513-16	Sequence 16, Appl
c	41	12.8	1.7	16	1	US-08-559-390-539	Sequence 539, App
	42	12.8	1.7	16	1	US-09-829-855-10	Sequence 10, Appl
	43	12.8	1.7	16	1	US-09-829-855-110	Sequence 110, App
	44	12.8	1.7	16	1	US-09-479-005A-187	Sequence 187, App
	45	12.8	1.7	16	1	US-08-031-801-17	Sequence 17, Appl
	46	12.8	1.7	16	1	US-08-031-801-29	Sequence 29, Appl
	47	12.8	1.7	16	1	US-09-696-791-4142	Sequence 4142, Ap
c	48	12.8	1.7	16	1	PCT-US93-11198-539	Sequence 539, App
	49	12.4	1.6	15	1	US-08-276-594A-8	Sequence 8, Appli
c	50	12.4	1.6	15	1	US-08-991-830A-9	Sequence 9, Appli
c	51	12.4	1.6	15	1	US-08-486-343A-6	Sequence 6, Appli
	52	12.4	1.6	15	1	US-09-081-646-654	Sequence 654, App
	53	12.4	1.6	15	1	US-09-625-634A-5	Sequence 5, Appli
c	54	12.4	1.6	15	1	US-09-716-320-9	Sequence 9, Appli
c	55	12.4	1.6	15	1	PCT-US95-07349-6	Sequence 6, Appli
	56	12	1.6	13	1	US-08-390-888A-12	Sequence 12, Appl
c	57	12	1.6	15	1	US-09-081-646-712	Sequence 712, App
c	58	12	1.6	15	1	US-09-081-646-713	Sequence 713, App
	59	11.4	1.5	14	1	US-08-544-381B-236	Sequence 236, App
c	60	11	1.4	12	1	US-09-614-034-75	Sequence 75, Appl
c	61	11	1.4	13	1	US-09-614-034-73	Sequence 73, Appl
	62	11	1.4	13	1	PCT-US94-05659-22	Sequence 22, Appl

ALIGNMENTS

```
RESULT 1
US-08-859-998-1170/c
; Sequence 1170, Application US/08859998
; Patent No. 5994076
;  GENERAL INFORMATION:
;    APPLICANT:  Chenchik, Alex
;    APPLICANT:  Jokhadze, George
;    APPLICANT:  Bibilashvilli, Robert
;    TITLE OF INVENTION:  METHOD OF ASSAYING DIFFERENTIAL
;    TITLE OF INVENTION:  EXPRESSION
;    NUMBER OF SEQUENCES:  1375
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson, P.C.
;      STREET:  2200 Sand Hill Road, Suite 100
;      CITY:  Menlo Park
;      STATE:  CA
;      COUNTRY:  US
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  Windows95
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/859,998
;      FILING DATE:  21-MAY-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Field, Bret E.
;      REGISTRATION NUMBER:  37,620
;      REFERENCE/DOCKET NUMBER:  09096/002001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-322-5070
;      TELEFAX:  415-854-0875
;  INFORMATION FOR SEQ ID NO:  1170:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      OTHER INFORMATION:  oligonucleotide primer
US-08-859-998-1170

  Query Match             3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.4;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 2
US-09-225-928-1170/c
; Sequence 1170, Application US/09225928
; Patent No. 6352829
;  GENERAL INFORMATION:
;       APPLICANT: Chenchik, Alex
;                  Jokhadze, George
;                  Bibilashvilli, Robert
;       TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                           EXPRESSION
;       NUMBER OF SEQUENCES: 1375
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Fish & Richardson, P.C.
;            STREET: 2200 Sand Hill Road, Suite 100
;            CITY: Menlo Park
;            STATE: CA
;            COUNTRY: US
;            ZIP: 94025
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: Windows95
;            SOFTWARE: FastSEQ for Windows Version 2.0
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/225,928
;            FILING DATE: 05-Jan-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/859,998
;            FILING DATE: 21-MAY-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Field, Bret E.
;            REGISTRATION NUMBER: 37,620
;            REFERENCE/DOCKET NUMBER: 09096/002001
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 415-322-5070
;            TELEFAX: 415-854-0875
;  INFORMATION FOR SEQ ID NO: 1170:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 25 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            OTHER INFORMATION:  oligonucleotide primer
;       SEQUENCE DESCRIPTION: SEQ ID NO: 1170:
US-09-225-928-1170

  Query Match             3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.4;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 3
US-09-225-201B-1170/c
; Sequence 1170, Application US/09225201B
; Patent No. 6489455
;  GENERAL INFORMATION:
;       APPLICANT: Chenchik, Alex
;                  Jokhadze, George
;                  Bibilashvilli, Robert
;       TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                           EXPRESSION
;       NUMBER OF SEQUENCES: 1375
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Fish & Richardson, P.C.
;            STREET: 2200 Sand Hill Road, Suite 100
;            CITY: Menlo Park
;            STATE: CA
;            COUNTRY: US
;            ZIP: 94025
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: Windows95
;            SOFTWARE: FastSEQ for Windows Version 2.0
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/225,201B
;            FILING DATE: 05-Jan-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/08/859,998
;            FILING DATE: 21-MAY-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Field, Bret E.
;            REGISTRATION NUMBER: 37,620
;            REFERENCE/DOCKET NUMBER: 09096/002001
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 415-322-5070
;            TELEFAX: 415-854-0875
;  INFORMATION FOR SEQ ID NO: 1170:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 25 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            OTHER INFORMATION:  oligonucleotide primer
;       SEQUENCE DESCRIPTION: SEQ ID NO: 1170:
US-09-225-201B-1170

  Query Match             3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.4;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 4
US-08-859-998-1169
; Sequence 1169, Application US/08859998
; Patent No. 5994076
;  GENERAL INFORMATION:
;    APPLICANT:  Chenchik, Alex
;    APPLICANT:  Jokhadze, George
;    APPLICANT:  Bibilashvilli, Robert
;    TITLE OF INVENTION:  METHOD OF ASSAYING DIFFERENTIAL
;    TITLE OF INVENTION:  EXPRESSION
;    NUMBER OF SEQUENCES:  1375
;    CORRESPONDENCE ADDRESS:
```

```
;       ADDRESSEE:  Fish & Richardson, P.C.
;       STREET:  2200 Sand Hill Road, Suite 100
;       CITY:  Menlo Park
;       STATE:  CA
;       COUNTRY:  US
;       ZIP:  94025
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  Windows95
;       SOFTWARE:  FastSEQ for Windows Version 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/859,998
;       FILING DATE:  21-MAY-1997
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Field, Bret E.
;       REGISTRATION NUMBER:  37,620
;       REFERENCE/DOCKET NUMBER:  09096/002001
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  415-322-5070
;       TELEFAX:  415-854-0875
;   INFORMATION FOR SEQ ID NO:  1169:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  24 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
;     FEATURE:
;       OTHER INFORMATION:  oligonucleotide primer
US-08-859-998-1169

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.8;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 5
US-09-225-928-1169
; Sequence 1169, Application US/09225928
; Patent No. 6352829
;   GENERAL INFORMATION:
;       APPLICANT: Chenchik, Alex
;                  Jokhadze, George
;                  Bibilashvilli, Robert
;       TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                           EXPRESSION
;       NUMBER OF SEQUENCES: 1375
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Fish & Richardson, P.C.
;            STREET: 2200 Sand Hill Road, Suite 100
;            CITY: Menlo Park
;            STATE: CA
;            COUNTRY: US
;            ZIP: 94025
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: Windows95
;            SOFTWARE: FastSEQ for Windows Version 2.0
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/225,928
;            FILING DATE: 05-Jan-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/859,998
;            FILING DATE: 21-MAY-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Field, Bret E.
;            REGISTRATION NUMBER: 37,620
;            REFERENCE/DOCKET NUMBER: 09096/002001
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 415-322-5070
;            TELEFAX: 415-854-0875
;   INFORMATION FOR SEQ ID NO: 1169:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 24 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            OTHER INFORMATION:  oligonucleotide primer
;       SEQUENCE DESCRIPTION: SEQ ID NO: 1169:
US-09-225-928-1169

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.8;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 6
US-09-225-201B-1169
; Sequence 1169, Application US/09225201B
; Patent No. 6489455
;   GENERAL INFORMATION:
;       APPLICANT: Chenchik, Alex
;                  Jokhadze, George
;                  Bibilashvilli, Robert
;       TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                           EXPRESSION
;       NUMBER OF SEQUENCES: 1375
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Fish & Richardson, P.C.
;            STREET: 2200 Sand Hill Road, Suite 100
;            CITY: Menlo Park
;            STATE: CA
;            COUNTRY: US
;            ZIP: 94025
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: Windows95
;            SOFTWARE: FastSEQ for Windows Version 2.0
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/225,201B
;            FILING DATE: 05-Jan-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/08/859,998
;            FILING DATE: 21-MAY-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Field, Bret E.
;            REGISTRATION NUMBER: 37,620
;            REFERENCE/DOCKET NUMBER: 09096/002001
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 415-322-5070
;            TELEFAX: 415-854-0875
;   INFORMATION FOR SEQ ID NO: 1169:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 24 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
```

```
;        MOLECULE TYPE: DNA
;        FEATURE:
;             OTHER INFORMATION:  oligonucleotide primer
;        SEQUENCE DESCRIPTION: SEQ ID NO: 1169:
US-09-225-201B-1169

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.8;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 7
US-09-396-196G-92419
; Sequence 92419, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92419
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-92419

  Query Match             2.7%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 5.8;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        499 CCCTGAGGGCACACTGACCGTGGA 522
              ||||||||||||||  |||||||
Db          2 CCCTGAGGGCACACTTTCCGTGGA 25


RESULT 8
US-09-396-196G-92432
; Sequence 92432, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92432
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-92432

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 7.1;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        375 TGGTGGAGATCACCGGCAAGCACGA 399
              | || |||||||| ||||||||||
Db          1 TTGTTGAGATCACTGGCAAGCACGA 25


RESULT 9
US-09-990-613A-7
; Sequence 7, Application US/09990613A
; Patent No. 6818446
; GENERAL INFORMATION:
;  APPLICANT: Wu, Reen
;  APPLICANT:  Chen, Yin
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE
;  TITLE OF INVENTION:  ANALYSIS OF MUCIN GENE EXPRESSION AND IDENTIFICATION OF
;  TITLE OF INVENTION:  DRUGS HAVING THE ABILITY TO INHIBIT MUCIN GENE EXPRESSION
;  FILE REFERENCE: 39754-0721A
;  CURRENT APPLICATION NUMBER: US/09/990,613A
;  CURRENT FILING DATE:  2001-11-21
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-990-613A-7

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 16;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        403 GCGGCAGGACGAGCATGGC 421
              ||||||  ||||||||||
Db          1 GCGGCACCACGAGCATGGC 19


RESULT 10
US-09-866-108A-10667
; Sequence 10667, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10667
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10667

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 14;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 11
US-09-081-646-605
; Sequence 605, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 605
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-605

  Query Match             2.0%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        529 CATGCCCAAGCTAGC 543
              |||||||||||||||
Db          1 CATGCCCAAGCTAGC 15


RESULT 12
US-07-977-284A-13/c
; Sequence 13, Application US/07977284A
; Patent No. 5558988
;  GENERAL INFORMATION:
;    APPLICANT:  Prockop, Darwin J.
;    APPLICANT:  Ala-Kokko, Leena
;    APPLICANT:  Williams, Charlene J.
;    APPLICANT:  Ritvaniemi, Pertti
;    APPLICANT:  Baldwin, Clinton
;    APPLICANT:  Hopkinson, Ian
;    APPLICANT:  Ahmad, Nilofer Nina
;    TITLE OF INVENTION:  METHODS OF DETECTING A GENETIC
;    TITLE OF INVENTION:  PREDISPOSITION FOR OSTEOARTHRITIS
;    NUMBER OF SEQUENCES:  261
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewicz & No. 5558988ris
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/977,284A
;      FILING DATE:  13-NOV-1992
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DeLuca, Mark
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-0697
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  SINGLE
;      TOPOLOGY:  LINEAR
;    ANTI-SENSE:  NO
US-07-977-284A-13

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 19;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        129 TGCCCCGGCTGCCGGAGG 146
              ||||| |||||| |||||
Db         18 TGCCCTGGCTGCAGGAGG 1


RESULT 13
US-08-256-426B-13/c
; Sequence 13, Application US/08256426B
; Patent No. 5948611
;  GENERAL INFORMATION:
;    APPLICANT:  Prockop, Darwin J.
;    APPLICANT:  Ala-Kokko, Leena
;    APPLICANT:  Williams, Charlene J.
;    APPLICANT:  Ritvaniemi, Pertti
;    APPLICANT:  Baldwin, Clinton
;    APPLICANT:  Hopkinson, Ian
;    APPLICANT:  Ahmad, Nilofer Nina
;    TITLE OF INVENTION:  Methods of Detecting A Genetic
;    NUMBER OF SEQUENCES:  293
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5948611ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  Windows 3.1
;      SOFTWARE:  WORDPERFECT 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/256,426B
;      FILING DATE:  03-FEB-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/10964
;      FILING DATE:  12-NOV-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/977,284
;      FILING DATE:  13-NOV-1992
```

```
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mark DeLuca
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-1082
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  SINGLE
;      TOPOLOGY:  LINEAR
;    ANTI-SENSE:  NO
US-08-256-426B-13

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 19;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        129 TGCCCCGGCTGCCGGAGG 146
              ||||| |||||| |||||
Db         18 TGCCCTGGCTGCAGGAGG 1


RESULT 14
US-09-663-834A-37/c
; Sequence 37, Application US/09663834A
; Patent No. 6613567
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF HER-2 EXPRESSION
;  FILE REFERENCE: RTS-0033
;  CURRENT APPLICATION NUMBER: US/09/663,834A
;  CURRENT FILING DATE:  2000-09-15
;  NUMBER OF SEQ ID NOS: 48
; SEQ ID NO 37
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-663-834A-37

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 19;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTGC 140
              |||||||| | |||||||
Db         18 TCGGGCTGGCTCGGCTGC 1


RESULT 15
US-08-411-796-466/c
; Sequence 466, Application US/08411796
; Patent No. 5677149
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/411,796
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  466:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-411-796-466

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 17;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 16
US-08-471-039-466/c
; Sequence 466, Application US/08471039
; Patent No. 6017523
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
```

```
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/471,039
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981,044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/5
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  466:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-471-039-466

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 17;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 17
US-08-559-390-466/c
; Sequence 466, Application US/08559390
; Patent No. 6479261
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/559,390
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/411,796
;      FILING DATE:
;      APPLICATION NUMBER:  US 07/981044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  466:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-559-390-466

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 17;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 18
PCT-US93-11198-466/c
; Sequence 466, Application PC/TUS9311198
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981044
;      FILING DATE:  24-NOV-1992
;    ATTORNEY/AGENT INFORMATION:
```

```
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  466:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
PCT-US93-11198-466

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 17;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 19
US-09-866-108A-10666
; Sequence 10666, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10666
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10666

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 19;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 20
US-09-866-108A-10668
; Sequence 10668, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10668
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10668

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 19;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 21
US-09-106-038A-27
; Sequence 27, Application US/09106038A
; Patent No. 6007995
;  GENERAL INFORMATION:
;    APPLICANT:  Brenda F. Baker and Lex M. Cowsert
;    TITLE OF INVENTION:  ANTISENSE MODULATION OF TNFR1
;    TITLE OF INVENTION:  EXPRESSION
;    NUMBER OF SEQUENCES:  91
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Isis Pharmaceuticals, Inc.
;      STREET:  2292 Faraday Avenue
```

```
;      CITY:  Carlsbad
;      STATE:  CA
;      COUNTRY:  U.S.A.
;      ZIP:  92008
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 1.44 Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  Windows NT
;      SOFTWARE:  Microsoft Word 97
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/106,038A
;      FILING DATE:  June 26, 1998
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Laurel Spear Bernstein
;      REGISTRATION NUMBER:  37,280
;      REFERENCE/DOCKET NUMBER:  RTS-0004
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (760) 931-9200
;      TELEFAX:  (760) 603-3820
;  INFORMATION FOR SEQ ID NO:  27:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-106-038A-27

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 22;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || ||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 22
US-08-513-974B-249
; Sequence 249, Application US/08513974B
; Patent No. 6114139
;  GENERAL INFORMATION:
;    APPLICANT:  Hinuma, Shuji
;    APPLICANT:  Hosoya, Masaki
;    APPLICANT:  Fujii, Ryo
;    APPLICANT:  Ohtaki, Tetsuya
;    APPLICANT:  Fukusumi, Shoji
;    APPLICANT:  Ohgi, Kazuhiro
;    TITLE OF INVENTION:  G PROTEIN COUPLED RECEPTOR PROTEIN,
;    TITLE OF INVENTION:  PRODUCTION, AND USE THEREOF
;    NUMBER OF SEQUENCES:  380
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
;      STREET:  130 Water Street
;      CITY:  Boston
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/513,974B
;      FILING DATE:  14-SEP-1995
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/JP95/01599
;      FILING DATE:  10-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 7-093989
;      FILING DATE:  19-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 7-057186
;      FILING DATE:  16-MAR-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 7-007177
;      FILING DATE:  20-JAN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-326611
;      FILING DATE:  28-DEC-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-270017
;      FILING DATE:  02-NOV-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-236357
;      FILING DATE:  30-SEP-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-236356
;      FILING DATE:  30-SEP-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-189274
;      FILING DATE:  11-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-189273
;      FILING DATE:  11-AUG-1945
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-189272
;      FILING DATE:  11-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Resnick, David S.
;      REGISTRATION NUMBER:  34,235
;      REFERENCE/DOCKET NUMBER:  45753
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-523-3400
;      TELEFAX:  617-523-6440
;  INFORMATION FOR SEQ ID NO:  249:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-513-974B-249

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 22;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        218 AGCCCCGCAGTGGCCG 233
              |||| ||||||||||||
Db          1 AGCCTCGCAGTGGCCG 16


RESULT 23
US-09-422-978-6095/c
; Sequence 6095, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6095
;   LENGTH: 18
```

```
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-8894 for SEQ 2161,
US-09-422-978-6095

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 22;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGA 716
              ||||||||||||| |||
Db         18 CTGTGTGTTCTTCTGA 3


RESULT 24
US-08-431-048F-150
; Sequence 150, Application US/08431048F
; Patent No. 6531586
;  GENERAL INFORMATION:
;       APPLICANT: ST. GEORGE-HYSLOP, PETER H
;                  ROMMENS, JOHANNA M
;                  FRASER, PAUL E
;       TITLE OF INVENTION: GENETIC SEQUENCES AND PROTEINS RELATED
;                           TO ALZHEIMER'S DISEASE
;       NUMBER OF SEQUENCES: 155
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: DARBY & DARBY P.C.
;            STREET: 805 THIRD AVENUE
;            CITY: NEW YORK
;            STATE: N.Y.
;            COUNTRY: U.S.A.
;            ZIP: 10022-7513
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/08/431,048F
;            FILING DATE: 28-Apr-1995
;            CLASSIFICATION: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: FEHLNER, PAUL F.
;            REGISTRATION NUMBER: 35135
;            REFERENCE/DOCKET NUMBER: 1034/0F808
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 212-527-7700
;            TELEFAX: 212-527-6237
;   INFORMATION FOR SEQ ID NO: 150:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 15 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 150:
US-08-431-048F-150

  Query Match             1.8%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          2 AGCCACGCAGTCCA 15


RESULT 25
US-09-275-680-11/c
; Sequence 11, Application US/09275680
; Patent No. 6221630
; GENERAL INFORMATION:
;  APPLICANT: Hopper, James E
;  TITLE OF INVENTION: A High Copy Number Recombinant Expression Construct for
;  TITLE OF INVENTION: Regulated High-level Production of Polypeptides in
;  TITLE OF INVENTION: Yeast
;  FILE REFERENCE: 98428
;  CURRENT APPLICATION NUMBER: US/09/275,680
;  CURRENT FILING DATE: 1999-03-24
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 11
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Saccharomyces cerevisiae
US-09-275-680-11

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        290 CGGCACACTGCGGACCG 306
              ||||||||| | ||||||
Db         17 CGGCACACAGTGGACCG 1


RESULT 26
US-08-881-450A-6/c
; Sequence 6, Application US/08881450A
; Patent No. 6274310
;  GENERAL INFORMATION:
;    APPLICANT:  Habener, J.F. and Stoffers, D.A.
;    TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR DETECTING
;    TITLE OF INVENTION:  PANCREATIC DISEASE
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Banner & Witcoff, Inc.
;      STREET:  One Financial Center
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/881,450A
;      FILING DATE:  June 24, 1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kathleen M. Williams
;      REGISTRATION NUMBER:  34,380
;      REFERENCE/DOCKET NUMBER:  11275/7823
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-345-9100
;      TELEFAX:  617-345-9111
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;    FEATURE:
;      NAME/KEY:  primer S17b
US-08-881-450A-6

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
```

```
  Best Local Similarity   88.2%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         38 CGCGTCCCCTTCTCGCT 54
              ||| |||||| ||||||
Db         17 CGCCTCCCCTGCTCGCT 1


RESULT 27
US-09-474-432B-773
; Sequence 773, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 773
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-773

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 23;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 28
US-09-476-387-772
; Sequence 772, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 772
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-772

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 23;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 29
US-09-866-108A-2329/c
; Sequence 2329, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2329
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2329

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1
```

```
RESULT 30
US-09-866-108A-2330/c
; Sequence 2330, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2330
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2330

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 31
US-09-866-108A-2331/c
; Sequence 2331, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2331
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2331

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              ||||| ||| |||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 32
US-09-866-108A-10669
; Sequence 10669, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10669
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-10669

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              ||| |||||||||||  |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 33
US-09-866-108A-10670
; Sequence 10670, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10670
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-10670

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||||  ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 34
US-09-404-912-599/c
; Sequence 599, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 599
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo Sapiens
US-09-404-912-599

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 AGTTCAAAGCAACCACC 762
              ||| ||||||||  ||||
Db         17 AGTACAAAGCAAACACC 1


RESULT 35
US-08-431-048F-151
; Sequence 151, Application US/08431048F
; Patent No. 6531586
;   GENERAL INFORMATION:
;        APPLICANT: ST. GEORGE-HYSLOP, PETER H
;                   ROMMENS, JOHANNA M
;                   FRASER, PAUL E
;        TITLE OF INVENTION: GENETIC SEQUENCES AND PROTEINS RELATED
;                            TO ALZHEIMER'S DISEASE
;        NUMBER OF SEQUENCES: 155
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: DARBY & DARBY P.C.
;             STREET: 805 THIRD AVENUE
;             CITY: NEW YORK
;             STATE: N.Y.
;             COUNTRY: U.S.A.
;             ZIP: 10022-7513
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/08/431,048F
;             FILING DATE: 28-Apr-1995
;             CLASSIFICATION: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: FEHLNER, PAUL F.
;             REGISTRATION NUMBER: 35135
;             REFERENCE/DOCKET NUMBER: 1034/0F808
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 212-527-7700
;             TELEFAX: 212-527-6237
;   INFORMATION FOR SEQ ID NO: 151:
```

```
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 151:
US-08-431-048F-151

  Query Match             1.8%;  Score 13.6;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 19;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||:|||||||
Db          2 AGCCACKCAGTCCA 15


RESULT 36
US-08-770-235A-24/c
; Sequence 24, Application US/08770235A
; Patent No. 5939538
;  GENERAL INFORMATION:
;    APPLICANT:  Leavitt, Markley C.
;    APPLICANT:  Tritz, Richard
;    APPLICANT:  Feng, Yu
;    APPLICANT:  Barber, Jack
;    APPLICANT:  Yu, Mang
;    TITLE OF INVENTION:  Methods and Compositions for Inhibiting
;    TITLE OF INVENTION:  HIV Infection of Cells By Cleaving HIV Co-Receptor RNA
;    NUMBER OF SEQUENCES:  77
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/770,235A
;      FILING DATE:  19-DEC-1996
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/027,875
;      FILING DATE:  25-OCT-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  QUINE, Jonathan A.
;      REGISTRATION NUMBER:  P-41,261
;      REFERENCE/DOCKET NUMBER:  016556-001610US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA
US-08-770-235A-24

  Query Match             1.8%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 23;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        402 AGCGGCAGGACGAGC 416
              ||||||||||| |||
Db         16 AGCGGCAGGACCAGC 2


RESULT 37
US-08-411-796-539/c
; Sequence 539, Application US/08411796
; Patent No. 5677149
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/411,796
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  539:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-411-796-539

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| |||||||||| ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 38
US-08-471-039-539/c
; Sequence 539, Application US/08471039
; Patent No. 6017523
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/471,039
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981,044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/5
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  539:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-471-039-539

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| |||||||||| ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 39
US-08-464-582-16
; Sequence 16, Application US/08464582
; Patent No. 6114598
; GENERAL INFORMATION:
;  APPLICANT: Kucherlapati, Raju
;  APPLICANT: Jakobovits, Aya
;  APPLICANT: Klapholz, Sue
;  APPLICANT: Brenner, Daniel G.
;  APPLICANT: Capon, Daniel J.
;  TITLE OF INVENTION: GENERATION OF XENOGENIC ANTIBODIES
;  FILE REFERENCE: CELL 4.10
;  CURRENT APPLICATION NUMBER: US/08/464,582
;  CURRENT FILING DATE: 1995-06-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: adapter
US-08-464-582-16

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 40
US-08-462-513-16
; Sequence 16, Application US/08462513
; Patent No. 6162963
; GENERAL INFORMATION:
;  APPLICANT: Kucherlapati, Raju
;  APPLICANT: Jakobovits, Aya
;  APPLICANT: Klapholz, Sue
;  APPLICANT: Brenner, Daniel G.
;  APPLICANT: Capon, Daniel J.
;  TITLE OF INVENTION: GENERATION OF XENOGENIC ANTIBODIES
;  FILE REFERENCE: CELL 4.16
;  CURRENT APPLICATION NUMBER: US/08/462,513
;  CURRENT FILING DATE: 1995-06-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: adapter
US-08-462-513-16

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 41
US-08-559-390-539/c
; Sequence 539, Application US/08559390
; Patent No. 6479261
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
```

```
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/559,390
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/411,796
;      FILING DATE:
;      APPLICATION NUMBER:  US 07/981044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  539:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-559-390-539

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||| ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 42
US-09-829-855-10
; Sequence 10, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
;  APPLICANT: Matthew, Ashby N.
;  TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;  FILE REFERENCE: ASHBY-1
;  CURRENT APPLICATION NUMBER: US/09/829,855
;  CURRENT FILING DATE:  2001-04-10
;  PRIOR APPLICATION NUMBER: US 60/196063
;  PRIOR FILING DATE: 2000-04-10
;  PRIOR APPLICATION NUMBER: US 60/196258
;  PRIOR FILING DATE: 2000-04-11
;  NUMBER OF SEQ ID NOS: 244
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: unknown
;   FEATURE:
;   OTHER INFORMATION: unidentified soil organism
US-09-829-855-10

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        525 CCCCCATGCCCAAGCT 540
              ||||| |||| |||||
Db          1 CCCCCGTGCCGAAGCT 16


RESULT 43
US-09-829-855-110
; Sequence 110, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
;  APPLICANT: Matthew, Ashby N.
;  TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;  FILE REFERENCE: ASHBY-1
;  CURRENT APPLICATION NUMBER: US/09/829,855
;  CURRENT FILING DATE:  2001-04-10
;  PRIOR APPLICATION NUMBER: US 60/196063
;  PRIOR FILING DATE: 2000-04-10
;  PRIOR APPLICATION NUMBER: US 60/196258
;  PRIOR FILING DATE: 2000-04-11
;  NUMBER OF SEQ ID NOS: 244
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 110
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: unknown
;   FEATURE:
;   OTHER INFORMATION: unidentified soil organism
US-09-829-855-110

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              |||||| ||| |||||
Db          1 CTGCGGTGCCGCAGCT 16


RESULT 44
US-09-479-005A-187
; Sequence 187, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 187
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-187

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   31.2%;  Pred. No. 28;
  Matches    5;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 TTCTTTTGATACATTT 723
              : |::::||:| |:::
Db          1 UCCUUUUGAUAAAUUU 16
```

```
RESULT 45
US-08-031-801-17
; Sequence 17, Application US/08031801
; Patent No. 6673986
; GENERAL INFORMATION:
;  APPLICANT: KUCHERLAPATI, RAJU
;  APPLICANT:  JAKOBOVITS, AYA
;  APPLICANT:  KLAPHOLZ, SUE
;  APPLICANT:  BRENNER, DANIEL G.
;  APPLICANT:  CAPON, DANIEL J.
;  TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
;  FILE REFERENCE: CELL 4.4 CPA RCE
;  CURRENT APPLICATION NUMBER: US/08/031,801
;  CURRENT FILING DATE:  2003-01-10
;  PRIOR APPLICATION NUMBER: 07/919,297
;  PRIOR FILING DATE: 1992-07-24
;  PRIOR APPLICATION NUMBER: PCT/US91/00245
;  PRIOR FILING DATE: 1991-01-11
;  PRIOR APPLICATION NUMBER: 07/610,515
;  PRIOR FILING DATE: 1990-11-08
;  PRIOR APPLICATION NUMBER: 07/466,008
;  PRIOR FILING DATE: 1990-01-12
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-08-031-801-17

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 46
US-08-031-801-29
; Sequence 29, Application US/08031801
; Patent No. 6673986
; GENERAL INFORMATION:
;  APPLICANT: KUCHERLAPATI, RAJU
;  APPLICANT:  JAKOBOVITS, AYA
;  APPLICANT:  KLAPHOLZ, SUE
;  APPLICANT:  BRENNER, DANIEL G.
;  APPLICANT:  CAPON, DANIEL J.
;  TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
;  FILE REFERENCE: CELL 4.4 CPA RCE
;  CURRENT APPLICATION NUMBER: US/08/031,801
;  CURRENT FILING DATE:  2003-01-10
;  PRIOR APPLICATION NUMBER: 07/919,297
;  PRIOR FILING DATE: 1992-07-24
;  PRIOR APPLICATION NUMBER: PCT/US91/00245
;  PRIOR FILING DATE: 1991-01-11
;  PRIOR APPLICATION NUMBER: 07/610,515
;  PRIOR FILING DATE: 1990-11-08
;  PRIOR APPLICATION NUMBER: 07/466,008
;  PRIOR FILING DATE: 1990-01-12
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: polylinker
US-08-031-801-29

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 47
US-09-696-791-4142
; Sequence 4142, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4142
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Hairpin ribozyme recognition site for cyclin B1
US-09-696-791-4142

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGACCAA 366
              |||| ||||||| |||
Db          1 TGACTGTCAAGAACAA 16


RESULT 48
PCT-US93-11198-539/c
; Sequence 539, Application PC/TUS9311198
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
```

```
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981044
;      FILING DATE:  24-NOV-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  539:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
PCT-US93-11198-539

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| |||||||||  ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 49
US-08-276-594A-8
; Sequence 8, Application US/08276594A
; Patent No. 5693499
;  GENERAL INFORMATION:
;    APPLICANT:  YONEMURA, Hiroshi
;    APPLICANT:  TAJIMA, Yoshitaka
;    APPLICANT:  SUGAWARA, Keishin
;    APPLICANT:  MASUDA, Kenichi
;    TITLE OF INVENTION:  PROCESS FOR PREPARING HUMAN COAGULATION
;    TITLE OF INVENTION:  FACTOR VIII PROTEIN COMPLEX
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Foley & Lardner
;      STREET:  3000 K Street, N.W., Suite 500
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20007-5109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/276,594A
;      FILING DATE:  18-JUL-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/950,191
;      FILING DATE:  24-SEP-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 243262/1991
;      FILING DATE:  24-SEP-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  WEGNER, Harold C.
;      REGISTRATION NUMBER:  25,258
;      REFERENCE/DOCKET NUMBER:  74129/195/AOPA
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)672-5300
;      TELEFAX:  (202)672-5399
;      TELEX:  904136
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-276-594A-8

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 28;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        594 AGCTTGGGGGCCCA 607
              ||||| ||||||||
Db          1 AGCTTTGGGGCCCA 14


RESULT 50
US-08-991-830A-9/c
; Sequence 9, Application US/08991830A
; Patent No. 6027892
;  GENERAL INFORMATION:
;    APPLICANT:  Chang, Esther H.
;    APPLICANT:  Pirollo, Kathleen F.
;    TITLE OF INVENTION:  Compositions and Methods for Reducing Radiation and Drug Resis
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sana A. Pratt
;      STREET:  10821 Hillbrooke Lane
;      CITY:  Potomac
;      STATE:  MARYLAND
;      COUNTRY:  USA
;      ZIP:  20854
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 7.5
;      SOFTWARE:  Microsoft Word 6.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/991,830A
;      FILING DATE:  16 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/034,160
;      FILING DATE:  30 December 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sana A. Pratt
;      REGISTRATION NUMBER:  39,441
;      REFERENCE/DOCKET NUMBER:
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (301) 294-9171
;      TELEFAX:  (301) 294-7357
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  Nucleic acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    MOLECULE TYPE:  DNA
US-08-991-830A-9

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 28;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        410 GACGAGCATGGCTA 423
              ||| ||||||||||
Db         15 GACAAGCATGGCTA 2


RESULT 51
```

```
US-08-486-343A-6/c
; Sequence 6, Application US/08486343A
; Patent No. 6071695
;  GENERAL INFORMATION:
;    APPLICANT:  OZKAYNAK, ENGIN
;    APPLICANT:  OPPERMANN, HERMANN
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR MODULATING
;    TITLE OF INVENTION:  MORPHOGENIC PROTEIN EXPRESSION
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
;      ADDRESSEE:  INC.
;      STREET:  45 SOUTH STREET
;      CITY:  HOPKINTON
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  07148
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,343A
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  PITCHER, Edmund R
;      REGISTRATION NUMBER:  27,829
;      REFERENCE/DOCKET NUMBER:  CRP-091CP
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617)-248-7000
;      TELEFAX:  (617)-248-7100
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..15
;      OTHER INFORMATION:  /note= "WT1/EGR MOUSE TCC BINDING
;      OTHER INFORMATION:  SITE"
US-08-486-343A-6

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 28;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        398 GAGGAGCGGCAGGA 411
              ||||||||| ||||
Db         14 GAGGAGCGGGAGGA 1


RESULT 52
US-09-081-646-654
; Sequence 654, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 654
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-654

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 28;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        369 ATGGCGTGGTGGAG 382
              |||||| |||||||
Db          2 ATGGCGGGGTGGAG 15


RESULT 53
US-09-625-634A-5
; Sequence 5, Application US/09625634A
; Patent No. 6653448
; GENERAL INFORMATION:
;  APPLICANT: Vernet, Corine
;  APPLICANT:  Rastelli, Luca
;  APPLICANT:  Herrmann, John
;  TITLE OF INVENTION: WNT-7B-LIKE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING
;  TITLE OF INVENTION:  SAME
;  FILE REFERENCE: Cura-244 (15966-744) US
;  CURRENT APPLICATION NUMBER: US/09/625,634A
;  CURRENT FILING DATE:  2000-07-26
;  PRIOR APPLICATION NUMBER: USSN 60/194,256
;  PRIOR FILING DATE: 2000-04-03
;  PRIOR APPLICATION NUMBER: USSN 60/192,838
;  PRIOR FILING DATE: 2000-03-29
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  SYNTHETIC PCR
;   OTHER INFORMATION: PRIMER
US-09-625-634A-5

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 28;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        426 TCTCCCGGTGCTTC 439
              |||||||| |||||
Db          1 TCTCCCGGCGCTTC 14


RESULT 54
US-09-716-320-9/c
; Sequence 9, Application US/09716320
; Patent No. 6803360
; GENERAL INFORMATION:
;  APPLICANT: Chang, Esther H
;  APPLICANT:  Pirollo, Kathleen F
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR REDUCING RADIATION AND DRUG RESISTAN
;  FILE REFERENCE: 2444-109
;  CURRENT APPLICATION NUMBER: US/09/716,320
;  CURRENT FILING DATE:  2000-11-21
;  PRIOR APPLICATION NUMBER: US 09/480,143
;  PRIOR FILING DATE: 2000-01-10
;  PRIOR APPLICATION NUMBER: US 08/991,830
;  PRIOR FILING DATE: 1997-12-16
;  PRIOR APPLICATION NUMBER: US 60/034,160
;  PRIOR FILING DATE: 1996-12-30
;  PRIOR APPLICATION NUMBER: US 09/601,444
;  PRIOR FILING DATE: 2001-01-04
;  PRIOR APPLICATION NUMBER: PCT/US98/24657
```

```
;  PRIOR FILING DATE: 1998-11-19
;  PRIOR APPLICATION NUMBER: US 60/066,188
;  PRIOR FILING DATE: 1997-11-19
;  PRIOR APPLICATION NUMBER: US 60/083,175
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: HER-2 control oligonucleotide scrambled 2
US-09-716-320-9

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 28;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        410 GACGAGCATGGCTA 423
              ||| ||||||||||
Db         15 GACAAGCATGGCTA 2


RESULT 55
PCT-US95-07349-6/c
; Sequence 6, Application PC/TUS9507349
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR MODULATING
;    TITLE OF INVENTION:  MORPHOGEN EXPRESSION
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
;      ADDRESSEE:  INC.
;      STREET:  45 SOUTH STREET
;      CITY:  HOPKINTON
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  07148
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/07349
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/938,021
;      FILING DATE:  28-AUG-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  KELLEY, ROBIN D
;      REGISTRATION NUMBER:  34,637
;      REFERENCE/DOCKET NUMBER:  CRP-091PC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (508)-435-9001
;      TELEFAX:  (508)-435-0992
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..15
;      OTHER INFORMATION:  /note= "WT1 MOUSE TCC BINDING SITE"
PCT-US95-07349-6

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 28;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        398 GAGGAGCGGCAGGA 411
              ||||||||| ||||
Db         14 GAGGAGCGGGAGGA 1


RESULT 56
US-08-390-888A-12
; Sequence 12, Application US/08390888A
; Patent No. 5916754
;  GENERAL INFORMATION:
;    APPLICANT:  Nichol, Stuart T.
;    APPLICANT:  Morzunov, Sergey
;    APPLICANT:  Ksiazek, Thomas G.
;    APPLICANT:  Rollin, Pierre E.
;    APPLICANT:  Spiropoulou, Christina F.
;    TITLE OF INVENTION:  THE BAYOU HANTAVIRUS AND RELATED METHODS
;    NUMBER OF SEQUENCES:  13
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  NEEDLE & ROSENBERG, P.C.
;      STREET:  127 Peachtree Street, N.E., Suite 1200
;      CITY:  Atlanta
;      STATE:  Georgia
;      COUNTRY:  USA
;      ZIP:  30303
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/390,888A
;      FILING DATE:
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spratt, Gwendolyn D.
;      REGISTRATION NUMBER:  36,016
;      REFERENCE/DOCKET NUMBER:  1414.623
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (404) 688-0770
;      TELEFAX:  (404) 688-9880
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA (genomic)
US-08-390-888A-12

  Query Match             1.6%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   83.3%;  Pred. No. 23;
  Matches   10;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        473 CCCACCCAAGTT 484
              ||||||||||::
Db          1 CCCACCCAAGUU 12


RESULT 57
US-09-081-646-712/c
; Sequence 712, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
```

```
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 712
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-712

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 31;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        500 CCTGAGGGCACA 511
              ||||||||||||
Db         14 CCTGAGGGCACA 3


RESULT 58
US-09-081-646-713/c
; Sequence 713, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 713
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-713

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 31;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        500 CCTGAGGGCACA 511
              ||||||||||||
Db         14 CCTGAGGGCACA 3


RESULT 59
US-08-544-381B-236
; Sequence 236, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;    TITLE OF INVENTION:  Detecting Cystic Fibrosis
;    NUMBER OF SEQUENCES:  250
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/544,381B
;      FILING DATE:  10-OCT-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004130US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-576-0200
;      TELEFAX:  415-576-0300
;  INFORMATION FOR SEQ ID NO:  236:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (oligonucleotide)
US-08-544-381B-236

  Query Match             1.5%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 32;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        377 GTGGAGATCACCG 389
              ||||||||| ||
Db          1 GTGGAGATCAACG 13


RESULT 60
US-09-614-034-75/c
; Sequence 75, Application US/09614034
; Patent No. 6489307
; GENERAL INFORMATION:
;  APPLICANT: PHILLIPS, M. IAN
;  APPLICANT:  ZHANG, YUAN
;  TITLE OF INVENTION: ANTISENSE COMPOSITIONS TARGETED TO BETA1-ADRENOCEPTOR-SPECIFIC mR
;  TITLE OF INVENTION:  METHODS OF USE
;  FILE REFERENCE: 4300.013900
;  CURRENT APPLICATION NUMBER: US/09/614,034
;  CURRENT FILING DATE:  2000-07-11
;  PRIOR APPLICATION NUMBER: 09/152,717
;  PRIOR FILING DATE: 1998-09-14
;  PRIOR APPLICATION NUMBER: PCT/US99/21007
;  PRIOR FILING DATE: 1999-09-14
;  NUMBER OF SEQ ID NOS: 204
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 75
;   LENGTH: 12
;   TYPE: DNA
```

```
;   ORGANISM: UNKNOWN
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-614-034-75

  Query Match             1.4%;  Score 11;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        407 CAGGACGAGCA 417
              ||||||||||| 
Db         11 CAGGACGAGCA 1


RESULT 61
US-09-614-034-73/c
; Sequence 73, Application US/09614034
; Patent No. 6489307
; GENERAL INFORMATION:
;  APPLICANT: PHILLIPS, M. IAN
;  APPLICANT:  ZHANG, YUAN
;  TITLE OF INVENTION: ANTISENSE COMPOSITIONS TARGETED TO BETA1-ADRENOCEPTOR-SPECIFIC mR
;  TITLE OF INVENTION:  METHODS OF USE
;  FILE REFERENCE: 4300.013900
;  CURRENT APPLICATION NUMBER: US/09/614,034
;  CURRENT FILING DATE:  2000-07-11
;  PRIOR APPLICATION NUMBER: 09/152,717
;  PRIOR FILING DATE: 1998-09-14
;  PRIOR APPLICATION NUMBER: PCT/US99/21007
;  PRIOR FILING DATE: 1999-09-14
;  NUMBER OF SEQ ID NOS: 204
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 73
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: UNKNOWN
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-614-034-73

  Query Match             1.4%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 31;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        407 CAGGACGAGCA 417
              ||||||||||| 
Db         12 CAGGACGAGCA 2


RESULT 62
PCT-US94-05659-22
; Sequence 22, Application PC/TUS9405659
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  TNF' RESPONSIVE ELEMENT, TNF'-INDUCED DNA-BINDING
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hamilton, Brook, Smith & Reynolds, P.C.
;      STREET:  Two Militia Drive
;      CITY:  Lexington
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02173
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/05659
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Granahan, Patricia
;      REGISTRATION NUMBER:  32,227
;      REFERENCE/DOCKET NUMBER:  FDC93-01 FF
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-861-6240
;      TELEFAX:  617-861-9540
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US94-05659-22

  Query Match             1.4%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 31;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        679 CTGGCTGTGCC 689
              ||||||||||| 
Db          1 CTGGCTGTGCC 11


Search completed: October 18, 2005, 09:41:57
Job time : 1 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: October 18, 2005, 09:43:09 ; Search time 2 Seconds
(without alignments)
4.003 Million cell updates/sec

Title: US-10-605-498-91-COPY
Perfect score: 764
Sequence: 1 ggcacgaggagcagagtcag.....aagttcaaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 301 seqs, 5240 residues

Total number of hits satisfying chosen parameters: 602

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 303 summaries

N. Geneseq

Database : ngsdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
c 1	25	3.3	25	1	ABK67082	Human gene specifi
2	24	3.1	24	1	ABK67081	Human gene specifi
3	21.4	2.8	23	1	ABL99424	Left PCR primer us
c 4	21	2.7	21	1	ADM94658	Human heat shock p
c 5	21	2.7	21	1	ADM94663	Human heat shock p
c 6	21	2.7	21	1	ADM94670	Human heat shock p
c 7	21	2.7	21	1	ADM94703	Human heat shock p
c 8	21	2.7	21	1	ADM94709	Human heat shock p
c 9	21	2.7	21	1	ADM94717	Human heat shock p
c 10	21	2.7	21	1	ADM94721	Human heat shock p
c 11	21	2.7	21	1	ADM94731	Human heat shock p
c 12	21	2.7	21	1	ADM94685	Human heat shock p
c 13	21	2.7	21	1	ADM94725	Human heat shock p
c 14	21	2.7	21	1	ADM94653	Human heat shock p
c 15	21	2.7	21	1	ADM94667	Human heat shock p
c 16	21	2.7	21	1	ADM94688	Human heat shock p
c 17	21	2.7	21	1	ADM94691	Human heat shock p
c 18	21	2.7	21	1	ADM94692	Human heat shock p
c 19	21	2.7	21	1	ADM94697	Human heat shock p
c 20	21	2.7	21	1	ADM94704	Human heat shock p
c 21	21	2.7	21	1	ADM94712	Human heat shock p
c 22	21	2.7	21	1	ADM94714	Human heat shock p
c 23	21	2.7	21	1	ADM94672	Human heat shock p
c 24	21	2.7	21	1	ADM94705	Human heat shock p
c 25	21	2.7	21	1	ADM94654	Human heat shock p
c 26	21	2.7	21	1	ADM94657	Human heat shock p
c 27	21	2.7	21	1	ADM94687	Human heat shock p
c 28	21	2.7	21	1	ADM94689	Human heat shock p
c 29	21	2.7	21	1	ADM94702	Human heat shock p
c 30	21	2.7	21	1	ADM94713	Human heat shock p
c 31	21	2.7	21	1	ADM94716	Human heat shock p
c 32	21	2.7	21	1	ADM94724	Human heat shock p
c 33	21	2.7	21	1	ADM94651	Human heat shock p
c 34	21	2.7	21	1	ADM94668	Human heat shock p
c 35	21	2.7	21	1	ADM94686	Human heat shock p
c 36	21	2.7	21	1	ADM94700	Human heat shock p
c 37	21	2.7	21	1	ADM94701	Human heat shock p
c 38	21	2.7	21	1	ADM94706	Human heat shock p
c 39	21	2.7	21	1	ADM94711	Human heat shock p
c 40	21	2.7	21	1	ADM94729	Human heat shock p
c 41	21	2.7	21	1	ADM94660	Human heat shock p
c 42	21	2.7	21	1	ADM94661	Human heat shock p
c 43	21	2.7	21	1	ADM94669	Human heat shock p
c 44	21	2.7	21	1	ADM94680	Human heat shock p
c 45	21	2.7	21	1	ADM94652	Human heat shock p
c 46	21	2.7	21	1	ADM94676	Human heat shock p
c 47	21	2.7	21	1	ADM94684	Human heat shock p
c 48	21	2.7	21	1	ADM94690	Human heat shock p
c 49	21	2.7	21	1	ADM94662	Human heat shock p
c 50	21	2.7	21	1	ADM94665	Human heat shock p
c 51	21	2.7	21	1	ADM94698	Human heat shock p
c 52	21	2.7	21	1	ADM94718	Human heat shock p
c 53	21	2.7	21	1	ADM94728	Human heat shock p
c 54	21	2.7	21	1	ADM94674	Human heat shock p
c 55	21	2.7	21	1	ADM94678	Human heat shock p
c 56	21	2.7	21	1	ADM94715	Human heat shock p
c 57	21	2.7	21	1	ADM94726	Human heat shock p
c 58	21	2.7	21	1	ADM94677	Human heat shock p
c 59	21	2.7	21	1	ADM94699	Human heat shock p
c 60	21	2.7	21	1	ADM94719	Human heat shock p
c 61	21	2.7	21	1	ADM94671	Human heat shock p
c 62	21	2.7	21	1	ADM94679	Human heat shock p
c 63	21	2.7	21	1	ADM94683	Human heat shock p
c 64	21	2.7	21	1	ADM94693	Human heat shock p
c 65	21	2.7	21	1	ADM94694	Human heat shock p
c 66	21	2.7	21	1	ADM94722	Human heat shock p
c 67	21	2.7	21	1	ADM94723	Human heat shock p
c 68	21	2.7	21	1	ADM94682	Human heat shock p
c 69	21	2.7	21	1	ADM94655	Human heat shock p
c 70	21	2.7	21	1	ADM94656	Human heat shock p
c 71	21	2.7	21	1	ADM94664	Human heat shock p
c 72	21	2.7	21	1	ADM94666	Human heat shock p
c 73	21	2.7	21	1	ADM94673	Human heat shock p
c 74	21	2.7	21	1	ADM94659	Human heat shock p
c 75	21	2.7	21	1	ADM94681	Human heat shock p
c 76	21	2.7	21	1	ADM94696	Human heat shock p
c 77	21	2.7	21	1	ADM94707	Human heat shock p
c 78	21	2.7	21	1	ADM94675	Human heat shock p
c 79	21	2.7	21	1	ADM94695	Human heat shock p
c 80	21	2.7	21	1	ADM94708	Human heat shock p
c 81	21	2.7	21	1	ADM94710	Human heat shock p
c 82	21	2.7	21	1	ADM94720	Human heat shock p
c 83	21	2.7	21	1	ADM94730	Human heat shock p
c 84	20	2.6	20	1	ADM94732	Human heat shock p
85	20	2.6	20	1	ADO55958	Probe HSP27 for de
86	19	2.5	19	1	ADM94740	Human heat shock p
87	19	2.5	19	1	ADM94737	Human heat shock p
88	18.4	2.4	21	1	ABA00784	HSP27 forward prim
c 89	18	2.4	18	1	ADM94727	Human heat shock p
90	17.8	2.3	21	1	ADM94739	Human heat shock p
c 91	17.8	2.3	22	1	ABA00785	HSP27 reverse prim
92	17.4	2.3	20	1	AAA66267	Dog genomic marker
93	17	2.2	17	1	ABT34675	Tumour suppression
94	17	2.2	17	1	ADB45935	Tumour suppression
95	17	2.2	17	1	ADB30781	Cholesterol homeos
96	17	2.2	17	1	ADI52044	Human tumour suppr
97	17	2.2	17	1	ACC51537	Human tumour suppr
c 98	16.4	2.1	18	1	ADR30706	Skunk cabbage S. f
99	15.8	2.1	19	1	ADI00879	RT-PCR 32P end-lab
100	15.8	2.1	19	1	ADM94733	Human heat shock p
101	15.8	2.1	21	1	ADM94657	Human heat shock p
102	15.4	2.0	17	1	ABN10675	Human GDMLP-1 17-m
103	15.4	2.0	17	1	ADB45924	Tumour suppression
104	15.4	2.0	17	1	ADI48414	Human tumour suppr
c 105	15.4	2.0	17	1	ADG71955	Human NOVX related
c 106	15.4	2.0	17	1	ADJ87293	Human G protein-co

107	15.4	2.0	17	1	ACN73765	Human GDMLP-1 prob
108	15.4	2.0	19	1	ADE29797	Mitogen activated
c 109	15.4	2.0	19	1	ADE29902	Mitogen activated
110	15.4	2.0	19	1	ADO14933	Human PDGFr-target
c 111	15.4	2.0	19	1	ADO14622	Human PDGFr-target
112	15	2.0	15	1	AAX31550	Tag sequence of a
113	15	2.0	15	1	AAF46290	IGFBP2 oligonucleo
114	15	2.0	15	1	ABK32504	Human pancreatic c
c 115	14.8	1.9	18	1	AAQ65740	Type II procollage
116	14.8	1.9	18	1	AAF77820	PCR primer BAR2.
c 117	14.8	1.9	18	1	AAD38938	Human Her-2 antise
118	14.8	1.9	18	1	ABK98126	Triple helix formi
c 119	14.8	1.9	18	1	ABS66626	TN-KpnI-fo PCR pri
120	14.8	1.9	18	1	ABZ98168	Human CD23 + A1261
121	14.8	1.9	18	1	ABD31199	Human CD23-derived
122	14.8	1.9	18	1	ADJ60033	Oligonucleotide as
123	14.8	1.9	18	1	ADL91732	Collagen type IX a
124	14.8	1.9	18	1	ADO45523	Human oligonucleot
c 125	14.4	1.9	16	1	ADC03006	Ex vivo stem-cell
c 126	14.4	1.9	16	1	ADI58681	Human interleukin
127	14.4	1.9	17	1	AAV92679	Human A-Raf substr
128	14.4	1.9	17	1	ABN10674	Human GDMLP-1 17-m
129	14.4	1.9	17	1	ABN10676	Human GDMLP-1 17-m
c 130	14.4	1.9	17	1	ABZ61415	Human H-Ras DNAzym
131	14.4	1.9	17	1	ADF64299	Human PCCP1 DNA fr
132	14.4	1.9	17	1	ADF64300	Human PCCP1 DNA fr
133	14.4	1.9	17	1	ADL47964	Human IKK-gamma su
134	14.4	1.9	17	1	ACN73764	Human GDMLP-1 prob
135	14.4	1.9	17	1	ACN73766	Human GDMLP-1 prob
136	14.4	1.9	18	1	AAZ48501	Human TNFR1 mRNA i
c 137	14.4	1.9	18	1	AAZ71739	Human biallelic ma
138	14.4	1.9	18	1	AAA87651	Rat hepatocyte car
139	14.4	1.9	18	1	ABT04997	TNFR1 expression m
140	14.4	1.9	18	1	ADR06029	Human TNFR1 antise
141	14	1.8	15	1	AAF46289	IGFBP2 oligonucleo
142	14	1.8	15	1	AAF46291	IGFBP2 oligonucleo
c 143	14	1.8	15	1	ADF32131	Probe #55 used to
c 144	14	1.8	17	1	AAQ78888	Humicola grisea gl
145	14	1.8	17	1	ABK01791	Human NOGO Zinzyme
146	14	1.8	17	1	ABK00765	Human NOGO Inozyme
147	14	1.8	17	1	ABA81385	PSEN1 mutation cor
c 148	14	1.8	17	1	ABA81384	PSEN1 mutation cor
149	14	1.8	17	1	ADF92264	Human cytokeratin
150	13.8	1.8	17	1	AAA17447	Aryl hydrocarbon n
151	13.8	1.8	17	1	AAV93490	Human B-raf substr
c 152	13.8	1.8	17	1	AAX01065	IPF1 gene exon 1 a
c 153	13.8	1.8	17	1	AAA36540	Human genomic SNP
154	13.8	1.8	17	1	ABK02414	Human NOGO Amberzy
c 155	13.8	1.8	17	1	AAH24028	Yeast GAL3 gene up
c 156	13.8	1.8	17	1	ABN02338	Human GDMLP-1 17-m
c 157	13.8	1.8	17	1	ABN02339	Human GDMLP-1 17-m
c 158	13.8	1.8	17	1	ABN02337	Human GDMLP-1 17-m
159	13.8	1.8	17	1	ABN10677	Human GDMLP-1 17-m
160	13.8	1.8	17	1	ABN10678	Human GDMLP-1 17-m
c 161	13.8	1.8	17	1	ABV78924	Human HTPL scannin
162	13.8	1.8	17	1	ABV90510	Human POSHL1 scann
163	13.8	1.8	17	1	ABK56935	Human CLCA1 gene e
c 164	13.8	1.8	17	1	ABK57534	Human CLCA1 gene e
c 165	13.8	1.8	17	1	ABK57533	Human CLCA1 gene e
c 166	13.8	1.8	17	1	ACN00114	WNV Hammerhead Rib
167	13.8	1.8	17	1	ACN09334	WNV minus strand H
168	13.8	1.8	17	1	ACN09335	WNV minus strand H
c 169	13.8	1.8	17	1	ACA07606	NFKB sub-unit modu
170	13.8	1.8	17	1	ABZ65193	Human HER2 DNAzyme
171	13.8	1.8	17	1	ABZ60372	Human K-Ras DNAzym
172	13.8	1.8	17	1	ACD65526	HCV minus strand D
173	13.8	1.8	17	1	ACC65874	Murine oligonucleo
c 174	13.8	1.8	17	1	ACC65548	Murine oligonucleo
175	13.8	1.8	17	1	ADC37976	Human AMLPla scann
c 176	13.8	1.8	17	1	ADC24273	Human NOV9 forward
c 177	13.8	1.8	17	1	ADF63855	Human PCCP1 DNA fr
c 178	13.8	1.8	17	1	ADF63856	Human PCCP1 DNA fr
179	13.8	1.8	17	1	ADI49311	Human tumour suppr
c 180	13.8	1.8	17	1	ADI48838	Human tumour suppr
c 181	13.8	1.8	17	1	ABZ76956	Bovine DGAT BAC-DN
182	13.8	1.8	17	1	ADL47965	Human IKK-gamma su
183	13.8	1.8	17	1	ADI87132	HCV DNAzyme substr
c 184	13.8	1.8	17	1	ACN65429	Human GDMLP-1 prob
185	13.8	1.8	17	1	ACN73767	Human GDMLP-1 prob
c 186	13.8	1.8	17	1	ACN65427	Human GDMLP-1 prob
187	13.8	1.8	17	1	ACN73768	Human GDMLP-1 prob
c 188	13.8	1.8	17	1	ACN65428	Human GDMLP-1 prob
189	13.4	1.8	15	1	AAF46292	IGFBP2 oligonucleo
c 190	13.4	1.8	16	1	AAV43464	HIV-1 beta-chemoki
191	13	1.7	15	1	AAF46288	IGFBP2 oligonucleo
c 192	13	1.7	15	1	AAF45796	IGFBP2 oligonucleo
c 193	13	1.7	15	1	AAF45798	IGFBP2 oligonucleo
c 194	13	1.7	15	1	AAF45797	IGFBP2 oligonucleo
c 195	13	1.7	15	1	ADD15802	K-ras targeting zi
196	13	1.7	21	1	ADM94700	Human heat shock p
197	12.8	1.7	16	1	AAA86552	Cyclin B1 hairpin
c 198	12.8	1.7	16	1	AAC73182	Reverse primer #28
c 199	12.8	1.7	16	1	AAF25893	Human c-sis/PDGF-B
c 200	12.8	1.7	16	1	AAF25892	Human c-sis/PDGF-B
201	12.8	1.7	16	1	AAH61718	Cyclin B1 hairpin/
202	12.8	1.7	16	1	AAS15504	N-acetyltransferas
203	12.8	1.7	16	1	AAS15520	N-acetyltransferas
204	12.8	1.7	16	1	AAS15516	N-acetyltransferas
205	12.8	1.7	16	1	ABA89669	Serial analysis of
206	12.8	1.7	16	1	ABA89738	Serial analysis of
c 207	12.8	1.7	16	1	ADC03079	Ex vivo stem-cell
208	12.8	1.7	16	1	ADF28804	Sense primer flank
c 209	12.8	1.7	16	1	ADM18315	Sequence added to
c 210	12.8	1.7	16	1	ADI58754	Human interleukin
c 211	12.8	1.7	16	1	ADR70038	Human survivin gen
212	12.6	1.6	15	1	ABA93324	Human ACAA1 gene p
213	12.6	1.6	21	1	ADM94710	Human heat shock p
214	12.4	1.6	15	1	AAQ39025	Mutagenic PCR prim
215	12.4	1.6	15	1	AAT42858	Primer #2 for the
216	12.4	1.6	15	1	AAX31599	Tag sequence of a
c 217	12.4	1.6	15	1	AAA59902	Murine OP-1 Wt-1/E
c 218	12.4	1.6	15	1	AAZ90409	Scrambled control
219	12.4	1.6	15	1	AAA95134	Allele specific pr
c 220	12.4	1.6	15	1	AAA95135	Allele specific pr
221	12.4	1.6	15	1	AAS02947	Human CHMR1 allele
c 222	12.4	1.6	15	1	AAF48536	IGFBP3 oligonucleo
223	12.4	1.6	15	1	AAF46293	IGFBP2 oligonucleo
c 224	12.4	1.6	15	1	AAF48537	IGFBP3 oligonucleo
c 225	12.4	1.6	15	1	AAF49788	IGF-I oligonucleot
c 226	12.4	1.6	15	1	AAF45880	IGFBP2 oligonucleo
c 227	12.4	1.6	15	1	AAF49789	IGF-I oligonucleot
c 228	12.4	1.6	15	1	AAF45998	IGFBP2 oligonucleo
c 229	12.4	1.6	15	1	AAF45879	IGFBP2 oligonucleo
c 230	12.4	1.6	15	1	AAF45997	IGFBP2 oligonucleo
231	12.4	1.6	15	1	AAD20988	Human Wnt-7B-like
232	12.4	1.6	15	1	AAF70359	Human DRD2 allele
233	12.4	1.6	15	1	AAF83156	NAT2 gene G191A po
c 234	12.4	1.6	15	1	AAD44441	Human F2RL1 gene p
235	12.4	1.6	15	1	ABK32553	Human pancreatic c
236	12.4	1.6	15	1	ACD66331	Anti-HCV nucleic a
237	12.4	1.6	15	1	ACD66430	Anti-HCV enzymatic
238	12.4	1.6	15	1	ADA27240	Human NOV5 reverse
239	12.4	1.6	15	1	ADA27237	Human NOV5 reverse
c 240	12.4	1.6	15	1	ADF32169	Probe #93 used to
c 241	12.4	1.6	15	1	ADH69864	Human Vbeta genes
242	12.4	1.6	15	1	ADI87750	Anti-HCV molecule
c 243	12.4	1.6	15	1	ADO50238	H. pylori strain J
c 244	12.4	1.6	15	1	ADO49955	H. pylori strain J
c 245	12.4	1.6	15	1	ADO55514	Human phosphodiest
246	12.2	1.6	17	1	ACA07606	NFKB sub-unit modu
c 247	12	1.6	12	1	AAF74725	Human smoothelin v
c 248	12	1.6	12	1	AAS01800	Human smoothelin g
c 249	12	1.6	12	1	ABH93536	Oligonucleotide pr
250	12	1.6	12	1	ABI17243	Oligonucleotide pr
c 251	12	1.6	12	1	ABI31739	Oligonucleotide pr
252	12	1.6	12	1	ABI67794	Oligonucleotide pr

c	253	12	1.6	12	1	ABH86717 Oligonucleotide pr
	254	12	1.6	12	1	ADM76066 NEPHA gene transcr
c	255	12	1.6	13	1	ABH41108 Oligonucleotide SE
	256	12	1.6	13	1	ABH41109 Oligonucleotide SE
	257	12	1.6	13	1	ABF75056 Oligonucleotide SE
c	258	12	1.6	13	1	ABH34624 Oligonucleotide SE
c	259	12	1.6	13	1	ABF75057 Oligonucleotide SE
	260	12	1.6	13	1	ABH34625 Oligonucleotide SE
c	261	12	1.6	14	1	AAS13442 DNA primer sequenc
c	262	12	1.6	14	1	ABS98192 Human lactoferrin
c	263	12	1.6	14	1	ADF78335 Chromosomal abnorm
c	264	12	1.6	14	1	ADH53140 Human APC (adenoma
	265	12	1.6	14	1	ABT13746 Population analysi
c	266	12	1.6	14	1	ADR97911 Human APC DNA frag
c	267	12	1.6	14	1	ADS08595 Human DNA oligonuc
c	268	12	1.6	15	1	AAX31657 Tag sequence of a
c	269	12	1.6	15	1	AAX31658 Tag sequence of a
c	270	12	1.6	15	1	AAI67292 Human FKBP8 allele
c	271	12	1.6	15	1	AAI67293 Human FKBP8 allele
c	272	12	1.6	15	1	AAF46723 IGFBP3 oligonucleo
c	273	12	1.6	15	1	AAF45517 IGFBP2 oligonucleo
c	274	12	1.6	15	1	AAF46724 IGFBP3 oligonucleo
c	275	12	1.6	15	1	AAF46722 IGFBP3 oligonucleo
	276	12	1.6	15	1	AAF45480 IGFBP2 oligonucleo
c	277	12	1.6	15	1	AAF45515 IGFBP2 oligonucleo
	278	12	1.6	15	1	AAF45478 IGFBP2 oligonucleo
c	279	12	1.6	15	1	AAF45795 IGFBP2 oligonucleo
c	280	12	1.6	15	1	AAF45169 IGFBP2 oligonucleo
c	281	12	1.6	15	1	AAF45170 IGFBP2 oligonucleo
	282	12	1.6	15	1	AAF45481 IGFBP2 oligonucleo
c	283	12	1.6	15	1	AAF46725 IGFBP3 oligonucleo
	284	12	1.6	15	1	AAF46287 IGFBP2 oligonucleo
c	285	12	1.6	15	1	AAF45171 IGFBP2 oligonucleo
c	286	12	1.6	15	1	AAF45172 IGFBP2 oligonucleo
	287	12	1.6	15	1	AAF45479 IGFBP2 oligonucleo
c	288	12	1.6	15	1	AAF45799 IGFBP2 oligonucleo
c	289	12	1.6	15	1	AAF45514 IGFBP2 oligonucleo
c	290	12	1.6	15	1	AAF45516 IGFBP2 oligonucleo
	291	12	1.6	15	1	ABK95953 Human LIPE gene po
	292	12	1.6	15	1	ABK95954 Human LIPE gene po
	293	12	1.6	15	1	AAL44242 Human interleukin
	294	12	1.6	15	1	ABN80605 Human P450(cytochr
	295	12	1.6	15	1	AAS19927 ASO primer #7 to d
	296	12	1.6	15	1	ABL91848 Human LIPG gene al
c	297	12	1.6	15	1	ABK64023 Human BF gene alle
c	298	12	1.6	15	1	ABK51277 Human Caspase-2, C
c	299	12	1.6	15	1	ABK32612 Human pancreatic c
c	300	12	1.6	15	1	ABK32611 Human pancreatic c
c	301	12	1.6	15	1	ABL36332 Human lysosomal ac
	302	12	1.6	15	1	AAS95898 Human CALM1 gene a
	303	12	1.6	15	1	ADG65423 UCP2 allele specif

ALIGNMENTS

RESULT 1
ABK67082/c
ID ABK67082 standard; DNA; 25 BP.
XX
AC ABK67082;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human gene specific PCR primer #1170.
XX
KW Primer; ss; DNA microarray; differential expression analysis; human.
XX
OS Homo sapiens.
XX
PN US6352829-B1.
XX
PD 05-MAR-2002.
XX
PF 05-JAN-1999; 99US-00225928.
XX
PR 21-MAY-1997; 97US-00859998.
XX
PA (CLON-) CLONTECH LAB INC.
XX
PI Chenchik A, Jokhadze G, Bibilashvilli R;
XX
DR WPI; 2002-314699/35.
XX
PT Producing sub-population of labeled nucleic acids, useful for analyzing
PT differences in RNA profiles between several different physiological
PT sources, using set of distinct gene specific primers.
XX
PS Example 3; SEQ ID NO 1170; 11pp; English.
XX
CC The invention relates to producing a sub-population of labeled nucleic
CC acids (NAs) comprising contacting a NA sample from a physiological
CC source, with a pool of 50 distinct gene specific primers under suitable
CC conditions to enzymatically generate sub-population of NAs, where each
CC gene specific primer has a sequence complementary to a distinct mRNA, and
CC each labeled NA is generated using a single gene specific primer. The
CC method is useful for producing a sub-population of labeled NAs which is
CC useful for analysing the differences in the RNA profiles between several
CC different physiological sources, where the method comprises producing
CC subpopulation of labeled NAs for the different physiological sources,
CC comprising the populations for each physiological source to identify
CC differences in the population, where the comparison is preferably
CC performed by hybridising the labeled NAs for each of the distinct
CC physiological sources to an array of probe NAs stably associated with the
CC surface of a substrate to produce a hybridisation pattern for each of the
CC sources, and comparing the patterns for each of the sources, where
CC differential gene expression assays are utilised in differential
CC expression analysis of diseased a normal tissue e.g. neoplastic a normal
CC tissue, or different tissue or subtissue types. The present sequence is a
CC human gene specific PCR primer used in the method of the invention. Note:
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from USPTO
CC at http.wipo.seqdata.uspto.gov/sequence.html?DocID=6352829B1
XX
SQ Sequence 25 BP; 4 A; 6 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 3.3%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 2;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
             |||||||||||||||||||||||||
Db        25 TGCCGCCAAGTAAAGCCTTAGCCCG 1
```

RESULT 2
ABK67081
ID ABK67081 standard; DNA; 24 BP.
XX
AC ABK67081;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human gene specific PCR primer #1169.
XX
KW Primer; ss; DNA microarray; differential expression analysis; human.
XX
OS Homo sapiens.
XX
PN US6352829-B1.
XX
PD 05-MAR-2002.
XX
PF 05-JAN-1999; 99US-00225928.
XX
PR 21-MAY-1997; 97US-00859998.

```
XX
PA   (CLON-) CLONTECH LAB INC.
XX
PI   Chenchik A,  Jokhadze G,  Bibilashvilli R;
XX
DR   WPI; 2002-314699/35.
XX
PT   Producing sub-population of labeled nucleic acids, useful for analyzing
PT   differences in RNA profiles between several different physiological
PT   sources, using set of distinct gene specific primers.
XX
PS   Example 3; SEQ ID NO 1169; 11pp; English.
XX
CC   The invention relates to producing a sub-population of labeled nucleic
CC   acids (NAs) comprising contacting a NA sample from a physiological
CC   source, with a pool of 50 distinct gene specific primers under suitable
CC   conditions to enzymatically generate sub-population of NAs, where each
CC   gene specific primer has a sequence complementary to a distinct mRNA, and
CC   each labeled NA is generated using a single gene specific primer. The
CC   method is useful for producing a sub-population of labeled NAs which is
CC   useful for analysing the differences in the RNA profiles between several
CC   different physiological sources, where the method comprises producing
CC   subpopulation of labeled NAs for the different physiological sources,
CC   comprising the populations for each physiological source to identify
CC   differences in the population, where the comparison is preferably
CC   performed by hybridising the labeled NAs for each of the distinct
CC   physiological sources to an array of probe NAs stably associated with the
CC   surface of a substrate to produce a hybridisation pattern for each of the
CC   sources, and comparing the patterns for each of the sources, where
CC   differential gene expression assays are utilised in differential
CC   expression analysis of diseased a normal tissue e.g. neoplastic a normal
CC   tissue, or different tissue or subtissue types. The present sequence is a
CC   human gene specific PCR primer used in the method of the invention. Note:
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from USPTO
CC   at http.wipo.seqdata.uspto.gov/sequence.html?DocID=6352829B1
XX
SQ   Sequence 24 BP; 7 A; 5 C; 11 G; 1 T; 0 U; 0 Other;

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 2.8;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 3
ABL99424
ID   ABL99424 standard; DNA; 23 BP.
XX
AC   ABL99424;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Left PCR primer used to target HSP27 canine gene.
XX
KW   Canine gene array; toxicological response; ss.
XX
OS   Canis sp.
XX
PN   WO200208453-A2.
XX
PD   31-JAN-2002.
XX
PF   23-JUL-2001; 2001WO-US023311.
XX
PR   21-JUL-2000; 2000US-0220057P.
XX
PA   (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY.
XX
PI   Farr SB,  Pickett GG,  Neft RE,  Dunn RT;
XX
DR   WPI; 2002-217063/27.
XX
PT   Identifying toxicologically relevant canine gene to determine
PT   toxicological responses of agents, by obtaining and comparing gene
PT   expression profiles of untreated canine cells and canine cells treated
PT   with an agent.
XX
PS   Example 5; Page 51; 140pp; English.
XX
CC   This invention relates to identifying a toxicologically relevant canine
CC   gene and the generation of an array of toxicologically relevant canine
CC   genes. The gene array is useful for obtaining a gene expression profile,
CC   by exposing a population of cells to an agent, obtaining cDNA from the
CC   population of cells, labeling the cDNA, and contacting the cDNA with the
CC   gene array. The relevant gene is useful for making and using arrays to
CC   determine toxicological responses to various agents, and also useful for
CC   identifying novel gene sequences and novel canine genes. The method for
CC   analysing toxicological responses using the canine gene array is rapid
CC   and efficient. The present sequence is related to the canine gene array
XX
SQ   Sequence 23 BP; 3 A; 9 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 7.7;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         73 GGACCCCTTCCGCGACTGGTACC 95
              |||||| ||||||||||||||||
Db          1 GGACCCTTTCCGCGACTGGTACC 23


RESULT 4
ADM94658/c
ID   ADM94658 standard; DNA; 21 BP.
XX
AC   ADM94658;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:8.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 8; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
```

```
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 7 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         71 TGGGACCCCTTCCGCGACTGG 91
              |||||||||||||||||||||
Db         21 TGGGACCCCTTCCGCGACTGG 1


RESULT 5
ADM94663/c
ID   ADM94663 standard; DNA; 21 BP.
XX
AC   ADM94663;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:13.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 13; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 7 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        121 CTTCGGGCTGCCCCGGCTGCC 141
              |||||||||||||||||||||
Db         21 CTTCGGGCTGCCCCGGCTGCC 1


RESULT 6
ADM94670/c
ID   ADM94670 standard; DNA; 21 BP.
XX
AC   ADM94670;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:20.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 20; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 4 C; 16 G; 0 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        191 CGCCCCCTGCCCCCCGCCGCC 211
              |||||||||||||||||||||
Db         21 CGCCCCCTGCCCCCCGCCGCC 1


RESULT 7
ADM94703/c
ID   ADM94703 standard; DNA; 21 BP.
XX
AC   ADM94703;
XX
DT   01-JUL-2004  (first entry)
```

```
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:53.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 53; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 5 C; 9 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        521 GAGGCCCCCATGCCCAAGCTA 541
              |||||||||||||||||||||
Db         21 GAGGCCCCCATGCCCAAGCTA 1


RESULT 8
ADM94709/c
ID   ADM94709 standard; DNA; 21 BP.
XX
AC   ADM94709;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:59.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 59; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 10 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        581 GAGTCGCGGGCCCAGCTTGGG 601
              |||||||||||||||||||||
Db         21 GAGTCGCGGGCCCAGCTTGGG 1


RESULT 9
ADM94717/c
ID   ADM94717 standard; DNA; 21 BP.
XX
AC   ADM94717;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:67.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
```

```
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 67; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 4 C; 12 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        661 CCACCCCTGCTGCCGCCACTG 681
              |||||||||||||||||||||
Db         21 CCACCCCTGCTGCCGCCACTG 1


RESULT 10
ADM94721/c
ID   ADM94721 standard; DNA; 21 BP.
XX
AC   ADM94721;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:71.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 71; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 11 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGATACAT 721
              |||||||||||||||||||||
Db         21 CTGTGTGTTCTTTTGATACAT 1


RESULT 11
ADM94731/c
ID   ADM94731 standard; DNA; 21 BP.
XX
AC   ADM94731;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:81.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 81; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 6 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCCCC 46
              |||||||||||||||||||||
Db         21 ATGACCGAGCGCCGCGTCCCC 1
```

```
RESULT 12
ADM94685/c
ID   ADM94685 standard; DNA; 21 BP.
XX
AC   ADM94685;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:35.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 35; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 8 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        341 CCGGACGAGCTGACGGTCAAG 361
              |||||||||||||||||||||
Db         21 CCGGACGAGCTGACGGTCAAG 1


RESULT 13
ADM94725/c
ID   ADM94725 standard; DNA; 21 BP.
XX
AC   ADM94725;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:75.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 75; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 2 C; 5 G; 11 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        741 AATAAAGTTCAAAGCAACCAC 761
              |||||||||||||||||||||
Db         21 AATAAAGTTCAAAGCAACCAC 1


RESULT 14
ADM94653/c
ID   ADM94653 standard; DNA; 21 BP.
XX
AC   ADM94653;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:3.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
```

```
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 3; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 7 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         21 CCAGCATGACCGAGCGCCGCG 41
              |||||||||||||||||||||
Db         21 CCAGCATGACCGAGCGCCGCG 1


RESULT 15
ADM94667/c
ID   ADM94667 standard; DNA; 21 BP.
XX
AC   ADM94667;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:17.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 17; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        161 TTAGGCGGCAGCAGCTGGCCA 181
              |||||||||||||||||||||
Db         21 TTAGGCGGCAGCAGCTGGCCA 1


RESULT 16
ADM94688/c
ID   ADM94688 standard; DNA; 21 BP.
XX
AC   ADM94688;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:38.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 38; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 10 C; 5 G; 3 T; 0 U; 0 Other;
```

```
  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        371 GGCGTGGTGGAGATCACCGGC 391
              |||||||||||||||||||||
Db         21 GGCGTGGTGGAGATCACCGGC 1


RESULT 17
ADM94691/c
ID   ADM94691 standard; DNA; 21 BP.
XX
AC   ADM94691;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:41.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 41; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 10 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        401 GAGCGGCAGGACGAGCATGGC 421
              |||||||||||||||||||||
Db         21 GAGCGGCAGGACGAGCATGGC 1


RESULT 18
ADM94692/c
ID   ADM94692 standard; DNA; 21 BP.
XX
AC   ADM94692;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:42.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 42; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        411 ACGAGCATGGCTACATCTCCC 431
              |||||||||||||||||||||
Db         21 ACGAGCATGGCTACATCTCCC 1


RESULT 19
ADM94697/c
ID   ADM94697 standard; DNA; 21 BP.
XX
AC   ADM94697;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:47.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
```

```
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 47; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 5 C; 10 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        461 CCCGGTGTGGACCCCACCCAA 481
              |||||||||||||||||||||
Db         21 CCCGGTGTGGACCCCACCCAA 1


RESULT 20
ADM94704/c
ID   ADM94704 standard; DNA; 21 BP.
XX
AC   ADM94704;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:54.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 54; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        531 TGCCCAAGCTAGCCACGCAGT 551
              |||||||||||||||||||||
Db         21 TGCCCAAGCTAGCCACGCAGT 1


RESULT 21
ADM94712/c
ID   ADM94712 standard; DNA; 21 BP.
XX
AC   ADM94712;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:62.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 62; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
```

```
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        611 GCTGCAAAATCCGATGAGACT 631
              |||||||||||||||||||||
Db         21 GCTGCAAAATCCGATGAGACT 1


RESULT 22
ADM94714/c
ID   ADM94714 standard; DNA; 21 BP.
XX
AC   ADM94714;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:64.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 64; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAG 651
              |||||||||||||||||||||
Db         21 TGCCGCCAAGTAAAGCCTTAG 1


RESULT 23
ADM94672/c
ID   ADM94672 standard; DNA; 21 BP.
XX
AC   ADM94672;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:22.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 22; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 7 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        211 CATCGAGAGCCCCGCAGTGGC 231
              |||||||||||||||||||||
Db         21 CATCGAGAGCCCCGCAGTGGC 1


RESULT 24
ADM94705/c
ID   ADM94705 standard; DNA; 21 BP.
XX
AC   ADM94705;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:55.
```

XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 55; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 5 C; 7 G; 7 T; 0 U; 0 Other;

```
  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCAACGAGAT 561
              |||||||||||||||||||||
Db         21 AGCCACGCAGTCCAACGAGAT 1
```

RESULT 25
ADM94654/c
ID ADM94654 standard; DNA; 21 BP.
XX
AC ADM94654;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:4.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 4; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 5 C; 11 G; 1 T; 0 U; 0 Other;

```
  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         31 CGAGCGCCGCGTCCCCTTCTC 51
              |||||||||||||||||||||
Db         21 CGAGCGCCGCGTCCCCTTCTC 1
```

RESULT 26
ADM94657/c
ID ADM94657 standard; DNA; 21 BP.
XX
AC ADM94657;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:7.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous

```
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 7; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         61 GGGCCCCAGCTGGGACCCCTT 81
              |||||||||||||||||||||
Db         21 GGGCCCCAGCTGGGACCCCTT 1


RESULT 27
ADM94687/c
ID   ADM94687 standard; DNA; 21 BP.
XX
AC   ADM94687;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:37.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 37; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 10 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        361 GACCAAGGATGGCGTGGTGGA 381
              |||||||||||||||||||||
Db         21 GACCAAGGATGGCGTGGTGGA 1


RESULT 28
ADM94689/c
ID   ADM94689 standard; DNA; 21 BP.
XX
AC   ADM94689;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:39.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 39; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 7 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        381 AGATCACCGGCAAGCACGAGG 401
              |||||||||||||||||||||
Db         21 AGATCACCGGCAAGCACGAGG 1


RESULT 29
```

```
ADM94702/c
ID   ADM94702 standard; DNA; 21 BP.
XX
AC   ADM94702;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:52.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 52; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        511 ACTGACCGTGGAGGCCCCCAT 531
              |||||||||||||||||||||
Db         21 ACTGACCGTGGAGGCCCCCAT 1


RESULT 30
ADM94713/c
ID   ADM94713 standard; DNA; 21 BP.
XX
AC   ADM94713;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:63.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 63; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        621 CCGATGAGACTGCCGCCAAGT 641
              |||||||||||||||||||||
Db         21 CCGATGAGACTGCCGCCAAGT 1


RESULT 31
ADM94716/c
ID   ADM94716 standard; DNA; 21 BP.
XX
AC   ADM94716;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:66.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
```

```
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 66; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        651 GCCCGGATGCCCACCCCTGCT 671
              |||||||||||||||||||||
Db         21 GCCCGGATGCCCACCCCTGCT 1


RESULT 32
ADM94724/c
ID   ADM94724 standard; DNA; 21 BP.
XX
AC   ADM94724;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:74.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 74; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 9 A; 2 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        731 GTTTTTCTCAAATAAAGTTCA 751
              |||||||||||||||||||||
Db         21 GTTTTTCTCAAATAAAGTTCA 1


RESULT 33
ADM94651/c
ID   ADM94651 standard; DNA; 21 BP.
XX
AC   ADM94651;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:1.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 1; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 9 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
```

```
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 GGCACGAGGAGCAGAGTCAGC 21
              |||||||||||||||||||||
Db         21 GGCACGAGGAGCAGAGTCAGC 1


RESULT 34
ADM94668/c
ID   ADM94668 standard; DNA; 21 BP.
XX
AC   ADM94668;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:18.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 18; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        171 GCAGCTGGCCAGGCTACGTGC 191
              |||||||||||||||||||||
Db         21 GCAGCTGGCCAGGCTACGTGC 1


RESULT 35
ADM94686/c
ID   ADM94686 standard; DNA; 21 BP.
XX
AC   ADM94686;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:36.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 36; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGACCAAGGATG 371
              |||||||||||||||||||||
Db         21 TGACGGTCAAGACCAAGGATG 1


RESULT 36
ADM94700/c
ID   ADM94700 standard; DNA; 21 BP.
XX
AC   ADM94700;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:50.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
```

```
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 50; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        491 TCCCTGTCCCCTGAGGGCACA 511
              |||||||||||||||||||||
Db         21 TCCCTGTCCCCTGAGGGCACA 1


RESULT 37
ADM94701/c
ID   ADM94701 standard; DNA; 21 BP.
XX
AC   ADM94701;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:51.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 51; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        501 CTGAGGGCACACTGACCGTGG 521
              |||||||||||||||||||||
Db         21 CTGAGGGCACACTGACCGTGG 1


RESULT 38
ADM94706/c
ID   ADM94706 standard; DNA; 21 BP.
XX
AC   ADM94706;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:56.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 56; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
```

```
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 2 C; 9 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCATCCCA 571
              |||||||||||||||||||||
Db         21 TCCAACGAGATCACCATCCCA 1


RESULT 39
ADM94711/c
ID   ADM94711 standard; DNA; 21 BP.
XX
AC   ADM94711;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:61.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 61; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 6 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        601 GGGCCCAGAAGCTGCAAAATC 621
              |||||||||||||||||||||
Db         21 GGGCCCAGAAGCTGCAAAATC 1


RESULT 40
ADM94729/c
ID   ADM94729 standard; DNA; 21 BP.
XX
AC   ADM94729;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:79.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 79; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        265 ACTCAGCAGCGGGGTCTCGGA 285
              |||||||||||||||||||||
Db         21 ACTCAGCAGCGGGGTCTCGGA 1


RESULT 41
ADM94660/c
ID   ADM94660 standard; DNA; 21 BP.
XX
AC   ADM94660;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:10.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
```

KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 10; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 91 GTACCCGCATAGCCGCCTCTT 111
||||||||||||||||||||
Db 21 GTACCCGCATAGCCGCCTCTT 1

RESULT 42
ADM94661/c
ID ADM94661 standard; DNA; 21 BP.
XX
AC ADM94661;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:11.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 11; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 5 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 101 AGCCGCCTCTTCGACCAGGCC 121
||||||||||||||||||||
Db 21 AGCCGCCTCTTCGACCAGGCC 1

RESULT 43
ADM94669/c
ID ADM94669 standard; DNA; 21 BP.
XX
AC ADM94669;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:19.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX

PS Claim 5; SEQ ID NO 19; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 6 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 181 AGGCTACGTGCGCCCCCTGCC 201
||||||||||||||||||||
Db 21 AGGCTACGTGCGCCCCCTGCC 1

RESULT 44
ADM94680/c
ID ADM94680 standard; DNA; 21 BP.
XX
AC ADM94680;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:30.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 30; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 8 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 291 GGCACACTGCGGACCGCTGGC 311
||||||||||||||||||||
Db 21 GGCACACTGCGGACCGCTGGC 1

RESULT 45
ADM94652/c
ID ADM94652 standard; DNA; 21 BP.
XX
AC ADM94652;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:2.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 2; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 GCAGAGTCAGCCAGCATGACC 31
||||||||||||||||||||
Db 21 GCAGAGTCAGCCAGCATGACC 1

RESULT 46
ADM94676/c
ID ADM94676 standard; DNA; 21 BP.

```
XX
AC   ADM94676;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:26.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 26; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 6 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        251 GCGCTCAGCCGGCAACTCAGC 271
              |||||||||||||||||||||
Db         21 GCGCTCAGCCGGCAACTCAGC 1


RESULT 47
ADM94684/c
ID   ADM94684 standard; DNA; 21 BP.
XX
AC   ADM94684;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:34.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 34; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        331 CCACTTCGCCCCGGACGAGCT 351
              |||||||||||||||||||||
Db         21 CCACTTCGCCCCGGACGAGCT 1


RESULT 48
ADM94690/c
ID   ADM94690 standard; DNA; 21 BP.
XX
AC   ADM94690;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:40.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
```

XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 40; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 0 A; 9 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 391 CAAGCACGAGGAGCGGCAGGA 411
||||||||||||||||||||
Db 21 CAAGCACGAGGAGCGGCAGGA 1

RESULT 49
ADM94662/c
ID ADM94662 standard; DNA; 21 BP.
XX
AC ADM94662;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:12.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 12; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 7 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 111 TCGACCAGGCCTTCGGGCTGC 131
||||||||||||||||||||
Db 21 TCGACCAGGCCTTCGGGCTGC 1

RESULT 50
ADM94665/c
ID ADM94665 standard; DNA; 21 BP.
XX
AC ADM94665;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:15.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 15; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 11 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        141 CGGAGGAGTGGTCGCAGTGGT 161
              |||||||||||||||||||||
Db         21 CGGAGGAGTGGTCGCAGTGGT 1


RESULT 51
ADM94698/c
ID   ADM94698 standard; DNA; 21 BP.
XX
AC   ADM94698;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:48.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 48; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 1 C; 11 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        471 ACCCCACCCAAGTTTCCTCCT 491
              |||||||||||||||||||||
Db         21 ACCCCACCCAAGTTTCCTCCT 1


RESULT 52
ADM94718/c
ID   ADM94718 standard; DNA; 21 BP.
XX
AC   ADM94718;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:68.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 68; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 6 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        671 TGCCGCCACTGGCTGTGCCTC 691
              |||||||||||||||||||||
Db         21 TGCCGCCACTGGCTGTGCCTC 1


RESULT 53
ADM94728/c
ID   ADM94728 standard; DNA; 21 BP.
XX
AC   ADM94728;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:78.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
```

```
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 78; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 10 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        365 AAGGATGGCGTGGTGGAGATC 385
              |||||||||||||||||||||
Db         21 AAGGATGGCGTGGTGGAGATC 1


RESULT 54
ADM94674/c
ID   ADM94674 standard; DNA; 21 BP.
XX
AC   ADM94674;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:24.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 24; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 6 C; 12 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        231 CCGCGCCCGCCTACAGCCGCG 251
              |||||||||||||||||||||
Db         21 CCGCGCCCGCCTACAGCCGCG 1


RESULT 55
ADM94678/c
ID   ADM94678 standard; DNA; 21 BP.
XX
AC   ADM94678;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:28.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 28; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
```

```
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 9 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        271 CAGCGGGGTCTCGGAGATCCG 291
              |||||||||||||||||||||
Db         21 CAGCGGGGTCTCGGAGATCCG 1


RESULT 56
ADM94715/c
ID   ADM94715 standard; DNA; 21 BP.
XX
AC   ADM94715;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:65.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 65; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        641 TAAAGCCTTAGCCCGGATGCC 661
              |||||||||||||||||||||
Db         21 TAAAGCCTTAGCCCGGATGCC 1


RESULT 57
ADM94726/c
ID   ADM94726 standard; DNA; 21 BP.
XX
AC   ADM94726;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:76.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 76; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 3 C; 6 G; 9 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        744 AAAGTTCAAAGCAACCACCTG 764
              |||||||||||||||||||||
Db         21 AAAGTTCAAAGCAACCACCTG 1


RESULT 58
ADM94677/c
ID   ADM94677 standard; DNA; 21 BP.
XX
AC   ADM94677;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:27.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
```

```
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 27; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        261 GGCAACTCAGCAGCGGGGTCT 281
              |||||||||||||||||||||
Db         21 GGCAACTCAGCAGCGGGGTCT 1


RESULT 59
ADM94699/c
ID   ADM94699 standard; DNA; 21 BP.
XX
AC   ADM94699;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:49.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 49; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 7 A; 2 C; 11 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        481 AGTTTCCTCCTCCCTGTCCCC 501
              |||||||||||||||||||||
Db         21 AGTTTCCTCCTCCCTGTCCCC 1


RESULT 60
ADM94719/c
ID   ADM94719 standard; DNA; 21 BP.
XX
AC   ADM94719;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:69.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 69; 38pp; English.
XX
```

```
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 12 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        681 GGCTGTGCCTCCCCCGCCACC 701
              |||||||||||||||||||||
Db         21 GGCTGTGCCTCCCCCGCCACC 1


RESULT 61
ADM94671/c
ID   ADM94671 standard; DNA; 21 BP.
XX
AC   ADM94671;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:21.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 21; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 5 C; 12 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        201 CCCCCGCCGCCATCGAGAGCC 221
              |||||||||||||||||||||
Db         21 CCCCCGCCGCCATCGAGAGCC 1


RESULT 62
ADM94679/c
ID   ADM94679 standard; DNA; 21 BP.
XX
AC   ADM94679;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:29.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 29; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        281 TCGGAGATCCGGCACACTGCG 301
              |||||||||||||||||||||
Db         21 TCGGAGATCCGGCACACTGCG 1


RESULT 63
ADM94683/c
ID   ADM94683 standard; DNA; 21 BP.
XX
AC   ADM94683;
```

```
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:33.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 33; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        321 TGGATGTCAACCACTTCGCCC 341
              |||||||||||||||||||||
Db         21 TGGATGTCAACCACTTCGCCC 1


RESULT 64
ADM94693/c
ID   ADM94693 standard; DNA; 21 BP.
XX
AC   ADM94693;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:43.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 43; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 6 A; 3 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        421 CTACATCTCCCGGTGCTTCAC 441
              |||||||||||||||||||||
Db         21 CTACATCTCCCGGTGCTTCAC 1


RESULT 65
ADM94694/c
ID   ADM94694 standard; DNA; 21 BP.
XX
AC   ADM94694;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:44.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
```

```
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 44; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        431 CGGTGCTTCACGCGGAAATAC 451
              |||||||||||||||||||||
Db         21 CGGTGCTTCACGCGGAAATAC 1


RESULT 66
ADM94722/c
ID   ADM94722 standard; DNA; 21 BP.
XX
AC   ADM94722;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:72.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 72; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 12 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        711 TTTTGATACATTTATCTTCTG 731
              |||||||||||||||||||||
Db         21 TTTTGATACATTTATCTTCTG 1


RESULT 67
ADM94723/c
ID   ADM94723 standard; DNA; 21 BP.
XX
AC   ADM94723;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:73.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 73; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 13 A; 1 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        721 TTTATCTTCTGTTTTTCTCAA 741
              |||||||||||||||||||||
```

```
Db         21 TTTATCTTCTGTTTTTCTCAA 1


RESULT 68
ADM94682/c
ID   ADM94682 standard; DNA; 21 BP.
XX
AC   ADM94682;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:32.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 32; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        311 CGCGTGTCCCTGGATGTCAAC 331
              |||||||||||||||||||||
Db         21 CGCGTGTCCCTGGATGTCAAC 1


RESULT 69
ADM94655/c
ID   ADM94655 standard; DNA; 21 BP.
XX
AC   ADM94655;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:5.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 5; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 6 A; 5 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         41 GTCCCCTTCTCGCTCCTGCGG 61
              |||||||||||||||||||||
Db         21 GTCCCCTTCTCGCTCCTGCGG 1


RESULT 70
ADM94656/c
ID   ADM94656 standard; DNA; 21 BP.
XX
AC   ADM94656;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:6.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
```

```
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 6; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 CGCTCCTGCGGGGCCCCAGCT 71
              |||||||||||||||||||||
Db         21 CGCTCCTGCGGGGCCCCAGCT 1


RESULT 71
ADM94664/c
ID   ADM94664 standard; DNA; 21 BP.
XX
AC   ADM94664;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:14.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 14; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 10 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        131 CCCCGGCTGCCGGAGGAGTGG 151
              |||||||||||||||||||||
Db         21 CCCCGGCTGCCGGAGGAGTGG 1


RESULT 72
ADM94666/c
ID   ADM94666 standard; DNA; 21 BP.
XX
AC   ADM94666;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:16.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 16; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
```

```
SQ   Sequence 21 BP; 4 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        151 GTCGCAGTGGTTAGGCGGCAG 171
              |||||||||||||||||||||
Db         21 GTCGCAGTGGTTAGGCGGCAG 1


RESULT 73
ADM94673/c
ID   ADM94673 standard; DNA; 21 BP.
XX
AC   ADM94673;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:23.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 23; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 7 C; 12 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        221 CCCGCAGTGGCCGCGCCCGCC 241
              |||||||||||||||||||||
Db         21 CCCGCAGTGGCCGCGCCCGCC 1


RESULT 74
ADM94659/c
ID   ADM94659 standard; DNA; 21 BP.
XX
AC   ADM94659;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:9.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 9; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         81 TCCGCGACTGGTACCCGCATA 101
              |||||||||||||||||||||
Db         21 TCCGCGACTGGTACCCGCATA 1


RESULT 75
ADM94681/c
ID   ADM94681 standard; DNA; 21 BP.
XX
AC   ADM94681;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:31.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
```

```
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 31; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 8 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        301 GGACCGCTGGCGCGTGTCCCT 321
              |||||||||||||||||||||
Db         21 GGACCGCTGGCGCGTGTCCCT 1


RESULT 76
ADM94696/c
ID   ADM94696 standard; DNA; 21 BP.
XX
AC   ADM94696;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:46.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 46; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        451 CACGCTGCCCCCCGGTGTGGA 471
              |||||||||||||||||||||
Db         21 CACGCTGCCCCCCGGTGTGGA 1


RESULT 77
ADM94707/c
ID   ADM94707 standard; DNA; 21 BP.
XX
AC   ADM94707;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:57.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 57; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
```

```
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 2 C; 10 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 TCACCATCCCAGTCACCTTCG 581
              |||||||||||||||||||||
Db         21 TCACCATCCCAGTCACCTTCG 1


RESULT 78
ADM94675/c
ID   ADM94675 standard; DNA; 21 BP.
XX
AC   ADM94675;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:25.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 25; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 6 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        241 CTACAGCCGCGCGCTCAGCCG 261
              |||||||||||||||||||||
Db         21 CTACAGCCGCGCGCTCAGCCG 1


RESULT 79
ADM94695/c
ID   ADM94695 standard; DNA; 21 BP.
XX
AC   ADM94695;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:45.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 45; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 5 C; 9 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        441 CGCGGAAATACACGCTGCCCC 461
              |||||||||||||||||||||
Db         21 CGCGGAAATACACGCTGCCCC 1


RESULT 80
ADM94708/c
ID   ADM94708 standard; DNA; 21 BP.
XX
AC   ADM94708;
XX
DT   01-JUL-2004  (first entry)
```

```
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:58.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 58; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        571 AGTCACCTTCGAGTCGCGGGC 591
              |||||||||||||||||||||
Db         21 AGTCACCTTCGAGTCGCGGGC 1


RESULT 81
ADM94710/c
ID   ADM94710 standard; DNA; 21 BP.
XX
AC   ADM94710;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:60.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 60; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        591 CCCAGCTTGGGGGCCCAGAAG 611
              |||||||||||||||||||||
Db         21 CCCAGCTTGGGGGCCCAGAAG 1


RESULT 82
ADM94720/c
ID   ADM94720 standard; DNA; 21 BP.
XX
AC   ADM94720;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:70.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
```

```
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 70; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 6 A; 4 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        691 CCCCCGCCACCTGTGTGTTCT 711
              |||||||||||||||||||||
Db         21 CCCCCGCCACCTGTGTGTTCT 1


RESULT 83
ADM94730/c
ID   ADM94730 standard; DNA; 21 BP.
XX
AC   ADM94730;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:80.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 80; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.5;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        264 AACTCAGCAGCGGGGTCTCGG 284
              |||||||||||||||||||||
Db         21 AACTCAGCAGCGGGGTCTCGG 1


RESULT 84
ADM94732/c
ID   ADM94732 standard; DNA; 20 BP.
XX
AC   ADM94732;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:82.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 6; SEQ ID NO 82; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCCC 45
              ||||||||||||||||||||
Db         20 ATGACCGAGCGCCGCGTCCC 1
```

```
RESULT 85
ADO55958
ID   ADO55958 standard; DNA; 20 BP.
XX
AC   ADO55958;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Probe HSP27 for detecting gene expression in metastatic melanoma cells.
XX
KW   ss; probe; detection; metastatic melanoma; GaINAcT; PAX3.
XX
OS   Homo sapiens.
XX
PN   WO2004045521-A2.
XX
PD   03-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-US036493.
XX
PR   14-NOV-2002; 2002US-0426216P.
XX
PA   (WAYN-) WAYNE CANCER INST JOHN.
XX
PI   Hoon DSB,  Takeuchi H;
XX
DR   WPI; 2004-420519/39.
XX
PT   Detecting metastatic melanoma cells in a patient by isolating nucleic
PT   acid from a biological sample obtained from the patient, amplifying
PT   nucleic acid targets, if present, from a panel of marker genes.
XX
PS   Example 4; SEQ ID NO 13; 43pp; English.
XX
CC   The invention relates to a method of detecting metastatic melanoma cells
CC   in a patient by: (a) isolating nucleic acid from a biological sample
CC   obtained from the patient; (b) amplifying nucleic acid targets, if
CC   present, from a panel of marker genes, where the panel comprises GaINAcT
CC   and/or PAX3; and (c) detecting the presence or absence of the nucleic
CC   acid targets. The method is useful in detecting metastatic melanoma
CC   cells. This sequence corresponds to a probe used in the method of the
CC   invention.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        399 AGGAGCGGCAGGACGAGCAT 418
              ||||||||||||||||||||
Db          1 AGGAGCGGCAGGACGAGCAT 20


RESULT 86
ADM94740
ID   ADM94740 standard; DNA; 19 BP.
XX
AC   ADM94740;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:90.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 10; SEQ ID NO 90; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC   which is used in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 3 A; 8 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 14;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCC 44
              |:|||||||||||||:||
Db          1 AUGACCGAGCGCCGCGUCC 19


RESULT 87
ADM94737
ID   ADM94737 standard; DNA; 19 BP.
XX
AC   ADM94737;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:87.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
```

```
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 10; SEQ ID NO 87; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC   which is used in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 5 A; 8 C; 3 G; 0 T; 3 U; 0 Other;

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 14;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        556 CGAGATCACCATCCCAGTC 574
              |||||:|||||:|||||:|
Db          1 CGAGAUCACCAUCCCAGUC 19


RESULT 88
ABA00784
ID   ABA00784 standard; DNA; 21 BP.
XX
AC   ABA00784;
XX
DT   01-APR-2003  (first entry)
XX
DE   HSP27 forward primer.
XX
KW   Primer; PCR; amplify; heat shock protein; HSP; HSP27; inducer;
KW   digestive system; nephropathy; inflammation; arthritis;
KW   chronic rheumatism; arthritis deformans; asthma; allergy;
KW   arteriosclerosis; diabetic complication; diabetic neuropathy;
KW   chronic obstructive pulmonary disease; systemic lupus erythematosus;
KW   autoimmune haemolytic anaemia; psoriasis; neurodegeneration;
KW   Parkinson's disease; AIDS related dementia; CNS; cerebral haemorrhage;
KW   cerebral ischaemia; toxaemia; cachexia; cancer; Addison's disease;
KW   viral infection; pain; chronic inflammation; toothache; angina; ss.
XX
OS   Synthetic.
XX
PN   WO200278705-A1.
XX
PD   10-OCT-2002.
XX
PF   27-MAR-2002; 2002WO-JP002946.
XX
PR   28-MAR-2001; 2001JP-00092704.
XX
PA   (TAKE ) TAKEDA CHEM IND LTD.
XX
PI   Terashita Z,  Naruo K,  Uchikawa O,  Nakanishi A;
XX
DR   WPI; 2003-111786/10.
XX
PT   Heat shock protein (HSP) inducer comprises a fused bicyclic or tricyclic
PT   compound.
XX
PS   Example 4; Page 46; 66pp; Japanese.
XX
CC   The sequences given in ABA00784-86 are primers and a probe which were
CC   used in the amplification and isolation of the heat shock protein (HSP)
CC   27 coding sequence. These sequences may be used to monitor the
CC   effectiveness of the heat shock protein inducer of the invention. The HSP
CC   inducer of the invention may be used for treating and preventing
CC   digestive system disorders, nephropathies, inflammatory diseases,
CC   arthritis, chronic rheumatism and arthritis deformans. The inducer may
CC   also be useful for treating and preventing asthma, allergic diseases,
CC   arteriosclerosis, diabetic complications (e.g. diabetic neuropathy),
CC   chronic obstructive pulmonary disease, systemic lupus erythematosus,
CC   autoimmune haemolytic anaemia, psoriasis, neuro- degenerative disorders
CC   (e.g. Parkinson's disease or AIDS related dementia), CNS disorders (e.g.
CC   cerebral haemorrhage or cerebral ischaemia), toxaemia, cachexia, cancer,
CC   Addison's disease, viral infections or pain (e.g. due to chronic
CC   inflammatory diseases, toothache or angina)
XX
SQ   Sequence 21 BP; 7 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 22;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        359 AAGACCAAGGATGGCGTGGT 378
              ||||||||||| ||||||||
Db          2 AAGACCAAGGAAGGCGTGGT 21


RESULT 89
ADM94727/c
ID   ADM94727 standard; DNA; 18 BP.
XX
AC   ADM94727;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:77.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 77; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
```

```
SQ   Sequence 18 BP; 2 A; 6 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        226 AGTGGCCGCGCCCGCCTA 243
              ||||||||||||||||||
Db         18 AGTGGCCGCGCCCGCCTA 1


RESULT 90
ADM94739
ID   ADM94739 standard; DNA; 21 BP.
XX
AC   ADM94739;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:89.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 10; SEQ ID NO 89; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC   which is used in the exemplification of the present invention.
XX
SQ   Sequence 21 BP; 0 A; 9 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 29;
  Matches   16;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        576 CCTTCGAGTCGCGGGCCCAGC 596
              ||::|| |:||||||||| ||
Db          1 CCUUCGUGUCGCGGGCCCUGC 21


RESULT 91
ABA00785/c
ID   ABA00785 standard; DNA; 22 BP.
XX
AC   ABA00785;
XX
DT   01-APR-2003  (first entry)
XX
DE   HSP27 reverse primer.
XX
KW   Primer; PCR; amplify; heat shock protein; HSP; HSP27; inducer;
KW   digestive system; nephropathy; inflammation; arthritis;
KW   chronic rheumatism; arthritis deformans; asthma; allergy;
KW   arteriosclerosis; diabetic complication; diabetic neuropathy;
KW   chronic obstructive pulmonary disease; systemic lupus erythematosus;
KW   autoimmune haemolytic anaemia; psoriasis; neurodegeneration;
KW   Parkinson's disease; AIDS related dementia; CNS; cerebral haemorrhage;
KW   cerebral ischaemia; toxaemia; cachexia; cancer; Addison's disease;
KW   viral infection; pain; chronic inflammation; toothache; angina; ss.
XX
OS   Synthetic.
XX
PN   WO200278705-A1.
XX
PD   10-OCT-2002.
XX
PF   27-MAR-2002; 2002WO-JP002946.
XX
PR   28-MAR-2001; 2001JP-00092704.
XX
PA   (TAKE ) TAKEDA CHEM IND LTD.
XX
PI   Terashita Z,  Naruo K,  Uchikawa O,  Nakanishi A;
XX
DR   WPI; 2003-111786/10.
XX
PT   Heat shock protein (HSP) inducer comprises a fused bicyclic or tricyclic
PT   compound.
XX
PS   Example 4; Page 46; 66pp; Japanese.
XX
CC   The sequences given in ABA00784-86 are primers and a probe which were
CC   used in the amplification and isolation of the heat shock protein (HSP)
CC   27 coding sequence. These sequences may be used to monitor the
CC   effectiveness of the heat shock protein inducer of the invention. The HSP
CC   inducer of the invention may be used for treating and preventing
CC   digestive system disorders, nephropathies, inflammatory diseases,
CC   arthritis, chronic rheumatism and arthritis deformans. The inducer may
CC   also be useful for treating and preventing asthma, allergic diseases,
CC   arteriosclerosis, diabetic complications (e.g. diabetic neuropathy),
CC   chronic obstructive pulmonary disease, systemic lupus erythematosus,
CC   autoimmune haemolytic anaemia, psoriasis, neuro- degenerative disorders
CC   (e.g. Parkinson's disease or AIDS related dementia), CNS disorders (e.g.
CC   cerebral haemorrhage or cerebral ischaemia), toxaemia, cachexia, cancer,
CC   Addison's disease, viral infections or pain (e.g. due to chronic
CC   inflammatory diseases, toothache or angina)
XX
SQ   Sequence 22 BP; 6 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 32;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        413 GAGCATGGCTACATCTCCCGG 433
              || |||||||||||||| |||
Db         21 GAACATGGCTACATCTCTCGG 1


RESULT 92
AAA66267
ID   AAA66267 standard; DNA; 20 BP.
XX
AC   AAA66267;
XX
DT   09-OCT-2000  (first entry)
```

XX
DE Dog genomic marker oligonucleotide sequence SEQ ID NO:129.
XX
KW Dog; genome; genomic marker; radiation hybrid map; identification;
KW chromosome location; gene marker; polymorphic microsatellite marker;
KW phenotype; behaviour; pedigree; ss.
XX
OS Canis familiaris.
XX
PN WO200029615-A2.
XX
PD 25-MAY-2000.
XX
PF 15-NOV-1999; 99WO-IB001907.
XX
PR 13-NOV-1998; 98US-0108193P.
XX
PA (CNRS) CNRS CENT NAT RECH SCI.
XX
PI Galibert F, Andre C;
XX
DR WPI; 2000-387821/33.
XX
PT New radiation hybrid map of the dog, Canine familiaris, genome, useful
PT for e.g. identifying genes implicated in phenotypic and behavioral traits
PT or in genetic diseases and for studying dog pedigrees.
XX
PS Claim 1; Page 58; 87pp; English.
XX
CC The present invention describes a radiation hybrid map of the dog (Canine
CC familiaris) genome comprising the genome location of a marker selected
CC from AAA66139 to AAA66942. The radiation hybrid map is useful for
CC identifying and localising dog genes, since it covers approximately 80 %
CC of the dog genome and provides a dense map integrating different types
CC (i.e. Type I and Type II) of markers. The map and the dog genome markers
CC (or complementary sequences) are especially useful to identify genes
CC responsible for phenotypic and behavioural traits in dogs, to identify
CC morbid genes, to analyse diseases and identify implicated genes in such
CC diseases and their alleles, and to study dog pedigrees. They may also be
CC useful for isolating corresponding human gene sequences e.g. genes
CC involved in genetic diseases
XX
SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 31;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        495 TGTCCCCTGAGGGCACACT 513
              ||||||||||||||||| ||
Db          1 TGTCCCCTGAGGGCACTCT 19
```

RESULT 93
ABT34675
ID ABT34675 standard; DNA; 17 BP.
XX
AC ABT34675;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 312.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 70; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17
```

RESULT 94
ADB45935
ID ADB45935 standard; DNA; 17 BP.
XX
AC ADB45935;
XX
DT 18-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #6258.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.

```
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 763; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 95
ADE30781
ID   ADE30781 standard; DNA; 17 BP.
XX
AC   ADE30781;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Cholesterol homeostasis/adipogenesis related DNA seq id 168.
XX
KW   expression vector; anorectic; antiarteriosclerotic; cardiant;
KW   antidiabetic; elevated cholesterol; elevated lipid; adipogenesis;
KW   obesity; athersclerosis; diabetes mellitus;
KW   coronary artery heart disease; cholesterol homeostasis; ss;
KW   differntial expression.
XX
OS   Homo sapiens.
XX
PN   US2003180764-A1.
XX
PD   25-SEP-2003.
XX
PF   08-JAN-2003; 2003US-00339793.
XX
PR   09-JAN-2002; 2002US-0347286P.
XX
PA   (LYNX-) LYNX THERAPEUTICS INC.
XX
PI   Shang J,  Bowen B;
XX
DR   WPI; 2003-830986/77.
XX
PT   Polynucleotides differentially regulated in response to cholesterol and
PT   adipogenesis are useful to detect and treat associated conditions such as
PT   obesity, athersclerosis, diabetes mellitus and coronary artery heart
PT   disease.
XX
PS   Claim 8; SEQ ID NO 168; 59pp; English.
XX
CC   The invention describes a composition comprising at least one expression
CC   vector comprising a polynucleotide of the invention. The composition has
CC   anorectic, antiarteriosclerotic, cardiant and antidiabetic properties.
CC   The invention is used to detect and treat conditions associated with
CC   elevated cholesterol and lipid or during adipogenesis, particularly
CC   obesity, athersclerosis, diabetes mellitus or coronary artery heart
CC   disease. This sequence represents a polynucleotide differentially
CC   expressed during cholesterol homeostasis and adipogenesis.
XX
SQ   Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 96
ADI52044
ID   ADI52044 standard; DNA; 17 BP.
XX
AC   ADI52044;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID4547.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 4547; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
```

```
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 97
ACC51537
ID   ACC51537 standard; DNA; 17 BP.
XX
AC   ACC51537;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #304.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 110; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 98
ADR30706/c
ID   ADR30706 standard; DNA; 18 BP.
XX
AC   ADR30706;
XX
DT   18-NOV-2004  (first entry)
XX
DE   Skunk cabbage S. foetidus alternative oxidase gene primer, RACE-R2-4.
XX
KW   skunk cabbage; Symplocarpus foetidus alternative oxidase; Sfaox;
KW   skunk cabbage origin cyanogen resistant respiratory enzyme; Sfpre-AOX;
KW   mitochondria transfer signal peptide; Sfmit1; low temperature; heat;
KW   plant; homeothermism; environmental purification; genetic engineering;
KW   crop breeding; diabetes; obesity; primer; ss.
XX
OS   Unidentified.
XX
PN   JP2004242643-A.
XX
PD   02-SEP-2004.
XX
PF   17-FEB-2003; 2003JP-00038874.
XX
PR   17-FEB-2003; 2003JP-00038874.
XX
PA   (IWAT-) UNIV IWATE.
XX
DR   WPI; 2004-629613/61.
XX
PT   Novel skunk cabbage Symplocarpus foetidus alternative oxidase gene
PT   encoding skunk cabbage origin cyanogen resistant respiratory enzyme Sfpre
PT   -AOX, useful in development of crops capable of growing at low
PT   temperature.
XX
PS   Example 1; SEQ ID NO 7; 26pp; Japanese.
XX
CC   The invention relates to a novel skunk cabbage Symplocarpus foetidus
CC   alternative oxidase (Sfaox) gene encoding a skunk cabbage origin cyanogen
CC   resistant respiratory enzyme, Sfpre-AOX, having a fully defined sequence
CC   of 349 amino acids as given in the specification. The invention further
CC   comprises: a polynucleotide purified from the genomic DNA, mRNA and cDNA
CC   or complementary sequence of the Sfaox gene; an oligonucleotide probe
CC   hybridising under stringent conditions with the purified polynucleotide
CC   from above; an oligonucleotide primer set carrying out PCR amplification
CC   of the purified polynucleotide; a recombinant vector containing the
CC   purified polynucleotide; transforming a somatic cell using the vector; an
CC   expression product of the Sfaox gene, comprising a skunk cabbage origin
CC   cyanogen resistant respiratory enzyme Sfpre-AOX having the 349 amino acid
CC   protein; a mitochondria transfer signal peptide Sfmit1, which is a
CC   portion of enzyme Sfpre-AOX; a protein SfmAOX having a fully defined
CC   sequence of 328 amino acids as given in the specification, and capable of
CC   being transferred to a mitochondrial inner membrane and functioning as a
CC   cyanogen resistant respiratory enzyme, where the protein is a portion of
CC   enzyme Sfpre-AOX; an oligonucleotide encoding the mitochondria transfer
CC   signal peptide; and a polynucleotide encoding the SfmAOX protein. The
CC   Sfaox gene is useful in the development of crops capable of growing at
CC   low temperature, as the cyanogen resistant respiratory enzyme encoded by
CC   the Sfaox gene is useful for generating heat in a plant, and for
CC   maintaining homeothermism. The Sfaox gene is useful in developing
CC   microorganisms involved in environmental purification. The expression
CC   product of the Sfaox gene is useful in genetic engineering for crop
CC   breeding and in the medicinal field for the development of drugs related
CC   to diabetes or obesity. This polynucleotide sequence represents a primer
CC   of the skunk cabbage Symplocarpus foetidus alternative oxidase (Sfaox)
CC   gene of the invention.
```

```
XX
SQ   Sequence 18 BP; 4 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.1%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 37;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        326 GTCAACCACTTCGCCCCG 343
              ||||||||||||||| ||
Db         18 GTCAACCACTTCGCCTCG 1


RESULT 99
ADI00879
ID   ADI00879 standard; DNA; 19 BP.
XX
AC   ADI00879;
XX
DT   22-APR-2004  (first entry)
XX
DE   RT-PCR 32P end-labelled Pell primer used to amplify human MUC5B RNA.
XX
KW   MUC5B-b1; MUC5B-b2; mucin; MUC5B promoter; ss; PCR; primer; human;
KW   RT-PCR; Pell.
XX
OS   Homo sapiens.
XX
PN   US2003096219-A1.
XX
PD   22-MAY-2003.
XX
PF   21-NOV-2001; 2001US-00990613.
XX
PR   21-NOV-2001; 2001US-00990613.
XX
PA   (WURR/) WU R.
PA   (CHEN/) CHEN Y.
XX
PI   Wu R,  Chen Y;
XX
DR   WPI; 2004-088749/09.
XX
PT   Novel MUC5B gene useful for identifying a compound capable of modulating
PT   MUC5B gene promoter activity.
XX
PS   Example 5; SEQ ID NO 7; 52pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid molecule
CC   comprising a nucleotide sequence chosen from a fully defined sequence of
CC   MUC5B-b1 and MUC5B-b2. The method of the invention may be useful for
CC   identifying a compound capable of modulating mucin MUC5B gene promoter
CC   activity. The current sequence is that of the RT-PCR 32P end-labelled
CC   Pell primer of the invention which was used to amplify human MUC5B RNA.
XX
SQ   Sequence 19 BP; 4 A; 7 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 53;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        403 GCGGCAGGACGAGCATGGC 421
              ||||||  ||||||||||
Db          1 GCGGCACCACGAGCATGGC 19


RESULT 100
ADM94733
ID   ADM94733 standard; DNA; 19 BP.
XX
AC   ADM94733;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:83.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 10; SEQ ID NO 83; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC   which is used in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 0 A; 6 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 53;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        266 CTCAGCAGCGGGGTCTCGG 284
              |:| || ||||||:|:|||
Db          1 CUCUGCUGCGGGGUCUCGG 19


RESULT 101
ADM94657
ID   ADM94657 standard; DNA; 21 BP.
XX
AC   ADM94657;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:7.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
```

```
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 7; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 65;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         60 GGGGCCCCAGCTGGGACCC 78
              |||| |||||||||| |||
Db          3 GGGGTCCCAGCTGGGGCCC 21


RESULT 102
ABN10675
ID   ABN10675 standard; DNA; 17 BP.
XX
AC   ABN10675;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10667.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10667; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 50;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 103
ADB45924
ID   ADB45924 standard; DNA; 17 BP.
XX
AC   ADB45924;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #6247.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
```

```
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 762; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 5 A; 8 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 50;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||||||||| ||
Db          1 GATCACCATCCCAGCCA 17


RESULT 104
ADI48414
ID   ADI48414 standard; DNA; 17 BP.
XX
AC   ADI48414;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID917.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 917; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 5 A; 8 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 50;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||||||||| ||
Db          1 GATCACCATCCCAGCCA 17


RESULT 105
ADG71955/c
ID   ADG71955 standard; DNA; 17 BP.
XX
AC   ADG71955;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human NOVX related primer #3.
XX
KW   human; NOVX-associated disorder; NOVX; cancer; infectious disease;
KW   anorexia; Alzheimer's disease; Parkinson's disease; immune disorder;
KW   haematopoietic disorder; dyslipidaemia; diabetes; obesity;
KW   metabolic syndrome X; tissue typing; vaccine; ss; primer.
XX
OS   Homo sapiens.
XX
PN   US2003232347-A1.
XX
PD   18-DEC-2003.
XX
PF   01-AUG-2002; 2002US-00211689.
XX
PR   08-AUG-2001; 2001US-0310795P.
PR   08-AUG-2001; 2001US-0310802P.
PR   09-AUG-2001; 2001US-0311292P.
PR   10-AUG-2001; 2001US-0311571P.
PR   10-AUG-2001; 2001US-0311594P.
PR   10-AUG-2001; 2001US-0311751P.
PR   13-AUG-2001; 2001US-0311979P.
PR   16-AUG-2001; 2001US-0312892P.
PR   17-AUG-2001; 2001US-0313201P.
PR   21-AUG-2001; 2001US-0314031P.
PR   29-AUG-2001; 2001US-0315853P.
PR   17-SEP-2001; 2001US-0322716P.
```

```
PR   21-SEP-2001; 2001US-0323944P.
PR   21-FEB-2002; 2002US-0359294P.
PR   28-FEB-2002; 2002US-0360890P.
PR   28-FEB-2002; 2002US-0361159P.
PR   16-APR-2002; 2002US-0372998P.
PR   16-APR-2002; 2002US-0373050P.
PR   15-MAY-2002; 2002US-0380970P.
PR   15-MAY-2002; 2002US-0380971P.
PR   16-MAY-2002; 2002US-0381030P.
XX
PA   (ANDE/) ANDERSON D W.
PA   (ALSO/) ALSOBROOK J P.
PA   (BOLD/) BOLDOG F L.
PA   (BURG/) BURGESS C E.
PA   (CASM/) CASMAN S J.
PA   (EDIN/) EDINGER S R.
PA   (GANG/) GANGOLLI E A.
PA   (GORM/) GORMAN L.
PA   (GUOX/) GUO X S.
PA   (KHRA/) KHRAMTSOV N V.
PA   (LEPL/) LEPLEY D M.
PA   (MACD/) MACDOUGALL J R.
PA   (PENA/) PENA C E A.
PA   (PEYM/) PEYMAN J A.
PA   (PATT/) PATTURAJAN M.
PA   (RIEG/) RIEGER D K.
PA   (SHIM/) SHIMKETS R A.
PA   (SMIT/) SMITHSON G.
PA   (SPYT/) SPYTEK K A.
PA   (VERN/) VERNET C A M.
PA   (VOSS/) VOSS E Z.
PA   (ZHON/) ZHONG M.
XX
PI   Anderson DW, Alsobrook JP, Boldog FL, Burgess CE, Casman SJ;
PI   Edinger SR, Gangolli EA, Gorman L, Guo XS, Khramtsov NV, Lepley DM;
PI   Macdougall JR, Pena CEA, Peyman JA, Patturajan M, Rieger DK;
PI   Shimkets RA, Smithson G, Spytek KA, Vernet CAM, Voss EZ, Zhong M;
XX
DR   WPI; 2004-061271/06.
XX
PT   New NOVX polypeptides and nucleic acids, useful for diagnosing,
PT   preventing or treating NOVX-associated disorders, e.g. cancer, diabetes
PT   or immune diseases, and in chromosome mapping, tissue typing or
PT   pharmacogenomics.
XX
PS   Example; SEQ ID NO 82; 115pp; English.
XX
CC   The invention relates to a new isolated polypeptide. The polypeptide is
CC   useful in the manufacture of a medicament for treating a syndrome
CC   associated with a human disease selected from a pathology associated with
CC   the polypeptide. These are used in diagnosing, treating or preventing
CC   NOVX-associated disorders such as cancer, infectious diseases, anorexia,
CC   Alzheimer's disease, Parkinson's disease, immune disorders,
CC   haematopoietic disorders, dyslipidaemias, diabetes, obesity or metabolic
CC   syndrome X. The nucleic acids are further used as hybridisation probes,
CC   in chromosome mapping, tissue typing, preventive medicine, and
CC   pharmacogenomics. The polypeptides are also useful as vaccines. The
CC   present sequence is used in the exemplification of the invention.
XX
SQ   Sequence 17 BP; 0 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 50;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        399 AGGAGCGGCAGGACGAG 415
              |||||| ||||||||||
Db         17 AGGAGCAGCAGGACGAG 1


RESULT 106
ADJ87293/c
ID   ADJ87293 standard; DNA; 17 BP.
XX
AC   ADJ87293;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human G protein-coupled receptor NOV4 forward PCR primer SEQ ID NO:82.
XX
KW   human; NOVX; G protein-coupled receptor; GPCR; antiarteriosclerotic;
KW   hypotensive; dermatological; anorectic; cytostatic; antidiabetic;
KW   haemostatic; immunosuppressive; anti-HIV; antiasthmatic;
KW   antiinflammatory; neuroprotective; antimicrobial; anabolic;
KW   eating disorder; immunomodulator; nootropic; antiparkinsonian;
KW   antilipaemic; gene therapy; vaccine; cardiomyopathy; atherosclerosis;
KW   hypertension; scleroderma; obesity; cancer; diabetes; haemophilia;
KW   graft-versus-host disease; AIDS; asthma; Crohn's disease;
KW   multiple sclerosis; infection; anorexia; cancer-associated cachexia;
KW   neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
KW   haematopoietic disorder; dyslipidaemia; wasting disorder;
KW   chromosome mapping; tissue typing; preventive medicine; pharmacogenomic;
KW   PCR; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004015060-A2.
XX
PD   19-FEB-2004.
XX
PF   02-AUG-2002; 2002WO-US024492.
XX
PR   08-AUG-2001; 2001US-0310795P.
PR   08-AUG-2001; 2001US-0310802P.
PR   09-AUG-2001; 2001US-0311292P.
PR   10-AUG-2001; 2001US-0311571P.
PR   10-AUG-2001; 2001US-0311594P.
PR   10-AUG-2001; 2001US-0311751P.
PR   13-AUG-2001; 2001US-0311979P.
PR   16-AUG-2001; 2001US-0312892P.
PR   17-AUG-2001; 2001US-0313201P.
PR   21-AUG-2001; 2001US-0314031P.
PR   29-AUG-2001; 2001US-0315853P.
PR   17-SEP-2001; 2001US-0322716P.
PR   21-SEP-2001; 2001US-0323944P.
PR   21-FEB-2002; 2002US-0359294P.
PR   28-FEB-2002; 2002US-0360890P.
PR   28-FEB-2002; 2002US-0361159P.
PR   16-APR-2002; 2002US-0372998P.
PR   16-APR-2002; 2002US-0373050P.
PR   15-MAY-2002; 2002US-0380970P.
PR   15-MAY-2002; 2002US-0380971P.
PR   16-MAY-2002; 2002US-0381030P.
PR   01-AUG-2002; 2002US-00211689.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Anderson DW, Boldog FL, Casman SJ, Edinger SR, Gangolli EA;
PI   Gerlach VL, Gorman L, Guo X, Khramtsov NV, Li L, Macdougall JR;
PI   Pena CEA, Peyman JA, Patturajan M, Shimkets RA, Smithson G;
PI   Spytek KA, Vernet CAM, Voss EZ, Zhong M;
XX
DR   WPI; 2004-191740/18.
XX
PT   New NOVX polypeptides and nucleic acids, useful for preventing or
PT   treating NOVX-associated disorders, e.g. cancer, diabetes,
PT   atherosclerosis, asthma, and in chromosome mapping, tissue typing or
PT   pharmacogenomics.
XX
PS   Example C; SEQ ID NO 82; 210pp; English.
XX
CC   The present sequence represents a PCR primer for a human NOVX polypeptide
CC   (I), which is a G protein-coupled receptor (GPCR). Also described: (1) a
CC   composition comprising (I) and a carrier; (2) a kit comprising, in one or
CC   more containers, the composition of (1); (3) determining the presence or
```

```
CC   amount of the above polypeptide (I) in a sample; (4) determining the
CC   presence of or predisposition to a disease associated with altered levels
CC   of expression of (I) in a first mammalian subject; (5) identifying an
CC   agent that binds to the polypeptide (I); (6) identifying a potential
CC   therapeutic agent for use in the treatment of a pathology, where the
CC   pathology is related to aberrant expression or aberrant physiological
CC   interactions of polypeptide (I); (7) screening for a modulator of
CC   activity of or of latency or predisposition to a pathology associated
CC   with the polypeptide (I); (8) modulating the activity of the polypeptide
CC   (I); (9) treating or preventing a pathology associated with polypeptide
CC   (I), or treating a pathological state in a mammal; (10) an isolated
CC   nucleic acid molecule (II) encoding (I); (11) a vector (III) comprising
CC   (II); (12) a cell (IV) comprising (III); (13) an antibody that
CC   immunospecifically binds to (I); (14) determining the presence of or
CC   amount of (II) in a sample; (15) determining the presence of or
CC   predisposition to a disease associated with altered levels of expression
CC   of the nucleic acid molecule (II) in a first mammalian subject; and (16)
CC   producing the above polypeptide (I). (I) has antiarteriosclerotic,
CC   hypotensive, dermatological, anorectic, cytostatic, antidiabetic,
CC   haemostatic, immunosuppressive, anti-HIV, antiasthmatic,
CC   antiinflammatory, neuroprotective, antimicrobial, anabolic, eating
CC   disorder, immunomodulator, nootropic, antiparkinsonian and antilipaemic
CC   activities, and can be used in gene therapy, and in vaccines. The NOVX
CC   polypeptide (I) is useful in the manufacture of a medicament for treating
CC   a syndrome associated with a human disease, the disease selected from a
CC   pathology associated with the polypeptide. (I) may also be used in
CC   diagnosing, treating or preventing NOVX-associated disorders such as
CC   cardiomyopathy, atherosclerosis, hypertension, scleroderma, obesity,
CC   cancer, diabetes, haemophilia, graft-versus-host disease, AIDS, asthma,
CC   Crohn's disease, multiple sclerosis, infections, anorexia, cancer-
CC   associated cachexia, neurodegenerative disorders (e.g. Alzheimer's
CC   disease or Parkinson's disease), haematopoietic disorders, dyslipidaemias
CC   and other wasting disorders associated with chronic diseases. The nucleic
CC   acids (II) are also used as hybridisation probes, in chromosome mapping,
CC   tissue typing, preventive medicine, and pharmacogenomics.
XX
SQ   Sequence 17 BP; 0 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 50;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        399 AGGAGCGGCAGGACGAG 415
              ||||||  ||||||||||
Db         17 AGGAGCAGCAGGACGAG 1


RESULT 107
ACN73765
ID   ACN73765 standard; DNA; 17 BP.
XX
AC   ACN73765;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:10667.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 10667; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63103
XX
SQ   Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 50;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              |||||  ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 108
ADE29797
ID   ADE29797 standard; RNA; 19 BP.
XX
AC   ADE29797;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:419.
XX
KW   short interfering nucleic acid; siNA; downregulation; inhibition;
KW   mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW   cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW   immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW   antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW   inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW   psoriasis; inflammatory bowel disease; drug screening;
KW   genetic engineering; pharmacogenomic; gene mapping; ss.
```

```
XX
OS   Synthetic.
XX
PN   WO2003072590-A1.
XX
PD   04-SEP-2003.
XX
PF   28-JAN-2003; 2003WO-US002510.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N,  Haeberli P,  Chowrira B;
XX
DR   WPI; 2003-689980/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of mitogen-activated
PT   protein kinase genes.
XX
PS   Example 3; SEQ ID NO 419; 164pp; English.
XX
CC   The present invention describes a short interfering nucleic acid (siNA)
CC   that downregulates expression of a mitogen-activated protein kinase
CC   (MAPK) genes by RNA interference. Also described: (1) a method for
CC   modulating expression of MAPK genes in cells, tissue explants or
CC   organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC   vectors that express siNA and cells containing these vectors. MAPK siNAs
CC   have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC   antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC   antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC   siNAs can be used to modulate the expression of MAPK genes, in cells,
CC   tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC   and II; a wide range of tumours, and inflammatory diseases (asthma,
CC   septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC   disease). They can also be used for drug screening; diagnosis; target
CC   identification and validation; genetic engineering; pharmacogenomics;
CC   studying gene function and gene mapping (e.g. of single-nucleotide
CC   polymorphisms). The present sequence represents a MAPK siNA which is used
CC   in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 3 A; 10 C; 1 G; 0 T; 5 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 62;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        471 ACCCCACCCAAGTTTCC 487
              ||||||||| ||:::||
Db          1 ACCCCACCCUAGUUUCC 17


RESULT 109
ADE29902/c
ID   ADE29902 standard; RNA; 19 BP.
XX
AC   ADE29902;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:524.
XX
KW   short interfering nucleic acid; siNA; downregulation; inhibition;
KW   mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW   cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW   immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW   antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW   inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW   psoriasis; inflammatory bowel disease; drug screening;
KW   genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS   Synthetic.
XX
PN   WO2003072590-A1.
XX
PD   04-SEP-2003.
XX
PF   28-JAN-2003; 2003WO-US002510.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N,  Haeberli P,  Chowrira B;
XX
DR   WPI; 2003-689980/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of mitogen-activated
PT   protein kinase genes.
XX
PS   Example 3; SEQ ID NO 524; 164pp; English.
XX
CC   The present invention describes a short interfering nucleic acid (siNA)
CC   that downregulates expression of a mitogen-activated protein kinase
CC   (MAPK) genes by RNA interference. Also described: (1) a method for
CC   modulating expression of MAPK genes in cells, tissue explants or
CC   organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC   vectors that express siNA and cells containing these vectors. MAPK siNAs
CC   have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC   antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC   antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC   siNAs can be used to modulate the expression of MAPK genes, in cells,
CC   tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC   and II; a wide range of tumours, and inflammatory diseases (asthma,
CC   septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC   disease). They can also be used for drug screening; diagnosis; target
CC   identification and validation; genetic engineering; pharmacogenomics;
CC   studying gene function and gene mapping (e.g. of single-nucleotide
CC   polymorphisms). The present sequence represents a MAPK siNA which is used
CC   in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 5 A; 1 C; 10 G; 0 T; 3 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 62;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        471 ACCCCACCCAAGTTTCC 487
              ||||||||| |||||||
Db         19 ACCCCACCCTAGTTTCC 3


RESULT 110
ADO14933
ID   ADO14933 standard; RNA; 19 BP.
XX
AC   ADO14933;
XX
DT   01-JUL-2004  (first entry)
XX
```

```
DE   Human PDGFr-targeted siNA lower strand SEQ ID NO:364.
XX
KW   cytostatic; vasotropic; nephrotropic; cerebroprotective;
KW   treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW   bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW   short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW   double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW   expression modulation; gene therapy; drug screening; diagnosis;
KW   therapeutic target identification; pharmacogenomics;
KW   gene function analysis; gene mapping; human;
KW   platelet derived growth factor receptor; PDGFr; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003072704-A2.
XX
PD   04-SEP-2003.
XX
PF   05-FEB-2003; 2003WO-US003473.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-731605/69.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of tumors, downregulates expression of the platelet-derived
PT   growth factor receptor gene.
XX
PS   Example 3; SEQ ID NO 364; 148pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human platelet-derived growth factor
CC   receptor (PDGFr) gene by RNA interference. The siNAs may or may not
CC   comprise ribonucleotides and may be double or single stranded. They
CC   further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA, double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC   complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC   modulate expression of the PDGFr gene in cells, tissue explants or
CC   organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC   for the treatment of a variety of conditions. They may be used for
CC   treating leukaemia and solid tumours, restenosis, polycystic kidney
CC   disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC   useful for drug screening, diagnosis, therapeutic target identification
CC   and validation, genetic engineering, pharmacogenomics, studying gene
CC   function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC   The present sequence represents the lower strand of a human PDGFr-
CC   targeted double-stranded siNA, which is identical to the PDGFr transcript
CC   target sequence.
XX
SQ   Sequence 19 BP; 3 A; 11 C; 1 G; 0 T; 4 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 62;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       485 TCCTCCTCCCTGTCCCC 501
             :|| ||:|||:|:|||| 
Db         3 UCCACCUCCCUGUCCCC 19


RESULT 111
ADO14622/c
ID   ADO14622 standard; RNA; 19 BP.
XX
AC   ADO14622;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human PDGFr-targeted siNA upper strand SEQ ID NO:53.
XX
KW   cytostatic; vasotropic; nephrotropic; cerebroprotective;
KW   treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW   bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW   short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW   double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW   expression modulation; gene therapy; drug screening; diagnosis;
KW   therapeutic target identification; pharmacogenomics;
KW   gene function analysis; gene mapping; human;
KW   platelet derived growth factor receptor; PDGFr; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003072704-A2.
XX
PD   04-SEP-2003.
XX
PF   05-FEB-2003; 2003WO-US003473.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-731605/69.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of tumors, downregulates expression of the platelet-derived
PT   growth factor receptor gene.
XX
PS   Example 3; SEQ ID NO 53; 148pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human platelet-derived growth factor
CC   receptor (PDGFr) gene by RNA interference. The siNAs may or may not
CC   comprise ribonucleotides and may be double or single stranded. They
CC   further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA, double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC   complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC   modulate expression of the PDGFr gene in cells, tissue explants or
CC   organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC   for the treatment of a variety of conditions. They may be used for
CC   treating leukaemia and solid tumours, restenosis, polycystic kidney
CC   disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC   useful for drug screening, diagnosis, therapeutic target identification
CC   and validation, genetic engineering, pharmacogenomics, studying gene
CC   function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC   The present sequence represents the upper strand of a human PDGFr-
```

```
CC   targeted double-stranded siNA, which is identical to the PDGFr transcript
CC   target sequence.
XX
SQ   Sequence 19 BP; 4 A; 1 C; 11 G; 0 T; 3 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 62;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        485 TCCTCCTCCCTGTCCCC 501
              ||| ||||||||||||
Db         17 TCCACCTCCCTGTCCCC 1


RESULT 112
AAX31550
ID   AAX31550 standard; DNA; 15 BP.
XX
AC   AAX31550;
XX
DT   21-MAY-1999  (first entry)
XX
DE   Tag sequence of a transcript increased in pancreatic cancer.
XX
KW   Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
KW   diagnosis; prognosis; treatment; ss.
XX
OS   Homo sapiens.
XX
PN   WO9853319-A2.
XX
PD   26-NOV-1998.
XX
PF   20-MAY-1998;   98WO-US010277.
XX
PR   21-MAY-1997;   97US-0047352P.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Vogelstein B,  Kinzler KW;
XX
DR   WPI; 1999-070161/06.
XX
PT   Use of isolated gene transcripts - useful for developing products for the
PT   diagnosis, prognosis and treatment of cancers, particularly colon and
PT   pancreatic cancer.
XX
PS   Claim 13; Page 60; 120pp; English.
XX
CC   AAX30947-31815 represent tag sequences of transcripts that are
CC   differentially expressed in colorectal cancer, in pancreatic cancer, or
CC   in both. The tag sequences can be used to identify genes by matching the
CC   tag to a gen data base member, or by using the tag sequences as probes to
CC   isolate unidentified genes from cDNA libraries. The tag sequences can
CC   also be used in a method for diagnosing colon or pancreatic cancer in a
CC   sample suspected of being neoplastic. The method comprises comparing the
CC   level of at least one transcript in a first sample of a tissue to a
CC   second sample, where the first sample is a colonic tissue suspected of
CC   being neoplastic and the second sample is a normal human colonic tissue.
CC   The transcript is identified by a tag selected from AAX30947-31815. The
CC   methods of the invention can be used in the diagnosis, prognosis and
CC   treatment of cancer
XX
SQ   Sequence 15 BP; 4 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        529 CATGCCCAAGCTAGC 543
              |||||||||||||||
Db          1 CATGCCCAAGCTAGC 15


RESULT 113
AAF46290
ID   AAF46290 standard; DNA; 15 BP.
XX
AC   AAF46290;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1129.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 12 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        194 CCCCTGCCCCCCGCC 208
              |||||||||||||||
Db          1 CCCCTGCCCCCCGCC 15


RESULT 114
ABK32504
ID   ABK32504 standard; DNA; 15 BP.
```

```
XX
AC   ABK32504;
XX
DT   23-APR-2002  (first entry)
XX
DE   Human pancreatic cancer SAGE tag #56.
XX
KW   Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
KW   serial analysis of gene expression; diagnostic; prognostic; probe;
KW   cancer marker; ss.
XX
OS   Homo sapiens.
XX
PN   US6333152-B1.
XX
PD   25-DEC-2001.
XX
PF   20-MAY-1998;   98US-00081646.
XX
PR   20-MAY-1998;   98US-00081646.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Vogelstein B,  Kinzler KW,  Zhang L,  Zhou W;
XX
DR   WPI; 2002-153821/20.
XX
PT   New human nucleic acid containing specific SAGE tags, useful as
PT   diagnostic markers for cancer, also derived probes.
XX
PS   Disclosure; Col 69; 161pp; English.
XX
CC   The invention relates to an isolated, purified human nucleic acid (I)
CC   that has the same sequence as a mRNA found in humans and is a SAGE
CC   (serial analysis of gene expression) tag comprising a single stranded
CC   probe containing at least 10 consecutive nucleotides. SAGE tags, are
CC   diagnostic and prognostic markers of cancer, especially of the colon and
CC   pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
CC   SAGE tags of the invention
XX
SQ   Sequence 15 BP; 4 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        529 CATGCCCAAGCTAGC 543
              |||||||||||||||
Db          1 CATGCCCAAGCTAGC 15


RESULT 115
AAQ65740/c
ID   AAQ65740 standard; DNA; 18 BP.
XX
AC   AAQ65740;
XX
DT   25-MAR-2003  (revised)
DT   19-DEC-1994  (first entry)
XX
DE   Type II procollagen sequencing primer CW-14.
XX
KW   Type II procollagen; COL2A1; amplification; primer;
KW   polymerase chain reaction; PCR; osteoarthritis; cartilage; ss.
XX
OS   Synthetic.
XX
PN   WO9411532-A1.
XX
PD   26-MAY-1994.
XX
PF   12-NOV-1993;   93WO-US010964.
XX
PR   13-NOV-1992;   92US-00977284.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI   Prockop DJ,  Ala-Kokko L,  Williams CJ,  Ritvaniemi P,  Baldwin C;
PI   Hopkinson I,  Ahmad NN;
XX
DR   WPI; 1994-183530/22.
XX
PT   Detecting genetic pre-disposition to osteoarthritis - and other diseases
PT   involving mutation in cartilage protein genes, by amplification and
PT   analysis of DNA and comparison with standards.
XX
PS   Claim 18; Page 20; 112pp; English.
XX
CC   Claim 18 claims primers for use in detecting mutations in a mammalian
CC   gene for a structural protein of cartilage comprising a sequence
CC   identified in Table I (Page 18-31). Table I includes 179 primer sequences
CC   (see AAQ65728-Q65906). The following details are given for primer CW-14:
CC   Region/exon: 11 Direction: sense Primer position: 1640 (Updated on 25-MAR
CC   -2003 to correct PN field.)
XX
SQ   Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 71;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        129 TGCCCCGGCTGCCGGAGG 146
              ||||| |||||| |||||
Db         18 TGCCCTGGCTGCAGGAGG 1


RESULT 116
AAF77820
ID   AAF77820 standard; DNA; 18 BP.
XX
AC   AAF77820;
XX
DT   29-MAY-2001  (first entry)
XX
DE   PCR primer BAR2.
XX
KW   PCR primer; gene amplification; ss.
XX
OS   Unidentified.
XX
PN   JP2001008680-A.
XX
PD   16-JAN-2001.
XX
PF   30-JUN-1999;   99JP-00185279.
XX
PR   30-JUN-1999;   99JP-00185279.
XX
PA   (SHMA ) SHIMADZU CORP.
XX
DR   WPI; 2001-248255/26.
XX
PT   Amplification of viral, bacterial or fungal nucleic acids, by adding
PT   biological sample of a host infected with a microbe directly to
PT   amplification solution containing polyamine, sulfated polysaccharide,
PT   dithiothreitol.
XX
PS   Example 3; Page 5; 7pp; Japanese.
XX
CC   The present invention relates to a method for gene amplification. The
CC   method is useful for direct nucleic acid amplification of bacterial,
CC   fungal, protozoal genes, viral genes including DNA, RNA or retrovirus
CC   genes or a cell containing a malignant neoplasm without pre-processing.
CC   Nucleic acid amplification is carried out quickly and sensitively.
CC   Nucleic acid synthesis is not inhibited by the presence of impurities.
CC   The present sequence is a PCR primer used in the method of the present
```

```
CC   invention
XX
SQ   Sequence 18 BP; 5 A; 1 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 71;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        366 AGGATGGCGTGGTGGAGA 383
              ||||||||||  |||||
Db          1 AGGATGGCGTGAGGGAGA 18


RESULT 117
AAD38938/c
ID   AAD38938 standard; DNA; 18 BP.
XX
AC   AAD38938;
XX
DT   23-SEP-2002  (first entry)
XX
DE   Human Her-2 antisense oligonucleotide, ISIS #27965.
XX
KW   Human; Her-2; epidermal growth factor receptor 2; infection; cancer;
KW   hyperproliferative disorder; prophylaxis; inflammation; antisense;
KW   tumour; gene therapy; phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .18
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone"
FT   modified_base    1. .4
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    2
FT                    /*tag=  d
FT                    /mod_base= m5c
FT   modified_base    5
FT                    /*tag=  e
FT                    /mod_base= m5c
FT   modified_base    6
FT                    /*tag=  f
FT                    /mod_base= m5c
FT   modified_base    10
FT                    /*tag=  g
FT                    /mod_base= m5c
FT   modified_base    11
FT                    /*tag=  h
FT                    /mod_base= m5c
FT   modified_base    14
FT                    /*tag=  i
FT                    /mod_base= m5c
FT   modified_base    15. .18
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    15
FT                    /*tag=  j
FT                    /mod_base= m5c
FT   modified_base    16
FT                    /*tag=  k
FT                    /mod_base= m5c
XX
PN   WO200222636-A1.
XX
PD   21-MAR-2002.
XX
PF   12-SEP-2001; 2001WO-US028572.
XX
PR   15-SEP-2000; 2000US-00663834.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Cowsert LM;
XX
DR   WPI; 2002-471192/50.
XX
PT   Novel antisense oligonucleotide which modulates the expression of Human
PT   Epidermal Growth Factor receptor, Her2, is useful for treating tumors
PT   inflammation or to prevent infection in humans.
XX
PS   Claim 1; Page 89; 116pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding Her2 (human Epidermal Growth Factor receptor 2) that
CC   specifically hybridises with and inhibits the expression of Her2.
CC   Antisense compounds of the invention are used for treating diseases or
CC   conditions associated with Her2 such as hyperproliferative disorders e.g.
CC   lung, breast, gastric, oesophageal, colon, bladder, salivary, neural or
CC   cardiac cancer. They are also useful prophylactically e.g. to prevent or
CC   delay infection, inflammation and tumour formation. The invention is also
CC   used in gene therapy. The present sequence is an antisense
CC   oligonucleotide targetted to human Her-2
XX
SQ   Sequence 18 BP; 4 A; 8 C; 6 G; 0 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 71;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTGC 140
              |||||||| | |||||||
Db         18 TCGGGCTGGCTCGGCTGC 1


RESULT 118
ABK98126
ID   ABK98126 standard; DNA; 18 BP.
XX
AC   ABK98126;
XX
DT   07-OCT-2002  (first entry)
XX
DE   Triple helix forming associated oligonucleotide #15.
XX
KW   Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW   gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW   pathogenic bacteria; virus; replication; virulence; cancer;
KW   oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX
OS   Synthetic.
XX
PN   US6403302-B1.
XX
PD   11-JUN-2002.
XX
PF   16-DEC-1993;   93US-00168920.
XX
PR   17-SEP-1992;   92US-00946976.
XX
PA   (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX
PI   Dervan PB,  Beal PA;
XX
DR   WPI; 2002-536030/57.
XX
PT   A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT   oligonucleotide which binds in parallel and antiparallel orientation,
PT   respectively, for targetting sequences on alternate strands of DHNA to
PT   control gene expression.
XX
```

```
PS   Example 7; Col 41; 108pp; English.
XX
CC   The present invention relates to methods and oligonucleotides for forming
CC   a triple-helix comprising a double helical nucleic acid comprising first
CC   and second substantially complementary strands, and an oligonucleotide
CC   bound to a purine-rich target sequence within the double helical nucleic
CC   acid, where the oligonucleotide binds in a parallel and antiparallel
CC   orientation, respectively, to target sequences on alternate strands of
CC   the double helical nucleic acid. The method has therapeutic applications,
CC   where gene expression is controlled by selective triple-helix formation
CC   within expression regulatory sequences of a target gene. The
CC   oligonucleotides can be used to form triple-helices, and are useful to
CC   detect the presence or absence of specific sequences within genomic DNA
CC   for diagnostic and therapeutic purposes. The oligonucleotides can be
CC   selected to specifically bind to pathogenic double-stranded DNA including
CC   specific sequences required by pathogenic bacteria or viruses for
CC   replication or virulence, reducing their pathogenicity. Alternatively,
CC   the oligonucleotide can be chosen to target a unique sequence of the
CC   pathogen which is not found in the genome of pathogen's host. The
CC   oligonucleotides can be used in cancer treatment by way of triple-helix
CC   suppression of specific oncogenes including those of endogenous or viral
CC   origin. Such therapeutic oligonucleotides are capable of forming triple-
CC   helices with such sequences in cancerous cells containing the activated
CC   oncogene, so preferentially killing or repressing the cancer causing
CC   cell. The present sequence represents an oligonucleotide used in the
CC   methods of the present invention
XX
SQ   Sequence 18 BP; 0 A; 2 C; 0 G; 14 T; 0 U; 2 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 71;
  Matches   15;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        721 TTTATCTTCTGTTTTTCT 738
              |||:| ||||:|||||||
Db          1 TTTDTTTTCTDTTTTTCT 18


RESULT 119
ABS66626/c
ID   ABS66626 standard; DNA; 18 BP.
XX
AC   ABS66626;
XX
DT   29-NOV-2002  (first entry)
XX
DE   TN-KpnI-fo PCR primer.
XX
KW   Scaffold protein; C-type lectin-like domain; CTLD; alpha-helix;
KW   beta-strand; connecting segment; 14loop region; tetranectin;
KW   ligand-binding specificity; human; PCR; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200248189-A2.
XX
PD   20-JUN-2002.
XX
PF   13-DEC-2001; 2001WO-DK000825.
XX
PR   13-DEC-2000; 2000DK-00001872.
PR   28-FEB-2001; 2001US-0272098P.
XX
PA   (BORE-) BOREAN PHARMA AS.
XX
PI   Etzerodt M,  Holtet TL,  Graversen NJH,  Thogersen HC;
XX
DR   WPI; 2002-643278/69.
XX
PT   Protein comprising a variant of model C-type lectin-like domains (CTLD),
PT   in which alpha helices, beta-strands, connecting segments are conserved
PT   to maintain CTLD scaffold structure, while the loop region is altered.
XX
PS   Example 5; Page 157; 168pp; English.
XX
CC   The present invention relates to a new protein with scaffold structure of
CC   C-type lectin-like domains (CTLD). The invention comprises a variant of a
CC   model CTLD where alpha-helices and beta-strands and connecting segments
CC   are conserved such that scaffold structure of C-type lectin-like domains
CC   (CTLD) is substantially maintained, while the 14loop region is altered by
CC   amino acid substitution, deletion, insertion or their combination. The
CC   invention is useful for preparing a library of nucleotide sequences
CC   encoding related proteins by randomising part or all of the nucleic acid
CC   sequence encoding the loop region of its CTLD. The artificial CTLD
CC   protein products are preferable to antibody derivatives as each binding
CC   site is a single structurally autonomous protein domain. When used as
CC   components of compositions to be used for in vivo diagnostic or
CC   therapeutic purposes, artificial CTLD protein products constructed on the
CC   basis of human CTLDs are virtually identical to the corresponding natural
CC   CTLD protein already present in the body and are therefore less
CC   immunogenic to the patient. They also have a smaller size, and thus
CC   provide tissue penetration and distribution, as well as shorter half life
CC   in circulation. Since murine and human tetranectin are identical in
CC   structure, straightforward swapping of polypeptide segments defining
CC   ligand-binding specificity between murine and human tetranectin
CC   derivatives may be achieved. The present nucleic acid sequence represents
CC   an oligonucleotide used in the methods of the invention
XX
SQ   Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 71;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         86 GACTGGTACCCGCATAGC 103
              ||| |||||||||||| ||
Db         18 GACCGGTACCCGCATCGC 1


RESULT 120
ABZ98168
ID   ABZ98168 standard; DNA; 18 BP.
XX
AC   ABZ98168;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human CD23 + A1261 oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
```

```
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 13410; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 71;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          3 CACGAGGAGCAGAGTCAG 20
              || ||| ||||||||||
Db          1 CAGGAGAAGCAGAGTCAG 18


RESULT 121
ABD31199
ID   ABD31199 standard; DNA; 18 BP.
XX
AC   ABD31199;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human CD23-derived oligonucleotide SEQ ID 13410.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 13410; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 71;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          3 CACGAGGAGCAGAGTCAG 20
              || ||| ||||||||||
Db          1 CAGGAGAAGCAGAGTCAG 18


RESULT 122
ADJ60033
ID   ADJ60033 standard; DNA; 18 BP.
XX
AC   ADJ60033;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Oligonucleotide associated to CD23-X04772 #27.
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2004011613-A2.
XX
PD   05-FEB-2004.
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
```

```
PR   29-JUL-2002; 2002US-0399076P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Tang L,  Sandrasagra A,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-203534/19.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
PS   Claim 2; SEQ ID NO 889; 85pp; English.
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 71;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          3 CACGAGGAGCAGAGTCAG 20
              || ||| ||||||||||
Db          1 CAGGAGAAGCAGAGTCAG 18


RESULT 123
ADL91732
ID   ADL91732 standard; DNA; 18 BP.
XX
AC   ADL91732;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Collagen type IX alpha 3 (SYX 4) control S-oligo, SEQ ID NO:133.
XX
KW   Synovial sarcoma; SYX; sarcoma-associated gene; drug screening;
KW   Frizzled homologue 10; FZD10-associated disease; colorectal cancer;
KW   gastric cancer; chronic myeloid leukaemia; acute myeloid leukaemia.;
KW   FZD10 antibody; diagnosis; prognosis; prevention; cytostatic;
KW   gene therapy; control oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004020668-A2.
XX
PD   11-MAR-2004.
XX
PF   21-AUG-2003; 2003WO-JP010591.
XX
PR   30-AUG-2002; 2002US-0407506P.
PR   11-JUL-2003; 2003US-0486195P.
XX
PA   (ONCO-) ONCOTHERAPY SCI INC.
PA   (UYTY ) UNIV TOKYO.
XX
PI   Nakamura Y,  Katagiri T;
XX
DR   WPI; 2004-239208/22.
XX
PT   Use of a compound or composition for diagnosing, treating or preventing
PT   synovial sarcoma or a disease associated with Frizzled homologue 10, e.g.
PT   colorectal cancer, gastric cancer, chronic myeloid leukemia or acute
PT   myeloid leukemia.
XX
PS   Example 4; SEQ ID NO 133; 143pp; English.
XX
CC   The invention relates to the use of a compound or composition for
CC   diagnosing, prognosing, treating or preventing synovial sarcoma or a
CC   Frizzled homologue 10 (FZD10)-associated disease in a patient. The
CC   invention encompasses the use of sarcoma-associated genes designated SYX
CC   1-26 or their encoded proteins in diagnosing of synovial sarcoma and in
CC   screening for compounds for treating or preventing this condition; and
CC   the use of antibodies specific for FZD10 (FZD10 is also referred to as
CC   SYX 1 in the specification) for diagnosing, treating or preventing FZD10-
CC   associated diseases. The compound, composition and methods of the
CC   invention are useful for diagnosing, treating or preventing synovial
CC   sarcoma or FZD10-associated diseases, such as colorectal cancer, gastric
CC   cancer, chronic myeloid leukaemia or acute myeloid leukaemia. Sequences
CC   ADL91688-ADL91751 represent antisense and control S-oligonucleotides used
CC   in a study of antisense-mediated inhibition of the expression of synovial
CC   sarcoma-associated genes.
XX
SQ   Sequence 18 BP; 4 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 71;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        100 TAGCCGCCTCTTCGACCA 117
              || | ||||||||||||||
Db          1 TAACTGCCTCTTCGACCA 18


RESULT 124
ADO45523
ID   ADO45523 standard; DNA; 18 BP.
XX
AC   ADO45523;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human oligonucleotide #889.
XX
KW   Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW   CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW   tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW   lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW   asthma; lung allergy; inflammation; inflammatory disease;
KW   airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW   chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW   acute respiratory distress syndrome; pulmonary hypertension;
KW   lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS   Homo sapiens.
XX
PN   US2004049022-A1.
XX
PD   11-MAR-2004.
XX
PF   25-JUL-2003; 2003US-00627930.
XX
PR   23-APR-2002; 2002WO-US013135.
PR   23-APR-2002; 2002WO-US013143.
XX
PA   (NYCE/) NYCE J W.
PA   (SAND/) SANDRASAGRA A.
PA   (TANG/) TANG L.
```

PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-293804/27.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 889; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

```
  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 71;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          3 CACGAGGAGCAGAGTCAG 20
              || ||| ||||||||||
Db          1 CAGGAGAAGCAGAGTCAG 18
```

RESULT 125
ADC03006/c
ID ADC03006 standard; DNA; 16 BP.
XX
AC ADC03006;
XX
DT 18-DEC-2003 (first entry)
XX
DE Ex vivo stem-cell expansion related polynucleotide #441.
XX
KW cytostatic; antianaemic; immunomodulator; immunostimulant;
KW immunosuppressive; antiinflammatory; interleukin agonist 3;
KW interleukin antagonist 3; gene therapy; ex vivo expansion of stem cell;
KW modified human interleukin-3; cell proliferatiion;
KW acute myelogenous leukaemia cell proliferation; TF-1 cell proliferation;
KW methylcellulose assay; haematopoietic disorder; cancer;
KW acute myelogenous leukaemia; B lymphoid cancer; leukopenia; neutropenia;
KW aplastic anaemia; Chediak-Higashi's syndrome;
KW systemic lupus erythematosus; myelodysplastic syndrome; myelofibrosis;
KW bone marrow; blood cell activation; blood cell growth; ds.
XX
OS Synthetic.
XX
PN US6479261-B1.
XX
PD 12-NOV-2002.
XX
PF 15-NOV-1995; 95US-00559390.
XX
PR 24-NOV-1992; 92US-00981044.
PR 22-NOV-1993; 93WO-US011198.
PR 06-APR-1995; 95US-00411796.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Bauer SC, Abrams MA, Braford-Goldberg SR, Caparon MH, Easton AM;
PI Klein BK, Mckearn JP, Olins P, Paik K, Polazzi J, Thomas JW;
XX
DR WPI; 2003-655574/62.
XX
PT Selective ex vivo expansion of stem cells, useful for treating a patient
PT having hematopoietic disorder, e.g. leukemia, neutropenia or aplastic
PT anemia, comprises using recombinant human interleukin-3 variant or mutant
PT proteins.
XX
PS Example 66; SEQ ID NO 466; 288pp; English.
XX
CC The invention describes selective ex vivo expansion of stem cells
CC comprising separating stem cells from other cells, culturing the cells
CC with modified human interleukin-3 polypeptide with at least 3 times
CC greater cell proliferative activity than native human interleukin-3 in at
CC least one assay selected from the group of acute myelogenous leukaemia
CC cell proliferation, TF-1 cell proliferation, and methylcellulose assay,
CC and harvesting the cultured cells. The method is useful for selective ex
CC vivo expansion of stem cells. The recombinant human interleukin-3 variant
CC or mutant proteins are useful for treating a patient having a
CC haematopoietic disorder, such as cancer (e.g. acute myelogenous leukaemia
CC or certain types of B lymphoid cancers), leukopenia, neutropenia,
CC aplastic anaemia, Chediak-Higashi's syndrome, systemic lupus
CC erythematosus, myelodysplastic syndrome, or myelofibrosis. The
CC interleukin-3 muteins are also useful as antagonists for producing
CC antibodies used in immunoassay and immunotherapy protocols, or for
CC stimulating bone marrow and blood cell activation and growth before
CC infusion into patients. This sequence represents an ex vivo stem cell
CC expansion method associated polynucleotide.
XX
SQ Sequence 16 BP; 5 A; 1 C; 7 G; 3 T; 0 U; 0 Other;

```
  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1
```

RESULT 126
ADI58681/c
ID ADI58681 standard; DNA; 16 BP.
XX
AC ADI58681;
XX
DT 22-APR-2004 (first entry)
XX
DE Human interleukin 3 expressing vector related DNA seq id 466.
XX
KW immunostimulant; antianemic; immunomodulator; antiinflammatory;
KW dermatological; immunosuppressive; cytostatic; neuroprotective;
KW gene therapy; interleukin-agonist-3; cultured stem cell;
KW ex-vivo cell expansion; interleukin-3 mutant; aplastic anaemia;
KW cyclic neutropenia; idiopathic neutropenia; Chediak-Higashi syndrome;

```
KW   systemic lupus erythematosus; leukaemia; myelodysplastic syndrome;
KW   myelofibrosis; interleukin 3; IL-3; mutagenesis; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   US2004018618-A1.
XX
PD   29-JAN-2004.
XX
PF   19-JUN-2002; 2002US-00179940.
XX
PR   24-NOV-1992;   92US-00981044.
PR   22-NOV-1993;   93WO-US011198.
PR   06-APR-1995;   95US-00411796.
PR   15-NOV-1995;   95US-00559390.
XX
PA   (BAUE/) BAUER S C.
PA   (ABRA/) ABRAMS M A.
PA   (BRAF/) BRAFORD-GOLDBERG S R.
PA   (CAPA/) CAPARON M H.
PA   (EAST/) EASTON A M.
PA   (KLEI/) KLEIN B K.
PA   (MCKE/) MCKEARN J P.
PA   (OLIN/) OLINS P.
PA   (PAIK/) PAIK K.
PA   (POLA/) POLAZZI J.
PA   (THOM/) THOMAS J W.
XX
PI   Bauer SC,  Abrams MA,  Braford-Goldberg SR,  Caparon MH,  Easton AM;
PI   Klein BK,  Mckearn JP,  Olins P,  Paik K,  Polazzi J,  Thomas JW;
XX
DR   WPI; 2004-122043/12.
XX
PT   Culturing stem cells using a recombinant human interleukin-3 mutant
PT   polypeptide, useful for treating aplastic anemia, neutropenia, Chediak-
PT   Higashi syndrome, systemic lupus erythematosus, leukemia and
PT   myelodysplastic syndrome.
XX
PS   Example 65; SEQ ID NO 466; 328pp; English.
XX
CC   The invention describes cultured stem cells obtained by a method for
CC   selective ex-vivo expansion of stem cells comprising separating stem
CC   cells from other cells, culturing the separated stem cells with a
CC   selected media which comprises a human interleukin-3 mutant polypeptide
CC   comprising defined amino acid sequences SEQ ID NO 15 or 19 given in the
CC   specification, and harvesting the cultured cells. The methods and
CC   compositions of the present invention are useful for treating aplastic
CC   anaemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi
CC   syndrome, systemic lupus erythematosus, leukaemia, myelodysplastic
CC   syndrome and myelofibrosis. This sequence represents a DNA used in the
CC   construction of human interleukin 3 (IL-3) mutants.
XX
SQ   Sequence 16 BP; 5 A; 1 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 127
AAV92679
ID   AAV92679 standard; RNA; 17 BP.
XX
AC   AAV92679;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human A-Raf substrate position 2408.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T,  Matulic-Adamic J,  Reynolds M,  Kisich K,  Bellon L;
PI   Parry T,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Burgin A;
PI   Thompson J,  Workman CT,  Beaudry A,  Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 162; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 1 A; 8 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 75;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        684 TGTGCCTCCCCCGCCA 699
              :|:| |:||||||||||
Db          2 UGUGUCUCCCCCGCCA 17


RESULT 128
ABN10674
ID   ABN10674 standard; DNA; 17 BP.
```

```
XX
AC   ABN10674;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10666.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10666; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 7 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 75;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
               ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 129
ABN10676
ID   ABN10676 standard; DNA; 17 BP.
XX
AC   ABN10676;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10668.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10668; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
```

```
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 75;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 130
ABZ61415/c
ID   ABZ61415 standard; RNA; 17 BP.
XX
AC   ABZ61415;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human H-Ras DNAzyme target #206.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 115; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 2 A; 7 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 75;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        227 GTGGCCGCGCCCGCCT 242
              ||||||||| ||||||
Db         16 GTGGCCGCGGCCGCCT 1


RESULT 131
ADF64299
ID   ADF64299 standard; DNA; 17 BP.
XX
AC   ADF64299;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2203.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 2203; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 75;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              ||| ||||||||||||
Db          2 CTGAGGGGCCCCAGCT 17


RESULT 132
ADF64300
ID   ADF64300 standard; DNA; 17 BP.
XX
AC   ADF64300;
XX
```

DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2204.
XX
KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
OS Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX
DR WPI; 2003-532916/50.
XX
PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS Example 2; SEQ ID NO 2204; 164pp; English.
XX
CC The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the WipoWeb
CC database.
XX
SQ Sequence 17 BP; 2 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 75;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 56 CTGCGGGGCCCCAGCT 71
||| |||||||||||||
Db 1 CTGAGGGGCCCCAGCT 16

RESULT 133
ADL47964
ID ADL47964 standard; RNA; 17 BP.
XX
AC ADL47964;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #474.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1497; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 0 A; 13 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 75;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 193 CCCCCTGCCCCCCGCC 208
|||| :||||||||||
Db 1 CCCCUUGCCCCCCGCC 16

RESULT 134
ACN73764
ID ACN73764 standard; DNA; 17 BP.
XX
AC ACN73764;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMLP-1 probe SEQ ID NO:10666.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX

```
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 10666; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63103
XX
SQ   Sequence 17 BP; 5 A; 7 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 75;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 135
ACN73766
ID   ACN73766 standard; DNA; 17 BP.
XX
AC   ACN73766;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:10668.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 10668; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63103
XX
SQ   Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 75;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 136
AAZ48501
ID   AAZ48501 standard; DNA; 18 BP.
XX
```

```
AC   AAZ48501;
XX
DT   31-MAR-2000  (first entry)
XX
DE   Human TNFR1 mRNA inhibiting antisense oligo ISIS# 18894.
XX
KW   Tumour necrosis factor receptor type 1; TNFR1; antisense; infection;
KW   inflammation; tumour formation; TNFR1; anticancer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US6007995-A.
XX
PD   28-DEC-1999.
XX
PF   26-JUN-1998;   98US-00106038.
XX
PR   26-JUN-1998;   98US-00106038.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Baker BF,  Cowsert LM;
XX
DR   WPI; 2000-105333/09.
XX
PT   Antisense inhibition of tumor necrosis factor type 1 expression for
PT   diagnosis, treatment and prevention of disease, particularly tumors.
XX
PS   Example 10; Col 24; 34pp; English.
XX
CC   The invention provides antisense compounds targeted to human tumour
CC   necrosis factor receptor type 1 (TNFR1) RNA. These antisense compounds
CC   can be used in a method of inhibiting the expression of TNFR1 human cells
CC   or tissues. The antisense compounds specifically hybridize with one or
CC   more nucleic acids encoding TNFR1 modulating the function of nucleic acid
CC   molecules encoding TNFR1, ultimately modulating the amount of TNFR1
CC   produced. The antisense compounds and method are useful as research
CC   reagents and diagnostics, and in the treatment and prophylaxis of
CC   infection, inflammation or tumour formation. Sequences AAZ48482-565
CC   represent antisense oligos used for inhibition of the human TNFR1 mRNA
XX
SQ   Sequence 18 BP; 1 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || |||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 137
AAZ71739/c
ID   AAZ71739 standard; DNA; 18 BP.
XX
AC   AAZ71739;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:6095.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 1530; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 18 BP; 9 A; 4 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGA 716
              |||||||||||| |||
Db         18 CTGTGTGTTCTTCTGA 3


RESULT 138
AAA87651
ID   AAA87651 standard; DNA; 18 BP.
XX
AC   AAA87651;
XX
DT   08-JAN-2001  (first entry)
XX
DE   Rat hepatocyte carcinogenesis biomarker nucleic acid SEQ ID NO:575.
XX
KW   Rat; phenobarbitol; carcinogenesis marker; carcinogenesis; detection;
KW   identification; carcinogenic; probe; primer; ds.
XX
OS   Rattus norvegicus.
XX
PN   WO200044902-A2.
XX
PD   03-AUG-2000.
XX
PF   28-JAN-2000; 2000WO-US000503.
XX
PR   29-JAN-1999;   99US-0118078P.
XX
PA   (SEAR ) SEARLE & CO G D.
XX
PI   Bunch RT,  Curtis SW,  Rodi CP,  Morris DL;
XX
DR   WPI; 2000-505977/45.
```

```
XX
PT   New nucleic acid encoding a carcinogenic biomarker, induced by
PT   phenobarbitol treatment of rat hepatocytes, useful for identifying
PT   carcinogenic compounds.
XX
PS   Claim 1; Page 239; 240pp; English.
XX
CC   AAA87080 to AAA87656 represent nucleic acid sequences (N1) encoding a
CC   carcinogenesis biomarkers. The carcinogenesis biomarkers are induced by
CC   treating rat hepatocytes with phenobarbitol. The nucleic acids are useful
CC   for identifying carcinogenic compounds. The nucleic acid molecules can be
CC   used to derive probes and/or primers for detecting or inducing
CC   carcinogenesis, respectively
XX
SQ   Sequence 18 BP; 7 A; 5 C; 6 G; 0 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        388 CGGCAAGCACGAGGAG 403
              ||||||||||||  |||
Db          3 CGGCAAGCACGAAGAG 18


RESULT 139
ABT04997
ID   ABT04997 standard; DNA; 18 BP.
XX
AC   ABT04997;
XX
DT   11-OCT-2002  (first entry)
XX
DE   TNFR1 expression modulation related antisense oligo SEQ ID No 27.
XX
KW   Antisense compound; tumour necrosis factor receptor 1; liver disease;
KW   TNFR1; hepatitis; liver injury; hyperproliferative disorder; cancer;
KW   human; ds.
XX
OS   Homo sapiens.
XX
PN   WO200248168-A1.
XX
PD   20-JUN-2002.
XX
PF   22-OCT-2001; 2001WO-US051224.
XX
PR   24-OCT-2000; 2000US-00695451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Baker BF,  Cowsert LM,  Zhang H,  Dean NM;
XX
DR   WPI; 2002-583481/62.
XX
PT   Novel antisense compound targeted to nucleic acid molecule encoding tumor
PT   necrosis factor receptor 1 (TNFR1), useful for treating humans having
PT   disease associated with TNFR1 e.g. hepatitis, liver injury, liver cancer.
XX
PS   Example 10; Page 44; 121pp; English.
XX
CC   The invention relates to an antisense compound 8 to 30 nucleotides in
CC   length targeted to nucleic acid molecule encoding tumour necrosis factor
CC   receptor 1 (TNFR1), where the antisense compound inhibits expression of
CC   TNFR1. The antisense compound is useful for inhibiting the expression of
CC   TNFR1 in cells or tissues. The antisense compound is also useful for
CC   treating an animal (preferably human) having a disease or condition
CC   associated with TNFR1, e.g. a liver disease (such as hepatitis, or liver
CC   injury) or a hyperproliferative disorder such as cancer, by inhibiting
CC   the expression of TNFR1. The antisense compound is useful for
CC   diagnostics, therapeutics, prophylaxis and as research reagents and kits.
CC   This polynucleotide sequence represents a human oligonucleotide relating
CC   to the TNFR1 of the invention
XX
SQ   Sequence 18 BP; 1 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || ||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 140
ADR06029
ID   ADR06029 standard; DNA; 18 BP.
XX
AC   ADR06029;
XX
DT   21-OCT-2004  (first entry)
XX
DE   Human TNFR1 antisense oligonucleotide seqid 27.
XX
KW   cytostatic; gene therapy; apoptosis inhibitor;
KW   radiation-induced apoptosis; tumour necrosis factor receptor 1; TNFR1;
KW   human; antisense oligonucleotide; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone"
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Optionally 2'-O-Methoxyethyl (2'-MOE)
FT                   nucleotides"
FT   modified_base   15. .18
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Optionally 2'-O-Methoxyethyl (2'-MOE)
FT                   nucleotides"
XX
PN   US2004147471-A1.
XX
PD   29-JUL-2004.
XX
PF   06-NOV-2003; 2003US-00702817.
XX
PR   26-JUN-1998;   98US-00106038.
PR   17-JUN-1999;   99WO-US013763.
PR   24-OCT-2000; 2000US-00695451.
XX
PA   (ZHAN/) ZHANG H.
XX
PI   Zhang H;
XX
DR   WPI; 2004-561407/54.
XX
PT   Inhibiting radiation-induced apoptosis in a cell or tissue comprises
PT   administering to the cell or tissue an antisense oligonucleotide targeted
PT   to a nucleic acid molecule encoding tumor necrosis factor receptor 1.
XX
PS   Example 10; SEQ ID NO 27; 24pp; English.
XX
CC   The invention describes a method of inhibiting radiation-induced
CC   apoptosis in a cell or tissue comprising administering to the cell or
CC   tissue an antisense oligonucleotide of 8-30 nucleotides in length
CC   targeted to a nucleic acid molecule encoding tumour necrosis factor
CC   receptor 1 (TNFR1). The method and antisense oligonucleotides are useful
CC   for inhibiting radiation-induced apoptosis in a cell or tissue, and for
CC   treating diseases associated with the expression of TNFR1. This sequence
```

```
CC   represents a human tumour necrosis factor receptor 1 (TNFR1) antisense
CC   oligonucleotide.
XX
SQ   Sequence 18 BP; 1 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || |||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 141
AAF46289
ID   AAF46289 standard; DNA; 15 BP.
XX
AC   AAF46289;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1128.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 11 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 69;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        194 CCCCTGCCCCCCGC 207
              ||||||||||||||
Db          2 CCCCTGCCCCCCGC 15


RESULT 142
AAF46291
ID   AAF46291 standard; DNA; 15 BP.
XX
AC   AAF46291;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1130.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 12 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 69;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        195 CCCTGCCCCCCGCC 208
              ||||||||||||||
Db          1 CCCTGCCCCCCGCC 14
```

RESULT 143
ADF32131/c
ID ADF32131 standard; DNA; 15 BP.
XX
AC ADF32131;
XX
DT 12-FEB-2004 (first entry)
XX
DE Probe #55 used to illustrate chip detection techniques.
XX
KW Chip detection; probe; Single Nucleotide Polymorphism; SNP; detection;
KW ss.
XX
OS Unidentified.
XX
PN CN1381590-A.
XX
PD 27-NOV-2002.
XX
PF 13-APR-2001; 2001CN-00105980.
XX
PR 13-APR-2001; 2001CN-00105980.
XX
PA (MIAO/) MIAO J.
XX
PI Miao J;
XX
DR WPI; 2003-249035/25.
XX
PT Simple and fast technique for detecting single nucleotide polymorphism
PT (SNP) by high-temp hybridized chip.
XX
PS Example 1; Page 14; 19pp; Chinese.
XX
CC The present invention related to an improvement to existing chip
CC detection techniques. The invention uses DNA oligonucleotide probes
CC (ADF32077-ADF32266) to detect Single Nucleotide Polymorphisms (SNP) in
CC genomic DNA. Its advantages are simple process and short time (within 2
CC hr).
XX
SQ Sequence 15 BP; 1 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match   1.8%; Score 14; DB 1; Length 15;
  Best Local Similarity   100.0%; Pred. No. 69;
  Matches   14; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         14 AGCCACGCAGTCCA 1
```

RESULT 144
AAQ78888/c
ID AAQ78888 standard; DNA; 17 BP.
XX
AC AAQ78888;
XX
DT 25-MAR-2003 (revised)
DT 18-DEC-1995 (first entry)
XX
DE Humicola grisea glucoamylase hybridization probe.
XX
KW Glucoamylase; DNA probe; gene cloning; protein secretion; ss.
XX
OS Synthetic.
XX
PN EP625577-A1.
XX
PD 23-NOV-1994.
XX
PF 27-AUG-1986; 94EP-00201751.
XX
PR 29-AUG-1985; 85US-00771374.
PR 07-JUL-1986; 86US-00882224.
PR 27-AUG-1986; 86EP-00306624.
XX
PA (GEMV) GENENCOR INT INC.
XX
PI Berka RM, Cullen D, Gray GL, Hayenga KJ, Lawlis VB;
XX
DR WPI; 1994-359750/45.
XX
PT Vectors and DNA for expressing polypeptide(s) in filamentous fungi -
PT include secretory signal sequences that are native or foreign to
PT heterologous polypeptide(s), such as chymosin or glucoamylase.
XX
PS Example 9A3; Page 22; 50pp; English.
XX
CC The DNA probe and corresponding probes covering the degenerate sites
CC (AAQ78885-Q78891) correspond to amino acids 17-22 of the H. grisea
CC glucoamylase peptide GA1 (AAR62933), and are used as hybridization probes
CC to detect and isolate H. grisea glucoamylase DNA in a Southern blot.
CC Resulting genomic DNA fragments are excised and cloned in plasmid pRSH1.
CC This illustrates the main claims of the patent, i.e. a vector containing
CC (i) DNA encoding a heterologous polypeptide (chymosin, prochymosin,
CC preprochymosin, Aspergillus niger glucoamylase, H. grisea glucoamylase,
CC or Mucor miehei carboxyl protease) and (ii) a secretory signal peptide,
CC and a filamentous fungus (Aspergillus, Trichoderma, Neurospora,
CC Podospora, Endothia, Mucor, Cochiobolus or Pyriclaria, especially A.
CC nidulans, A. awamori or T. reesei) transformed with the vector for
CC recombinant protein (enzyme) production. (Updated on 25-MAR-2003 to
CC correct PF field.) (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ Sequence 17 BP; 10 A; 2 C; 0 G; 4 T; 0 U; 1 Other;

  Query Match   1.8%; Score 14; DB 1; Length 17;
  Best Local Similarity   87.5%; Pred. No. 88;
  Matches   14; Conservative   1; Mismatches   1; Indels   0; Gaps   0;

```
Qy        713 TTGATACATTTATCTT 728
              |||||| ||||||:||
Db         17 TTGATATATTTATMTT 2
```

RESULT 145
ABK01791
ID ABK01791 standard; RNA; 17 BP.
XX
AC ABK01791;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Zinzyme #113.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX

PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 97; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a zinzyme molecule of the invention
XX
SQ Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 164 GGCGGCAGCAGCTG 177
||||||||||||:|
Db 2 GGCGGCAGCAGCUG 15

RESULT 146
ABK00765
ID ABK00765 standard; RNA; 17 BP.
XX
AC ABK00765;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Inozyme #35.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 78; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident

```
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an inozyme of the invention
XX
SQ   Sequence 17 BP; 2 A; 6 C; 8 G; 0 T; 1 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 88;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        164 GGCGGCAGCAGCTG 177
              ||||||||||||:|
Db          3 GGCGGCAGCAGCUG 16


RESULT 147
ABA81385
ID   ABA81385 standard; DNA; 17 BP.
XX
AC   ABA81385;
XX
DT   24-JAN-2002  (first entry)
XX
DE   PSEN1 mutation correcting oligonucleotide SEQ ID NO: 4231.
XX
KW   Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW   retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW   cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW   adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW   haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW   mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW   familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW   UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW   Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW   antilipemic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200173002-A2.
XX
PD   04-OCT-2001.
XX
PF   27-MAR-2001; 2001WO-US009761.
XX
PR   27-MAR-2000; 2000US-0192176P.
PR   27-MAR-2000; 2000US-0192179P.
PR   01-JUN-2000; 2000US-0208538P.
PR   30-OCT-2000; 2000US-0244989P.
XX
PA   (UYDE ) UNIV DELAWARE.
XX
PI   Kmiec EB,  Gamper HB,  Rice MC;
XX
DR   WPI; 2001-639230/73.
XX
PT   Oligonucleotide for targeted alterations of genetic sequences and for
PT   treating cystic fibrosis, comprises at least one mismatch and chemical
PT   modification.
XX
PS   Claim 7; Page 272; 294pp; English.
XX
CC   The present invention provides single-stranded oligonucleotides which can
CC   be used for the targeted alteration of genomic sequences, where the
CC   oligonucleotide has at least one mismatch compared with the genomic
CC   sequence to be altered. In particular, these sequences are directed at
CC   the following genes: adenosine deaminase, p53, beta-globin,
CC   retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC   (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC   1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC   apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC   (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC   presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC   such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC   haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC   Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC   various syndromes. The present sequence is one of the gene correcting
CC   oligonucleotides of the invention
XX
SQ   Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 88;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          3 AGCCACGCAGTCCA 16


RESULT 148
ABA81384/c
ID   ABA81384 standard; DNA; 17 BP.
XX
AC   ABA81384;
XX
DT   24-JAN-2002  (first entry)
XX
DE   PSEN1 mutation correcting oligonucleotide SEQ ID NO: 4230.
XX
KW   Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW   retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW   cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW   adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW   haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW   mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW   familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW   UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW   Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW   antilipemic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200173002-A2.
XX
PD   04-OCT-2001.
XX
PF   27-MAR-2001; 2001WO-US009761.
XX
PR   27-MAR-2000; 2000US-0192176P.
PR   27-MAR-2000; 2000US-0192179P.
PR   01-JUN-2000; 2000US-0208538P.
PR   30-OCT-2000; 2000US-0244989P.
XX
PA   (UYDE ) UNIV DELAWARE.
XX
PI   Kmiec EB,  Gamper HB,  Rice MC;
XX
DR   WPI; 2001-639230/73.
XX
PT   Oligonucleotide for targeted alterations of genetic sequences and for
PT   treating cystic fibrosis, comprises at least one mismatch and chemical
PT   modification.
XX
PS   Claim 7; Page 271; 294pp; English.
XX
CC   The present invention provides single-stranded oligonucleotides which can
CC   be used for the targeted alteration of genomic sequences, where the
CC   oligonucleotide has at least one mismatch compared with the genomic
CC   sequence to be altered. In particular, these sequences are directed at
CC   the following genes: adenosine deaminase, p53, beta-globin,
CC   retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC   (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC   1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
```

```
CC   apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC   (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC   presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC   such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC   haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC   Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC   various syndromes. The present sequence is one of the gene correcting
CC   oligonucleotides of the invention
XX
SQ   Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 88;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         15 AGCCACGCAGTCCA 2


RESULT 149
ADF92264
ID   ADF92264 standard; DNA; 17 BP.
XX
AC   ADF92264;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human cytokeratin 19-derived F2 DNA - SEQ ID 352.
XX
KW   human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;
KW   tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
KW   PCR; probe; F2.
XX
OS   Homo sapiens.
XX
PN   WO2003097878-A1.
XX
PD   27-NOV-2003.
XX
PF   20-MAY-2003; 2003WO-JP006256.
XX
PR   21-MAY-2002; 2002JP-00145689.
PR   17-JUN-2002; 2002JP-00175271.
PR   09-JUL-2002; 2002JP-00199759.
XX
PA   (SYSM-) SYSMEX CORP.
XX
PI   Tada S,  Akai Y,  Imura Y,  Abe S,  Minekawa H;
XX
DR   WPI; 2004-012543/01.
XX
PT   LAMP nucleic acid amplification primers for detection of cytokeratin
PT   expression as indicator in diagnosis of tumour metastasis.
XX
PS   Claim 19; SEQ ID NO 352; 266pp; Japanese.
XX
CC   The invention relates to novel nucleic acid amplification primers for the
CC   detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
CC   (loop mediated isothermal amplification) method. The primers of the
CC   invention may be useful for the detecting cytokeratin 18-20 expression as
CC   an indicator for the diagnosis of tumour metastasis, particularly
CC   prostate cancer and lymphoma. The amplification using the primers is
CC   highly efficient and allows very sensitive detection of tumour
CC   metastasis. The current sequence is that of the human CK19-derived DNA of
CC   the invention.
XX
SQ   Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 88;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         81 TCCGCGACTGGTAC 94
              ||||||||||||||
Db          4 TCCGCGACTGGTAC 17


RESULT 150
AAA17447
ID   AAA17447 standard; RNA; 17 BP.
XX
AC   AAA17447;
XX
DT   19-JUN-2000  (first entry)
XX
DE   Aryl hydrocarbon nuclear transport substrate sequence SEQ ID NO:673.
XX
KW   Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW   integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW   hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW   ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW   dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW   age related macular degeneration; inflammation; neovascular glaucoma;
KW   myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW   tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW   Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS   Homo sapiens.
XX
PN   WO9950403-A2.
XX
PD   07-OCT-1999.
XX
PF   24-MAR-1999;   99WO-US006507.
XX
PR   27-MAR-1998;   98US-0079678P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Pavco PA,  Roberts E,  Jarvis T,  Coeshott C,  Mcswiggen JA;
XX
DR   WPI; 1999-591315/50.
XX
PT   Novel ribozymes for modulating the synthesis, expression and/or stability
PT   of an mRNA encoding an angiogenic factors.
XX
PS   Claim 53; Page 80; 305pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   cleaving activity, which specifically cleave RNA encoded by an aryl
CC   hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC   gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC   AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC   and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC   corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC   AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC   and AAA19155 to AAA19222 represent their corresponding target sequences;
CC   AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 3 A; 9 C; 2 G; 0 T; 3 U; 0 Other;
```

```
  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 95;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         64 CCCCAGCTGGGACCCCT 80
              ||||| |: |||||||:
Db          1 CCCCAACUUGGACCCCU 17


RESULT 151
AAV93490
ID   AAV93490 standard; RNA; 17 BP.
XX
AC   AAV93490;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human B-raf substrate nucleotide position 1221.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T,  Matulic-Adamic J,  Reynolds M,  Kisich K,  Bellon L;
PI   Parry T,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Burgin A;
PI   Thompson J,  Workman CT,  Beaudry A,  Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 168; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 95;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        363 CCAAGGATGGCGTGGTG 379
              |||||||:  ||:||:|
Db          1 CCAAGGAUUUCGUGGUG 17


RESULT 152
AAX01065/c
ID   AAX01065 standard; DNA; 17 BP.
XX
AC   AAX01065;
XX
DT   06-APR-1999  (first entry)
XX
DE   IPF1 gene exon 1 amplifying primer S17b.
XX
KW   Mature onset diabetes of the young; MODY; insulin promoter factor 1;
KW   IPF1; mutation; MODY4; pancreatic disorder; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9859078-A1.
XX
PD   30-DEC-1998.
XX
PF   24-JUN-1998;   98WO-US013467.
XX
PR   24-JUN-1997;   97US-00881450.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Habener JF,  Stoffers DA;
XX
DR   WPI; 1999-105636/09.
XX
PT   Detecting heterozygosity for insulin promoter factor 1 - useful to detect
PT   the presence of, or predisposition for, mature onset diabetes of the
PT   young.
XX
PS   Example 1; Page 9; 46pp; English.
XX
CC   The invention relates to a new method to screen for mature onset diabetes
CC   of the young (MODY). The method comprises detecting a mutation in the
CC   gene encoding insulin promoter factor 1 (IPF1), wherein heterozygosity
CC   for the mutation is indicative of MODY. The method may be used to
CC   determine if a patient with MODY symptoms has MODY4, to assess patients
CC   risk of developing MODY4, to assess the risk of a couple's progeny of
CC   inheriting MODY, and to assist in determining the genetic basis for other
CC   pancreatic disorders that might result from IPF-1 deficiency. Sequences
CC   AAX01063-66 represent primers used for amplifying the exon 1 of the IPF1
CC   gene using a nested PCR priming scheme
XX
SQ   Sequence 17 BP; 4 A; 3 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         38 CGCGTCCCCTTCTCGCT 54
              ||| |||||| ||||||
Db         17 CGCCTCCCCTGCTCGCT 1
```

```
RESULT 153
AAA36540/c
ID   AAA36540 standard; DNA; 17 BP.
XX
AC   AAA36540;
XX
DT   26-JUL-2000  (first entry)
XX
DE   Human genomic SNP allele specific oligonucleotide SEQ ID NO:605.
XX
KW   Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW   allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW   genomic classification; identification; DNA fingerprinting;
KW   tumour characterisation; hybridisation; ss.
XX
OS   Homo sapiens.
XX
PN   WO200018960-A2.
XX
PD   06-APR-2000.
XX
PF   24-SEP-1999;   99WO-US022283.
XX
PR   25-SEP-1998;   98US-0101757P.
XX
PA   (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX
PI   Landers JE,  Jordan B,  Housman DE,  Charest A;
XX
DR   WPI; 2000-293181/25.
XX
PT   Detection of single nucleotide polymorphisms in genomes by preparation
PT   and analysis of reduced complexity genomes, useful for genotyping,
PT   fingerprinting and determining allele frequency of SNPs.
XX
PS   Disclosure; Page 71; 111pp; English.
XX
CC   A method has been developed for detecting the presence or absence of a
CC   single nucleotide polymorphism (SNP) allele in a genomic sample. The
CC   method comprises preparing a reduced complexity genome (RCG) from the
CC   genomic sample and analysing the RCG for the presence or absence of a SNP
CC   allele. The method can be used to characterise a tumour, to generate a
CC   genomic pattern for an individual genome or to generate a genomic
CC   classification code for a genome. The method can be used to assess
CC   whether a subject is at risk for developing a disease or to identify a
CC   set of SNP alleles associated with a disease. The method can also be used
CC   to perform linkage analysis. AAA35944 to AAA35947 represent sequences
CC   used in the exemplification of the present invention. AAA35948 to
CC   AAA36632 represent nucleotide sequences containing SNPs
XX
SQ   Sequence 17 BP; 1 A; 2 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 AGTTCAAAGCAACCACC 762
              ||| ||||||||| ||||
Db         17 AGTACAAAGCAAACACC 1


RESULT 154
ABK02414
ID   ABK02414 standard; RNA; 17 BP.
XX
AC   ABK02414;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #86.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 132; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an amberzyme molecule of the invention
XX
```

```
SQ   Sequence 17 BP; 1 A; 9 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 95;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        462 CCGGTGTGGACCCCACC 478
              || |:|:||||||| ||
Db          1 CCCGUGUGGACCCCGCC 17


RESULT 155
AAH24028/c
ID   AAH24028 standard; DNA; 17 BP.
XX
AC   AAH24028;
XX
DT   29-AUG-2001  (first entry)
XX
DE   Yeast GAL3 gene upstream UASgal site, SEQ ID NO:11.
XX
KW   UASgal site; cis-acting transcription control element; Gal4; Gal3; Gal80;
KW   stoichiometrically balanced expression; yeast;
KW   galactose-inducible expression; expression construct; promoter; ds.
XX
OS   Saccharomyces cerevisiae.
XX
PN   US6221630-B1.
XX
PD   24-APR-2001.
XX
PF   24-MAR-1999;   99US-00275680.
XX
PR   24-MAR-1999;   99US-00275680.
XX
PA   (PENN-) PENN STATE RES FOUND.
XX
PI   Hopper JE;
XX
DR   WPI; 2001-307557/32.
XX
PT   Expression construct for inducing and sustaining high level recombinant
PT   polypeptide production in yeast, comprises nucleic acids encoding a trans
PT   -acting transcription factor, selectable marker and yeast origin of
PT   replication.
XX
PS   Disclosure; Col 15; 22pp; English.
XX
CC   The invention relates to high copy number expression constructs for high
CC   level polypeptide expression in yeast. The yeast expression constructs
CC   comprise a nucleic acid sequence encoding a set of trans- acting
CC   transcription factors, a nucleic acid encoding a yeast selectable marker
CC   providing an inefficiently or efficiently selected phenotype, a nucleic
CC   acid encoding a yeast or bacterial origin of replication (ori), and a
CC   unique restriction site downstream of a promoter containing a cis- acting
CC   transcription control element that is regulated by the transcription
CC   factors which are encoded by the expression construct. In a specific
CC   embodiment of the invention, the expression construct provides for
CC   galactose-inducible protein expression. Such constructs contain DNA
CC   encoding the transcription factors Gal3, Gal4 and Gal80, and a UASgal cis
CC   -acting control element within the promoter which drives expression of
CC   the inserted gene of interest. The vector-encoded transcription factors
CC   are expressed in stoichiometrically-balanced amounts, which is
CC   particularly important for a galactose-inducible system, as Gal4, when
CC   not balanced by stoichiometric levels of Gal3 and Gal80, becomes a
CC   constitutive transcription factor, and can become toxic to the cell. The
CC   constructs of the invention express the transcription factors at levels
CC   higher than those found in native yeast cells, thereby ensuring
CC   expression of the gene of interest. The expression constructs provide
CC   robust, high level expression of a gene of interest (which can encode an
CC   endogenous or heterologous polypeptide) in yeast. Sequences AAH24019-
CC   AAH24035 represent actual UASgal sites found within the promoters of
CC   various yeast galactose-inducible genes which may be used as the cis-
CC   acting control element in a galactose-inducible expression construct of
CC   the invention
XX
SQ   Sequence 17 BP; 1 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        290 CGGCACACTGCGGACCG 306
              ||||||||  | ||||||
Db         17 CGGCACACAGTGGACCG 1


RESULT 156
ABN02338/c
ID   ABN02338 standard; DNA; 17 BP.
XX
AC   ABN02338;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2330.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2330; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
```

```
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 157
ABN02339/c
ID   ABN02339 standard; DNA; 17 BP.
XX
AC   ABN02339;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2331.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2331; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              ||||||  ||| ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 158
ABN02337/c
ID   ABN02337 standard; DNA; 17 BP.
XX
AC   ABN02337;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2329.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
```

```
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2329; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 159
ABN10677
ID   ABN10677 standard; DNA; 17 BP.
XX
AC   ABN10677;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10669.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10669; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              ||| |||||||||| |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 160
ABN10678
ID   ABN10678 standard; DNA; 17 BP.
XX
AC   ABN10678;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10670.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
```

```
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10670; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||||  ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 161
ABV78924/c
ID   ABV78924 standard; DNA; 17 BP.
XX
AC   ABV78924;
XX
DT   03-JAN-2003  (first entry)
XX
DE   Human HTPL scanning oligonucleotide SEQ ID 170.
XX
KW   Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW   human testis expressed Patched like protein; testis; adrenal; liver;
KW   male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW   prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1229046-A2.
XX
PD   07-AUG-2002.
XX
PF   28-JAN-2002; 2002EP-00001167.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   23-MAY-2001; 2001US-00864761.
PR   09-OCT-2001; 2001US-0327898P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhan J;
XX
DR   WPI; 2002-676582/73.
XX
PT   Novel isolated human testis expressed Patched like protein (HTPL), useful
PT   for identifying agonist and antagonist and specific binding partners, and
PT   for treating subjects having defects in HTPL.
XX
PS   Example 2; Page 86; 718pp; English.
XX
CC   The present invention relates to human testis expressed Patched like
CC   protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC   has two isoforms, with a few single base pair differences between the
CC   two. One of the single base pair changes introduces a premature stop
CC   codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC   shares an overall structure organisation with the Patched protein. The
CC   shared structural features strongly imply that HTPL plays a role similar
CC   to that of Patched, and is a potential tumour suppressor. HTPL is
CC   important in regulating male germ cell development, and the HTPL gene was
CC   mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC   useful for diagnosing a disorder caused by mutation in HTPL, and in
CC   therapy and manufacture of a medicament for treatment or prevention of
CC   such disorder associated with decreased expression or activity of human
CC   HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC   foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC   skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC   clinically useful diagnostic markers and potenial therapeutic agents for
CC   male infertility and cancer. The present oligonucleotide was used in an
CC   example from the invention
XX
SQ   Sequence 17 BP; 2 A; 7 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        295 CACTGCGGACCGCTGGC 311
              ||||||||  |||  ||||
Db         17 CACTGCGGCCCGGTGGC 1


RESULT 162
ABV90510
```

```
ID   ABV90510 standard; DNA; 17 BP.
XX
AC   ABV90510;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 1223.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-00001165.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   10-OCT-2001; 2001US-0328205P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT   -1, useful for treating disorders associated with decreased expression or
PT   activity of human POSHL1.
XX
PS   Example 2; SEQ ID NO 1223; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 5 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        557 GAGATCACCATCCCAGT 573
              ||||||| || ||||||
Db          1 GAGATCAGCACCCCAGT 17
```

```
RESULT 163
ABK56935
ID   ABK56935 standard; RNA; 17 BP.
XX
AC   ABK56935;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human CLCA1 gene enzymatic nucleic acid #1306.
XX
KW   Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW   antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW   chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW   oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW   acetylcysteine.
XX
OS   Homo sapiens.
XX
PN   WO200211674-A2.
XX
PD   14-FEB-2002.
XX
PF   09-AUG-2001; 2001WO-US024970.
XX
PR   09-AUG-2000; 2000US-0224383P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (SYNT ) SYNTEX USA LLC.
PA   (THOM/) THOMPSON J.
XX
PI   Thompson J,  Mcswiggen J,  Mckenzie T,  Ayers D,  Szymkowski DE;
PI   Grupe A;
XX
DR   WPI; 2002-217145/27.
XX
PT   Enzymatic polynucleotide that down regulates expression of chloride
PT   channel calcium activated gene, useful for treating Chronic obstructive
PT   pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS   Claim 4; Page 87; 152pp; English.
XX
CC   The invention relates to enzymatic nucleic acid molecules that down
CC   regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC   by cleaving RNA derived from the genes. The nucleic acid sequences are
CC   useful as pharmaceutical agents for treating conditions such as chronic
CC   obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC   fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC   that are related to or will respond to the levels of CLCA1 in a cell or
CC   tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC   hence, are useful for treatment of a patient having a condition
CC   associated with the level of CLCA1, where the invention further comprises
CC   the use of one or more therapies under conditions suitable for the
CC   treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC   antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC   nucleic acids of the invention are also used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of CLCA1 RNA in a cell. This sequence represents an
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 95;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        506 GGCACACTGACCGTGGA 522
              |||||| :|| ||:|||
Db          1 GGCACAGUGAUCGUGGA 17


RESULT 164
ABK57534/c
```

```
ID   ABK57534 standard; RNA; 17 BP.
XX
AC   ABK57534;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human CLCA1 gene enzymatic nucleic acid #1905.
XX
KW   Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW   antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW   chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW   oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW   acetylcysteine.
XX
OS   Homo sapiens.
XX
PN   WO200211674-A2.
XX
PD   14-FEB-2002.
XX
PF   09-AUG-2001; 2001WO-US024970.
XX
PR   09-AUG-2000; 2000US-0224383P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (SYNT ) SYNTEX USA LLC.
PA   (THOM/) THOMPSON J.
XX
PI   Thompson J,  Mcswiggen J,  Mckenzie T,  Ayers D,  Szymkowski DE;
PI   Grupe A;
XX
DR   WPI; 2002-217145/27.
XX
PT   Enzymatic polynucleotide that down regulates expression of chloride
PT   channel calcium activated gene, useful for treating Chronic obstructive
PT   pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS   Claim 4; Page 128; 152pp; English.
XX
CC   The invention relates to enzymatic nucleic acid molecules that down
CC   regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC   by cleaving RNA derived from the genes. The nucleic acid sequences are
CC   useful as pharmaceutical agents for treating conditions such as chronic
CC   obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC   fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC   that are related to or will respond to the levels of CLCA1 in a cell or
CC   tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC   hence, are useful for treatment of a patient having a condition
CC   associated with the level of CLCA1, where the invention further comprises
CC   the use of one or more therapies under conditions suitable for the
CC   treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC   antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC   nucleic acids of the invention are also used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of CLCA1 RNA in a cell. This sequence represents an
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 7 A; 2 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        422 TACATCTCCCGGTGCTT 438
              ||||||||||  ||| ||
Db         17 TACATCTCCCTGTGATT 1


RESULT 165
ABK57533/c
ID   ABK57533 standard; RNA; 17 BP.
XX
AC   ABK57533;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human CLCA1 gene enzymatic nucleic acid #1904.
XX
KW   Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW   antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW   chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW   oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW   acetylcysteine.
XX
OS   Homo sapiens.
XX
PN   WO200211674-A2.
XX
PD   14-FEB-2002.
XX
PF   09-AUG-2001; 2001WO-US024970.
XX
PR   09-AUG-2000; 2000US-0224383P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (SYNT ) SYNTEX USA LLC.
PA   (THOM/) THOMPSON J.
XX
PI   Thompson J,  Mcswiggen J,  Mckenzie T,  Ayers D,  Szymkowski DE;
PI   Grupe A;
XX
DR   WPI; 2002-217145/27.
XX
PT   Enzymatic polynucleotide that down regulates expression of chloride
PT   channel calcium activated gene, useful for treating Chronic obstructive
PT   pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS   Claim 4; Page 128; 152pp; English.
XX
CC   The invention relates to enzymatic nucleic acid molecules that down
CC   regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC   by cleaving RNA derived from the genes. The nucleic acid sequences are
CC   useful as pharmaceutical agents for treating conditions such as chronic
CC   obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC   fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC   that are related to or will respond to the levels of CLCA1 in a cell or
CC   tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC   hence, are useful for treatment of a patient having a condition
CC   associated with the level of CLCA1, where the invention further comprises
CC   the use of one or more therapies under conditions suitable for the
CC   treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC   antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC   nucleic acids of the invention are also used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of CLCA1 RNA in a cell. This sequence represents an
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 6 A; 2 C; 6 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        423 ACATCTCCCGGTGCTTC 439
              |||||||||  ||| |||
Db         17 ACATCTCCCTGTGATTC 1


RESULT 166
ACN00114/c
ID   ACN00114 standard; RNA; 17 BP.
XX
AC   ACN00114;
XX
DT   22-APR-2004  (first entry)
XX
```

```
DE   WNV Hammerhead Ribozyme substrate SEQ ID NO 104.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 104; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        728 TCTGTTTTTCTCAAATA 744
              |||||||||  ||||||
Db         17 TCTGTTTTTACCAAATA 1


RESULT 167
ACN09334
ID   ACN09334 standard; RNA; 17 BP.
XX
AC   ACN09334;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9337.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 9337; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 4 A; 3 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 95;
  Matches    6;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        727 TTCTGTTTTTCTCAAAT 743
              ::|:|:::::  ||||:
Db          1 UUCUGUUUUUACCAAAU 17


RESULT 168
ACN09335
ID   ACN09335 standard; RNA; 17 BP.
XX
AC   ACN09335;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9338.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
```

```
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 9338; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 3 C; 1 G; 0 T; 8 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 95;
  Matches    7;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        728 TCTGTTTTTCTCAAATA 744
              :|:|:::::  ||||:|
Db          1 UCUGUUUUUACCAAAUA 17


RESULT 169
ACA07606/c
ID   ACA07606 standard; RNA; 17 BP.
XX
AC   ACA07606;
XX
DT   03-JUN-2003  (first entry)
XX
DE   NFKB sub-unit modulating zinzyme substrate #5.
XX
KW   Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW   G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW   lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW   oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW   cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW   lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW   chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW   cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW   gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW   rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW   gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW   transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW   allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS   Homo sapiens.
XX
PN   US2002177568-A1.
XX
PD   28-NOV-2002.
XX
PF   23-MAY-2001; 2001US-00864785.
XX
PR   07-DEC-1992;   92US-00987132.
PR   18-MAY-1994;   94US-00245466.
PR   15-AUG-1994;   94US-00291932.
PR   23-DEC-1996;   96US-00777916.
XX
PA   (STIN/) STINCHCOMB D T.
PA   (MCSW/) MCSWIGGEN J.
PA   (DRAP/) DRAPER K G.
XX
PI   Stinchcomb DT,  Mcswiggen J,  Draper KG;
XX
DR   WPI; 2003-340953/32.
XX
PT   Novel enzymatic nucleic acid molecules which down regulates expression of
PT   a sequence encoding a subunit of nuclear factor kappa B useful for
PT   treating cancer, inflammatory disorders and autoimmune diseases.
XX
PS   Claim 3; Page 37; 72pp; English.
XX
CC   The invention describes an enzymatic nucleic acid molecule (I) which down
CC   regulates expression of a sequence encoding a subunit of nuclear factor
CC   kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC   configuration. The enzymatic nucleic acid molecule is adapted to treat
CC   cancer and is useful for down-regulating REL-A activity in a cell, for
CC   treating a patient having a condition associated with the level of REL-A.
CC   (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC   the presence of a divalent cation, especially Mg^2^+. The enzymatic and
CC   antisense nucleic acid molecules are useful for treating breast, lung,
CC   prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC   cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC   multidrug resistant cancer. The method involves use of other drug
CC   therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC   chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC   cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC   gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC   acid molecules are also useful for treating inflammatory disease such as
CC   rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC   obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC   rejection, gene therapy applications, ischaemia/reperfusion injury
CC   (central nervous system (CNS) and myocardial), glomerulonephritis,
CC   sepsis, allergic airway inflammation, inflammatory bowel disease or
CC   infection. This sequence represents the substrate of a novel enzymatic
CC   nucleic acid molecule
XX
SQ   Sequence 17 BP; 1 A; 6 C; 8 G; 0 T; 2 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         62 GGCCCCAGCTGGGACCC 78
              || |||||||| |||||
Db         17 GGGCCCAGCTGCGACCC 1


RESULT 170
ABZ65193
ID   ABZ65193 standard; RNA; 17 BP.
XX
AC   ABZ65193;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human HER2 DNAzyme substrate #650.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
```

```
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 4; Page 145; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 0 A; 5 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 95;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 171
ABZ60372
ID   ABZ60372 standard; RNA; 17 BP.
XX
AC   ABZ60372;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human K-Ras DNAzyme substrate #484.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 94; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 95;
  Matches    6;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 TTCTTTTGATACATTTA 724
              : |::::||:| |:::|
Db          1 UCCUUUUGAUAAAUUUA 17


RESULT 172
ACD65526
ID   ACD65526 standard; RNA; 17 BP.
XX
AC   ACD65526;
XX
DT   30-SEP-2003  (first entry)
XX
DE   HCV minus strand DNAzyme substrate sequence #2101.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
```

```
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 312; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 1 A; 9 C; 4 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 95;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCCC 693
              | |:||| |:|||:|||
Db          1 CCCUGGCAGUGCCUCCC 17


RESULT 173
ACC65874
ID   ACC65874 standard; DNA; 17 BP.
XX
AC   ACC65874;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 3121.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 395; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 7 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||  |||||||
Db          1 GATCACCAAACCAGTCA 17


RESULT 174
ACC65548/c
ID   ACC65548 standard; DNA; 17 BP.
XX
AC   ACC65548;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 2795.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 357; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
```

```
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        273 GCGGGGTCTCGGAGATC 289
              || ||||||| ||||||
Db         17 GCTGGGTCTCAGAGATC 1


RESULT 175
ADC37976
ID   ADC37976 standard; DNA; 17 BP.
XX
AC   ADC37976;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:325.
XX
KW   human; angiomotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW   AMLP1a; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003037931-A2.
XX
PD   08-MAY-2003.
XX
PF   01-NOV-2002; 2002WO-US035129.
XX
PR   01-NOV-2001; 2001US-0334773P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Shannon M,  Phan T;
XX
DR   WPI; 2003-430501/40.
XX
PT   New isolated nucleic acid molecule encoding a human angiomotin-like
PT   protein, useful for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of AMLP1.
XX
PS   Example 2; SEQ ID NO 325; 172pp; English.
XX
CC   The present invention describes the human angiomotin-like protein 1
CC   (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC   therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC   compositions of the present invention can be used for treating or
CC   preventing a disorder associated with decreased or increased expression
CC   or activity of AMLP1. The present sequence represents a scanning
CC   oligonucleotide for human AMLP1a, which is used in an example from the
CC   present invention.
XX
SQ   Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        243 ACAGCCGCGCGCTCAGC 259
              ||| |||| ||||||||
Db          1 ACATCCGCTCGCTCAGC 17


RESULT 176
ADC24273/c
ID   ADC24273 standard; DNA; 17 BP.
XX
AC   ADC24273;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human NOV9 forward PCR primer SEQ ID NO:80.
XX
KW   human; NOVX; cardiant; antiarteriosclerotic; hypotensive; vasotropic;
KW   dermatological; anorectic; immunosuppressive; cytostatic;
KW   antiinfertility; haemostatic; anti-HIV; antiasthmatic; antiinflammatory;
KW   neuroprotective; anabolic; nootropic; antiparkinsonian; gene therapy;
KW   cardiomyopathy; atherosclerosis; hypertension; congenital heart defect;
KW   pulmonary stenosis; scleroderma; obesity; metabolic disturbance; obesity;
KW   transplantation; adrenoleukodystrophy; congenital adrenal hyperplasia;
KW   prostate cancer; diabetes; metabolic disorder; neoplasm; adenocarcinoma;
KW   fertility; haemophilia; graft versus host disease; AIDS;
KW   bronchial asthma; Crohn's disease; multiple sclerosis;
KW   infectious disease; anorexia; neurodegenerative disorder;
KW   Alzheimer's disease; Parkinson's disease; immune disorder;
KW   haematopoietic disorder; dyslipidaemia; wasting disorder; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003076584-A2.
XX
PD   18-SEP-2003.
XX
PF   06-MAR-2003; 2003WO-US006951.
XX
PR   06-MAR-2002; 2002US-0361974P.
PR   19-MAR-2002; 2002US-0365477P.
PR   22-MAR-2002; 2002US-0366928P.
PR   06-AUG-2002; 2002US-0401661P.
PR   05-MAR-2003; 2003US-00401661.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Alsobrook JP,  Burgess CE,  Edinger SR,  Gerlach VL,  Ji W,  Kekuda R;
PI   Li L,  Macdougall JR,  Miller CE,  Millet I,  Patturajan M,  Pena CEA;
PI   Rieger DK,  Sciore P,  Shenoy SG,  Smithson G,  Spytek KA,  Stone DJ;
PI   Voss EZ,  Zhong M;
XX
DR   WPI; 2003-722330/68.
XX
PT   New NOVX polypeptides and nucleic acids, useful for diagnosing or
PT   treating e.g. cardiomyopathy, atherosclerosis, hypertension, scleroderma,
PT   obesity, prostate cancer, AIDS, bronchial asthma, Crohn's disease, or
PT   multiple sclerosis.
XX
PS   Example C; SEQ ID NO 80; 229pp; English.
XX
CC   The present invention describes novel human proteins, designated NOVX
CC   proteins. The NOVX sequences have cardiant, antiarteriosclerotic,
CC   hypotensive, vasotropic, dermatological, anorectic, immunosuppressive,
CC   cytostatic, antiinfertility, haemostatic, anti-HIV, antiasthmatic,
CC   antiinflammatory, neuroprotective, anabolic, nootropic and
CC   antiparkinsonian activities, and can be used in gene therapy. The NOVX
CC   sequences can be used as a therapeutic in the manufacture of a medicament
CC   for treating a syndrome associated with a human disease, such as a
CC   pathology associated with NOVX. The NOVX proteins and nucleic acids
CC   encoding them are useful for diagnosing or treating pathologies, diseases
CC   or conditions associated with NOVX sequences, including cardiomyopathy,
CC   atherosclerosis, hypertension, congenital heart defects, pulmonary
CC   stenosis, scleroderma, obesity, metabolic disturbances associated with
CC   obesity, transplantation, adrenoleukodystrophy, congenital adrenal
CC   hyperplasia, prostate cancer, diabetes, metabolic disorders, neoplasm,
CC   adenocarcinoma, fertility, haemophilia, graft versus host disease, AIDS,
```

```
CC   bronchial asthma, Crohn's disease, multiple sclerosis, infectious
CC   disease, anorexia, neurodegenerative disorders (e.g. Alzheimer's disease,
CC   or Parkinson's disease), immune disorders, haematopoietic disorders,
CC   dyslipidaemias, and wasting disorders associated with chronic diseases.
CC   The proteins can also be used as immunogens to produce antibodies and as
CC   vaccines. The sequences may further be used in chromosome mapping,
CC   identifying individual from minute biological samples (tissue typing),
CC   and in forensic identification of a biological sample. The present
CC   sequence represents a PCR primer for a human NOVX sequence, which is used
CC   in an example from the present invention.
XX
SQ   Sequence 17 BP; 4 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        664 CCCCTGCTGCCGCCACT 680
              ||||| |||| ||||||
Db         17 CCCCTTCTGCAGCCACT 1


RESULT 177
ADF63855/c
ID   ADF63855 standard; DNA; 17 BP.
XX
AC   ADF63855;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1759.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 1759; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 0 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        520 GGAGGCCCCCATGCCCA 536
              ||||| |||| |||||
Db         17 GGAGGCACCCAGGCCCA 1


RESULT 178
ADF63856/c
ID   ADF63856 standard; DNA; 17 BP.
XX
AC   ADF63856;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1760.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 1760; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 1 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        519 TGGAGGCCCCCATGCCC 535
              ||||||| |||| ||||
Db         17 TGGAGGCACCCAGGCCC 1


RESULT 179
ADI49311
ID   ADI49311 standard; DNA; 17 BP.
XX
AC   ADI49311;
XX
```

```
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID1814.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 1814; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 7 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||  |||||||
Db          1 GATCACCAAACCAGTCA 17


RESULT 180
ADI48838/c
ID   ADI48838 standard; DNA; 17 BP.
XX
AC   ADI48838;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID1341.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 1341; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 7 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        734 TTTCTCAAATAAAGTTC 750
              ||||||||||| | ||
Db         17 TTTCTCAAATAATGATC 1


RESULT 181
ABZ76956/c
ID   ABZ76956 standard; DNA; 17 BP.
XX
AC   ABZ76956;
XX
DT   07-MAY-2003  (first entry)
XX
DE   Bovine DGAT BAC-DNA sequencing primer #29.
XX
KW   Acyl CoA:diacylglycerol transferase; DGAT; enzyme; chromosome 14; bovine;
KW   milk; meat marbling; low fat; polymorphic; SNP;
KW   single nucleotide polymorphism; PCR primer; ss.
XX
OS   Bos taurus.
OS   Synthetic.
XX
PN   WO2003004630-A2.
XX
PD   16-JAN-2003.
XX
PF   05-JUL-2002; 2002WO-EP007520.
```

```
XX
PR   06-JUL-2001; 2001EP-00116412.
PR   13-MAY-2002; 2002US-0379412P.
XX
PA   (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
XX
PI   Fries H,  Winter A;
XX
DR   WPI; 2003-239205/23.
XX
PT   New nucleic acid molecule comprising a sequence of an allele of a
PT   polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
PT   testing a mammal for its predisposition for fat content of milk and for
PT   meat marbling.
XX
PS   Example 1; Page 35; 91pp; English.
XX
CC   The present invention describes a nucleic acid molecule (NA) (I) encoding
CC   a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
CC   indicative for low fat content of milk and to low meat marbling
CC   (intramuscular fat content). Human DGAT is located to chromosome 8, and
CC   bovine DGAT is located to chromosome 14. (I) is useful for testing a
CC   mammal for its predisposition for fat content of milk and/or its
CC   predisposition for meat marbling. The method comprises analysing the gene
CC   encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
CC   polymorphisms (SNPs)) which are connected with the predisposition. The
CC   nucleotide polymorphisms are located in the coding region of the DGAT
CC   gene and result in substitution, deletion and/or addition of an amino
CC   acid sequence of the polypeptide which is encoded by the gene. The
CC   nucleic acid molecule has at the position 10433 and 10434 of the DGAT
CC   gene a guanine and a cytosine residue, at position 3343 a cytosine or
CC   guanine, 11030 a guanine, 11048 a cytosine or thymine and 11093 a
CC   thymine, which correlate with a predisposition for low fat content of
CC   milk and low meat marbling. The nucleic acid molecule has at the position
CC   corresponding to position 10433 and 10434 of the DGAT gene two adenine
CC   residues which correlate with a predisposition for high content of milk
CC   and high meat marbling. The nucleotide polymorphisms are located in a
CC   region which is responsible for the regulation of the expression of the
CC   product of the gene encoding DGAT. ABZ76924 to ABZ77045 and ABP96035 to
CC   ABP96046 represent sequences used in the exemplification of the present
CC   invention
XX
SQ   Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        467 GTGGACCCCACCCAAGT 483
              ||||||||||| ||| ||
Db         17 GTGGACCCCATCCAGGT 1


RESULT 182
ADL47965
ID   ADL47965 standard; RNA; 17 BP.
XX
AC   ADL47965;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human IKK-gamma substrate sequence #475.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 1498; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human IKK-
CC   gamma substrate sequence.
XX
SQ   Sequence 17 BP; 0 A; 13 C; 2 G; 0 T; 2 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 95;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        194 CCCCTGCCCCCCGCCGC 210
              ||| :|||||||||| |
Db          1 CCCUUGCCCCCCGCCCC 17


RESULT 183
ADI87132
ID   ADI87132 standard; RNA; 17 BP.
XX
AC   ADI87132;
XX
DT   03-JUN-2004  (first entry)
XX
DE   HCV DNAzyme substrate sequence #4378.
XX
KW   ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW   HCV infection; type I interferon; DNAzyme.
XX
OS   Hepatitis C virus.
XX
PN   US2003125270-A1.
XX
PD   03-JUL-2003.
XX
PF   18-DEC-2000; 2000US-00740332.
```

```
XX
PR   18-DEC-2000; 2000US-00740332.
XX
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (ROBE/) ROBERTS E.
PA   (PAVC/) PAVCO P A.
PA   (MACE/) MACEJACK D.
XX
PI   Blatt L,  Mcswiggen J,  Roberts E,  Pavco PA,  Macejack D;
XX
DR   WPI; 2004-031273/03.
XX
PT   Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT   from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT   especially in combination with type I interferon therapy.
XX
PS   Claim 1; SEQ ID NO 4378; 198pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule which
CC   specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC   the binding arms of the enzymatic nucleic acid molecule comprises
CC   sequences complementary to any of the defined substrate sequences given
CC   in the specification. The nucleic acid molecule may be administered for
CC   the treatment of HCV infections, especially in combination with type I
CC   interferons. The present sequence represents a HCV DNAzyme substrate
CC   sequence.
XX
SQ   Sequence 17 BP; 1 A; 9 C; 4 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 95;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCCC 693
              | |:||| |:|||:|||
Db          1 CCCUGGCAGUGCCUCCC 17


RESULT 184
ACN65429/c
ID   ACN65429 standard; DNA; 17 BP.
XX
AC   ACN65429;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:2331.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 2331; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 95;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              ||||||  |||  ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 185
ACN73767
ID   ACN73767 standard; DNA; 17 BP.
XX
AC   ACN73767;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:10669.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
```

PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUYY/) GU Y.
PA (JIYY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
DR WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 10669; 0pp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 14 GAGTCAGCCAGCATGAC 30
||| |||||||||| |
Db 1 GAGCCAGCCAGCATGGC 17

RESULT 186
ACN65427/c
ID ACN65427 standard; DNA; 17 BP.
XX
AC ACN65427;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMLP-1 probe SEQ ID NO:2329.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUYY/) GU Y.
PA (JIYY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
DR WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 2329; 0pp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SQ Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 551 TCCAACGAGATCACCAT 567
|||| ||| ||||||||
Db 17 TCCAGCGACATCACCAT 1

RESULT 187
ACN73768
ID ACN73768 standard; DNA; 17 BP.
XX
AC ACN73768;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMLP-1 probe SEQ ID NO:10670.
XX

KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUYY/) GU Y.
PA (JIYY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
DR WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 10670; 0pp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 15 AGTCAGCCAGCATGACC 31
|| |||||||||| ||
Db 1 AGCCAGCCAGCATGGCC 17

RESULT 188
ACN65428/c
ID ACN65428 standard; DNA; 17 BP.
XX
AC ACN65428;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMLP-1 probe SEQ ID NO:2330.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUYY/) GU Y.
PA (JIYY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
DR WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 2330; 0pp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SQ Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 189
AAF46292
ID   AAF46292 standard; DNA; 15 BP.
XX
AC   AAF46292;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1131.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 12 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 88;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        196 CCTGCCCCCCGCCGC 210
              ||||||||||||| |
Db          1 CCTGCCCCCCGCCCC 15


RESULT 190
AAV43464/c
ID   AAV43464 standard; RNA; 16 BP.
XX
AC   AAV43464;
XX
DT   17-OCT-2003  (revised)
DT   14-SEP-1998  (first entry)
XX
DE   HIV-1 beta-chemokine receptor (CKR)-5 target sequence 11.
XX
KW   Endo-ribonuclease; ribozyme; cleave; co-receptor RNA; HIV infection;
KW   chemokine receptor; CKR; fusin; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   WO9817308-A1.
XX
PD   30-APR-1998.
XX
PF   24-OCT-1997;   97WO-US019923.
XX
PR   25-OCT-1996;   96US-0027875P.
PR   19-DEC-1996;   96US-00770235.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Leavitt MC,  Tritz R,  Feng Y,  Barber J,  Yu M;
XX
DR   WPI; 1998-261188/23.
XX
PT   Endo-ribonuclease nucleic acids - which encode ribozymes which cleave co-
PT   receptor RNA expressed in cells, used particularly for inhibiting HIV
PT   infection of cells.
XX
PS   Claim 3; Page 27; 83pp; English.
XX
CC   This represents a target sequence of HIV-1 co-receptor beta-chemokine
CC   receptor (CKR)-5. The invention provides endo-ribonuclease nucleic acid
CC   that encodes a ribozyme which cleaves a co-receptor RNA expressed in a
CC   cell. The co-receptor RNA is a member of the seven trans-membrane protein
CC   receptor family. This can be used in a method of inhibiting HIV infection
CC   of a cell which comprises cleaving a co-receptor mRNA expressed in the
CC   cell. The co-receptor mRNA encodes an HIV co-receptor protein selected
CC   from fusin, beta-chemokine receptor-5 (CKR-5), CKR-3 and CKR-2b. The
CC   cleavage of the co-receptor mRNA inhibits the production of the selected
CC   co-receptor protein, thereby inhibiting HIV infection of the cell. The
CC   endo-ribonucleases can be used to specifically cleave RNAs. The method
CC   can be used for inhibiting HIV infection of cells by inhibiting
CC   expression of HIV co-receptor on the surface of cells. Because the level
CC   of co-receptor on the surface of the cell is reduced, HIV entry into the
CC   cells is inhibited. Cleavage of HIV co-receptor mRNA using targeted
CC   ribozymes is not cytotoxic to cells expressing the co-receptor and the
CC   cells retain normal immune function. (Updated on 17-OCT-2003 to
CC   standardise OS field)
XX
SQ   Sequence 16 BP; 0 A; 6 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             1.8%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 99;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        402 AGCGGCAGGACGAGC 416
              ||||||||||| |||
Db         16 AGCGGCAGGACCAGC 2


RESULT 191
AAF46288
ID   AAF46288 standard; DNA; 15 BP.
XX
```

```
AC   AAF46288;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1127.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 11 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        194 CCCCTGCCCCCCG 206
              |||||||||||||
Db          3 CCCCTGCCCCCCG 15


RESULT 192
AAF45796/c
ID   AAF45796 standard; DNA; 15 BP.
XX
AC   AAF45796;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #635.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 38; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 2 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        686 TGCCTCCCCCGCC 698
              |||||||||||||
Db         15 TGCCTCCCCCGCC 3


RESULT 193
AAF45798/c
ID   AAF45798 standard; DNA; 15 BP.
XX
AC   AAF45798;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #637.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
```

```
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 38; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 2 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        686 TGCCTCCCCCGCC 698
              |||||||||||||
Db         13 TGCCTCCCCCGCC 1


RESULT 194
AAF45797/c
ID   AAF45797 standard; DNA; 15 BP.
XX
AC   AAF45797;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #636.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 38; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 2 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        686 TGCCTCCCCCGCC 698
              |||||||||||||
Db         14 TGCCTCCCCCGCC 2


RESULT 195
ADD15802/c
ID   ADD15802 standard; RNA; 15 BP.
XX
AC   ADD15802;
XX
DT   15-JAN-2004  (first entry)
XX
DE   K-ras targeting zinzyme substrate sequence #11.
XX
KW   Zinzyme; ss; K-ras; human; gene therapy; cytostatic; catalytic RNA;
KW   gene expression; cancer; HER-2.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US2003105308-A1.
XX
PD   05-JUN-2003.
XX
```

```
PF   31-JUL-2001; 2001US-00918728.
XX
PR   05-NOV-1997;   97US-0064866P.
PR   29-APR-1998;   98US-0083727P.
PR   04-NOV-1998;   98US-00186675.
PR   28-APR-1999;   99US-00301511.
PR   29-DEC-1999;   99US-00474432.
PR   30-DEC-1999;   99US-00476387.
PR   23-MAY-2000; 2000US-00578223.
PR   04-APR-2001; 2001US-00825805.
XX
PA   (BEIG/) BEIGELMAN L.
PA   (ZINN/) ZINNEN S.
XX
PI   Beigelman L,  Zinnen S;
XX
DR   WPI; 2003-801249/75.
XX
PT   New nucleoside triphosphate compound for use in inhibiting gene
PT   expression and in human therapy, such as, for the treatment of cancer.
XX
PS   Example 3; SEQ ID NO 11; 100pp; English.
XX
CC   The invention relates to a catalytic RNA compound (termed a Zinzyme)
CC   which is a nucleoside triphosphate, where the structure (A) is given in
CC   the specification, and has a sequence of ADD15811, comprising a core
CC   zinzyme sequence(ADD15811) flanked by sequences homologous to the target
CC   molecule and incorporating a 5' linker. The zinzyme is used to inhibit
CC   gene expression, in human therapy of e.g. cancer), in diagnosing gene
CC   expression, in pharmaceutical, agricultural, research and diagnostic
CC   applications. Examples were given showing the optimisation of zinzymes
CC   targeting human K-ras and HER2 mRNA. The present sequence is a zinzyme
CC   target/substrate sequence.
XX
SQ   Sequence 15 BP; 2 A; 4 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        685 GTGCCTCCCCCGC 697
              |||||||||||||
Db         15 GTGCCTCCCCCGC 3


RESULT 196
ADM94700
ID   ADM94700 standard; DNA; 21 BP.
XX
AC   ADM94700;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:50.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 50; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 13;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 1.8e+02;
  Matches   16;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy        495 TGTCCCCTGAGGGCACACTGA 515
              ||| |||| |||| |||  ||
Db          1 TGTGCCCTCAGGGGACAGGGA 21


RESULT 197
AAA86552
ID   AAA86552 standard; DNA; 16 BP.
XX
AC   AAA86552;
XX
DT   04-DEC-2000  (first entry)
XX
DE   Cyclin B1 hairpin ribozyme recognition site #12.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Example 1; Page 16; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
```

```
CC   restenosis treatment
XX
SQ   Sequence 16 BP; 7 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGACCAA 366
              |||| ||||||| |||
Db          1 TGACTGTCAAGAACAA 16


RESULT 198
AAC73182/c
ID   AAC73182 standard; DNA; 16 BP.
XX
AC   AAC73182;
XX
DT   02-FEB-2001  (first entry)
XX
DE   Reverse primer #28 used in multiplexing PCR/SBE assay.
XX
KW   Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW   PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
XX
OS   Unidentified.
XX
PN   WO200058516-A2.
XX
PD   05-OCT-2000.
XX
PF   27-MAR-2000; 2000WO-US008069.
XX
PR   26-MAR-1999;   99US-0126473P.
PR   23-JUN-1999;   99US-0140359P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Fan J,  Hirschhorn JN,  Huang X,  Kaplan P,  Lander ES,  Lockhart DJ;
PI   Ryder T,  Sklar P;
XX
DR   WPI; 2000-656171/63.
XX
PT   Universal array of oligonucleotides tags attached to a solid substrate
PT   along with locus-specific tagged oligonucleotides useful in genotyping
PT   using single base extension reactions.
XX
PS   Example 7; Page 50; 70pp; English.
XX
CC   The present invention relates to an oligonucleotide array comprising
CC   oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC   array is useful for genotyping a nucleic acid sample at one or more loci
CC   via single base extension (SBE) reactions. A pair of primers is used to
CC   amplify a polymorphic locus in a sample e.g. a single nucleotide
CC   polymorphism (SNP). The present sequence is one of the primers used in
CC   the method of the present invention to amplify a polymorphic sample. The
CC   amplified nucleic acid product is then used as a template in a SBE
CC   reaction with an extension primer. The SBE reaction products are used to
CC   form the oligonucleotide array
XX
SQ   Sequence 16 BP; 1 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        464 GGTGTGGACCCCACCC 479
              |||| |||||||| ||
Db         16 GGTGAGGACCCCAGCC 1


RESULT 199
AAF25893/c
ID   AAF25893 standard; DNA; 16 BP.
XX
AC   AAF25893;
XX
DT   19-APR-2001  (first entry)
XX
DE   Human c-sis/PDGF-B proto-oncogene promoter primer TFO-1.
XX
KW   PDGF-B; platelet derived growth factor; c-sis; promoter; cytostatic;
KW   antiarteriosclerotic; antiinflammatory; TFO; tumor; drug; primer;
KW   triplex forming oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO200104290-A1.
XX
PD   18-JAN-2001.
XX
PF   10-JUL-2000; 2000WO-GB002645.
XX
PR   09-JUL-1999;   99CN-00113864.
XX
PA   (SHAN-) SHANGHAI BIO-CHEM INST.
PA   (GENE-) GENEMEDIX PLC.
XX
PI   Jin Y,  Liu J;
XX
DR   WPI; 2001-138343/14.
XX
PT   Novel triplex forming oligonucleotides useful for treating tumor,
PT   atherosclerosis and inflammation, binds to double-stranded promoter
PT   region of the c-sis/platelet-derived growth factor proto-oncogene.
XX
PS   Claim 3; Page 21; 27pp; English.
XX
CC   This invention describes a novel polynucleotide (I) capable of
CC   selectively binding to the double-stranded promoter region of the c-
CC   sis/platelet-derived growth factor B (PDGF-B) proto-oncogene to form a
CC   triplex, which inhibits the function of the promoter and affects
CC   expression of the proto-oncogene. The products of the invention have
CC   antiarteriosclerotic, cytostatic and antiinflammatory activity. The
CC   effect of triplex formation on c-sis/PDGF-B transcription was studied. A
CC   reporter plasmid pGL3 promoter carrying a firefly luciferase gene driven
CC   by the 255 base pair (bp) c-sis/PDGF-B promoter was constructed to
CC   measure the in vivo effects of triplex forming oligonucleotide (TFO) 1,
CC   2, 6 and 8, which have sequences of 86, 85, 85 and 85 bp, respectively
CC   defined in the specification, on c-sis/PDGF-B transcription. Triplex was
CC   formed in vitro by incubating supercoil pGL3 promoter plasmid with TFOs,
CC   and then the entire DNA complex was transfected into K562 cells.
CC   Incubation of TFO1 resulted in a 56.2% luciferase activity while TFO6
CC   caused 85.3% and TFO8 caused 76.3% decrease in luciferase activity. As a
CC   non-triplex forming control, TFO2 had little effect on the expression of
CC   the firefly luciferase. (I) is useful as a therapeutic agent for treating
CC   a condition associated with the expression of c-sis/PDGF-B, including
CC   tumors, atherosclerosis or inflammation. (I) binds to the promoter region
CC   of c-sis/PDGF-B proto-oncogene preventing nuclear factors binding to the
CC   promoter and initiating transcription. (I) is useful for preparing drugs
CC   which are specific and stable. The triplex oligonucleotides have
CC   generally one to two targets per cell as compared with the 100-1000s of
CC   mRNA target for antisense oligonucleotide thus offering the potential for
CC   low dose long-acting therapeutics
XX
SQ   Sequence 16 BP; 8 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        483 TTTCCTCCTCCCTGTC 498
              ||||||| ||||| ||
Db         16 TTTCCTCTTCCCTCTC 1
```

```
RESULT 200
AAF25892/c
ID   AAF25892 standard; DNA; 16 BP.
XX
AC   AAF25892;
XX
DT   19-APR-2001  (first entry)
XX
DE   Human c-sis/PDGF-B proto-oncogene promoter primer TFO-p.
XX
KW   PDGF-B; platelet derived growth factor; c-sis; promoter; cytostatic;
KW   antiarteriosclerotic; antiinflammatory; TFO; tumor; drug; primer;
KW   triplex forming oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO200104290-A1.
XX
PD   18-JAN-2001.
XX
PF   10-JUL-2000; 2000WO-GB002645.
XX
PR   09-JUL-1999;   99CN-00113864.
XX
PA   (SHAN-) SHANGHAI BIO-CHEM INST.
PA   (GENE-) GENEMEDIX PLC.
XX
PI   Jin Y,  Liu J;
XX
DR   WPI; 2001-138343/14.
XX
PT   Novel triplex forming oligonucleotides useful for treating tumor,
PT   atherosclerosis and inflammation, binds to double-stranded promoter
PT   region of the c-sis/platelet-derived growth factor proto-oncogene.
XX
PS   Disclosure; Page 21; 27pp; English.
XX
CC   This invention describes a novel polynucleotide (I) capable of
CC   selectively binding to the double-stranded promoter region of the c-
CC   sis/platelet-derived growth factor B (PDGF-B) proto-oncogene to form a
CC   triplex, which inhibits the function of the promoter and affects
CC   expression of the proto-oncogene. The products of the invention have
CC   antiarteriosclerotic, cytostatic and antiinflammatory activity. The
CC   effect of triplex formation on c-sis/PDGF-B transcription was studied. A
CC   reporter plasmid pGL3 promoter carrying a firefly luciferase gene driven
CC   by the 255 base pair (bp) c-sis/PDGF-B promoter was constructed to
CC   measure the in vivo effects of triplex forming oligonucleotide (TFO) 1,
CC   2, 6 and 8, which have sequences of 86, 85, 85 and 85 bp, respectively
CC   defined in the specification, on c-sis/PDGF-B transcription. Triplex was
CC   formed in vitro by incubating supercoil pGL3 promoter plasmid with TFOs,
CC   and then the entire DNA complex was transfected into K562 cells.
CC   Incubation of TFO1 resulted in a 56.2% luciferase activity while TFO6
CC   caused 85.3% and TFO8 caused 76.3% decrease in luciferase activity. As a
CC   non-triplex forming control, TFO2 had little effect on the expression of
CC   the firefly luciferase. (I) is useful as a therapeutic agent for treating
CC   a condition associated with the expression of c-sis/PDGF-B, including
CC   tumors, atherosclerosis or inflammation. (I) binds to the promoter region
CC   of c-sis/PDGF-B proto-oncogene preventing nuclear factors binding to the
CC   promoter and initiating transcription. (I) is useful for preparing drugs
CC   which are specific and stable. The triplex oligonucleotides have
CC   generally one to two targets per cell as compared with the 100-1000s of
CC   mRNA target for antisense oligonucleotide thus offering the potential for
CC   low dose long-acting therapeutics
XX
SQ   Sequence 16 BP; 8 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        483 TTTCCTCCTCCCTGTC 498
                  ||||||| ||||| ||
Db         16 TTTCCTCTTCCCTCTC 1


RESULT 201
AAH61718
ID   AAH61718 standard; DNA; 16 BP.
XX
AC   AAH61718;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cyclin B1 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4142.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 19; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 16 BP; 7 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy        351 TGACGGTCAAGACCAA 366
              |||| ||||||| |||
Db          1 TGACTGTCAAGAACAA 16
```

```
RESULT 202
AAS15504
ID   AAS15504 standard; DNA; 16 BP.
XX
AC   AAS15504;
XX
DT   16-JAN-2002  (first entry)
XX
DE   N-acetyltransferase 2 (NAT2) G191A SNP hybridisation probe #1.
XX
KW   N-acetyltransferase 2; NAT2; human; genotyping; SNP; G191A; probe;
KW   single nucleotide polymorphism; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   variation       replace(8,G)
FT                   /*tag=  a
FT                   /standard_name= "Single nucleotide polymorphism"
XX
PN   WO200166804-A2.
XX
PD   13-SEP-2001.
XX
PF   09-MAR-2001; 2001WO-US007775.
XX
PR   09-MAR-2000; 2000US-00521983.
PR   10-JUL-2000; 2000US-00613517.
XX
PA   (PROT-) PROTOGENE LAB INC.
XX
PI   Cronin MT,  Frueh F,  Brennan TM;
XX
DR   WPI; 2001-616243/71.
XX
PT   Determining sequence variation in, or monitoring expression of genes in
PT   target nucleic acid for high-throughput genotyping of (un)known
PT   polymorphisms/mutations, comprises hybridization pattern differences
PT   between target and probe sequences.
XX
PS   Example 5; Page 34; 60pp; English.
XX
CC   The invention relates to a method of simultaneously determining the
CC   presence of 2 or more sequence variations in target nucleic acids, or
CC   simultaneously monitoring expression of 2 or more genes. The method
CC   comprises determining differences in hybridisation between the target
CC   nucleic acid and immobilised probes, where differences in hybridisation
CC   between indicates sequence variations or transcription levels. The method
CC   is used for simultaneously determining the presence or absence of two or
CC   more sequence variations in target nucleic acids or simultaneously
CC   monitoring expression of two or more genes in target nucleic acids. The
CC   methods are applicable to high-throughput genotyping of known and unknown
CC   polymorphisms and mutations. The method maximises the information yield
CC   of hybridisation-based array applications by increasing the number of
CC   informative array-immobilised polynucleotide probes. The present sequence
CC   represents N-acetyltransferase 2 (NAT2) G191A single nucleotide
CC   polymorphism (SNP) hybridisation probe #1
XX
SQ   Sequence 16 BP; 2 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        473 CCCACCCAAGTTTCCT 488
              |||||||| ||||| |
Db          1 CCCACCCAGGTTTCTT 16
```

```
RESULT 203
AAS15520
ID   AAS15520 standard; DNA; 16 BP.
XX
AC   AAS15520;
XX
DT   16-JAN-2002  (first entry)
XX
DE   N-acetyltransferase 2 (NAT2) G191A SNP hybridisation probe #17.
XX
KW   N-acetyltransferase 2; NAT2; human; genotyping; SNP; G191A; probe;
KW   single nucleotide polymorphism; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   variation       replace(8,G)
FT                   /*tag=  a
FT                   /standard_name= "Single nucleotide polymorphism"
FT   variation       replace(9,G)
FT                   /*tag=  b
FT                   /standard_name= "Single nucleotide polymorphism"
XX
PN   WO200166804-A2.
XX
PD   13-SEP-2001.
XX
PF   09-MAR-2001; 2001WO-US007775.
XX
PR   09-MAR-2000; 2000US-00521983.
PR   10-JUL-2000; 2000US-00613517.
XX
PA   (PROT-) PROTOGENE LAB INC.
XX
PI   Cronin MT,  Frueh F,  Brennan TM;
XX
DR   WPI; 2001-616243/71.
XX
PT   Determining sequence variation in, or monitoring expression of genes in
PT   target nucleic acid for high-throughput genotyping of (un)known
PT   polymorphisms/mutations, comprises hybridization pattern differences
PT   between target and probe sequences.
XX
PS   Example 5; Page 35; 60pp; English.
XX
CC   The invention relates to a method of simultaneously determining the
CC   presence of 2 or more sequence variations in target nucleic acids, or
CC   simultaneously monitoring expression of 2 or more genes. The method
CC   comprises determining differences in hybridisation between the target
CC   nucleic acid and immobilised probes, where differences in hybridisation
CC   between indicates sequence variations or transcription levels. The method
CC   is used for simultaneously determining the presence or absence of two or
CC   more sequence variations in target nucleic acids or simultaneously
CC   monitoring expression of two or more genes in target nucleic acids. The
CC   methods are applicable to high-throughput genotyping of known and unknown
CC   polymorphisms and mutations. The method maximises the information yield
CC   of hybridisation-based array applications by increasing the number of
CC   informative array-immobilised polynucleotide probes. The present sequence
CC   represents N-acetyltransferase 2 (NAT2) G191A single nucleotide
CC   polymorphism (SNP) hybridisation probe #20
XX
SQ   Sequence 16 BP; 2 A; 8 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        473 CCCACCCAAGTTTCCT 488
              ||||||| |||||| |
Db          1 CCCACCCCAGTTTCTT 16
```

```
RESULT 204
AAS15516
ID   AAS15516 standard; DNA; 16 BP.
XX
AC   AAS15516;
XX
DT   16-JAN-2002  (first entry)
XX
DE   N-acetyltransferase 2 (NAT2) G191A SNP hybridisation probe #13.
XX
KW   N-acetyltransferase 2; NAT2; human; genotyping; SNP; G191A; probe;
KW   single nucleotide polymorphism; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   variation       replace(8,G)
FT                   /*tag=  a
FT                   /standard_name= "Single nucleotide polymorphism"
FT   variation       replace(9,G)
FT                   /*tag=  b
FT                   /standard_name= "Single nucleotide polymorphism"
XX
PN   WO200166804-A2.
XX
PD   13-SEP-2001.
XX
PF   09-MAR-2001; 2001WO-US007775.
XX
PR   09-MAR-2000; 2000US-00521983.
PR   10-JUL-2000; 2000US-00613517.
XX
PA   (PROT-) PROTOGENE LAB INC.
XX
PI   Cronin MT,  Frueh F,  Brennan TM;
XX
DR   WPI; 2001-616243/71.
XX
PT   Determining sequence variation in, or monitoring expression of genes in
PT   target nucleic acid for high-throughput genotyping of (un)known
PT   polymorphisms/mutations, comprises hybridization pattern differences
PT   between target and probe sequences.
XX
PS   Example 5; Page 35; 60pp; English.
XX
CC   The invention relates to a method of simultaneously determining the
CC   presence of 2 or more sequence variations in target nucleic acids, or
CC   simultaneously monitoring expression of 2 or more genes. The method
CC   comprises determining differences in hybridisation between the target
CC   nucleic acid and immobilised probes, where differences in hybridisation
CC   between indicates sequence variations or transcription levels. The method
CC   is used for simultaneously determining the presence or absence of two or
CC   more sequence variations in target nucleic acids or simultaneously
CC   monitoring expression of two or more genes in target nucleic acids. The
CC   methods are applicable to high-throughput genotyping of known and unknown
CC   polymorphisms and mutations. The method maximises the information yield
CC   of hybridisation-based array applications by increasing the number of
CC   informative array-immobilised polynucleotide probes. The present sequence
CC   represents N-acetyltransferase 2 (NAT2) G191A single nucleotide
CC   polymorphism (SNP) hybridisation probe #13
XX
SQ   Sequence 16 BP; 2 A; 7 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        473 CCCACCCAAGTTTCCT 488
              ||||||| ||||||  |
Db          1 CCCACCCTAGTTTCTT 16
```

```
RESULT 205
ABA89669
ID   ABA89669 standard; DNA; 16 BP.
XX
AC   ABA89669;
XX
DT   12-FEB-2002  (first entry)
XX
DE   Serial analysis of ribosomal DNA tag #28.
XX
KW   Serial analysis of ribosomal DNA; SARD; genetic diversity;
KW   geochemical exploration; agriculture; bioremediation; forensic science;
KW   environmental analysis; parasite detection; virus detection; ss.
XX
OS   Unidentified.
XX
PN   WO200177392-A2.
XX
PD   18-OCT-2001.
XX
PF   10-APR-2001; 2001WO-US011609.
XX
PR   10-APR-2000; 2000US-0196063P.
PR   11-APR-2000; 2000US-0196258P.
XX
PA   (ASHB/) ASHBY M.
XX
PI   Ashby M;
XX
DR   WPI; 2002-010926/01.
XX
PT   Determining genetic diversity of population by analyzing a specific
PT   polymorphic region characteristic of particular genome in population of
PT   interest, useful for locating mineral deposits or petroleum reserves.
XX
PS   Example 3; Fig 15; 83pp; English.
XX
CC   The present invention relates to a method of determining the genetic
CC   diversity of a population, involving amplifying a genome subregion with a
CC   polymorphic site, cleaving amplified fragment close to the polymorphic
CC   site, immobilising the amplified fragment, splitting into two pools,
CC   adding a linker to each pool, digesting the immobilised product to form
CC   tags that are ligated to form ditags, and amplifying, cleaving and
CC   ligating to form concatemers and sequencing. The method is known as
CC   serial analysis of ribosomal DNA (SARD).This can be used to determine the
CC   genetic diversity of a population including microbial, viral or immune
CC   cell populations. The microbial population whose genetic diversity can be
CC   determined is from a sample associated with a site for petroleum or
CC   natural gas exploration, i.e., at a site of oil or gas reserves,
CC   associated with a site of mineral exploration, associated with a
CC   agricultural field, of patient sample suspected to have bacterial or
CC   fungal infection, associated with bioremediation site, or of an insect or
CC   parasite. The methods have application in fields of geochemical
CC   exploration, agriculture, bioremediation, environmental analysis,
CC   clinical microbiology, forensic science and medicine. The present
CC   sequence is an oligonucleotide described in the exemplification of the
CC   invention
XX
SQ   Sequence 16 BP; 2 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        525 CCCCCATGCCCAAGCT 540
              ||||| |||| |||||
Db          1 CCCCCGTGCCGAAGCT 16
```

```
RESULT 206
ABA89738
ID   ABA89738 standard; DNA; 16 BP.
XX
```

```
AC   ABA89738;
XX
DT   12-FEB-2002  (first entry)
XX
DE   Serial analysis of ribosomal DNA tag #97.
XX
KW   Serial analysis of ribosomal DNA; SARD; genetic diversity;
KW   geochemical exploration; agriculture; bioremediation; forensic science;
KW   environmental analysis; parasite detection; virus detection; ss.
XX
OS   Unidentified.
XX
PN   WO200177392-A2.
XX
PD   18-OCT-2001.
XX
PF   10-APR-2001; 2001WO-US011609.
XX
PR   10-APR-2000; 2000US-0196063P.
PR   11-APR-2000; 2000US-0196258P.
XX
PA   (ASHB/) ASHBY M.
XX
PI   Ashby M;
XX
DR   WPI; 2002-010926/01.
XX
PT   Determining genetic diversity of population by analyzing a specific
PT   polymorphic region characteristic of particular genome in population of
PT   interest, useful for locating mineral deposits or petroleum reserves.
XX
PS   Example 3; Fig 16; 83pp; English.
XX
CC   The present invention relates to a method of determining the genetic
CC   diversity of a population, involving amplifying a genome subregion with a
CC   polymorphic site, cleaving amplified fragment close to the polymorphic
CC   site, immobilising the amplified fragment, splitting into two pools,
CC   adding a linker to each pool, digesting the immobilised product to form
CC   tags that are ligated to form ditags, and amplifying, cleaving and
CC   ligating to form concatemers and sequencing. The method is known as
CC   serial analysis of ribosomal DNA (SARD).This can be used to determine the
CC   genetic diversity of a population including microbial, viral or immune
CC   cell populations. The microbial population whose genetic diversity can be
CC   determined is from a sample associated with a site for petroleum or
CC   natural gas exploration, i.e., at a site of oil or gas reserves,
CC   associated with a site of mineral exploration, associated with a
CC   agricultural field, of patient sample suspected to have bacterial or
CC   fungal infection, associated with bioremediation site, or of an insect or
CC   parasite. The methods have application in fields of geochemical
CC   exploration, agriculture, bioremediation, environmental analysis,
CC   clinical microbiology, forensic science and medicine. The present
CC   sequence is an oligonucleotide described in the exemplification of the
CC   invention
XX
SQ   Sequence 16 BP; 1 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              |||||| ||| |||||
Db          1 CTGCGGTGCCGCAGCT 16


RESULT 207
ADC03079/c
ID   ADC03079 standard; DNA; 16 BP.
XX
AC   ADC03079;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Ex vivo stem-cell expansion related polynucleotide #514.
XX
KW   cytostatic; antianaemic; immunomodulator; immunostimulant;
KW   immunosuppressive; antiinflammatory; interleukin agonist 3;
KW   interleukin antagonist 3; gene therapy; ex vivo expansion of stem cell;
KW   modified human interleukin-3; cell proliferatiion;
KW   acute myelogenous leukaemia cell proliferation; TF-1 cell proliferation;
KW   methylcellulose assay; haematopoietic disorder; cancer;
KW   acute myelogenous leukaemia; B lymphoid cancer; leukopenia; neutropenia;
KW   aplastic anaemia; Chediak-Higashi's syndrome;
KW   systemic lupus erythematosus; myelodysplastic syndrome; myelofibrosis;
KW   bone marrow; blood cell activation; blood cell growth; ds.
XX
OS   Synthetic.
XX
PN   US6479261-B1.
XX
PD   12-NOV-2002.
XX
PF   15-NOV-1995;   95US-00559390.
XX
PR   24-NOV-1992;   92US-00981044.
PR   22-NOV-1993;   93WO-US011198.
PR   06-APR-1995;   95US-00411796.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Bauer SC,  Abrams MA,  Braford-Goldberg SR,  Caparon MH,  Easton AM;
PI   Klein BK,  Mckearn JP,  Olins P,  Paik K,  Polazzi J,  Thomas JW;
XX
DR   WPI; 2003-655574/62.
XX
PT   Selective ex vivo expansion of stem cells, useful for treating a patient
PT   having hematopoietic disorder, e.g. leukemia, neutropenia or aplastic
PT   anemia, comprises using recombinant human interleukin-3 variant or mutant
PT   proteins.
XX
PS   Example 66; SEQ ID NO 539; 288pp; English.
XX
CC   The invention describes selective ex vivo expansion of stem cells
CC   comprising separating stem cells from other cells, culturing the cells
CC   with modified human interleukin-3 polypeptide with at least 3 times
CC   greater cell proliferative activity than native human interleukin-3 in at
CC   least one assay selected from the group of acute myelogenous leukaemia
CC   cell proliferation, TF-1 cell proliferation, and methylcellulose assay,
CC   and harvesting the cultured cells. The method is useful for selective ex
CC   vivo expansion of stem cells. The recombinant human interleukin-3 variant
CC   or mutant proteins are useful for treating a patient having a
CC   haematopoietic disorder, such as cancer (e.g. acute myelogenous leukaemia
CC   or certain types of B lymphoid cancers), leukopenia, neutropenia,
CC   aplastic anaemia, Chediak-Higashi's syndrome, systemic lupus
CC   erythematosus, myelodysplastic syndrome, or myelofibrosis. The
CC   interleukin-3 muteins are also useful as antagonists for producing
CC   antibodies used in immunoassay and immunotherapy protocols, or for
CC   stimulating bone marrow and blood cell activation and growth before
CC   infusion into patients. This sequence represents an ex vivo stem cell
CC   expansion method associated polynucleotide.
XX
SQ   Sequence 16 BP; 4 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| |||||||||| ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 208
ADF28804
ID   ADF28804 standard; DNA; 16 BP.
XX
```

```
AC   ADF28804;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Sense primer flanking T-vector insertion site.
XX
KW   Dendritic cell; T cell immunity; ss; DC; primer; PCR.
XX
OS   Synthetic.
XX
PN   WO2003082891-A1.
XX
PD   09-OCT-2003.
XX
PF   28-MAR-2003; 2003WO-KR000631.
XX
PR   29-MAR-2002; 2002KR-00017470.
XX
PA   (CREA-) CREAGENE INC.
PA   (LEES/) LEE S.
XX
PI   Ahn J,  Lee Y,  Jeon C,  Lee B,  Choi K,  Bae Y;
XX
DR   WPI; 2003-804020/75.
XX
PT   New dendritic cell-specific polynucleotide comprising e.g. a myosin
PT   phosphatase target subunit 1, a CD20-like precursor, a Ig superfamily
PT   protein or a 5-lipoxygenase activating protein gene, useful in modulating
PT   T cell immunity.
XX
PS   Example; Page 27; 70pp; English.
XX
CC   The invention relates to dendritic cell-specific polynucleotides. The
CC   dendritic cell-specific nucleotide sequence comprises myosin phosphatase
CC   target subunit 1 gene, CD20-like precursor gene, Ig superfamily protein
CC   gene, glycoprotein nmb gene, 5-lipoxygenase activating protein gene,
CC   dihydropyrimidinase related protein-2 gene, cystatin A gene,
CC   Immunoglobulin transcription factor 2 gene, transforming growth factor
CC   beta-induced 68kD gene, myeloid DAP12-associating lectin gene, B cell
CC   linker protein gene, activated RNA polymerase II transcription cofactor 4
CC   gene, enolase 1 alpha gene, 90 kDa heat shock protein gene, accessory
CC   proteins BAP31/BAP29 gene, isocitrate dehydrogenase 3 (NAD+) alpha gene,
CC   microsomal glutathione S-transferase 2 gene, GABA(A) receptor-associated
CC   protein gene, nicastrin gene, purinergic receptor (family A group 5)
CC   gene, Rho GDP dissociation inhibitor beta gene, MAD homolog 2 gene, MLN51
CC   gene, interferon regulatory factor 4 gene, the fragments of these genes,
CC   or a polynucleotide selected from
CC   ADF28789ADF28790ADF28791ADF28792ADF28793ADF28794. The dendritic cell-
CC   specific polynucleotide is useful in modulating T cell immunity. Methods
CC   for detecting a dendritic cell; for identifying a lymphoid CD11c-
CC   dendritic cell; for identifying a myeloid monocyte-derived dendritic cell
CC   ; for identifying a myeloid CD1a&oplus; dendritic cell; for identifying a
CC   myeloid CD14&oplus dendritic cell; for identifying a maturation stage of
CC   a lymphoid CD11c&ominus; dendritic cell; for identifying a maturation
CC   stage of a myeloid monocyte-derived dendritic cell are all provided. The
CC   dendritic cell-specific polynucleotide is useful in modulating T cell
CC   immunity. The present sequence represents a primer flanking T-vector
CC   insertion site, used in back hybridizationto screen out reduntant clones.
XX
SQ   Sequence 16 BP; 1 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        198 TGCCCCCCGCCGCCAT 213
              ||| ||| ||||||||
Db          1 TGCTCCCGGCCGCCAT 16


RESULT 209
ADM18315/c
ID   ADM18315 standard; DNA; 16 BP.
XX
AC   ADM18315;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Sequence added to 5' end of Chlamydia sense primers.
XX
KW   anti-bacterial; antilipemic; antiarteriosclerotic; antiasthmatic;
KW   antiinflammatory; antiarthritic; neuroprotective; nootropic;
KW   opthalmological; antigen; pneumonia; cardiovascular disease;
KW   atherosclerosis; bronchitis; pharyngitis; laryngitis; sinusitis;
KW   obstructive lung disease; asthma; chronic pulmonary disease;
KW   reactive arthritis; otis media; abdominal aortic aneurysm;
KW   erythema nodosum; Reiter syndrome; sarcoidosis; Alzheimer's disease;
KW   multiple sclerosis; lymphogranuloma venereum; ocular trachoma;
KW   pelvic inflammatory disease; inclusion conjunctivitis; genital trachoma;
KW   infant pneumonitis; incipient trachoma; keratitis; papillary hypertrophy;
KW   corneal infiltration; vulvovaginitis; mucopurulent rhinitis; salpingitis;
KW   cervicitis; cervical follicle; prostatitis; proctitis; urethritis;
KW   lymphogranule inguinale; climatic bubo; tropical bubo; esthiomene;
KW   primer; ss.
XX
OS   Synthetic.
XX
PN   WO2003068811-A2.
XX
PD   21-AUG-2003.
XX
PF   13-FEB-2003; 2003WO-IB001161.
XX
PR   13-FEB-2002; 2002GB-00003403.
XX
PA   (CHIR ) CHIRON SRL.
XX
PI   Bensi G,  Grandi G;
XX
DR   WPI; 2003-646479/61.
XX
PT   Peptides derived from Chlamydia pneumoniae and C. trachomatis bind to
PT   human class 1 MHC molecules and are useful to diagnose, treat and
PT   immunize against Chlamydia infections.
XX
PS   Disclosure; SEQ ID NO 182; 61pp; English.
XX
CC   The invention relates to a polypeptide (P1) derived from Chlamydia
CC   pneumoniae for use as an antigen, or a sequence with at least 50%
CC   identity; or a sequence comprising a fragment of at least 7 amino acids
CC   of (P1). The invention is used to treat or prevent disease or infection
CC   caused by Chlamydia, particularly preferably pneumonia, a cardiovascular
CC   disease, atherosclerosis, bronchitis, pharyngitis, laryngitis, sinusitis,
CC   an obstructive lung disease, asthma, chronic pulmonary disease, reactive
CC   arthritis, otis media, abdominal aortic aneurysm, erythema nodosum,
CC   Reiter syndrome, sarcoidosis, Alzheimer's disease, multiple sclerosis,
CC   lymphogranuloma venereum, ocular trachoma, pelvic inflammatory disease,
CC   inclusion conjunctivitis, genital trachoma, infant pneumonitis, incipient
CC   trachoma, keratitis, papillary hypertrophy, corneal infiltration,
CC   vulvovaginitis, mucopurulent rhinitis, salpingitis, cervicitis, cervical
CC   follicles, prostatitis, proctitis, urethritis, lymphogranule inguinale,
CC   climatic bubo, tropical bubo and/or esthiomene. The invention is also
CC   used to diagnose Chlamydia infection. This sequence represents a fragment
CC   added to the 5' end of a PCR primer used to amplify the DNA sequence
CC   encoding the peptide of the invention.
XX
SQ   Sequence 16 BP; 3 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        538 GCTAGCCACGCAGTCC 553
              |||||||| ||||| |
Db         16 GCTAGCCATGCAGTGC 1
```

```
RESULT 210
ADI58754/c
ID   ADI58754 standard; DNA; 16 BP.
XX
AC   ADI58754;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human interleukin 3 expressing vector related DNA seq id 539.
XX
KW   immunostimulant; antianemic; immunomodulator; antiinflammatory;
KW   dermatological; immunosuppressive; cytostatic; neuroprotective;
KW   gene therapy; interleukin-agonist-3; cultured stem cell;
KW   ex-vivo cell expansion; interleukin-3 mutant; aplastic anaemia;
KW   cyclic neutropenia; idiopathic neutropenia; Chediak-Higashi syndrome;
KW   systemic lupus erythematosus; leukaemia; myelodysplastic syndrome;
KW   myelofibrosis; interleukin 3; IL-3; mutagenesis; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   US2004018618-A1.
XX
PD   29-JAN-2004.
XX
PF   19-JUN-2002; 2002US-00179940.
XX
PR   24-NOV-1992;   92US-00981044.
PR   22-NOV-1993;   93WO-US011198.
PR   06-APR-1995;   95US-00411796.
PR   15-NOV-1995;   95US-00559390.
XX
PA   (BAUE/) BAUER S C.
PA   (ABRA/) ABRAMS M A.
PA   (BRAF/) BRAFORD-GOLDBERG S R.
PA   (CAPA/) CAPARON M H.
PA   (EAST/) EASTON A M.
PA   (KLEI/) KLEIN B K.
PA   (MCKE/) MCKEARN J P.
PA   (OLIN/) OLINS P.
PA   (PAIK/) PAIK K.
PA   (POLA/) POLAZZI J.
PA   (THOM/) THOMAS J W.
XX
PI   Bauer SC,  Abrams MA,  Braford-Goldberg SR,  Caparon MH,  Easton AM;
PI   Klein BK,  Mckearn JP,  Olins P,  Paik K,  Polazzi J,  Thomas JW;
XX
DR   WPI; 2004-122043/12.
XX
PT   Culturing stem cells using a recombinant human interleukin-3 mutant
PT   polypeptide, useful for treating aplastic anemia, neutropenia, Chediak-
PT   Higashi syndrome, systemic lupus erythematosus, leukemia and
PT   myelodysplastic syndrome.
XX
PS   Example 65; SEQ ID NO 539; 328pp; English.
XX
CC   The invention describes cultured stem cells obtained by a method for
CC   selective ex-vivo expansion of stem cells comprising separating stem
CC   cells from other cells, culturing the separated stem cells with a
CC   selected media which comprises a human interleukin-3 mutant polypeptide
CC   comprising defined amino acid sequences SEQ ID NO 15 or 19 given in the
CC   specification, and harvesting the cultured cells. The methods and
CC   compositions of the present invention are useful for treating aplastic
CC   anaemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi
CC   syndrome, systemic lupus erythematosus, leukaemia, myelodysplastic
CC   syndrome and myelofibrosis. This sequence represents a DNA used in the
CC   construction of human interleukin 3 (IL-3) mutants.
XX
SQ   Sequence 16 BP; 4 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
    Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| |||||||||  ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 211
ADR70038/c
ID   ADR70038 standard; DNA; 16 BP.
XX
AC   ADR70038;
XX
DT   04-NOV-2004  (first entry)
XX
DE   Human survivin gene modulatory oligonucleotide #106.
XX
KW   ss; antiangiogenic; cytostatic; antiarteriosclerotic; antipsoriatic;
KW   antidiabetic; ophthalmological; antiarthritic; antirheumatic;
KW   antiasthmatic; antiallergic; antiinflammatory; dermatological; anti-HIV;
KW   virucide; survivin antagonist; apoptosis inhibitor;
KW   cellular proliferation inhibitor; survivin; gene expression;
KW   abnormal angiogenesis; chemotherapeutic agent; busulfan; myleran;
KW   carboplatin; paraplatin; Taxol; doxorubicin; adriamycin; atherosclerosis;
KW   psoriasis; diabetic retinopathy; rheumatoid arthritis; asthma; warts;
KW   allergic dermatitis; cancer; tumour; sarcoma; glioma; carcinoma;
KW   melanoma; osteosarcoma; Ewing's sarcoma; chondrosarcoma;
KW   malignant fibrous histiocytoma; fibrosarcoma; Kaposi's sarcoma;
KW   Paclitaxel; Docetaxel.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .16
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER = phosphorothioate internucleotide
FT                   linkages, all locked nucleic acid (LNA) residues are 5'-
FT                   methyl cytosine residues"
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER = beta-D-oxy-locked nucleic acid but
FT                   optionally DNA nucleotides, optionally phosphate
FT                   internucleotide linkages"
FT   modified_base   13. .16
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER = beta-D-oxy-locked nucleic acid but
FT                   optionally DNA nucleotides, optionally phosphate
FT                   internucleotide linkages"
XX
PN   WO2004069991-A2.
XX
PD   19-AUG-2004.
XX
PF   10-FEB-2004; 2004WO-DK000096.
XX
PR   10-FEB-2003; 2003DK-00000183.
PR   18-NOV-2003; 2003DK-00001708.
XX
PA   (SANT-) SANTARIS PHARMA AS.
XX
PI   Hansen B,  Thrue CA,  Petersen KD,  Westergaard M,  Wissenbach M;
XX
DR   WPI; 2004-625494/60.
XX
PT   New locked nucleic acid containing oligomeric compound capable of
PT   modulating survivin expression, useful for treating cancer such as breast
PT   carcinoma, lung carcinoma, etc.
XX
PS   Claim 1; SEQ ID NO 107; 122pp; English.
```

```
XX
CC   The invention relates to an oligomeric compound (I) capable of modulating
CC   survivin expression, having 8-50 nucleotides and/or nucleotide analogues,
CC   where the compound comprises a subsequence of at least 8 nucleotides or
CC   nucleotide analogues, where the subsequence is located within a sequence
CC   chosen from one of 143 sequences given in the specification. (I) is
CC   useful for treating a mammal suffering from or susceptible from a disease
CC   caused by abnormal angiogenesis, by administering (I) containing one or
CC   more LNA units that are targeted to survivin. (I) is useful as a
CC   medicament and for the manufacture of a medicament for the treatment of
CC   cancer, in combination with chemotherapeutic agent such as busulfan
CC   (myleran), carboplatin (paraplatin), Taxol, doxorubicin (adriamycin),
CC   etc. (I) or a conjugate (II) containing (I) is useful in the preparation
CC   of a medicament for the treatment of atherosclerosis, psoriasis, diabetic
CC   retinopathy, rheumatoid arthritis, asthma, warts and allergic dermatitis.
CC   (I), (II) or a pharmaceutical (III) containing (I) is useful for treating
CC   cancer in the form of a solid tumour, sarcoma, glioma or carcinoma chosen
CC   from malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast
CC   carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder
CC   carcinoma, recurrent superficial bladder cancer, stomach carcinoma,
CC   prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical
CC   carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma,
CC   colorectal carcinoma and carcinoid tumours. The malignant melanoma is
CC   chosen from superficial spreading melanoma, nodular melanoma, lentigo
CC   maligna melanoma, acral melagnoma, amelanotic melanoma, and desmoplastic
CC   melanoma. The sarcoma is chosen from osteosarcoma, Ewing's sarcoma,
CC   chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma and Kaposi's
CC   sarcoma. The treatment further involves administration of a
CC   chemotherapeutic agent such as taxanes, preferably Taxol, Paclitaxel or
CC   Docetaxel. (I), (II) or (III) is also useful for preventing or limiting
CC   apoptosis or for preventing cellular proliferation. This sequence
CC   corresponds to an antisense oligonucleotide targeted to the human
CC   survivin gene.
XX
SQ   Sequence 16 BP; 4 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        161 TTAGGCGGCAGCAGCT 176
              || || ||||||||||
Db         16 TTTGGAGGCAGCAGCT 1


RESULT 212
ABA93324
ID   ABA93324 standard; DNA; 15 BP.
XX
AC   ABA93324;
XX
DT   22-APR-2002  (first entry)
XX
DE   Human ACAA1 gene polymorphism detection ASO primer SEQ ID NO:39.
XX
KW   Human; acetyl-Coenzyme A acyltransferase; ACAA1; chromosome 3p23-p22;
KW   peroxisomal 3-oxoacyl-Coenzyme A thiolase; SNP; genotype; haplotype;
KW   single nucleotide polymorphism; polymorphic variant; enzyme; probe;
KW   primer; allele specific oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO200187903-A2.
XX
PD   22-NOV-2001.
XX
PF   03-MAY-2001; 2001WO-US014330.
XX
PR   18-MAY-2000; 2000US-0205022P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
PA   (DUDA/) DUDA A E.
XX
PI   Chew A,  Koshy B;
XX
DR   WPI; 2002-164134/21.
XX
PT   Isolated polynucleotide, comprising a polymorphic variant of the acetyl-
PT   Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiolase)
PT   gene useful for providing haplotype information and in therapy for
PT   treating related disorders.
XX
PS   Claim 15; Page 13; 93pp; English.
XX
CC   The present invention describes a polypeptide (I) which is a polymorphic
CC   variant (PV) of the acetyl-Coenzyme A acyltransferase (peroxisomal 3-
CC   oxoacyl-Coenzyme A thiolase) ACAA1 protein (ABB05516). ACAA1 is located
CC   on chromosome 3p23-p22. (I) can be encoded by ABA93286 (or ABA93288)
CC   where the sequence comprises one of the haplotypes shown in Table 4 or
CC   one of the haplotype pairs shown in Table 3, where Tables 3 and 4 are
CC   given in the specification. The polynucleotide encoding ACAA1 can be used
CC   for providing haplotype and genotype information of an individual.
CC   Furthermore, the polynucleotide is useful for the treatment of disorders
CC   related to its abnormal expression or function. ABA93289 to ABA93383
CC   represent allele specific oligonucleotides (ASOs) which are used in the
CC   detection of polymorphisms in the human ACAA1 gene
XX
SQ   Sequence 15 BP; 3 A; 4 C; 6 G; 1 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12.6;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        171 GCAGCTGGCCAGG 183
              ||||||||||:|
Db          3 GCAGCTGGCCASG 15


RESULT 213
ADM94710
ID   ADM94710 standard; DNA; 21 BP.
XX
AC   ADM94710;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:60.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 60; 38pp; English.
```

```
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.6;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        596 CTTGGGGGCCCAGAAGCTG 614
              |||  ||||||  ||||||
Db          1 CTTCTGGGCCCCCAAGCTG 19


RESULT 214
AAQ39025
ID   AAQ39025 standard; DNA; 15 BP.
XX
AC   AAQ39025;
XX
DT   25-MAR-2003  (revised)
DT   19-JUL-1993  (first entry)
XX
DE   Mutagenic PCR primer 4 to make mutant Factor VIII.
XX
KW   FVIII; amplification; heavy; light; chain; expression; ss.
XX
OS   Synthetic.
XX
PN   EP534383-A2.
XX
PD   31-MAR-1993.
XX
PF   23-SEP-1992;   92EP-00116246.
XX
PR   24-SEP-1991;   91JP-00243262.
XX
PA   (KAGA ) CHEMO SERO THERAPEUTIC RES INS.
PA   (TEIJ ) TEIJIN LTD.
XX
PI   Yonemura H,  Tajima Y,  Sugawara K,  Masuda K;
XX
DR   WPI; 1993-102540/13.
XX
PT   Plasmids for expression of human factor VIII H and L chains - comprises
PT   promoter active in animal cell, DNA encoding signal peptide and including
PT   initiation codon, DNA encoding A1-A2 domain and aminoacid(s) at N-
PT   terminus of B-domain of factor 8, etc.
XX
PS   Example 6; Page 10; 34pp; English.
XX
CC   Using PCR utilising the expression plasmid 8.1 contg. the full length of
CC   Factor VIII (FVIII) cDNA as a template, the FVIII signal sequence was
CC   linked to the upstream of Glu 1649 at the N-terminus of the light chain.
CC   Two synthetic oligomers (primers 3 and -4) were used as PCR primers for
CC   the amplification of the N-terminal portion of the L-chain. The mutant
CC   thus has most of the B domains deleted and is expressed in a separate
CC   cistron so that each chain is obtd. in large amts. Recombinant prodn.
CC   removes risk of infection from e.g. hepatitis virus, present when Factor
CC   VIII is prepd. from human plasma. See also AAQ39022-27. (Updated on 25-
CC   MAR-2003 to correct PN field.)
XX
SQ   Sequence 15 BP; 2 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        594 AGCTTGGGGGCCCA 607
              ||||| ||||||||
Db          1 AGCTTTGGGGCCCA 14


RESULT 215
AAT42858
ID   AAT42858 standard; DNA; 15 BP.
XX
AC   AAT42858;
XX
DT   16-JUN-1997  (first entry)
XX
DE   Primer #2 for the phospholipase D protein coding sequence.
XX
KW   Phospholipase D; rice; promoter; PLD; probe; primer; amplify; PCR;
KW   polymerase chain reaction; ss.
XX
OS   Synthetic.
XX
PN   WO9630510-A1.
XX
PD   03-OCT-1996.
XX
PF   28-MAR-1996;   96WO-JP000812.
XX
PR   29-MAR-1995;   95JP-00096126.
XX
PA   (NISB ) JAPAN TOBACCO INC.
XX
PI   Morioka S,  Ueki J;
XX
DR   WPI; 1996-455357/45.
XX
PT   Promoter DNA sequence derived from rice - used to increase expression of
PT   foreign genes in transformed hosts.
XX
PS   Example 9; Page 13; 29pp; Japanese.
XX
CC   AAT42857 and AAT42858 represent amplification primers for the promoter of
CC   the rice phospholipase D gene (PLD). The PLD gene sequence (see AAT42853)
CC   was identified using the probes shown in AAT42855 and AAT42856. The
CC   promoters (see AAT42851 and AAT42852) are efficient promoters for greatly
CC   increasing the expression of foreign genes in transformant rice and other
CC   plants
XX
SQ   Sequence 15 BP; 1 A; 10 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        184 CTACGTGCGCCCCC 197
              |||| |||||||||
Db          2 CTACCTGCGCCCCC 15


RESULT 216
AAX31599
ID   AAX31599 standard; DNA; 15 BP.
XX
AC   AAX31599;
XX
DT   21-MAY-1999  (first entry)
XX
DE   Tag sequence of a transcript increased in pancreatic cancer.
XX
KW   Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
KW   diagnosis; prognosis; treatment; ss.
XX
```

OS Homo sapiens.
XX
PN WO9853319-A2.
XX
PD 26-NOV-1998.
XX
PF 20-MAY-1998; 98WO-US010277.
XX
PR 21-MAY-1997; 97US-0047352P.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Vogelstein B, Kinzler KW;
XX
DR WPI; 1999-070161/06.
XX
PT Use of isolated gene transcripts - useful for developing products for the
PT diagnosis, prognosis and treatment of cancers, particularly colon and
PT pancreatic cancer.
XX
PS Claim 13; Page 63; 120pp; English.
XX
CC AAX30947-31815 represent tag sequences of transcripts that are
CC differentially expressed in colorectal cancer, in pancreatic cancer, or
CC in both. The tag sequences can be used to identify genes by matching the
CC tag to a gen data base member, or by using the tag sequences as probes to
CC isolate unidentified genes from cDNA libraries. The tag sequences can
CC also be used in a method for diagnosing colon or pancreatic cancer in a
CC sample suspected of being neoplastic. The method comprises comparing the
CC level of at least one transcript in a first sample of a tissue to a
CC second sample, where the first sample is a colonic tissue suspected of
CC being neoplastic and the second sample is a normal human colonic tissue.
CC The transcript is identified by a tag selected from AAX30947-31815. The
CC methods of the invention can be used in the diagnosis, prognosis and
CC treatment of cancer
XX
SQ Sequence 15 BP; 2 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 369 ATGGCGTGGTGGAG 382
||||||| |||||||
Db 2 ATGGCGGGGTGGAG 15

RESULT 217
AAA59902/c
ID AAA59902 standard; DNA; 15 BP.
XX
AC AAA59902;
XX
DT 16-OCT-2000 (first entry)
XX
DE Murine OP-1 Wt-1/Egr-1 binding site.
XX
KW Osteogenic protein-1; OP-1; morphogenic protein; mouse; osteoporosis;
KW morphogen concentration; bone metabolism disease; ss.
XX
OS Mus sp.
XX
PN US6071695-A.
XX
PD 06-JUN-2000.
XX
PF 07-JUN-1995; 95US-00486343.
XX
PR 21-FEB-1992; 92US-00841646.
PR 01-NOV-1993; 93US-00147023.
PR 07-JUN-1994; 94US-00255250.
PR 23-MAY-1995; 95US-00449700.
PR 24-MAY-1995; 95US-00449699.
XX
PA (CREA-) CREATIVE BIOMOLECULES INC.
XX
PI Oppermann H, Ozkaynak E;
XX
DR WPI; 2000-422077/36.
XX
PT Screening for compounds able to modulate osteogenic protein-1 (OP-1)
PT expression by incubating a candidate compound with a nucleic acid with a
PT reporter gene operatively associated with an OP-1 non-coding nucleic acid
PT fragment.
XX
PS Disclosure; Col 47; 33pp; English.
XX
CC A method for screening a candidate compound for its ability to modulate
CC the expression of osteogenic protein-1 (OP-1) uses a cell transfected
CC with a nucleic acid sequence comprising a reporter gene and an upstream
CC non-coding sequence from OP-1. OP-1 is a tissue morphogenic protein. The
CC method is useful for screening compounds capable of stimulating or
CC inhibiting transcription and/or translation of the OP-1 gene, as well as
CC compounds which may be used as therapeutics for in vivo and ex vivo
CC mammalian applications, e.g. morphogen expression inducing compounds for
CC correcting and alleviating a diseased condition or to regenerate lost or
CC damaged tissue. The compounds may also be used to maintain viability of
CC the differentiated phenotype of cells in culture. Morphogen expression
CC inhibiting compounds identified by the new method can be used to modulate
CC the degree and/or timing of morphogen concentration. Compounds which up-
CC regulate levels of circulating OP-1 in vivo can be used to correct bone
CC metabolism diseases such as osteoporosis. This sequence represents the
CC TCC binding sequence or Wt-1/Egr-1 binding site sequence contained in the
CC upstream region of the osteogenic protein-1 (OP-1) gene. The DNA binding
CC proteins Wt-1 and Egr-1 bind to and control transcription of DNA
CC sequences at these sites
XX
SQ Sequence 15 BP; 0 A; 10 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 398 GAGGAGCGGCAGGA 411
||||||||| ||||
Db 14 GAGGAGCGGGAGGA 1

RESULT 218
AAZ90409/c
ID AAZ90409 standard; DNA; 15 BP.
XX
AC AAZ90409;
XX
DT 30-MAY-2000 (first entry)
XX
DE Scrambled control oligomer 2 for HER-2 gene.
XX
KW Radiation; drug resistance; HER-2; raf-1; radioresistant; tumour; cancer;
KW restenosis; osteoarthritis; neurological; pre-eclampsia;
KW intestinal abnormality; antisense; ss.
XX
OS Homo sapiens.
XX
PN US6027892-A.
XX
PD 22-FEB-2000.
XX
PF 16-DEC-1997; 97US-00991830.
XX
PR 30-DEC-1996; 96US-0034160P.
XX
PA (CHAN/) CHANG E H.
PA (PIRO/) PIROLLO K F.
XX
PI Chang EH, Pirollo KF;

```
XX
DR   WPI; 2000-194828/17.
XX
PT   Reducing radiation or drug resistance in a cell comprises introduction of
PT   antisense nucleic acid for treating or diagnosing cancer, restenosis,
PT   osteoarthritis, neurological and intestinal abnormalities and pre-
PT   eclampsia.
XX
PS   Disclosure; Col 10; 18pp; English.
XX
CC   The invention provides a method for reducing radiation or drug resistance
CC   of a cell, in vitro, which does not overexpress HER-2 or raf-1 genes. The
CC   method comprises introducing to the cell an antisense nucleic acid
CC   comprising a segment complementary to HER-2 or raf-1. The method is
CC   useful for increasing drug and radiation sensitivity in a cell,
CC   particularly in the treatment of radioresistant tumours. The antisense
CC   nucleic acids are useful for treating or diagnosing cancer, restenosis,
CC   osteoarthritis, neurological and intestinal abnormalities and pre-
CC   eclampsia. The present sequence represents a scrambled control oligomer
CC   for HER-2 gene
XX
SQ   Sequence 15 BP; 2 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        410 GACGAGCATGGCTA 423
              ||| ||||||||||
Db         15 GACAAGCATGGCTA 2


RESULT 219
AAA95134
ID   AAA95134 standard; DNA; 15 BP.
XX
AC   AAA95134;
XX
DT   12-JAN-2001  (first entry)
XX
DE   Allele specific primer #5 for detection of TNFR1 gene polymorphism.
XX
KW   TNFR1; tumour necrosis factor receptor; polymorphism; human; tumour;
KW   cancer; apoptosis; bacterial infection; primer;
KW   allele specific oligonucleotide; ASO; ss.
XX
OS   Homo sapiens.
XX
PN   WO200050436-A1.
XX
PD   31-AUG-2000.
XX
PF   23-FEB-2000; 2000WO-US004606.
XX
PR   23-FEB-1999;   99US-0121314P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
PA   (NAND/) NANDABALAN K.
PA   (SCHU/) SCHULZ V P.
PA   (STEP/) STEPHENS J C.
PA   (CHEW/) CHEW A.
XX
PI   Nandabalan K,  Schulz VP,  Stephens JC,  Chew A;
XX
DR   WPI; 2000-543909/49.
XX
PT   Polynucleotides comprising polymorphic variants of a reference sequence
PT   for tumor necrosis factor receptor 1 (TNFR1), useful for studying the
PT   biological function of TNFR1 and identifying drugs targeting the protein
PT   for treating disorders.
XX
PS   Claim 14; Page 20; 79pp; English.
XX
CC   The present invention relates to polymorphic variants of the tumour
CC   necrosis factor receptor 1 (TNFR1) gene. The sequence of the gene is
CC   given in AAA95102, AAA95103 and AAA95104. The polymorphisms were
CC   identified by amplifying and sequencing regions of the gene. Twelve
CC   polymorphic loci were discovered. Of these twelve polymorphisms, four can
CC   cause a change in the TNFR1 protein. The present sequence is an allele
CC   specific oligonucleotide (ASO) primer that may be used to detect a TNFR1
CC   gene polymorphism. The TNFR1 polymorphisms may be useful for studying the
CC   biological function of TNFR1 as well as for identifying drugs targeting
CC   the protein for treatment of disorders related to its abnormal expression
CC   or function such as tumours, apoptosis related disorders and bacterial
CC   infection
XX
SQ   Sequence 15 BP; 2 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        666 CCTGCTGCCGCCAC 679
              ||||||| |||||
Db          2 CCTGCTGCTGCCAC 15


RESULT 220
AAA95135/c
ID   AAA95135 standard; DNA; 15 BP.
XX
AC   AAA95135;
XX
DT   12-JAN-2001  (first entry)
XX
DE   Allele specific primer #6 for detection of TNFR1 gene polymorphism.
XX
KW   TNFR1; tumour necrosis factor receptor; polymorphism; human; tumour;
KW   cancer; apoptosis; bacterial infection; primer;
KW   allele specific oligonucleotide; ASO; ss.
XX
OS   Homo sapiens.
XX
PN   WO200050436-A1.
XX
PD   31-AUG-2000.
XX
PF   23-FEB-2000; 2000WO-US004606.
XX
PR   23-FEB-1999;   99US-0121314P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
PA   (NAND/) NANDABALAN K.
PA   (SCHU/) SCHULZ V P.
PA   (STEP/) STEPHENS J C.
PA   (CHEW/) CHEW A.
XX
PI   Nandabalan K,  Schulz VP,  Stephens JC,  Chew A;
XX
DR   WPI; 2000-543909/49.
XX
PT   Polynucleotides comprising polymorphic variants of a reference sequence
PT   for tumor necrosis factor receptor 1 (TNFR1), useful for studying the
PT   biological function of TNFR1 and identifying drugs targeting the protein
PT   for treating disorders.
XX
PS   Claim 14; Page 20; 79pp; English.
XX
CC   The present invention relates to polymorphic variants of the tumour
CC   necrosis factor receptor 1 (TNFR1) gene. The sequence of the gene is
CC   given in AAA95102, AAA95103 and AAA95104. The polymorphisms were
CC   identified by amplifying and sequencing regions of the gene. Twelve
CC   polymorphic loci were discovered. Of these twelve polymorphisms, four can
CC   cause a change in the TNFR1 protein. The present sequence is an allele
CC   specific oligonucleotide (ASO) primer that may be used to detect a TNFR1
CC   gene polymorphism. The TNFR1 polymorphisms may be useful for studying the
```

```
CC   biological function of TNFR1 as well as for identifying drugs targeting
CC   the protein for treatment of disorders related to its abnormal expression
CC   or function such as tumours, apoptosis related disorders and bacterial
CC   infection
XX
SQ   Sequence 15 BP; 1 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        165 GCGGCAGCAGCTGG 178
              ||||||||||| ||
Db         15 GCGGCAGCAGCAGG 2


RESULT 221
AAS02947
ID   AAS02947 standard; DNA; 15 BP.
XX
AC   AAS02947;
XX
DT   29-AUG-2001  (first entry)
XX
DE   Human CHMR1 allele specific oligonucleotide probe #7.
XX
KW   Human; m1 acetylcholine receptor; CHRM1; immunogen; antibody;
KW   Alzheimer's disease; dementia with Lewy bodies; DLB;
KW   allele specific oligonucleotide probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200127312-A2.
XX
PD   19-APR-2001.
XX
PF   12-OCT-2000; 2000WO-US028211.
XX
PR   13-OCT-1999;   99US-0159269P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Choi JY,  Denton RR,  Nandabalan K,  Stephens JC;
XX
DR   WPI; 2001-282046/29.
XX
PT   New variants of the m1 muscarinic acetylcholine receptor gene, useful to
PT   find treatment for Alzheimer's and dementia, have single nucleotide
PT   variations at one or more of five polymorphic sites.
XX
PS   Claim 15; Page 18; 52pp; English.
XX
CC   The sequence represents an allele specific oligonucleotide probe for
CC   genotyping individuals using the Human gene encoding the m1 muscarinic
CC   acetylcholine receptor, CHMR1. CHMR1 is one subtype of a family of 5
CC   genetically distinct muscarinic acetylcholine receptors, mAChR, that play
CC   important roles in higher brain function such as learning and memory. The
CC   protein is a possible drug target for treatments for Alzheimer's disease
CC   and dementia with Lewy bodies (DLB). The gene, polypeptide, haplotypes
CC   and antibodies raised against the protein are useful for diagnosing and
CC   developing treatments for diseases associated with the abnormal
CC   expression of the gene or activity of the protein, e.g. Alzheimer's
CC   disease and dementia with Lewy bodies
XX
SQ   Sequence 15 BP; 4 A; 4 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        168 GCAGCAGCTGGCCA 181
              | ||||||||||||
Db          2 GGAGCAGCTGGCCA 15


RESULT 222
AAF48536/c
ID   AAF48536 standard; DNA; 15 BP.
XX
AC   AAF48536;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #1956.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 56; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 8 A; 1 C; 6 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        484 TTCCTCCTCCCTGT 497
              |||||||| |||||
Db         15 TTCCTCCTTCCTGT 2


RESULT 223
AAF46293
```

```
ID   AAF46293 standard; DNA; 15 BP.
XX
AC   AAF46293;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1132.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 11 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        197 CTGCCCCCCGCCGC 210
              ||||||||||||  |
Db          1 CTGCCCCCCGCCCC 14


RESULT 224
AAF48537/c
ID   AAF48537 standard; DNA; 15 BP.
XX
AC   AAF48537;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #1957.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 56; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 7 A; 1 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        484 TTCCTCCTCCCTGT 497
              ||||||| |||||
Db         14 TTCCTCCTTCCTGT 1


RESULT 225
AAF49788/c
ID   AAF49788 standard; DNA; 15 BP.
XX
AC   AAF49788;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGF-I oligonucleotide #748.
XX
```

```
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 8; Page 65; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        171 GCAGCTGGCCAGGC 184
              ||||||| ||||||
Db         15 GCAGCTGCCCAGGC 2


RESULT 226
AAF45880/c
ID   AAF45880 standard; DNA; 15 BP.
XX
AC   AAF45880;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #719.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 38; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 4 A; 4 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        424 CATCTCCCGGTGCT 437
              ||||| ||||||||
Db         14 CATCTGCCGGTGCT 1


RESULT 227
AAF49789/c
ID   AAF49789 standard; DNA; 15 BP.
XX
AC   AAF49789;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGF-I oligonucleotide #749.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
```

```
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 8; Page 65; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        171 GCAGCTGGCCAGGC 184
              ||||||| ||||||
Db         14 GCAGCTGCCCAGGC 1


RESULT 228
AAF45998/c
ID   AAF45998 standard; DNA; 15 BP.
XX
AC   AAF45998;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #837.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 39; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        372 GCGTGGTGGAGATC 385
              || ||||||||||||
Db         14 GCATGGTGGAGATC 1


RESULT 229
AAF45879/c
ID   AAF45879 standard; DNA; 15 BP.
XX
AC   AAF45879;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #718.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
```

XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 38; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 4 A; 5 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 424 CATCTCCCGGTGCT 437
|||||.|||||||
Db 15 CATCTGCCGGTGCT 2

RESULT 230
AAF45997/c
ID AAF45997 standard; DNA; 15 BP.
XX
AC AAF45997;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #836.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 39; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 372 GCGTGGTGGAGATC 385
|| ||||||||||
Db 15 GCATGGTGGAGATC 2

RESULT 231
AAD20988
ID AAD20988 standard; DNA; 15 BP.
XX
AC AAD20988;
XX
DT 28-JAN-2002 (first entry)
XX
DE Human Wnt-7B-like DNA clone 29518614 expressing reverse RT-PCR primer.
XX
KW Human; Wnt-7B-like protein; gene therapy; hypotensive; neoplasia; cancer;
KW tranquillizer; inflammatory disorder; arthritis; haematopoiesis; allergy;
KW immune disorder; autoimmune disease; thyroiditis; restenosis; thrombosis;
KW neurological disease; Alzheimer's disease; cardiovascular disorder; burn;
KW diabetes mellitus; periodontal disease; haemorrhage; multiple sclerosis;
KW rheumatoid arthritis; thrombocytopaenia; skin disorder; atherosclerosis;
KW lung fibrosis; skeletal disorder; platelet disorder; cell proliferation;
KW transplant rejection; acquired immune deficiency syndrome; AIDS; wound;
KW connective tissue disease; drug screening; ulcer; liver fibrosis;
KW RT-PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200174856-A2.
XX
PD 11-OCT-2001.
XX
PF 03-APR-2001; 2001WO-US010679.
XX
PR 03-APR-2000; 2000US-0194256P.
PR 26-JUL-2000; 2000US-00625634.
XX
PA (CURA-) CURAGEN CORP.
XX

```
PI   Vernet CAM,  Rastelli L,  Herrmann JL;
XX
DR   WPI; 2001-626382/72.
XX
PT   New Wnt-7B-like polypeptides and polynucleotides for diagnosing,
PT   preventing and treating broad range of pathological states such as
PT   cancer, hematopoietic, inflammatory, skin, skeletal disorders and
PT   atherosclerosis.
XX
PS   Example 1; Page 100; 115pp; English.
XX
CC   The invention relates to human Wnt-7B-like protein and its cDNA molecule.
CC   Human Wnt-7B-like proteins and their nucleic acids are useful for
CC   treating and preventing Wnt-7B-like-associated disorders such as
CC   neoplasia, cancer, e.g., colorectal carcinoma, prostate cancer, immune
CC   disorder, autoimmune diseases, such as connective tissue disease,
CC   multiple sclerosis, rheumatoid arthritis, autoimmune thyroiditis,
CC   acquired immune deficiency syndrome (AIDS), transplant rejection,
CC   allergy, infection, inflammatory disorder, arthritis, haematopoietic
CC   disorder, skin disorder (keloid), restenosis, neurological disease,
CC   Alzheimer's disease, trauma, wound, spinal cord injury, skeletal disorder
CC   and cardiovascular disorders such as diabetes mellitus, atherosclerosis,
CC   cerebral thrombosis or haemorrhage, and other diseases, including
CC   hypertension, hypothyroidism, myeloid or lymphoid cell deficiencies and
CC   various platelet disorders such as thrombocytopaenia. Wnt-7B-like protein
CC   is also useful for cell proliferation, tissue repair and in the treatment
CC   of burns, incisions and ulcers, periodontal disease and treatment of lung
CC   or liver fibrosis. Wnt-7B-like protein plays an important role in
CC   autocrine stimulation of tumour growth, chemoresistance, radiotherapy
CC   resistance and also for screening drugs. Wnt-7B-like nucleic acids are
CC   useful in gene therapy. The present DNA sequence is reverse RT (reverse
CC   transcriptase)-PCR primer Ag 316, which is used for expressing human Wnt-
CC   7B-like DNA clone 29518614
XX
SQ   Sequence 15 BP; 0 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        426 TCTCCCGGTGCTTC 439
              ||||||||| |||||
Db          1 TCTCCCGGCGCTTC 14


RESULT 232
AAF70359
ID   AAF70359 standard; DNA; 15 BP.
XX
AC   AAF70359;
XX
DT   20-APR-2001  (first entry)
XX
DE   Human DRD2 allele specific oligonucleotide primer SEQ ID NO:102.
XX
KW   Human; dopamine receptor D2; DRD2; polymorphism; allele specific;
KW   drug target isogene; detection; single nucleotide polymorphism; SNP;
KW   genotype; schizophrenia; Parkinson's disease; myoclonus dystonia; MD;
KW   probe; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200105832-A1.
XX
PD   25-JAN-2001.
XX
PF   19-JUL-2000; 2000WO-US019644.
XX
PR   19-JUL-1999;   99US-0144493P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Chew A,  Denton RR,  Duda A,  Nandabalan K,  Stephens JC;
XX
DR   WPI; 2001-091967/10.
XX
PT   Polynucleotides comprising single nucleotide polymorphisms in the human
PT   dopamine receptor D2, useful for detecting mutations associated with,
PT   e.g. schizophrenia, Parkinson's and myoclonus dystonia.
XX
PS   Claim 15; Page 23; 135pp; English.
XX
CC   The present invention describes polynucleotides comprising single
CC   nucleotide polymorphisms (SNPs) in the human dopamine receptor D2 (DRD2).
CC   The polynucleotides may be used in assays to detect and characterise
CC   polymorphisms in DRD2 that affect its expression and activity and are
CC   involved in disorders such as schizophrenia, Parkinson's and myoclonus
CC   dystonia (MD). This information would be useful for studying the
CC   biological function of DRD2 as well as in identifying drugs targeting
CC   this protein for the treatment of disorders related to its abnormal
CC   expression or function. Polymorphisms in the DRD2 gene affect the
CC   expression of active and functional polypeptides. Therefore it is
CC   advantageous to detect polymorphisms in the DRD2 gene and how those
CC   polymorphisms are combined in different copies of the gene. AAF70261 to
CC   AAF70308 represent human DRD2 allele specific oligonucleotide probes, and
CC   AAF70309 to AAF70404 represent human DRD2 allele specific oligonucleotide
CC   primers which are used in the detection of DRD2 polymorphisms. AAF70405
CC   to AAF70452 represent oligonucleotide primers for the detection of human
CC   DRD2 polymorphisms which are given in the exemplification of the present
CC   invention. AAF70453 to AAF70538 represent PCR primers for the human DRD2
CC   gene which are used in examples from the present invention
XX
SQ   Sequence 15 BP; 3 A; 6 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        528 CCATGCCCAAGCTA 541
              ||||||||| ||||
Db          1 CCATGCCCATGCTA 14


RESULT 233
AAF83156
ID   AAF83156 standard; DNA; 15 BP.
XX
AC   AAF83156;
XX
DT   09-JUL-2001  (first entry)
XX
DE   NAT2 gene G191A polymorphism determining probe 191C_A.
XX
KW   Immobilisation; chemical; biological; polynucleotide amplification;
KW   nucleic acid detection; probe; hybridisation; PCR primer; NAT2 gene; ss.
XX
OS   Synthetic.
XX
PN   WO200127327-A2.
XX
PD   19-APR-2001.
XX
PF   06-OCT-2000; 2000WO-US027872.
XX
PR   08-OCT-1999;   99US-0158315P.
XX
PA   (PROT-) PROTOGENE LAB INC.
XX
PI   Brennan TM,  Chatelain F,  Berninger M;
XX
DR   WPI; 2001-290733/30.
XX
PT   Apparatus and method for performing a large number of chemical and
PT   biological reactions by bringing two arrays into close apposition and
PT   allowing reactants on the surfaces of the two arrays to come into
PT   contact.
```

```
XX
PS   Example 9; Fig 13; 112pp; English.
XX
CC   The invention provides a novel system for performing reactions, that
CC   comprises a first solid support with a reactant of each reaction
CC   immobilized on to it, and a second solid support either providing a
CC   second reactant confined to a specific area on the surface, or a chemical
CC   /mechanical separation of the reactions, where the first and second solid
CC   supports are assembled to provide an environment for performing the
CC   reactions in parallel. The methods and apparatus are useful for
CC   performing a large number of chemical and biological reactions,
CC   especially polynucleotide amplification reactions and the detection of
CC   sequence variations, expression levels and their functions. The method is
CC   capable of generating large amounts of data or products per unit time by
CC   carrying out large numbers of reactions in parallel. The process is also
CC   amenable to full automation. Sequences AAF83154-161 represent primers and
CC   probes used for determining G191A polymorphic site of the NAT2 gene
XX
SQ   Sequence 15 BP; 3 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        473 CCCACCCAAGTTTC 486
              ||||||||| |||||
Db          2 CCCACCCAGGTTTC 15


RESULT 234
AAD44441/c
ID   AAD44441 standard; DNA; 15 BP.
XX
AC   AAD44441;
XX
DT   13-DEC-2002  (first entry)
XX
DE   Human F2RL1 gene polymorphisms detecting ASO probe #3.
XX
KW   Human; haplotype; coagulation factor II receptor like 1; F2RL1; asthma;
KW   polymorphism; chronic pulmonary disease; inflammatory disorder;
KW   gene therapy; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200255534-A2.
XX
PD   18-JUL-2002.
XX
PF   13-NOV-2001; 2001WO-US046475.
XX
PR   10-NOV-2000; 2000US-0247516P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Bieglecki KM,  Sanchis A,  Shah N;
XX
DR   WPI; 2002-566728/60.
XX
PT   New genetic variants having polymorphisms in the coagulation factor II
PT   (thrombin) receptor like 1 (F2RL1) gene, useful for studying the function
PT   of F2RL1 and treating disorders associated with abnormal expression or
PT   function of F2RL1.
XX
PS   Claim 14; Page 13; 65pp; English.
XX
CC   The invention relates to an isolated polynucleotide comprising genes and
CC   haplotypes of the coagulation factor II (thrombin) receptor like 1
CC   (F2RL1) gene. Polymorphic variants of the F2RL1 gene are useful in
CC   studying the expression and biological function of F2RL1, and in
CC   identifying drugs targetting F2RL1 protein for treating disorders
CC   associated with abnormal expression or function of F2RL1, e.g. asthma,
CC   chronic pulmonary disease, and inflammatory disorders. Polynucleotides
CC   comprising a polymorphic gene variant or fragment may be used for
CC   therapeutic purposes, where a patient could benefit from expression or
CC   increased expression of a particular F2RL1 protein isoform, or an
CC   expression vector encoding the isoform may be administered to the
CC   patient. Haplotype information is useful in improving the efficiency and
CC   output of several steps in drug discovery and development process,
CC   including target validation, identifying lead compounds, and early phase
CC   clinical trials. Information on polymorphisms may be applied in studying
CC   biological functions of F2RL1 as well as in identifying drugs targetting
CC   this protein for the treatment of disorders related to its abnormal
CC   expression or function. The invention is useful in gene therapy. The
CC   present sequence is human F2RL1 gene polymorphism detecting ASO (allele
CC   specific oligonucleotide) probe
XX
SQ   Sequence 15 BP; 1 A; 2 C; 11 G; 0 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        191 CGCCCCCTGCCCCC 204
              ||||||| ||||||
Db         15 CGCCCCCRGCCCCC 2


RESULT 235
ABK32553
ID   ABK32553 standard; DNA; 15 BP.
XX
AC   ABK32553;
XX
DT   23-APR-2002  (first entry)
XX
DE   Human pancreatic cancer SAGE tag #105.
XX
KW   Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
KW   serial analysis of gene expression; diagnostic; prognostic; probe;
KW   cancer marker; ss.
XX
OS   Homo sapiens.
XX
PN   US6333152-B1.
XX
PD   25-DEC-2001.
XX
PF   20-MAY-1998;   98US-00081646.
XX
PR   20-MAY-1998;   98US-00081646.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Vogelstein B,  Kinzler KW,  Zhang L,  Zhou W;
XX
DR   WPI; 2002-153821/20.
XX
PT   New human nucleic acid containing specific SAGE tags, useful as
PT   diagnostic markers for cancer, also derived probes.
XX
PS   Disclosure; Col 75; 161pp; English.
XX
CC   The invention relates to an isolated, purified human nucleic acid (I)
CC   that has the same sequence as a mRNA found in humans and is a SAGE
CC   (serial analysis of gene expression) tag comprising a single stranded
CC   probe containing at least 10 consecutive nucleotides. SAGE tags, are
CC   diagnostic and prognostic markers of cancer, especially of the colon and
CC   pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
CC   SAGE tags of the invention
XX
SQ   Sequence 15 BP; 2 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy        369 ATGGCGTGGTGGAG 382
              |||||| |||||||
Db          2 ATGGCGGGGTGGAG 15


RESULT 236
ACD66331
ID   ACD66331 standard; RNA; 15 BP.
XX
AC   ACD66331;
XX
DT   23-SEP-2003  (first entry)
XX
DE   Anti-HCV nucleic acid molecule target sequence #214.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; anti-HCV;
KW   viral replication; degenerative; disease state; HBV infection;
KW   HCV infection; cirrhosis; liver failure; hepatocellular carcinoma;
KW   hepatotropic; cytostatic; virucide; antiinflammatory; target; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 322; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a target for one of the anti-
CC   HCV nucleic acid molecules disclosed in the present invention
XX
SQ   Sequence 15 BP; 0 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   71.4%;  Pred. No. 1.3e+02;
  Matches   10;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         35 CGCCGCGTCCCCTT 48
              |||||||:|| |::
Db          2 CGCCGCGUCCUCUU 15


RESULT 237
ACD66430
ID   ACD66430 standard; RNA; 15 BP.
XX
AC   ACD66430;
XX
DT   23-SEP-2003  (first entry)
XX
DE   Anti-HCV enzymatic nucleic acid substrate sequence #16.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; anti-HCV;
KW   viral replication; degenerative; disease state; HBV infection;
KW   HCV infection; cirrhosis; liver failure; hepatocellular carcinoma;
KW   hepatotropic; cytostatic; virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 326; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
```

```
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the
CC   anti-HCV enzymatic nucleic acid sequences disclosed in the present
CC   invention
XX
SQ   Sequence 15 BP; 0 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   71.4%;  Pred. No. 1.3e+02;
  Matches   10;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         35 CGCCGCGTCCCCTT 48
              |||||||:|| |::
Db          2 CGCCGCGUCCUCUU 15


RESULT 238
ADA27240
ID   ADA27240 standard; DNA; 15 BP.
XX
AC   ADA27240;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human NOV5 reverse PCR primer SEQ ID NO:14.
XX
KW   human; NOVX; NOV5; antidiabetic; anorectic; cardiant; hypotensive;
KW   antiarteriosclerotic; anorectic; virucide; antibacterial; fungicide;
KW   protozoacide; nootropic; neuroprotective; antiparkinsonian;
KW   anticonvulsant; osteopathic; antiarthritic; antiinflammatory;
KW   dermatological; antiasthmatic; antilipaemic; gene therapy;
KW   metabolic disorder; diabetes; obesity; infectious disease; anorexia;
KW   cancer; cardiovascular disease; hypertension; atherosclerosis;
KW   neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
KW   epilepsy; immune disorder; osteoarthritis; haematopoietic disorder;
KW   inflammatory skin disorder; asthma; dyslipidaemia; neurogenesis;
KW   cell differentiation; cell proliferation; haematopoiesis; wound healing;
KW   angiogenesis; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003068921-A2.
XX
PD   21-AUG-2003.
XX
PF   12-FEB-2003; 2003WO-US004188.
XX
PR   12-FEB-2002; 2002US-0356375P.
PR   07-JUN-2002; 2002US-0387082P.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Rastelli L,  Zhong H,  Boldog FL,  Gangolli EA,  Guo X,  Malyankar UM;
PI   Patturajan M,  Pena CEA,  Shimkets RA,  Spytek KA,  Vernet CAM;
PI   Rieger DK,  Edinger SR,  Burgess CE;
XX
DR   WPI; 2003-679626/64.
XX
PT   Isolated NOVX polypeptides and polynucleotides, useful for preventing,
PT   diagnosing or treating NOVX-associated disorders, e.g. osteoarthritis,
PT   obesity, atherosclerosis, cancer, Parkinson's disease, asthma, or
PT   infections.
XX
PS   Example C; Page 129; 167pp; English.
XX
CC   The present invention describes novel human proteins designated NOVX,
CC   where X can be 5a, 5b, 5c, or 5d. The NOVX proteins have antidiabetic,
CC   anorectic, cardiant, hypotensive, antiarteriosclerotic, anorectic,
CC   virucide, antibacterial, fungicide, protozoacide, nootropic,
CC   neuroprotective, antiparkinsonian, anticonvulsant, osteopathic,
CC   antiarthritic, antiinflammatory, dermatological, antiasthmatic and
CC   antilipaemic activities, and can be used in gene therapy. The NOVX
CC   polypeptides, nucleic acid molecules and antibodies can be used in the
CC   manufacture of a medicament for treating a syndrome associated with a
CC   human disease, preferably a NOVX-associated disorder. The nucleic acid
CC   molecules, polypeptides and antibodies are useful for treating,
CC   preventing or diagnosing diseases such as metabolic disorders, diabetes,
CC   obesity, infectious diseases (viral, bacterial, fungal, helminthic, and
CC   protozoal), anorexia, cancer, cardiovascular diseases (hypertension,
CC   atherosclerosis), neurodegenerative disorders, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, immune disorders (osteoarthritis),
CC   haematopoietic disorders, inflammatory skin disorders, asthma, and
CC   various dyslipidaemias. The nucleic acids and polypeptides may also be
CC   used as targets for the identification of small molecules that modulate
CC   or inhibit e.g. neurogenesis, cell differentiation, cell proliferation,
CC   haematopoiesis, wound healing and angiogenesis, in gene therapy, in
CC   generation of antibodies that bind immunospecifically to NOVX substances
CC   for use in therapeutic or diagnostic methods. The nucleic acids are
CC   further useful as hybridisation probes, in chromosome mapping, tissue
CC   typing, preventive medicine, and pharmacogenomics. The present sequence
CC   represents a PCR primer for a human NOV5 gene, which is used in an
CC   example from the present invention.
XX
SQ   Sequence 15 BP; 0 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        426 TCTCCCGGTGCTTC 439
              ||||||| |||||
Db          1 TCTCCCGGCGCTTC 14


RESULT 239
ADA27237
ID   ADA27237 standard; DNA; 15 BP.
XX
AC   ADA27237;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human NOV5 reverse PCR primer SEQ ID NO:11.
XX
KW   human; NOVX; NOV5; antidiabetic; anorectic; cardiant; hypotensive;
KW   antiarteriosclerotic; anorectic; virucide; antibacterial; fungicide;
KW   protozoacide; nootropic; neuroprotective; antiparkinsonian;
KW   anticonvulsant; osteopathic; antiarthritic; antiinflammatory;
KW   dermatological; antiasthmatic; antilipaemic; gene therapy;
KW   metabolic disorder; diabetes; obesity; infectious disease; anorexia;
KW   cancer; cardiovascular disease; hypertension; atherosclerosis;
KW   neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
KW   epilepsy; immune disorder; osteoarthritis; haematopoietic disorder;
KW   inflammatory skin disorder; asthma; dyslipidaemia; neurogenesis;
KW   cell differentiation; cell proliferation; haematopoiesis; wound healing;
KW   angiogenesis; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003068921-A2.
XX
PD   21-AUG-2003.
XX
```

```
PF   12-FEB-2003; 2003WO-US004188.
XX
PR   12-FEB-2002; 2002US-0356375P.
PR   07-JUN-2002; 2002US-0387082P.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Rastelli L,  Zhong H,  Boldog FL,  Gangolli EA,  Guo X,  Malyankar UM;
PI   Patturajan M,  Pena CEA,  Shimkets RA,  Spytek KA,  Vernet CAM;
PI   Rieger DK,  Edinger SR,  Burgess CE;
XX
DR   WPI; 2003-679626/64.
XX
PT   Isolated NOVX polypeptides and polynucleotides, useful for preventing,
PT   diagnosing or treating NOVX-associated disorders, e.g. osteoarthritis,
PT   obesity, atherosclerosis, cancer, Parkinson's disease, asthma, or
PT   infections.
XX
PS   Example C; Page 129; 167pp; English.
XX
CC   The present invention describes novel human proteins designated NOVX,
CC   where X can be 5a, 5b, 5c, or 5d. The NOVX proteins have antidiabetic,
CC   anorectic, cardiant, hypotensive, antiarteriosclerotic, anorectic,
CC   virucide, antibacterial, fungicide, protozoacide, nootropic,
CC   neuroprotective, antiparkinsonian, anticonvulsant, osteopathic,
CC   antiarthritic, antiinflammatory, dermatological, antiasthmatic and
CC   antilipaemic activities, and can be used in gene therapy. The NOVX
CC   polypeptides, nucleic acid molecules and antibodies can be used in the
CC   manufacture of a medicament for treating a syndrome associated with a
CC   human disease, preferably a NOVX-associated disorder. The nucleic acid
CC   molecules, polypeptides and antibodies are useful for treating,
CC   preventing or diagnosing diseases such as metabolic disorders, diabetes,
CC   obesity, infectious diseases (viral, bacterial, fungal, helminthic, and
CC   protozoal), anorexia, cancer, cardiovascular diseases (hypertension,
CC   atherosclerosis), neurodegenerative disorders, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, immune disorders (osteoarthritis),
CC   haematopoietic disorders, inflammatory skin disorders, asthma, and
CC   various dyslipidaemias. The nucleic acids and polypeptides may also be
CC   used as targets for the identification of small molecules that modulate
CC   or inhibit e.g. neurogenesis, cell differentiation, cell proliferation,
CC   haematopoiesis, wound healing and angiogenesis, in gene therapy, in
CC   generation of antibodies that bind immunospecifically to NOVX substances
CC   for use in therapeutic or diagnostic methods. The nucleic acids are
CC   further useful as hybridisation probes, in chromosome mapping, tissue
CC   typing, preventive medicine, and pharmacogenomics. The present sequence
CC   represents a PCR primer for a human NOV5 gene, which is used in an
CC   example from the present invention.
XX
SQ   Sequence 15 BP; 0 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        426 TCTCCCGGTGCTTC 439
              ||||||||  |||||
Db          1 TCTCCCGGCGCTTC 14


RESULT 240
ADF32169/c
ID   ADF32169 standard; DNA; 15 BP.
XX
AC   ADF32169;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Probe #93 used to illustrate chip detection techniques.
XX
KW   Chip detection; probe; Single Nucleotide Polymorphism; SNP; detection;
KW   ss.
XX
OS   Unidentified.
XX
PN   CN1381590-A.
XX
PD   27-NOV-2002.
XX
PF   13-APR-2001; 2001CN-00105980.
XX
PR   13-APR-2001; 2001CN-00105980.
XX
PA   (MIAO/) MIAO J.
XX
PI   Miao J;
XX
DR   WPI; 2003-249035/25.
XX
PT   Simple and fast technique for detecting single nucleotide polymorphism
PT   (SNP) by high-temp hybridized chip.
XX
PS   Example 1; Page 14; 19pp; Chinese.
XX
CC   The present invention related to an improvement to existing chip
CC   detection techniques. The invention uses DNA oligonucleotide probes
CC   (ADF32077-ADF32266) to detect Single Nucleotide Polymorphisms (SNP) in
CC   genomic DNA. Its advantages are simple process and short time (within 2
CC   hr).
XX
SQ   Sequence 15 BP; 2 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||  |||||||
Db         14 AGCCACTCAGTCCA 1


RESULT 241
ADH69864/c
ID   ADH69864 standard; DNA; 15 BP.
XX
AC   ADH69864;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Vbeta genes intron 1 3' splice site #4.
XX
KW   human; T-cell associated disease; Vbeta; autoimmune disease;
KW   degenerative nervous system disease; graft versus host disease;
KW   hypersensitivity disease; infectious disease; neoplastic disease;
KW   Addison's disease; atrophic gastritis;
KW   degenerative nervous system disease; multiple sclerosis;
KW   Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW   allergy; type II hypersensitivity; Goodpasture's syndrome;
KW   type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW   HIV; fungal infection; Candida; parasitic infection; schistosome;
KW   filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW   lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW   breast cancer; ds.
XX
OS   Homo sapiens.
XX
PN   US2002150891-A1.
XX
PD   17-OCT-2002.
XX
PF   05-MAR-1999;   99US-00263959.
XX
PR   19-SEP-1994;   94US-00309335.
PR   19-SEP-1995;   95US-00531241.
XX
PA   (HOOD/) HOOD L E.
PA   (ROWE/) ROWEN L.
```

```
XX
PI   Hood LE,  Rowen L;
XX
DR   WPI; 2004-059052/06.
XX
PT   Kit for diagnozing and treating T-cell associated diseases e.g.
PT   autoimmune, degenerative nervous system and infectious disease, comprises
PT   nucleic acid primers specifically priming and allowing amplification of a
PT   Vbeta gene.
XX
PS   Disclosure; SEQ ID NO 58; 164pp; English.
XX
CC   The invention relates to a kit for diagnosing and treating T-cell
CC   associated diseases which comprises a panel of nucleic acid primers
CC   specifically priming and allowing amplification of each Vbeta gene,
CC   VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
CC   rejection and diagnosing and treating T-cell associated diseases
CC   including autoimmune diseases, degenerative nervous system diseases,
CC   graft versus host disease, hypersensitivity diseases, infectious diseases
CC   and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC   atrophic gastritis. Degenerative nervous system diseases include multiple
CC   sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
CC   I hypersensitivities such as contact with allergens that lead to
CC   allergies, Type II hypersensitivities such as those present in
CC   Goodpasture's syndrome and Type IV hypersensitivities such as those
CC   manifested in leprosy. Infectious diseases include viral infections
CC   caused by viruses such as HIV, fungal infections such as those caused by
CC   the yeast genus Candida, parasitic infections such as those caused by
CC   schistosomes, filaria and bacterial infections such as those caused by
CC   Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC   such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC   breast. The present sequence represents a Vbeta gene intron splice site.
XX
SQ   Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        698 CACCTGTGTGTTCT 711
              ||||||||||.|||
Db         14 CACCTGTGTGATCT 1


RESULT 242
ADI87750
ID   ADI87750 standard; RNA; 15 BP.
XX
AC   ADI87750;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Anti-HCV molecule target sequence #239.
XX
KW   ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW   HCV infection; type I interferon; DNAzyme.
XX
OS   Hepatitis C virus.
XX
PN   US2003125270-A1.
XX
PD   03-JUL-2003.
XX
PF   18-DEC-2000; 2000US-00740332.
XX
PR   18-DEC-2000; 2000US-00740332.
XX
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (ROBE/) ROBERTS E.
PA   (PAVC/) PAVCO P A.
PA   (MACE/) MACEJACK D.
XX
PI   Blatt L,  Mcswiggen J,  Roberts E,  Pavco PA,  Macejack D;
XX
DR   WPI; 2004-031273/03.
XX
PT   Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT   from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT   especially in combination with type I interferon therapy.
XX
PS   Claim 1; SEQ ID NO 4793; 198pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule which
CC   specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC   the binding arms of the enzymatic nucleic acid molecule comprises
CC   sequences complementary to any of the defined substrate sequences given
CC   in the specification. The nucleic acid molecule may be administered for
CC   the treatment of HCV infections, especially in combination with type I
CC   interferons. The present sequence represents an anti-HCV molecule target
CC   sequence.
XX
SQ   Sequence 15 BP; 0 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   71.4%;  Pred. No. 1.3e+02;
  Matches   10;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         35 CGCCGCGTCCCCTT 48
              |||||||:|| |::
Db          2 CGCCGCGUCCUCUU 15


RESULT 243
ADO50238/c
ID   ADO50238 standard; DNA; 15 BP.
XX
AC   ADO50238;
XX
DT   29-JUL-2004  (first entry)
XX
DE   H. pylori strain J99 genome fragment SEQ ID NO:861.
XX
KW   ds; stroke; phosphodiesterase 4D; PDE4D.
XX
OS   Helicobacter pylori.
XX
PN   US2004091865-A1.
XX
PD   13-MAY-2004.
XX
PF   25-SEP-2002; 2002US-00255120.
XX
PR   19-MAR-2001; 2001US-00811352.
PR   04-FEB-2002; 2002US-00067514.
XX
PA   (DECO-) DECODE GENETICS EHF.
XX
PI   Gretarsdottir S,  Jonsdottir S,  Reynisdottir ST,  Thorleifsson G;
XX
DR   WPI; 2004-374932/35.
XX
PT   Diagnosing susceptibility to a stroke in an individual comprising
PT   screening for an at-risk haplotype in the phosphodiesterase 4D gene.
XX
PS   Disclosure; SEQ ID NO 861; 574pp; English.
XX
CC   The invention relates to a method of diagnosing susceptibility to a
CC   stroke in an individual comprising screening for an at-risk haplotype in
CC   the phosphodiesterase 4D (PDE4D) gene that is more frequently present in
CC   an individual susceptible to stroke (affected) compared to a healthy
CC   individual (control), where the at-risk haplotype increases risk of
CC   stroke significantly. The composition, methods and kit are useful for
CC   diagnosing, predicting of clinical course and treating stroke using
CC   polymorphisms in the PDE4D gene. These may also be used in identifying
CC   agents that enhance or inhibit PDE4D polypeptide expression or activity.
```

```
CC   The present sequence represents a fragment of H. pylori strain J99 genome
CC   which is not referred to at all in the main body of the specification.
XX
SQ   Sequence 15 BP; 8 A; 1 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        730 TGTTTTTCTCAAAT 743
              ||||||||| ||||
Db         15 TGTTTTTCTAAAAT 2


RESULT 244
ADO49955/c
ID   ADO49955 standard; DNA; 15 BP.
XX
AC   ADO49955;
XX
DT   29-JUL-2004  (first entry)
XX
DE   H. pylori strain J99 genome fragment SEQ ID NO:578.
XX
KW   ds; stroke; phosphodiesterase 4D; PDE4D.
XX
OS   Helicobacter pylori.
XX
PN   US2004091865-A1.
XX
PD   13-MAY-2004.
XX
PF   25-SEP-2002; 2002US-00255120.
XX
PR   19-MAR-2001; 2001US-00811352.
PR   04-FEB-2002; 2002US-00067514.
XX
PA   (DECO-) DECODE GENETICS EHF.
XX
PI   Gretarsdottir S,  Jonsdottir S,  Reynisdottir ST,  Thorleifsson G;
XX
DR   WPI; 2004-374932/35.
XX
PT   Diagnosing susceptibility to a stroke in an individual comprising
PT   screening for an at-risk haplotype in the phosphodiesterase 4D gene.
XX
PS   Disclosure; SEQ ID NO 578; 574pp; English.
XX
CC   The invention relates to a method of diagnosing susceptibility to a
CC   stroke in an individual comprising screening for an at-risk haplotype in
CC   the phosphodiesterase 4D (PDE4D) gene that is more frequently present in
CC   an individual susceptible to stroke (affected) compared to a healthy
CC   individual (control), where the at-risk haplotype increases risk of
CC   stroke significantly. The composition, methods and kit are useful for
CC   diagnosing, predicting of clinical course and treating stroke using
CC   polymorphisms in the PDE4D gene. These may also be used in identifying
CC   agents that enhance or inhibit PDE4D polypeptide expression or activity.
CC   The present sequence represents a fragment of H. pylori strain J99 genome
CC   which is not referred to at all in the main body of the specification.
XX
SQ   Sequence 15 BP; 8 A; 1 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        730 TGTTTTTCTCAAAT 743
              ||||||||| ||||
Db         15 TGTTTTTCTAAAAT 2


RESULT 245
ADO55514/c
ID   ADO55514 standard; DNA; 15 BP.
XX
AC   ADO55514;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human phosphodiesterase 4D (PDE4D) gene known microsatellite marker #12.
XX
KW   ds; stroke; phosphodiesterase 4D; PDE4D; human; microsatellite marker.
XX
OS   Homo sapiens.
XX
PN   US2004091865-A1.
XX
PD   13-MAY-2004.
XX
PF   25-SEP-2002; 2002US-00255120.
XX
PR   19-MAR-2001; 2001US-00811352.
PR   04-FEB-2002; 2002US-00067514.
XX
PA   (DECO-) DECODE GENETICS EHF.
XX
PI   Gretarsdottir S,  Jonsdottir S,  Reynisdottir ST,  Thorleifsson G;
XX
DR   WPI; 2004-374932/35.
XX
PT   Diagnosing susceptibility to a stroke in an individual comprising
PT   screening for an at-risk haplotype in the phosphodiesterase 4D gene.
XX
PS   Example 1; SEQ ID NO 26; 574pp; English.
XX
CC   The invention relates to a method of diagnosing susceptibility to a
CC   stroke in an individual comprising screening for an at-risk haplotype in
CC   the phosphodiesterase 4D (PDE4D) gene that is more frequently present in
CC   an individual susceptible to stroke compared to a healthy individual,
CC   where the at-risk haplotype increases risk of stroke significantly. The
CC   composition, methods and kit are useful for diagnosing, predicting of
CC   clinical course and treating stroke using polymorphisms in the PDE4D
CC   gene. These may also be used in identifying agents that enhance or
CC   inhibit PDE4D polypeptide expression or activity. The present sequence
CC   represents a human phosphodiesterase 4D (PDE4D) gene known microsatellite
CC   marker.
XX
SQ   Sequence 15 BP; 3 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        491 TCCCTGTCCCCTGA 504
              |||| |||||||||
Db         14 TCCCAGTCCCCTGA 1


RESULT 246
ACA07606
ID   ACA07606 standard; RNA; 17 BP.
XX
AC   ACA07606;
XX
DT   03-JUN-2003  (first entry)
XX
DE   NFKB sub-unit modulating zinzyme substrate #5.
XX
KW   Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW   G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW   lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW   oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW   cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW   lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW   chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW   cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
```

```
KW   gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW   rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW   gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW   transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW   allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS   Homo sapiens.
XX
PN   US2002177568-A1.
XX
PD   28-NOV-2002.
XX
PF   23-MAY-2001; 2001US-00864785.
XX
PR   07-DEC-1992;   92US-00987132.
PR   18-MAY-1994;   94US-00245466.
PR   15-AUG-1994;   94US-00291932.
PR   23-DEC-1996;   96US-00777916.
XX
PA   (STIN/) STINCHCOMB D T.
PA   (MCSW/) MCSWIGGEN J.
PA   (DRAP/) DRAPER K G.
XX
PI   Stinchcomb DT,  Mcswiggen J,  Draper KG;
XX
DR   WPI; 2003-340953/32.
XX
PT   Novel enzymatic nucleic acid molecules which down regulates expression of
PT   a sequence encoding a subunit of nuclear factor kappa B useful for
PT   treating cancer, inflammatory disorders and autoimmune diseases.
XX
PS   Claim 3; Page 37; 72pp; English.
XX
CC   The invention describes an enzymatic nucleic acid molecule (I) which down
CC   regulates expression of a sequence encoding a subunit of nuclear factor
CC   kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC   configuration. The enzymatic nucleic acid molecule is adapted to treat
CC   cancer and is useful for down-regulating REL-A activity in a cell, for
CC   treating a patient having a condition associated with the level of REL-A.
CC   (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC   the presence of a divalent cation, especially Mg^2^+. The enzymatic and
CC   antisense nucleic acid molecules are useful for treating breast, lung,
CC   prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC   cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC   multidrug resistant cancer. The method involves use of other drug
CC   therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC   chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC   cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC   gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC   acid molecules are also useful for treating inflammatory disease such as
CC   rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC   obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC   rejection, gene therapy applications, ischaemia/reperfusion injury
CC   (central nervous system (CNS) and myocardial), glomerulonephritis,
CC   sepsis, allergic airway inflammation, inflammatory bowel disease or
CC   infection. This sequence represents the substrate of a novel enzymatic
CC   nucleic acid molecule
XX
SQ   Sequence 17 BP; 1 A; 6 C; 8 G; 0 T; 2 U; 0 Other;

  Query Match             1.6%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.7e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy         61 GGGCCCCAGCTGGGACC 77
              ||| | ||||:||| ||
Db          1 GGGUCGCAGCUGGGCCC 17


RESULT 247
AAF74725/c
ID   AAF74725 standard; DNA; 12 BP.
XX
AC   AAF74725;
XX
DT   17-MAY-2001  (first entry)
XX
DE   Human smoothelin variant intron-exon splice recognition sequence #21.
XX
KW   Human; smoothelin; smoothelin B gene; smooth muscle cell promoter;
KW   vascular contractile smooth muscle cell; gene therapy; PCR primer;
KW   visceral contractile smooth muscle cell; cardiovascular; ss.
XX
OS   Homo sapiens.
XX
PN   EP1083231-A1.
XX
PD   14-MAR-2001.
XX
PF   09-SEP-1999;   99EP-00202943.
XX
PR   09-SEP-1999;   99EP-00202943.
XX
PA   (INTR-) INTROGENE BV.
XX
DR   WPI; 2001-236858/25.
XX
PT   Nucleic acids encoding smooth muscle cell specific promoters, useful e.g.
PT   for treating cardiovascular diseases or in targeting transgene expression
PT   to smooth muscle cells expressing endogenous smoothelin proteins.
XX
PS   Example 3; Page 16; 51pp; English.
XX
CC   The present invention describes a nucleic acid delivery vehicle (I)
CC   comprising a nucleic acid capable of expressing specifically in a
CC   contractile smooth muscle cell, preferably a vascular contractile smooth
CC   muscle cell and/or a visceral contractile smooth muscle cell. Also
CC   described are smooth muscle cell specific promoters which can be
CC   incorporated into a nucleic acid delivery vehicle, where the nucleic acid
CC   delivery vehicle preferably comprises a virus-like particle such as an
CC   adenovirus particle, an adeno-associated virus particle or a retrovirus
CC   particle. (I) has cardiovascular activity and can be used in gene
CC   therapy. The nucleic acid delivery vehicle is useful for the preparation
CC   of a pharmaceutical for the treatment of a cardiovascular disease. The
CC   promoter of the smoothelin gene (a smooth muscle cell specific promoter)
CC   is useful for providing a particular nucleic acid with the capacity to
CC   express proteins specifically in contractile smooth muscle cells. The
CC   promoter may also be used in targeting transgene expression to smooth
CC   muscle cells that express endogenous smoothelin protein, in
CC   distinguishing subsets of smooth muscle cells, and in expressing foreign
CC   genetic material specifically in contractile smooth muscle cells.
CC   AAF74719 to AAF74756 represent human smoothelin variant intron-exon
CC   splice recognition sites, which are used in an example from the present
CC   invention
XX
SQ   Sequence 12 BP; 1 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 99;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        606 CAGAAGCTGCAA 617
              ||||||||||||
Db         12 CAGAAGCTGCAA 1


RESULT 248
AAS01800/c
ID   AAS01800 standard; DNA; 12 BP.
XX
AC   AAS01800;
XX
DT   12-SEP-2001  (first entry)
XX
DE   Human smoothelin gene intron-exon splice recognition sequence #7.
XX
```

KW Human; smoothelin; promoter; nucleic acid delivery vehicle; restenosis;
KW contractile smooth muscle cell; pharmaceutical; cardiovascular disease;
KW hypertension; atherosclerosis; transgene expression; oligo linker; ds;
KW percutaneous transluminal coronary angioplasty.
XX
OS Homo sapiens.
XX
PN WO200118048-A2.
XX
PD 15-MAR-2001.
XX
PF 08-SEP-2000; 2000WO-NL000638.
XX
PR 09-SEP-1999; 99EP-00202943.
PR 09-SEP-1999; 99US-0153284P.
XX
PA (INTR-) INTROGENE BV.
XX
PI Van Eijs GJJM, Hateboer G, Havenga MJE;
XX
DR WPI; 2001-244559/25.
XX
PT New nucleic acids encoding smooth muscle cell specific promoters, useful
PT for treating a cardiovascular disease or in targeting transgene
PT expression to smooth muscle cells expressing endogenous smoothelin
PT protein.
XX
PS Example 3; Page 45; 60pp; English.
XX
CC The sequence represents an intron-exon splice recognition sequence of the
CC human smoothelin gene. The smoothelin gene promoter, or its functional
CC part, derivative and/or analogue, can be used as part of a nucleic acid
CC delivery vehicle, comprising a nucleic acid capable of expressing
CC specifically in a contractile smooth muscle cell. The nucleic acid
CC delivery vehicle is useful for the preparation of a pharmaceutical for
CC the treatment of cardiovascular diseases, such as hypertension,
CC atherosclerosis and restenosis after percutaneous transluminal coronary
CC angioplasty. The promoter of a smoothelin gene is useful for providing a
CC particular nucleic acid with the capacity to express foreign genetic
CC material specifically in a contractile smooth muscle cell. The promoter
CC may also be used in targeting transgene expression to smooth muscle cells
CC that express endogenous smoothelin protein, in distinguishing subsets of
CC smooth muscle cells, and in expressing foreign genetic material
CC specifically in contractile smooth muscle cells
XX
SQ Sequence 12 BP; 1 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 606 CAGAAGCTGCAA 617
||||||||||||
Db 12 CAGAAGCTGCAA 1

RESULT 249
ABH93536/c
ID ABH93536 standard; DNA; 12 BP.
XX
AC ABH93536;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 293529 for detecting SNP TSC0015658.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 293529; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 735 TTCTCAAATAAA 746
||||||||||||
Db 12 TTCTCAAATAAA 1

RESULT 250
ABI17243
ID ABI17243 standard; DNA; 12 BP.
XX
AC ABI17243;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 317216 for detecting SNP TSC0027870.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

```
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 317216; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 99;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        734 TTTCTCAAATAA 745
              ||||||||||||
Db          1 TTTCTCAAATAA 12


RESULT 251
ABI31739/c
ID   ABI31739 standard; DNA; 12 BP.
XX
AC   ABI31739;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 331712 for detecting SNP TSC0036426.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 331712; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 99;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        732 TTTTTCTCAAAT 743
              ||||||||||||
Db         12 TTTTTCTCAAAT 1


RESULT 252
ABI67794
ID   ABI67794 standard; DNA; 12 BP.
XX
AC   ABI67794;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 367767 for detecting SNP TSC0056551.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 367767; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 99;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        716 ATACATTTATCT 727
```

```
                    ||||||||||||
Db    .       1 ATACATTTATCT 12


RESULT 253
ABH86717/c
ID   ABH86717 standard; DNA; 12 BP.
XX
AC   ABH86717;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 286710 for detecting SNP TSC0012789.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 286710; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 0 A; 1 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 99;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        470 GACCCCACCCAA 481
              ||||||||||||
Db         12 GACCCCACCCAA 1


RESULT 254
ADM76066
ID   ADM76066 standard; DNA; 12 BP.
XX
AC   ADM76066;
XX
DT   03-JUN-2004  (first entry)
XX
DE   NEPHA gene transcriptional control region Pax-4 binding site.
XX
KW   Human; NEPHA; ephrin receptor; brain; chromosome 1; apoptosis;
KW   drug screening; antisense therapy; gene therapy; cancer; tumour;
KW   lung cancer; ovarian cancer; breast cancer; cervical cancer;
KW   prostate cancer; bladder cancer; stomach cancer; colorectal cancer;
KW   cytostatic; transcriptional control region; promoter;
KW   transcription factor binding site; ds.
XX
OS   Homo sapiens.
XX
PN   JP2003289876-A.
XX
PD   14-OCT-2003.
XX
PF   05-APR-2002; 2002JP-00103497.
XX
PR   05-APR-2002; 2002JP-00103497.
XX
PA   (TAKE ) TAKEDA CHEM IND LTD.
XX
DR   WPI; 2004-038434/04.
XX
PT   Novel antisense oligonucleotide useful as anticancer agent for preventing
PT   cancer e.g. lung cancer, stomach cancer, breast cancer.
XX
PS   Example 2; Page 19; 38pp; Japanese.
XX
CC   The invention relates to antisense oligonucleotides (ADM76030 and
CC   ADM76031) targeted to the human NEPHA gene (ADM76029), which encodes a
CC   novel brain-derived ephrin receptor (ADM76028). The NEPHA protein has
CC   50.7% homology to the human EphA7 ephrin receptor and its gene is located
CC   on chromosome 1. Ephrin receptors are overexpressed in various cancers
CC   and it has been found that inhibition of NEPHA expression promotes
CC   apoptosis. The invention also relates to the NEPHA transcriptional
CC   control (promoter) region (ADM76037); recombinant vectors and host cells
CC   comprising the NEPHA promoter operably linked to a reporter gene; a
CC   method of screening for compounds which inhibit or activate transcription
CC   of the NEPHA gene; and pharmaceutical compositions comprising an
CC   antisense oligonucleotide or a transcriptional inhibitor or activator.
CC   The antisense oligonucleotides and modulators of NEPHA transcription are
CC   useful for inducing apoptosis for the treatment and/or prevention of
CC   cancers in which NEPHA is overexpressed such as lung cancer, ovarian
CC   cancer, breast cancer, cervical cancer, prostate cancer, bladder cancer,
CC   stomach cancer and colorectal cancer. Sequences ADM76038-ADM76371
CC   represent transcription factor binding sites within the transcriptional
CC   control region of the NEPHA gene.
XX
SQ   Sequence 12 BP; 1 A; 1 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 99;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        371 GGCGTGGTGGAG 382
              ||||||||||||
Db          1 GGCGTGGTGGAG 12


RESULT 255
ABH41108/c
ID   ABH41108 standard; DNA; 13 BP.
XX
AC   ABH41108;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 241085 for detecting SNP TSC0058802.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
```

```
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 241085; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        734 TTTCTCAAATAA 745
              ||||||||||||
Db         12 TTTCTCAAATAA 1


RESULT 256
ABH41109
ID   ABH41109 standard; DNA; 13 BP.
XX
AC   ABH41109;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 241086 for detecting SNP TSC0058802.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 241086; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 3 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        734 TTTCTCAAATAA 745
              ||||||||||||
Db          2 TTTCTCAAATAA 13


RESULT 257
ABF75056
ID   ABF75056 standard; DNA; 13 BP.
XX
AC   ABF75056;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 175053 for detecting SNP TSC0043508.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 175053; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
```

```
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 1 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        369 ATGGCGTGGTGG 380
              ||||||||||||
Db          2 ATGGCGTGGTGG 13


RESULT 258
ABH34624/c
ID   ABH34624 standard; DNA; 13 BP.
XX
AC   ABH34624;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 234601 for detecting SNP TSC0057252.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 234601; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        735 TTCTCAAATAAA 746
              ||||||||||||
Db         12 TTCTCAAATAAA 1


RESULT 259
ABF75057/c
ID   ABF75057 standard; DNA; 13 BP.
XX
AC   ABF75057;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 175054 for detecting SNP TSC0043508.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 175054; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        369 ATGGCGTGGTGG 380
              ||||||||||||
Db         12 ATGGCGTGGTGG 1


RESULT 260
ABH34625
ID   ABH34625 standard; DNA; 13 BP.
XX
AC   ABH34625;
XX
DT   22-FEB-2002  (first entry)
```

```
XX
DE   Oligonucleotide SEQ ID NO 234602 for detecting SNP TSC0057252.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 234602; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        735 TTCTCAAATAAA 746
              ||||||||||||
Db          2 TTCTCAAATAAA 13


RESULT 261
AAS13442/c
ID   AAS13442 standard; DNA; 14 BP.
XX
AC   AAS13442;
XX
DT   18-DEC-2001  (first entry)
XX
DE   DNA primer sequence for nanoparticle positioning #2.
XX
KW   nanoparticle positioning; food industry; surgical implant;
KW   autoimmune reaction; rejection; primer; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_binding    1. .5
FT                   /*tag=  a
FT                   /bound_moiety= "Nucleotides 5-1 of sequence appearing as
FT                   AAS13439"
FT                   /note= "Forms double stranded region with nucleotides 5-1
FT                   of sequence appearing as AAS13439"
FT   misc_feature    6. .8
FT                   /*tag=  b
FT                   /note= "Double stranded region"
FT   modified_base   7
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "Other= G is linked to a Cell type 3 via a
FT                   disulphide linkage"
FT   misc_feature    9. .10
FT                   /*tag=  d
FT                   /note= "May be multiple GC units"
FT   misc_feature    11. .13
FT                   /*tag=  e
FT                   /note= "Double stranded region"
FT   modified_base   12
FT                   /*tag=  f
FT                   /mod_base= OTHER
FT                   /note= "Other= G is linked to a Cell type 4 via a
FT                   disulphide linkage"
XX
PN   WO200160316-A2.
XX
PD   23-AUG-2001.
XX
PF   16-FEB-2001; 2001WO-SE000355.
XX
PR   18-FEB-2000; 2000SE-00000546.
XX
PA   (OSCA/) OSCARSSON S.
PA   (QUIS/) QUIST A.
PA   (PAHL/) PAHLSSON C.
XX
PI   Oscarsson S,  Quist A,  Pahlsson C;
XX
DR   WPI; 2001-570540/64.
XX
PT   Positioning particles on a surface for separating macromolecules, cells,
PT   bacteria or viruses, comprises contacting surface bound nucleic acid
PT   polymers with particles labeled with complementary primer sequences.
XX
PS   Example 1; Fig 1; 18pp; English.
XX
CC   The invention relates to positioning particles or macromolecules on a
CC   surface, involves arranging surface defects, attaching nucleic acid
CC   polymers of known sequence to the surface defects, labeling the
CC   particles/macromolecules with known nucleotide sequences in the form of
CC   primers corresponding to specific locations on the bound nucleic acid
CC   sequence, and contacting surface bound nucleic acid with the primers with
CC   by which binding between corresponding base pairs occurs. The method is
CC   useful for positioning particles or macromolecules, preferably bioactive
CC   particles or macromolecules such as enzymes, hormones, signal substances,
CC   antibodies and receptor molecules, cells or their parts, bacteria,
CC   viruses or their parts, or pharmaceutically active substances, on a
CC   surface. A two-dimensional or three-dimensional gradient is useful for
CC   separating macromolecules, cells, bacteria or viruses and for detecting
CC   macromolecules or creation of mixed separation surface where the upper
CC   part of the surface is a hydrophobic surface and the lower part is an
CC   ionic surface. Thus the gradients are useful for producing a mosaic or
CC   pattern of different kind of bacteria on predetermined positions which
CC   has applications in food industry. The method is useful for creating
CC   novel biocompatible materials or to form an interface between an
CC   artificial implant and a living organism e.g., creating a surface on an
CC   implant (such as surgical implants such as stents), which surface
CC   eliminates or minimises autoimmune reactions or rejection mechanisms.
CC   Surfaces with artifacts produced by the above method have utility in
CC   medicine, electronics, micromechanics, analysis and synthesis, etc. A
CC   sensor incorporating the surface is useful in medical and analytical
CC   applications for detecting trace amounts of specific compounds. The
CC   present sequence is a primer sequence used to demonstrate the method of
CC   the invention
XX
```

```
SQ   Sequence 14 BP; 1 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         59 CGGGGCCCCAGC 70
               ||||||||||||
Db         14 CGGGGCCCCAGC 3


RESULT 262
ABS98192/c
ID   ABS98192 standard; DNA; 14 BP.
XX
AC   ABS98192;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human lactoferrin (LTF) gene PCR primer #7.
XX
KW   Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
KW   cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
KW   adrenergic receptor beta1; ADBR1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW   aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW   cyclooxgenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW   epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW   glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW   HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
KW   NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
KW   UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW   UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW   multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW   multidrug resistance associated protein 3; cancer; prostate;
KW   acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW   altered drug metabolism; cardiovascular function; colorectal tumour;
KW   central nervous system; pulmonary; immunological.
XX
OS   Homo sapiens.
XX
PN   WO200257410-A2.
XX
PD   25-JUL-2002.
XX
PF   28-NOV-2001; 2001WO-US044838.
XX
PR   28-NOV-2000; 2000US-00724389.
XX
PA   (DNAS-) DNA SCI LAB INC.
XX
PI   Guida M,  Hall J;
XX
DR   WPI; 2002-698522/75.
XX
PT   Isolated nucleic acid molecules having polymorphisms in known human genes
PT   e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
PT   for locating, identifying and characterizing the genes responsible for
PT   disorder-related traits.
XX
PS   Example 23; Page 146; 714pp; English.
XX
CC   This invention relates to the sequence of an isolated nucleic acid
CC   molecule comprising at least one base variation from that of a known
CC   human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
CC   cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
CC   aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
CC   (ARNT), cathepsin S (CTSS), cyclooxgenase 2 (COX2), diazepam binding
CC   inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
CC   protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
CC   transferase (HNMT), (kallikrein 2) KLK2, nicotinamide -N-methyl
CC   transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
CC   sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC   (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC   transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
CC   (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
CC   (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
CC   receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
CC   The polymorphisms in the human genes cited in the invention are useful as
CC   genetic linkage markers for locating and characterising the genes that
CC   are responsible for specific traits within the genome and eventually
CC   identifying the genes responsible for a variety of disorder-related
CC   traits as a result of their e.g., overexpression, constitutive
CC   expression, mutation or underexpression, which may be used in diagnosing
CC   and/or treating the disorders. The nucleic acid molecules comprising the
CC   polymorphic sequences contained in CYP4501A1, CYPP4501A2, CYP4502E1,
CC   ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
CC   MDR1 and/or MDR3 are useful for screening individuals for altered drug
CC   metabolism. The polymorphic sequences contained in CYP4501A1, CYPP4501A2,
CC   AHR, MDR1 and/or MDR3 may also be used to screen individuals for
CC   susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
CC   used to screen for altered cardiovascular function, in COX2 for altered
CC   susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
CC   nervous system function, in FLAP and HNMT for altered pulmonary,
CC   immunological or haematological function, in KLK2 for altered serine
CC   protease activity in the prostate, in LTF for altered immunological or
CC   haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
CC   peripheral nervous system function. The present sequence represents a PCR
CC   primer used to amplify the sequences of the invention
XX
SQ   Sequence 14 BP; 3 A; 3 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        682 GCTGTGCCTCCC 693
              ||||||||||||
Db         14 GCTGTGCCTCCC 3


RESULT 263
ADF78335/c
ID   ADF78335 standard; DNA; 14 BP.
XX
AC   ADF78335;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Chromosomal abnormality detection-related APC small deletion DNA 81.
XX
KW   chromosomal abnormality; maternal locus; genetic disorder; foetus;
KW   mutation; translocation; transversion; monosomy; trisomy; trisomy 21;
KW   chromosome 21; Down's Syndrome; anueoplodies; chromosome deletion;
KW   chromosome addition; chromosome amplification; chromosome translocation;
KW   chromosome rearrangement; single nucleotide polymorphism detection;
KW   SNP detection; pregnant female; APC; adenomatous polyposis coli; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003074723-A2.
XX
PD   12-SEP-2003.
XX
PF   28-FEB-2003; 2003WO-US006198.
XX
PR   01-MAR-2002; 2002US-0360232P.
PR   11-MAR-2002; 2002US-00093618.
PR   08-MAY-2002; 2002US-0378354P.
XX
PA   (DHAL/) DHALLAN R.
XX
PI   Dhallan R;
XX
DR   WPI; 2003-845073/78.
XX
PT   Detection of chromosomal abnormalities e.g. Down's Syndrome, non-
```

```
PT   invasively in a fetus, comprises forming a ratio of amounts of alleles at
PT   a locus of interest and a different heterozygous locus.
XX
PS   Example 7; Page 159; 164pp; English.
XX
CC   This invention relates to a novel method of detecting chromosomal
CC   abnormalities by determining the sequence of alleles of a locus of
CC   interest from template DNA, determining which alleles are present and
CC   comparing to amounts of alleles at a different, selected heterozygous
CC   locus (for example on another chromosome or a maternal locus); relative
CC   amounts are expressed as a ratio indicating presence or absence of the
CC   abnormality. The method is useful for the detection of genetic disorders,
CC   especially in a foetus, including chromosomal abnormalities and
CC   mutations, for example translocations, transversions, monosomies,
CC   trisomies (for example trisomy 21 in which an additional copy of
CC   chromosome 21 results in Down's Syndrome) and other anueoplodies,
CC   deletions, additions, amplifications, translocations and rearrangements.
CC   It can be used to detect any alterations in a gene sequence, especially
CC   single nucleotide polymorphisms (SNPs), and may be used to detect
CC   numerous abnormalities simultaneously, for example if several SNPs are
CC   associated with a particular disease. The method provides a rapid, non-
CC   invasive method for determining the sequence of DNA from a foetus using a
CC   sample from a pregnant female, for example to detect genetic disorders as
CC   above or to determine if a foetus is a carrier of a disease or
CC   predisposed to a disease.
XX
SQ   Sequence 14 BP; 4 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        374 GTGGTGGAGATC 385
              ||||||||||||
Db         14 GTGGTGGAGATC 3


RESULT 264
ADH53140/c
ID   ADH53140 standard; DNA; 14 BP.
XX
AC   ADH53140;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human APC (adenomatous polyposis coli) DNA fragment 80.
XX
KW   sequence determination; recognition site; restriction endonuclease;
KW   human; APC; adenomatous polyposis coli; chromosome 5q21-22;
KW   colorectal cancer; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003074740-A1.
XX
PD   12-SEP-2003.
XX
PF   28-FEB-2003; 2003WO-US006376.
XX
PR   01-MAR-2002; 2002US-0360232P.
PR   11-MAR-2002; 2002US-00093618.
PR   08-MAY-2002; 2002US-0378354P.
XX
PA   (DHAL/) DHALLAN R.
XX
PI   Dhallan R;
XX
DR   WPI; 2003-756772/71.
XX
PT   Determining a sequence of a locus of interest comprises replicating a
PT   region of DNA comprising a locus of interest from a template
PT   polynucleotide by using a first and a second primer.
XX
PS   Example 5; Page 137; 190pp; English.
XX
CC   The invention relates to a novel method for determining the sequence of a
CC   locus of interest which comprises replicating a region of DNA comprising
CC   a locus of interest from a template polynucleotide by using a first and a
CC   second primer where the second primer contains a sequence that generates
CC   a recognition site for a restriction enzyme such that digestion with the
CC   restriction enzyme generates a 5' overhang containing the locus of
CC   interest. The method may be useful for determining the sequences of
CC   multiple loci of interest concurrently and for determining the sequence
CC   of a mutant allele in the presence of a normal allele. The current
CC   sequence is that of the human APC (adenomatous polyposis coli) DNA
CC   fragment of the invention which is located on chromosome 5q21-22 and in
CC   which mutations are associated with colorectal cancer.
XX
SQ   Sequence 14 BP; 4 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        374 GTGGTGGAGATC 385
              ||||||||||||
Db         14 GTGGTGGAGATC 3


RESULT 265
ABT13746
ID   ABT13746 standard; DNA; 14 BP.
XX
AC   ABT13746;
XX
DT   07-FEB-2003  (first entry)
XX
DE   Population analysis related TAG sequence #52.
XX
KW   Qualitative; quantitative; analysis; population; invariable chain;
KW   nuclease; gene expression profile; ds.
XX
OS   Unidentified.
XX
PN   WO200266676-A2.
XX
PD   29-AUG-2002.
XX
PF   15-FEB-2002; 2002WO-FR000600.
XX
PR   16-FEB-2001; 2001FR-00002183.
XX
PA   (CNRS ) CNRS CENT NAT RECH SCI.
XX
PI   Pugnere D,  Marti J,  Manchon L,  Piquemal D;
XX
DR   WPI; 2003-018634/01.
XX
PT   Analysis of nucleic acid populations, useful for comparing gene
PT   expression profiles, by sequencing and identifying tags based on nuclease
PT   recognition sites.
XX
PS   Example 2; Page 37; 51pp; French.
XX
CC   The invention relates to a novel method for qualitative or quantitative
CC   analysis of a population of nucleic acids in a sample where each nucleic
CC   acid contains many copies of an invariable chain of nucleotides,
CC   recognised by a nuclease. The number of bases separating two successive
CC   copies is constant and determined by the number of nucleotides between
CC   the invariable chain and the nuclease cutting site. The method is used to
CC   determine gene expression profiles in a population of cells, especially
CC   eukaryotes, e.g. where one population has been treated with a compound
CC   that may affect its physiology, or where one population represents normal
CC   cells and the other diseased cells. This polynucleotide sequence
CC   represents a nucleic acid of the population of the invention
XX
```

```
SQ   Sequence 14 BP; 7 A; 1 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        738 TCAAATAAAGTT 749
              ||||||||||||
Db          3 TCAAATAAAGTT 14


RESULT 266
ADR97911/c
ID   ADR97911 standard; DNA; 14 BP.
XX
AC   ADR97911;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human APC DNA fragment containing deletion at codon 879.
XX
KW   ds; chromosomal abnormality; detection; foetus; translocation;
KW   transversion; monosomy; trisomy; aneuploidy; deletion; addition;
KW   amplification; prenatal diagnosis; SNP; single nucleotide polymorphism;
KW   human; chromosome 5q21-22; adenomatous polyposis coli; mutation.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004079011-A1.
XX
PD   16-SEP-2004.
XX
PF   29-AUG-2003; 2003WO-US027308.
XX
PR   28-FEB-2003; 2003WO-US006198.
XX
PA   (RAVG-) RAVGEN INC.
XX
PI   Dhallan R;
XX
DR   WPI; 2004-677127/66.
XX
PT   Detecting a chromosomal abnormality, e.g. translocations, transversions,
PT   monosomies, trisomies, aneuplodies, deletions, or arrangements, comprises
PT   determining the sequence of alleles of a locus of interest in the sample
PT   from template DNA.
XX
PS   Example 7; Page 151; 429pp; English.
XX
CC   This invention describes a novel method for detecting a chromosomal
CC   abnormality in a sample which comprises determining the sequence of
CC   alleles of a locus of interest in a sample from template DNA where
CC   determining the sequence of the alleles comprises amplifying the locus of
CC   interest, hybridising the amplified loci to GeneCHIP array, washing
CC   GeneCHIP array, staining the GeneCHIP array with detectable reagents, and
CC   scanning GeneCHIP array. The amplification method is self-sustained
CC   sequence reaction, ligase chain reaction, rapid amplification of cDNA
CC   ends, PCR and ligase chain reaction, Q-beta phage amplification, strand
CC   displacement amplification, or splice overlap extension PCR, preferably
CC   PCR. The determination of the sequence of the alleles comprises
CC   amplifying the locus of interest, fragmenting the amplicon, hybridising
CC   fragmented amplicons to CodeLink Arrays, extension reaction to
CC   incorporate a nucleotide and detecting incorporated nucleotides. The
CC   amplicon fragmentation is by exonuclease digestion. Detecting a
CC   chromosomal abnormality in a sample comprises determining the sequence of
CC   alleles of a locus of interest from template DNA, where determining the
CC   sequence of the alleles comprises using BeadArray Technology. The
CC   determination of the sequence of the alleles may also be done by
CC   amplifying the locus of interest, dephosphorylation of the unused
CC   reagents, in vitro transcription reaction of the products, RNase A
CC   cleavage of the products, mixing the products with CleanResin,
CC   transferring products to SpectroCHIP, and analysing the SpectroCHIP. The
CC   dephosphorylation reaction is with shrimp alkaline phosphatase.
CC   Alternatively, the determination of the sequence of the alleles comprises
CC   amplifying the locus of interest, dephosphorylation of the unused
CC   reagents, hybridising a primer to the locus of interest, incorporating a
CC   nucleotide, mixing the products with CleanResin, transferring products to
CC   SpectroCHIP, and analysing the SpectroCHIP. The hybridisation of primer
CC   is adjacent to the locus of interest. The determination of the sequence
CC   of the alleles may also comprise amplifying the locus of interest,
CC   treating the products with exonuclease, single stranded DNA is annealed
CC   to an oligonucleotide, incorporating a nucleotide using the annealed
CC   template and primer, and detecting the incorporated nucleotide. The
CC   method is useful for detecting a chromosomal abnormality in a sample.
CC   Specifically, the method is useful for detecting chromosomal
CC   abnormalities in a fetus including translocations, transversions,
CC   monosomies, trisomies, and other aneuplodies, deletions, additions,
CC   amplifications, and arrangements. The method of the invention can also be
CC   used for prenatal diagnosis. This sequence represents a fragment of the
CC   human adenomatous polyposis coli (APC) gene which contains a nucleotide
CC   deletion.
XX
SQ   Sequence 14 BP; 4 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        374 GTGGTGGAGATC 385
              ||||||||||||
Db         14 GTGGTGGAGATC 3


RESULT 267
ADS08595/c
ID   ADS08595 standard; DNA; 14 BP.
XX
AC   ADS08595;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human DNA oligonucleotide #84.
XX
KW   Human; nucleic acid detection; cell lysis; chromosomal abnormality;
KW   cancer; carcinoma; bladder; breast; bronchus; colon; kidney; liver; lung;
KW   oesophagus; gall bladder; ovary; pancreas; stomach; cervix; thyroid;
KW   prostate; skin; small cell lung cancer; squamous cell carcinoma;
KW   leukaemia; lymphoma; myelodysplastic syndrome; fibrosarcoma;
KW   rhabdomyosarcoma; astrocytoma; neuroblastoma; glioma; schwannoma;
KW   melanoma; seminoma; teratocarcinoma; osteosarcoma; ds.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004078994-A2.
XX
PD   16-SEP-2004.
XX
PF   01-MAR-2004; 2004WO-US006337.
XX
PR   28-FEB-2003; 2003WO-US006198.
XX
PA   (RAVG-) RAVGEN INC.
XX
PI   Dhallan R;
XX
DR   WPI; 2004-662434/64.
XX
PT   Detecting presence or absence of nucleic acid, containing mutation,
PT   involves isolating nucleic acid from sample containing cell lysis
PT   inhibitor, and detecting presence or absence of nucleic acid.
XX
PS   Example 7; Page 160; 440pp; English.
XX
CC   The invention relates to a method for detecting a nucleic acid, involving
```

```
CC   isolating a nucleic acid from a sample, where an agent that impedes cell
CC   lysis was added to the sample, and detecting the presence or absence of
CC   the nucleic acid. The invention also relates to a method for detecting
CC   chromosomal abnormalities in a DNA sample and determining the sequence of
CC   foetal DNA from a sample of a pregnant female. The nucleic acid contains
CC   at least one mutation chosen from a single point mutation, multiple point
CC   mutations, an insertion, a frameshift, a truncation, a deletion, a
CC   duplication and a transversion. The method is useful for detecting
CC   nucleic acid in a sample obtained from a source chosen from bacteria,
CC   viruses, fungi, mycobacteria, protozoa, molds, yeasts, plants, humans,
CC   non-humans, multi-cellular parasites, animals and archaebacteria. The
CC   method is useful for detecting, diagnosing or monitoring a disease such
CC   as cancer chosen from carcinoma of the bladder, breast, bronchus, colon,
CC   kidney, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach,
CC   cervix, thyroid, prostate and skin, small cell lung cancer, squamous cell
CC   carcinoma, haematopoietic tumours of lymphoid lineage, leukaemia, acute
CC   lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-
CC   cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell
CC   lymphoma, Burkett's lymphoma, haematopoietic tumours of myeloid lineage,
CC   acute and chronic myelogenous leukaemias, myelodysplastic syndrome and
CC   promyelocytic leukaemia, tumours of mesenchymal origin, fibrosarcoma and
CC   rhabdomyosarcoma, tumours of the central and peripheral nervous system,
CC   astrocytoma, neuroblastoma, glioma and schwannomas, melanoma, seminoma,
CC   teratocarcinoma and osteosarcoma. The method is also useful for
CC   monitoring response to treatment chosen from surgery, radiation,
CC   lifestyle change, dietary protocol and supplementation and administration
CC   of a drug. The drug is chosen from chemotherapeutic agents, anti-
CC   bacterial agents, anti-viral agents, anti-fungal agents, targeted-cancer
CC   drugs, cytotoxic agents, cytostatic agents and anti-proliferative agents.
CC   This sequence represents a DNA oligonucleotide used in the scope of the
CC   invention.
XX
SQ   Sequence 14 BP; 4 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        374 GTGGTGGAGATC 385
              ||||||||||||
Db         14 GTGGTGGAGATC 3


RESULT 268
AAX31657/c
ID   AAX31657 standard; DNA; 15 BP.
XX
AC   AAX31657;
XX
DT   21-MAY-1999  (first entry)
XX
DE   Tag sequence of a transcript increased in pancreatic cancer.
XX
KW   Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
KW   diagnosis; prognosis; treatment; ss.
XX
OS   Homo sapiens.
XX
PN   WO9853319-A2.
XX
PD   26-NOV-1998.
XX
PF   20-MAY-1998;   98WO-US010277.
XX
PR   21-MAY-1997;   97US-0047352P.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Vogelstein B;  Kinzler KW;
XX
DR   WPI; 1999-070161/06.
XX
PT   Use of isolated gene transcripts - useful for developing products for the
PT   diagnosis, prognosis and treatment of cancers, particularly colon and
PT   pancreatic cancer.
XX
PS   Claim 13; Page 67; 120pp; English.
XX
CC   AAX30947-31815 represent tag sequences of transcripts that are
CC   differentially expressed in colorectal cancer, in pancreatic cancer, or
CC   in both. The tag sequences can be used to identify genes by matching the
CC   tag to a gen data base member, or by using the tag sequences as probes to
CC   isolate unidentified genes from cDNA libraries. The tag sequences can
CC   also be used in a method for diagnosing colon or pancreatic cancer in a
CC   sample suspected of being neoplastic. The method comprises comparing the
CC   level of at least one transcript in a first sample of a tissue to a
CC   second sample, where the first sample is a colonic tissue suspected of
CC   being neoplastic and the second sample is a normal human colonic tissue.
CC   The transcript is identified by a tag selected from AAX30947-31815. The
CC   methods of the invention can be used in the diagnosis, prognosis and
CC   treatment of cancer
XX
SQ   Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        500 CCTGAGGGCACA 511
              ||||||||||||
Db         14 CCTGAGGGCACA 3


RESULT 269
AAX31658/c
ID   AAX31658 standard; DNA; 15 BP.
XX
AC   AAX31658;
XX
DT   21-MAY-1999  (first entry)
XX
DE   Tag sequence of a transcript increased in pancreatic cancer.
XX
KW   Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
KW   diagnosis; prognosis; treatment; ss.
XX
OS   Homo sapiens.
XX
PN   WO9853319-A2.
XX
PD   26-NOV-1998.
XX
PF   20-MAY-1998;   98WO-US010277.
XX
PR   21-MAY-1997;   97US-0047352P.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Vogelstein B,  Kinzler KW;
XX
DR   WPI; 1999-070161/06.
XX
PT   Use of isolated gene transcripts - useful for developing products for the
PT   diagnosis, prognosis and treatment of cancers, particularly colon and
PT   pancreatic cancer.
XX
PS   Claim 13; Page 67; 120pp; English.
XX
CC   AAX30947-31815 represent tag sequences of transcripts that are
CC   differentially expressed in colorectal cancer, in pancreatic cancer, or
CC   in both. The tag sequences can be used to identify genes by matching the
CC   tag to a gen data base member, or by using the tag sequences as probes to
CC   isolate unidentified genes from cDNA libraries. The tag sequences can
CC   also be used in a method for diagnosing colon or pancreatic cancer in a
CC   sample suspected of being neoplastic. The method comprises comparing the
CC   level of at least one transcript in a first sample of a tissue to a
```

```
CC   second sample, where the first sample is a colonic tissue suspected of
CC   being neoplastic and the second sample is a normal human colonic tissue.
CC   The transcript is identified by a tag selected from AAX30947-31815. The
CC   methods of the invention can be used in the diagnosis, prognosis and
CC   treatment of cancer
XX
SQ   Sequence 15 BP; 2 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        500 CCTGAGGGCACA 511
              ||||||||||||
Db         14 CCTGAGGGCACA 3


RESULT 270
AAI67292/c
ID   AAI67292 standard; DNA; 15 BP.
XX
AC   AAI67292;
XX
DT   11-FEB-2002  (first entry)
XX
DE   Human FKBP8 allele-specific oligonucleotide (ASO) probe.
XX
KW   FK506-binding protein 8; FKBP8; haplotyping; polymorphism; cancer; ss;
KW   immunosuppression; human; allele-specific oligonucleotide; ASO; probe.
XX
OS   Homo sapiens.
XX
PN   WO200172965-A2.
XX
PD   04-OCT-2001.
XX
PF   26-MAR-2001; 2001WO-US009718.
XX
PR   24-MAR-2000; 2000US-0192125P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Anastasio AE,  Bentivegna SC,  Choi JY,  Kliem SE,  Koshy B;
PI   Stephens JC;
XX
DR   WPI; 2001-626261/72.
XX
PT   New haplotypes of the FK506-binding protein 8 gene, useful for genotyping
PT   that gene in individual and to design new therapy for associated disease
PT   such as immunosuppression and cancer.
XX
PS   Claim 15; Page 13; 98pp; English.
XX
CC   The invention relates to haplotyping the FK506-binding protein 8 (38kD)
CC   (FKBP8) gene in an individual. The method involves determining the
CC   identity of the nucleotide pair at one or more polymorphic sites selected
CC   from P1 to P26 ( described in the specification). The invention is useful
CC   to improve the efficiency and reliability of several steps in the
CC   discovery and development of drugs for treating diseases associated with
CC   FKBP8 activity, for example immunosuppression and cancer. Sequences
CC   AAI67274-299 represent allele-specific oligonucleotide (ASO) probes for
CC   detecting FKBP8 gene polymorphisms
XX
SQ   Sequence 15 BP; 2 A; 5 C; 6 G; 1 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        457 GCCCCCCGGTGTGG 470
              || ||||:||||||
Db         15 GCACCCCRGTGTGG 2


RESULT 271
AAI67293/c
ID   AAI67293 standard; DNA; 15 BP.
XX
AC   AAI67293;
XX
DT   11-FEB-2002  (first entry)
XX
DE   Human FKBP8 allele-specific oligonucleotide (ASO) probe.
XX
KW   FK506-binding protein 8; FKBP8; haplotyping; polymorphism; cancer; ss;
KW   immunosuppression; human; allele-specific oligonucleotide; ASO; probe.
XX
OS   Homo sapiens.
XX
PN   WO200172965-A2.
XX
PD   04-OCT-2001.
XX
PF   26-MAR-2001; 2001WO-US009718.
XX
PR   24-MAR-2000; 2000US-0192125P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Anastasio AE,  Bentivegna SC,  Choi JY,  Kliem SE,  Koshy B;
PI   Stephens JC;
XX
DR   WPI; 2001-626261/72.
XX
PT   New haplotypes of the FK506-binding protein 8 gene, useful for genotyping
PT   that gene in individual and to design new therapy for associated disease
PT   such as immunosuppression and cancer.
XX
PS   Claim 15; Page 13; 98pp; English.
XX
CC   The invention relates to haplotyping the FK506-binding protein 8 (38kD)
CC   (FKBP8) gene in an individual. The method involves determining the
CC   identity of the nucleotide pair at one or more polymorphic sites selected
CC   from P1 to P26 ( described in the specification). The invention is useful
CC   to improve the efficiency and reliability of several steps in the
CC   discovery and development of drugs for treating diseases associated with
CC   FKBP8 activity, for example immunosuppression and cancer. Sequences
CC   AAI67274-299 represent allele-specific oligonucleotide (ASO) probes for
CC   detecting FKBP8 gene polymorphisms
XX
SQ   Sequence 15 BP; 2 A; 7 C; 4 G; 1 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        457 GCCCCCCGGTGTGG 470
              || |||:|||||||
Db         14 GCACCCYGGTGTGG 1


RESULT 272
AAF46723/c
ID   AAF46723 standard; DNA; 15 BP.
XX
AC   AAF46723;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #143.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
```

```
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 45; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 AGCAGAGTCAGC 21
               ||||||||||||
Db         14 AGCAGAGTCAGC 3


RESULT 273
AAF45517/c
ID   AAF45517 standard; DNA; 15 BP.
XX
AC   AAF45517;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #356.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 36; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        340 CCCGGACGAGCT 351
              ||||||||||||
Db         12 CCCGGACGAGCT 1


RESULT 274
AAF46724/c
ID   AAF46724 standard; DNA; 15 BP.
XX
AC   AAF46724;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #144.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
```

```
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 45; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 AGCAGAGTCAGC 21
               ||||||||||||
Db         13 AGCAGAGTCAGC 2


RESULT 275
AAF46722/c
ID   AAF46722 standard; DNA; 15 BP.
XX
AC   AAF46722;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #142.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 45; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 AGCAGAGTCAGC 21
               ||||||||||||
Db         15 AGCAGAGTCAGC 4


RESULT 276
AAF45480
ID   AAF45480 standard; DNA; 15 BP.
XX
AC   AAF45480;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #319.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
```

```
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 36; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 5 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        222 CCGCAGTGGCCG 233
              ||||||||||||
Db          2 CCGCAGTGGCCG 13


RESULT 277
AAF45515/c
ID   AAF45515 standard; DNA; 15 BP.
XX
AC   AAF45515;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #354.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 36; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        340 CCCGGACGAGCT 351
              ||||||||||||
Db         14 CCCGGACGAGCT 3


RESULT 278
AAF45478
ID   AAF45478 standard; DNA; 15 BP.
XX
AC   AAF45478;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #317.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
```

```
XX
PS   Example 6; Page 36; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 5 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        222 CCGCAGTGGCCG 233
              ||||||||||||
Db          4 CCGCAGTGGCCG 15


RESULT 279
AAF45795/c
ID   AAF45795 standard; DNA; 15 BP.
XX
AC   AAF45795;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #634.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 38; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 2 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        687 GCCTCCCCCGCC 698
              ||||||||||||
Db         15 GCCTCCCCCGCC 4


RESULT 280
AAF45169/c
ID   AAF45169 standard; DNA; 15 BP.
XX
AC   AAF45169;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #8.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 34; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
```

```
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 5 A; 1 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        484 TTCCTCCTCCCT 495
              ||||||||||||
Db         15 TTCCTCCTCCCT 4


RESULT 281
AAF45170/c
ID   AAF45170 standard; DNA; 15 BP.
XX
AC   AAF45170;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #9.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 34; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 5 A; 1 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        484 TTCCTCCTCCCT 495
              ||||||||||||
Db         14 TTCCTCCTCCCT 3


RESULT 282
AAF45481
ID   AAF45481 standard; DNA; 15 BP.
XX
AC   AAF45481;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #320.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 36; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
```

```
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 5 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        222 CCGCAGTGGCCG 233
              ||||||||||||
Db          1 CCGCAGTGGCCG 12


RESULT 283
AAF46725/c
ID   AAF46725 standard; DNA; 15 BP.
XX
AC   AAF46725;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #145.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 45; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 AGCAGAGTCAGC 21
              ||||||||||||
Db         12 AGCAGAGTCAGC 1


RESULT 284
AAF46287
ID   AAF46287 standard; DNA; 15 BP.
XX
AC   AAF46287;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1126.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 11 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        194 CCCCTGCCCCCC 205
              ||||||||||||
Db          4 CCCCTGCCCCCC 15


RESULT 285
AAF45171/c
ID   AAF45171 standard; DNA; 15 BP.
XX
AC   AAF45171;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #10.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 34; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 6 A; 0 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        484 TTCCTCCTCCCT 495
              ||||||||||||
Db         13 TTCCTCCTCCCT 2


RESULT 286
AAF45172/c
ID   AAF45172 standard; DNA; 15 BP.
XX
AC   AAF45172;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #11.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 34; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 7 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        484 TTCCTCCTCCCT 495
              ||||||||||||
Db         12 TTCCTCCTCCCT 1


RESULT 287
AAF45479
```

```
ID   AAF45479 standard; DNA; 15 BP.
XX
AC   AAF45479;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #318.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 36; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 5 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        222 CCGCAGTGGCCG 233
              ||||||||||||
Db          3 CCGCAGTGGCCG 14


RESULT 288
AAF45799/c
ID   AAF45799 standard; DNA; 15 BP.
XX
AC   AAF45799;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #638.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 38; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 2 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        686 TGCCTCCCCCGC 697
              ||||||||||||
Db         12 TGCCTCCCCCGC 1


RESULT 289
AAF45514/c
ID   AAF45514 standard; DNA; 15 BP.
XX
AC   AAF45514;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #353.
XX
```

```
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 36; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 5 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        340 CCCGGACGAGCT 351
              ||||||||||||
Db         15 CCCGGACGAGCT 4


RESULT 290
AAF45516/c
ID   AAF45516 standard; DNA; 15 BP.
XX
AC   AAF45516;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #355.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 36; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        340 CCCGGACGAGCT 351
              ||||||||||||
Db         13 CCCGGACGAGCT 2


RESULT 291
ABK95953
ID   ABK95953 standard; DNA; 15 BP.
XX
AC   ABK95953;
XX
DT   24-SEP-2002  (first entry)
XX
DE   Human LIPE gene polymorphism detection ASO probe #15.
XX
KW   Human; lipase; hormone sensitive; LIPE; isogene; obesity; probe; ss;
KW   male sterility; polymorphism; allele-specific oligonucleotide; ASO.
XX
OS   Homo sapiens.
XX
PN   WO200240502-A2.
XX
PD   23-MAY-2002.
```

XX
PF 16-NOV-2001; 2001WO-US043518.
XX
PR 16-NOV-2000; 2000US-0249302P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Anastasio AE, Bentivegna SC, Chew A, Koshy B, Rounds E;
XX
DR WPI; 2002-519369/55.
XX
PT Novel genetic variants of Lipase, Hormone-Sensitive isogenes, useful for
PT improving efficiency and reliability in drug development for treating
PT diseases associated with LIPE activity, e.g. obesity and male sterility.
XX
PS Claim 15; Page 14; 142pp; English.
XX
CC The present invention relates to a new polynucleotide comprising a
CC nucleotide sequence which comprises lipase, hormone sensitive (LIPE)
CC isogenes. The invention is useful in screening for drugs targeting LIPE
CC isogenes that are useful for treating obesity and male sterility. The
CC methods of the invention are useful for improving the efficiency and
CC reliability of several steps in the discovery and development of drugs
CC for treating diseases associated with LIPE activity. The polynucleotide
CC is useful in studying the expression and function of LIPE, and in
CC expressing LIPE protein for use in screening for candidate drugs to treat
CC diseases related to LIPE activity. It is also useful in studying the
CC effect of the variation on the biological activity of LIPE as well as on
CC the binding affinity of candidate drugs targeting LIPE for the treatment
CC of obesity and male sterility. The invention is useful for studying the
CC expression of LIPE isogenes in vivo, for in vivo screening and testing of
CC drugs targeted against LIPE protein, and for testing the efficacy of
CC therapeutic agents and compounds for treating obesity and male sterility
CC in a biological system. The present nucleic acid sequence represents one
CC of a collection (ABK95939-ABK95967) of allele-specific oligonucleotide
CC (ASO) probes that were used in the invention to detect polymorphisms in
CC the human LIPE gene
XX
SQ Sequence 15 BP; 0 A; 8 C; 4 G; 2 T; 0 U; 1 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.5e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 227 GTGGCCGCGCCCGC 240
||||||:||||| |
Db 2 GTGGCCRCGCCCCC 15

RESULT 292
ABK95954
ID ABK95954 standard; DNA; 15 BP.
XX
AC ABK95954;
XX
DT 24-SEP-2002 (first entry)
XX
DE Human LIPE gene polymorphism detection ASO probe #16.
XX
KW Human; lipase; hormone sensitive; LIPE; isogene; obesity; probe; ss;
KW male sterility; polymorphism; allele-specific oligonucleotide; ASO.
XX
OS Homo sapiens.
XX
PN WO200240502-A2.
XX
PD 23-MAY-2002.
XX
PF 16-NOV-2001; 2001WO-US043518.
XX
PR 16-NOV-2000; 2000US-0249302P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Anastasio AE, Bentivegna SC, Chew A, Koshy B, Rounds E;
XX
DR WPI; 2002-519369/55.
XX
PT Novel genetic variants of Lipase, Hormone-Sensitive isogenes, useful for
PT improving efficiency and reliability in drug development for treating
PT diseases associated with LIPE activity, e.g. obesity and male sterility.
XX
PS Claim 15; Page 14; 142pp; English.
XX
CC The present invention relates to a new polynucleotide comprising a
CC nucleotide sequence which comprises lipase, hormone sensitive (LIPE)
CC isogenes. The invention is useful in screening for drugs targeting LIPE
CC isogenes that are useful for treating obesity and male sterility. The
CC methods of the invention are useful for improving the efficiency and
CC reliability of several steps in the discovery and development of drugs
CC for treating diseases associated with LIPE activity. The polynucleotide
CC is useful in studying the expression and function of LIPE, and in
CC expressing LIPE protein for use in screening for candidate drugs to treat
CC diseases related to LIPE activity. It is also useful in studying the
CC effect of the variation on the biological activity of LIPE as well as on
CC the binding affinity of candidate drugs targeting LIPE for the treatment
CC of obesity and male sterility. The invention is useful for studying the
CC expression of LIPE isogenes in vivo, for in vivo screening and testing of
CC drugs targeted against LIPE protein, and for testing the efficacy of
CC therapeutic agents and compounds for treating obesity and male sterility
CC in a biological system. The present nucleic acid sequence represents one
CC of a collection (ABK95939-ABK95967) of allele-specific oligonucleotide
CC (ASO) probes that were used in the invention to detect polymorphisms in
CC the human LIPE gene
XX
SQ Sequence 15 BP; 2 A; 10 C; 0 G; 2 T; 0 U; 1 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.5e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 689 CTCCCCCGCCACCT 702
||||||: |||||
Db 1 CTCCCCCSACACCT 14

RESULT 293
AAL44242
ID AAL44242 standard; DNA; 15 BP.
XX
AC AAL44242;
XX
DT 08-NOV-2002 (first entry)
XX
DE Human interleukin 12A (IL-12A) allele specific oligonucleotide primer 10.
XX
KW Human; primer; interleukin 12A; IL-12A; drug screening; AIDS; malaria;
KW tuberculosis; cancer; haplotyping; genotyping; transgenic animal; ss.
XX
OS Homo sapiens.
XX
PN WO200229115-A1.
XX
PD 11-APR-2002.
XX
PF 05-OCT-2001; 2001WO-US031656.
XX
PR 06-OCT-2000; 2000US-0238693P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Armstrong B, Cappola G, Choi JY, Gilson CR, Kliem SE, Koshy B;
PI Parks KE;
XX
DR WPI; 2002-315865/35.
XX

```
PT   New interleukin 12A (IL-12A) gene polymorphic variants, for studying the
PT   expression and function of IL-12A and screening candidate drugs for
PT   treating AIDS and cancer.
XX
PS   Claim 15; Page 13; 72pp; English.
XX
CC   The invention comprises the amino acid and coding sequence of the human
CC   interleukin 12A (IL-12A) protein. Specifically the invention relates to
CC   the identification of polymorphisms within the human (IL-12A) gene
CC   sequence. The polymorphisms identified in the human IL-12A gene sequence
CC   are useful in studying the expression and function of IL-12A, and in
CC   screening drugs for the treatment of disorders such as AIDS, malaria,
CC   tuberculosis and cancer. The IL-12A polymorphisms may be used to
CC   haplotype and genotype the IL-12A gene of an individual. The IL-12A DNA
CC   sequences of the invention can be used to create transgenic animals for
CC   studying expression of the IL-12A isogenes in vivo. The present DNA
CC   sequence represents a human interleukin 12A (IL-12A) gene allele specific
CC   oligonucleotide primer
XX
SQ   Sequence 15 BP; 3 A; 5 C; 4 G; 2 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        257 AGCCGGCAACTCAG 270
              |||| |||||||:|
Db          2 AGCCTGCAACTCRG 15


RESULT 294
ABN80605
ID   ABN80605 standard; DNA; 15 BP.
XX
AC   ABN80605;
XX
DT   19-JUL-2002  (first entry)
XX
DE   Human P450(cytochrome) oxidoreductase allele specific PCR primer #45.
XX
KW   Human; P450(cytochrome) oxidoreductase; POR; cancer; haplotype; SNP;
KW   single nucleotide polymorphism; flavoprotein; enzyme; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200226768-A2.
XX
PD   04-APR-2002.
XX
PF   01-OCT-2001; 2001WO-US030877.
XX
PR   29-SEP-2000; 2000US-0236449P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Kazemi A,  Kliem SE,  Lanz EM,  Messer C,  Tanguay DA;
XX
DR   WPI; 2002-394236/42.
XX
PT   New genetic variants comprising haplotypes of the P450 (cytochrome)
PT   oxidoreductase (POR) isogene, useful in improving the efficiency of drug
PT   screening protocols for compounds targeting POR.
XX
PS   Claim 14; Page 15; 141pp; English.
XX
CC   The present invention provides the protein, gene and cDNA sequences of
CC   human P450(cytochrome) oxidoreductase POR, and single nucleotide
CC   polymorphisms (SNPs) identified therein. The sequences can be used to
CC   haplotype the POR gene of an individual, and to establish whether POR is
CC   a suitable target for drugs to treat cancer and disorders associated with
CC   impaired protein synthesis in cells. The present sequence is an allele
CC   specific primer for the coding sequences of the invention
XX
SQ   Sequence 15 BP; 0 A; 6 C; 6 G; 2 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        669 GCTGCCGCCACTGG 682
              |||||||||| ||:|
Db          2 GCTGCCGCCGCTSG 15


RESULT 295
AAS19927
ID   AAS19927 standard; DNA; 15 BP.
XX
AC   AAS19927;
XX
DT   26-MAR-2002  (first entry)
XX
DE   ASO primer #7 to detect human DNAL4 gene polymorphisms.
XX
KW   Human; single nucleotide polymorphism; SNP; DNAL4; chromosome 22q13.1;
KW   dynein axonemal light polypeptide chain 4; haplotyping; genotyping;
KW   neuroprotective; neurological disorder; allele-specific oligonucleotide;
KW   ASO; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200179235-A2.
XX
PD   25-OCT-2001.
XX
PF   16-APR-2001; 2001WO-US012304.
XX
PR   17-APR-2000; 2000US-0197460P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Bentivegna SC,  Chew A,  Choi JY,  Koshy B;
XX
DR   WPI; 2002-075065/10.
XX
PT   Genotyping human dynein, axonemal light polypeptide chain 4 gene of
PT   individual, useful for determining haplotype of individual, comprises
PT   determining identity of nucleotide pair at specific polymorphic sites for
PT   two copies of gene.
XX
PS   Claim 16; Page 13; 79pp; English.
XX
CC   The present invention relates to novel single nucleotide polymorphisms
CC   (SNPs) in the human dynein, axonemal light polypeptide chain 4 (DNAL4)
CC   gene located on chromosome 22q13.1, and methods for haplotyping and/or
CC   genotyping the DNAL4 gene. The methods of the invention make use of
CC   allele-specific oligonucleotides (ASOs) as probes and primers and/or
CC   primer-extension oligonucleotides for detecting the DNAL4 gene
CC   polymorphisms. The polynucleotides and screened compounds are useful for
CC   the treatment of diseases associated with DNAL4 activity, such as
CC   neurological disorders. AAS19921-AAS19948 represent ASO primers for
CC   detecting human DNAL4 gene polymorphisms
XX
SQ   Sequence 15 BP; 3 A; 2 C; 1 G; 8 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        713 TTGATACATTTATC 726
              ||||||| |||||:
Db          1 TTGATACTTTTATY 14


RESULT 296
ABL91848
```

```
ID   ABL91848 standard; DNA; 15 BP.
XX
AC   ABL91848;
XX
DT   11-JUL-2002  (first entry)
XX
DE   Human LIPG gene allele specific oligonucleotide primer 27.
XX
KW   Human; ss; allele specific oligonucleotide; primer;
KW   single nucleotide polymorphism; SNP; lipase endothelial isogene; LIPG;
KW   drug screening; atherosclerosis; cardiovascular disorder;
KW   LIPG haplotyping; LIPG genotyping.
XX
OS   Homo sapiens.
XX
PN   WO200216397-A2.
XX
PD   28-FEB-2002.
XX
PF   17-AUG-2001; 2001WO-US026639.
XX
PR   25-AUG-2000; 2000US-0227825P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Duda A,  Kazemi A,  Kliem SE,  Messer C;
XX
DR   WPI; 2002-292055/33.
XX
PT   Novel genetic variants of Lipase, Endothelial isogenes, useful for
PT   improving efficiency and reliability in drug development for treating
PT   diseases associated with LIPG activity, e.g. atherosclerosis.
XX
PS   Claim 16; Page 14; 134pp; English.
XX
CC   The invention comprises the DNA and amino acid sequence of the human
CC   lipase, endothelial (LIPG) isogene. Specifically, the invention relates
CC   to the discovery of 20 novel polymorphic sites within the LIPG gene. The
CC   LIPG coding sequence and protein are useful for screening drugs that can
CC   be used to treat atherosclerosis and other cardiovascular disorders. The
CC   LIPG coding sequence can also be used to haplotype and genotype the LIPG
CC   gene of an individual. The DNA sequences ABL91822 - ABL91861 represent
CC   LIPG gene allele specific oligonucleotide primers
XX
SQ   Sequence 15 BP; 4 A; 3 C; 6 G; 1 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         23 AGCATGACCGAGCG 36
              ||||||| |||||:
Db          1 AGCATGAGCGAGCS 14


RESULT 297
ABK64023/c
ID   ABK64023 standard; DNA; 15 BP.
XX
AC   ABK64023;
XX
DT   18-JUN-2002  (first entry)
XX
DE   Human BF gene allele-specific oligonucleotide sequencing primer #30.
XX
KW   Human; B-factor; properdin; BF; primer; ss; gene therapy; drug screening;
KW   antidiabetic; dermatological; diabetes; immunosuppressive;
KW   antiinflammatory; systemic lupus erythematosus.
XX
OS   Homo sapiens.
XX
PN   WO200218414-A2.
XX
PD   07-MAR-2002.
XX
PF   29-AUG-2001; 2001WO-US027098.
XX
PR   29-AUG-2000; 2000US-0228940P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Anastasio AE,  Finkel K,  Kazemi A,  Koshy B;
XX
DR   WPI; 2002-304244/34.
XX
PT   New genetic variants having polymorphisms in the B-Factor, Properdin (BF)
PT   gene, useful for studying the function of BF, and for treating disorders
PT   affected by expression or function of the BF isogene.
XX
PS   Claim 17; Page 16; 151pp; English.
XX
CC   The invention relates to single nucleotide polymorphisms in the gene
CC   encoding the human B-factor properdin protein (BF). A method for
CC   haplotyping the BF gene in an individual comprises identifying the
CC   nucleotide at one or more polymorphic sites and determining whether one
CC   of the copies of the gene is defined by one of the BF haplotypes given in
CC   the specification or whether both copies are defined by a haplotype pair.
CC   This method is useful in genotyping, whereby all possible haplotype pairs
CC   can be assigned to specific genotypes. An association between a trait and
CC   a haplotype or haplotype pair of the BF gene can be identified by
CC   comparing the frequency of the haplotype or haplotype pair in a
CC   population exhibiting the trait with the frequency of the haplotype or
CC   haplotype pair in a reference population, where a higher haplotype
CC   frequency in the trait population indicates the trait is associated with
CC   the haplotype or haplotype pair. BF and its corresponding DNA are used
CC   for studying the expression and function of BF, for use in screening for
CC   candidate drugs to treat diseases related to BF activity, such as
CC   diabetes and systemic lupus erythematosus. Sequences ABK63994-ABK64049
CC   represent allele-specific sequencing primers used to detect human BF gene
CC   polymorphisms
XX
SQ   Sequence 15 BP; 3 A; 3 C; 8 G; 0 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        489 CCTCCCTGTCCC 500
              ||||||||||||
Db         12 CCTCCCTGTCCC 1


RESULT 298
ABK51277/c
ID   ABK51277 standard; DNA; 15 BP.
XX
AC   ABK51277;
XX
DT   13-AUG-2002  (first entry)
XX
DE   Human Caspase-2, CASP2, allele specific probe #1.
XX
KW   Human; ss; caspase-2; CASP2; apoptosis; cysteine protease;
KW   probe programmed cell death; chromosome 7q34-q35; tumour suppressor; SNP;
KW   single nucleotide polymorphism; haplotype; genotype; transgenic.
XX
OS   Homo sapiens.
XX
PN   WO200226767-A2.
XX
PD   04-APR-2002.
XX
PF   27-SEP-2001; 2001WO-US030412.
XX
PR   27-SEP-2000; 2000US-0235801P.
XX
```

```
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Bentivegna SC,  Choi JY,  Russo DP;
XX
DR   WPI; 2002-416472/44.
XX
PT   New isolated human caspase 2, apoptosis-related cysteine protease
PT   polynucleotide, useful for therapeutic purposes, for studying expression
PT   and function of the polynucleotide and for expressing the protease.
XX
PS   Claim 14; Page 13; 64pp; English.
XX
CC   The invention relates to an isolated human caspase 2, CASP2, (an
CC   apoptosis-related cysteine protease which is neural precursor cell
CC   expressed, developmentally down-regulated 2 and is a possible tumour
CC   suppressor associated with programmed cell death) (CASP2) polynucleotide
CC   comprising a sequence which is a polymorphic variant for a reference
CC   sequence for the CASP2 gene or its fragment, or a polymorphic variant of
CC   a reference sequence for a CASP2 cDNA or its fragment. Also included are
CC   methods of genotyping and haplotyping the CASP2 gene of an individual,
CC   predicting a haplotype pair for the CASP2 gene of a female individual,
CC   identifying an association between a trait and at least one haplotype or
CC   haplotype pair of the CASP2 gene, an isolated oligonucleotide for
CC   detecting a polymorphism in CASP2 gene, a kit for haplotyping/genotyping
CC   the CASP2 gene of an individual, which comprises a set of
CC   oligonucleotides designed to haplotype or genotype each of the four
CC   polymorphic sites, a recombinant non-human organism transformed or
CC   transfected with a CASP2 nucleic acid, where the organism expresses a
CC   CASP2 protein encoded by the first nucleotide sequence or by the
CC   polymorphic variant sequence, a computer system for storing and analysing
CC   polymorphism data for the CASP2 gene and a genome anthology for the CASP2
CC   gene which comprises two or more CASP2 isogenes selected from isogenes 1-
CC   5 given in the specification. The CASP2 nucleic acid is useful in
CC   studying the expression and function of CASP2, and in expressing CASP2
CC   protein for use in screening for candidate drugs to treat diseases
CC   related to CASP2 activity and is useful for therapeutic purposes. The non
CC   -human transgenic organism is useful for studying expression of the CASP2
CC   isogenes in vivo, for in vivo screening and testing of drugs targeted
CC   against CASP2 protein, and for testing the efficacy of therapeutic agents
CC   and compounds for diseases involving apoptosis, in a biological system.
CC   The gene for CASP2 is located on chromosome 7q34-q35. The present
CC   sequence is an allele specific probe for detection of CASP2 polymorphisms
XX
SQ   Sequence 15 BP; 3 A; 6 C; 5 G; 0 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        118 GGCCTTCGGGCTGC 131
              ||||||:|| ||||
Db         14 GGCCTTYGGCCTGC 1


RESULT 299
ABK32612/c
ID   ABK32612 standard; DNA; 15 BP.
XX
AC   ABK32612;
XX
DT   23-APR-2002  (first entry)
XX
DE   Human pancreatic cancer SAGE tag #164.
XX
KW   Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
KW   serial analysis of gene expression; diagnostic; prognostic; probe;
KW   cancer marker; ss.
XX
OS   Homo sapiens.
XX
PN   US6333152-B1.
XX
PD   25-DEC-2001.
XX
PF   20-MAY-1998;   98US-00081646.
XX
PR   20-MAY-1998;   98US-00081646.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Vogelstein B,  Kinzler KW,  Zhang L,  Zhou W;
XX
DR   WPI; 2002-153821/20.
XX
PT   New human nucleic acid containing specific SAGE tags, useful as
PT   diagnostic markers for cancer, also derived probes.
XX
PS   Disclosure; Col 81; 161pp; English.
XX
CC   The invention relates to an isolated, purified human nucleic acid (I)
CC   that has the same sequence as a mRNA found in humans and is a SAGE
CC   (serial analysis of gene expression) tag comprising a single stranded
CC   probe containing at least 10 consecutive nucleotides. SAGE tags, are
CC   diagnostic and prognostic markers of cancer, especially of the colon and
CC   pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
CC   SAGE tags of the invention
XX
SQ   Sequence 15 BP; 2 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        500 CCTGAGGGCACA 511
              ||||||||||||
Db         14 CCTGAGGGCACA 3


RESULT 300
ABK32611/c
ID   ABK32611 standard; DNA; 15 BP.
XX
AC   ABK32611;
XX
DT   23-APR-2002  (first entry)
XX
DE   Human pancreatic cancer SAGE tag #163.
XX
KW   Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
KW   serial analysis of gene expression; diagnostic; prognostic; probe;
KW   cancer marker; ss.
XX
OS   Homo sapiens.
XX
PN   US6333152-B1.
XX
PD   25-DEC-2001.
XX
PF   20-MAY-1998;   98US-00081646.
XX
PR   20-MAY-1998;   98US-00081646.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Vogelstein B,  Kinzler KW,  Zhang L,  Zhou W;
XX
DR   WPI; 2002-153821/20.
XX
PT   New human nucleic acid containing specific SAGE tags, useful as
PT   diagnostic markers for cancer, also derived probes.
XX
PS   Disclosure; Col 81; 161pp; English.
XX
CC   The invention relates to an isolated, purified human nucleic acid (I)
CC   that has the same sequence as a mRNA found in humans and is a SAGE
CC   (serial analysis of gene expression) tag comprising a single stranded
```

```
CC   probe containing at least 10 consecutive nucleotides. SAGE tags, are
CC   diagnostic and prognostic markers of cancer, especially of the colon and
CC   pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
CC   SAGE tags of the invention
XX
SQ   Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        500 CCTGAGGGCACA 511
              ||||||||||||
Db         14 CCTGAGGGCACA 3


RESULT 301
ABL36332/c
ID   ABL36332 standard; DNA; 15 BP.
XX
AC   ABL36332;
XX
DT   22-APR-2002  (first entry)
XX
DE   Human lysosomal acid phosphatase 2 (ACP2) allele-specific PCR primer 12.
XX
KW   Human; ss; lysosomal acid phosphatase 2; ACP2; gene; chromosome 11;
KW   lysosome-specific enzyme; orthophosphoric monoester hydrolysis;
KW   Hodgkin's disease; HD; acid phosphatase deficiency;
KW   novel polymorphic site; ACP2 haplotype; ACP2 genotype; polymorphism;
KW   transgenic animal; primer; probe; primer-extension oligonucleotide; SNP;
KW   single nucleotide polymorphism.
XX
OS   Homo sapiens.
XX
PN   WO200194362-A2.
XX
PD   13-DEC-2001.
XX
PF   07-JUN-2001; 2001WO-US018457.
XX
PR   07-JUN-2000; 2000US-0210047P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Kliem SE,  Messer C,  Tanguay DA;
XX
DR   WPI; 2002-154563/20.
XX
PT   Novel genetic variants of acid phosphatase 2, lysosomal polypeptide gene
PT   useful in studying expression and function of the protein, and for
PT   screening drugs to treat diseases e.g. Hodgkin's disease.
XX
PS   Claim 17; Page 14; 109pp; English.
XX
CC   The invention comprises the human lysosomal acid phosphatase 2 (ACP2)
CC   nucleic acid and protein sequences. Specifically, the invention relates
CC   to the discovery of 22 novel polymorphic sites within the APC2 gene. The
CC   invention also comprises methods for haplotyping and genotyping the ACP2
CC   gene in an individual. The ACP2 gene (located on chromosome 11) encodes a
CC   lysosomal-specific enzyme that catalyses the hydrolysis of
CC   orthophosphoric monoesters to alcohol and phosphate. The ACP2 gene and
CC   protein are pharmaceutically important in the treatment of Hodgkin's
CC   disease (HD) and acid phosphatase deficiency. The novel ACP2 gene
CC   polymorphisms of the invention are useful in haplotyping the ACP2 gene.
CC   ACP2 haplotyping is useful in validating ACP2 as a target (and designing
CC   drugs) for treating an ACP2-related disease or condition (e.g. Hodgkin's
CC   disease and acid phosphatase deficiency). The ACP2 gene polymorphisms are
CC   useful for ACP2 genotyping, which can also be used to develop diagnostic
CC   tests and therapeutic treatments. The ACP2 protein and nucleic acids of
CC   the invention are useful in the production of a transgenic animal which
CC   expresses ACP2 protein. The ACP2 nucleic acids of the invention are
CC   useful in the production of allele-specific oligonucleotides designed to
CC   genotype each of the ACP2 polymorphisms. Nucleic acids ABL36299-ABL36320
CC   represent claimed ACP2 allele-specific probes. Nucleic acids ABL36321-
CC   ABL36364 represent claimed ACP2 allele-specific PCR primers. Nucleic
CC   acids ABL36365-ABL36408 represent claimed ACP2 primer-extension
CC   oligonucleotides
XX
SQ   Sequence 15 BP; 2 A; 3 C; 5 G; 4 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        383 ATCACCGGCAAG 394
              ||||||||||||
Db         12 ATCACCGGCAAG 1


RESULT 302
AAS95898
ID   AAS95898 standard; DNA; 15 BP.
XX
AC   AAS95898;
XX
DT   26-FEB-2002  (first entry)
XX
DE   Human CALM1 gene allele-specific oligonucleotide #7.
XX
KW   Calmodulin 1; CALM1; human; single nucleotide polymorphism; SNP;
KW   haplotyping; SCYA3; Alzheimer's disease; drug screening;
KW   calcium-dependent signal transduction; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200179218-A2.
XX
PD   25-OCT-2001.
XX
PF   09-APR-2001; 2001WO-US011509.
XX
PR   12-APR-2000; 2000US-0196340P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Bentivegna SC,  Chew A,  Choi JY,  Koshy B,  Stephens JC;
XX
DR   WPI; 2002-049190/06.
XX
PT   New calmodulin-1 (CALM-1) isogene polymorphic variants, useful in
PT   expressing CALM1 protein for use in screening for candidate drugs to
PT   treat diseases related to CALM1 activity such as Alzheimer's disease.
XX
PS   Claim 15; Page 13; 82pp; English.
XX
CC   The invention relates to an isolated polynucleotide comprising a sequence
CC   selected from a polymorphic variant of calmodulin 1 (CALM1). The
CC   polymorphic variant comprises an CALM1 isogene defined by a haplotype
CC   selected from haplotypes 1-21 given in the specification. The
CC   polymorphisms are useful for studying the biological function of CALM1 as
CC   well as in identifying drugs targeting this protein for the treatment of
CC   a disorder related to its abnormal expression or function. The
CC   polymorphic variants may also be used in screening for compounds
CC   targeting CALM1 to treat a specific condition or disease predicted to be
CC   associated with CALM1 activity. Establishing CALM1 haplotype or haplotype
CC   pair of an individual is useful for improving the efficiency and
CC   reliability of several steps in the discovery and development of drugs
CC   for treating diseases associated with SCYA3 activity, e.g. Alzheimer's
CC   disease and diseases involving defects in calcium-dependent signal
CC   transduction. Haplotyping the CALM1 gene in an individual is also useful
CC   in the design of clinical trials of candidate drugs for treating a
CC   specific condition or disease predicted to be associated with CALM1
CC   activity. AAS95892-AAS96018 represent human CALM1 allele- specific
CC   oligonucleotides and PCR primers of the invention
XX
```

```
SQ   Sequence 15 BP; 1 A; 7 C; 5 G; 1 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        670 CTGCCGCCACTGGC 683
              | |||||:||||||
Db          1 CCGCCGCSACTGGC 14


RESULT 303
ADG65423
ID   ADG65423 standard; DNA; 15 BP.
XX
AC   ADG65423;
XX
DT   11-MAR-2004  (first entry)
XX
DE   UCP2 allele specific oligonucleotide probe seq id 19.
XX
KW   anorectic; antidiabetic; immunomodulator; gene therapy; haplotyping;
KW   uncoupling protein 2; mitochondrial; proton carrier; UCP2;
KW   polymorphic site; haplotype; haplotype pair; obesity; diabetes;
KW   immunological disorder; body mass defect; thermoregulation defect; human;
KW   ASO; allele specific oligonucleotide; probe; ss.
XX
OS   Homo sapiens.
XX
PN   US2003207284-A1.
XX
PD   06-NOV-2003.
XX
PF   16-JUL-2002; 2002US-00197019.
XX
PR   25-JAN-2001; 2001WO-US002485.
XX
PA   (CHEW/) CHEW A.
PA   (DENT/) DENTON R R.
PA   (GILS/) GILSON C R.
PA   (NAND/) NANDABALAN K.
PA   (PARK/) PARKS K E.
XX
PI   Chew A,  Denton RR,  Gilson CR,  Nandabalan K,  Parks KE;
XX
DR   WPI; 2004-051505/05.
XX
PT   Haplotyping Uncoupling Protein 2 gene of an individual comprises
PT   identifying the phased sequence of nucleotides at polymorphic sites of
PT   the gene and assigning a haplotype or haplotype pair consistent with the
PT   phased sequence.
XX
PS   Disclosure; SEQ ID NO 19; 64pp; English.
XX
CC   The invention describes haplotyping the uncoupling protein 2
CC   (mitochondrial, proton carrier) (UCP2) gene of an individual comprising
CC   identifying the phased sequence of nucleotides at polymorphic sites (PS)1
CC   -23 for at least one copy of the individual's UCP2 gene and assigning to
CC   the individual a UCP2 haplotype or haplotype pair that is consistent with
CC   the phased sequence. The composition and methods are useful in
CC   haplotyping and/or genotyping the UCP2 gene in an individual to e.g.
CC   screen for drugs targeting the UCP2 protein to treat a condition or
CC   disease predicted to be associated with UCP2 activity. The disease or
CC   condition may include obesity, diabetes, immunological disorders and
CC   other diseases associated with defects in body mass and thermoregulation.
CC   This sequence represents an allele specific oligonucleotide probe used
CC   for detecting human uncoupling protein 2 (UCP2) gene polymorphisms.
XX
SQ   Sequence 15 BP; 1 A; 7 C; 1 G; 5 T; 0 U; 1 Other;

  Query Match             1.6%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        483 TTTCCTCCTCCCTG 496
              |||||||:|||| |
Db          1 TTTCCTCSTCCCCG 14


Search completed: October 18, 2005, 09:43:13
Job time : 4 secs
```

OM nucleic - nucleic search, using sw model

Run on: October 18, 2005, 09:44:28 ; Search time 2 Seconds
(without alignments)
3.420 Million cell updates/sec

Title: US-10-605-498-91-COPY
Perfect score: 764
Sequence: 1 ggcacgaggagcagagtcag.....aagttcaaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 222 seqs, 4477 residues

Total number of hits satisfying chosen parameters: 444

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 224 summaries

Published - Applications - NA

Database : pubdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	23.4	3.1	25	1	US-10-719-900-265359	Sequence 265359,
c	2	23.4	3.1	25	1	US-10-719-900-475563	Sequence 475563,
	3	23.4	3.1	25	1	US-10-719-900-618137	Sequence 618137,
c	4	23.4	3.1	25	1	US-10-719-900-657749	Sequence 657749,
c	5	23.4	3.1	25	1	US-10-719-900-858223	Sequence 858223,
c	6	23	3.0	23	1	US-10-840-038-4	Sequence 4, Appli
c	7	22.4	2.9	25	1	US-10-719-900-152005	Sequence 152005,
	8	22.4	2.9	25	1	US-10-719-900-653170	Sequence 653170,
	9	22.4	2.9	25	1	US-10-719-900-653171	Sequence 653171,
	10	22.4	2.9	25	1	US-10-719-900-855205	Sequence 855205,
	11	22.4	2.9	25	1	US-10-719-900-855206	Sequence 855206,
	12	22	2.9	22	1	US-10-840-038-5	Sequence 5, Appli
c	13	21.8	2.9	25	1	US-10-719-900-51105	Sequence 51105, A
	14	21.8	2.9	25	1	US-10-719-900-248862	Sequence 248862,
	15	21.8	2.9	25	1	US-10-719-900-265360	Sequence 265360,
	16	21.8	2.9	25	1	US-10-719-900-376560	Sequence 376560,
	17	21.8	2.9	25	1	US-10-719-900-415441	Sequence 415441,
c	18	21.8	2.9	25	1	US-10-719-900-472172	Sequence 472172,
c	19	21.8	2.9	25	1	US-10-719-900-475562	Sequence 475562,
	20	21.8	2.9	25	1	US-10-719-900-592386	Sequence 592386,
	21	21.8	2.9	25	1	US-10-719-900-618136	Sequence 618136,
c	22	21.8	2.9	25	1	US-10-719-900-657748	Sequence 657748,
	23	21.8	2.9	25	1	US-10-719-900-830334	Sequence 830334,
c	24	21.8	2.9	25	1	US-10-719-900-858224	Sequence 858224,
	25	21.8	2.9	25	1	US-10-719-956-435353	Sequence 435353,
	26	21.4	2.8	23	1	US-09-911-904-63	Sequence 63, Appl
c	27	21	2.7	21	1	US-10-605-498-1	Sequence 1, Appli
c	28	21	2.7	21	1	US-10-605-498-2	Sequence 2, Appli
c	29	21	2.7	21	1	US-10-605-498-3	Sequence 3, Appli
c	30	21	2.7	21	1	US-10-605-498-4	Sequence 4, Appli
c	31	21	2.7	21	1	US-10-605-498-5	Sequence 5, Appli
c	32	21	2.7	21	1	US-10-605-498-6	Sequence 6, Appli
c	33	21	2.7	21	1	US-10-605-498-7	Sequence 7, Appli
c	34	21	2.7	21	1	US-10-605-498-8	Sequence 8, Appli
c	35	21	2.7	21	1	US-10-605-498-9	Sequence 9, Appli
c	36	21	2.7	21	1	US-10-605-498-10	Sequence 10, Appl
c	37	21	2.7	21	1	US-10-605-498-11	Sequence 11, Appl
c	38	21	2.7	21	1	US-10-605-498-12	Sequence 12, Appl
c	39	21	2.7	21	1	US-10-605-498-13	Sequence 13, Appl
c	40	21	2.7	21	1	US-10-605-498-14	Sequence 14, Appl
c	41	21	2.7	21	1	US-10-605-498-15	Sequence 15, Appl
c	42	21	2.7	21	1	US-10-605-498-16	Sequence 16, Appl
c	43	21	2.7	21	1	US-10-605-498-17	Sequence 17, Appl
c	44	21	2.7	21	1	US-10-605-498-18	Sequence 18, Appl
c	45	21	2.7	21	1	US-10-605-498-19	Sequence 19, Appl
c	46	21	2.7	21	1	US-10-605-498-20	Sequence 20, Appl
c	47	21	2.7	21	1	US-10-605-498-21	Sequence 21, Appl
c	48	21	2.7	21	1	US-10-605-498-22	Sequence 22, Appl
c	49	21	2.7	21	1	US-10-605-498-23	Sequence 23, Appl
c	50	21	2.7	21	1	US-10-605-498-24	Sequence 24, Appl
c	51	21	2.7	21	1	US-10-605-498-25	Sequence 25, Appl
c	52	21	2.7	21	1	US-10-605-498-26	Sequence 26, Appl
c	53	21	2.7	21	1	US-10-605-498-27	Sequence 27, Appl
c	54	21	2.7	21	1	US-10-605-498-28	Sequence 28, Appl
c	55	21	2.7	21	1	US-10-605-498-29	Sequence 29, Appl
c	56	21	2.7	21	1	US-10-605-498-30	Sequence 30, Appl
c	57	21	2.7	21	1	US-10-605-498-31	Sequence 31, Appl
c	58	21	2.7	21	1	US-10-605-498-32	Sequence 32, Appl
c	59	21	2.7	21	1	US-10-605-498-33	Sequence 33, Appl
c	60	21	2.7	21	1	US-10-605-498-34	Sequence 34, Appl
c	61	21	2.7	21	1	US-10-605-498-35	Sequence 35, Appl
c	62	21	2.7	21	1	US-10-605-498-36	Sequence 36, Appl
c	63	21	2.7	21	1	US-10-605-498-37	Sequence 37, Appl
c	64	21	2.7	21	1	US-10-605-498-38	Sequence 38, Appl
c	65	21	2.7	21	1	US-10-605-498-39	Sequence 39, Appl
c	66	21	2.7	21	1	US-10-605-498-40	Sequence 40, Appl
c	67	21	2.7	21	1	US-10-605-498-41	Sequence 41, Appl
c	68	21	2.7	21	1	US-10-605-498-42	Sequence 42, Appl
c	69	21	2.7	21	1	US-10-605-498-43	Sequence 43, Appl
c	70	21	2.7	21	1	US-10-605-498-44	Sequence 44, Appl
c	71	21	2.7	21	1	US-10-605-498-45	Sequence 45, Appl
c	72	21	2.7	21	1	US-10-605-498-46	Sequence 46, Appl
c	73	21	2.7	21	1	US-10-605-498-47	Sequence 47, Appl
c	74	21	2.7	21	1	US-10-605-498-48	Sequence 48, Appl
c	75	21	2.7	21	1	US-10-605-498-49	Sequence 49, Appl
c	76	21	2.7	21	1	US-10-605-498-50	Sequence 50, Appl
c	77	21	2.7	21	1	US-10-605-498-51	Sequence 51, Appl
c	78	21	2.7	21	1	US-10-605-498-52	Sequence 52, Appl
c	79	21	2.7	21	1	US-10-605-498-53	Sequence 53, Appl
c	80	21	2.7	21	1	US-10-605-498-54	Sequence 54, Appl
c	81	21	2.7	21	1	US-10-605-498-55	Sequence 55, Appl
c	82	21	2.7	21	1	US-10-605-498-56	Sequence 56, Appl
c	83	21	2.7	21	1	US-10-605-498-57	Sequence 57, Appl
c	84	21	2.7	21	1	US-10-605-498-58	Sequence 58, Appl
c	85	21	2.7	21	1	US-10-605-498-59	Sequence 59, Appl
c	86	21	2.7	21	1	US-10-605-498-60	Sequence 60, Appl
c	87	21	2.7	21	1	US-10-605-498-61	Sequence 61, Appl
c	88	21	2.7	21	1	US-10-605-498-62	Sequence 62, Appl
c	89	21	2.7	21	1	US-10-605-498-63	Sequence 63, Appl
c	90	21	2.7	21	1	US-10-605-498-64	Sequence 64, Appl
c	91	21	2.7	21	1	US-10-605-498-65	Sequence 65, Appl
c	92	21	2.7	21	1	US-10-605-498-66	Sequence 66, Appl
c	93	21	2.7	21	1	US-10-605-498-67	Sequence 67, Appl
c	94	21	2.7	21	1	US-10-605-498-68	Sequence 68, Appl
c	95	21	2.7	21	1	US-10-605-498-69	Sequence 69, Appl
c	96	21	2.7	21	1	US-10-605-498-70	Sequence 70, Appl
c	97	21	2.7	21	1	US-10-605-498-71	Sequence 71, Appl
c	98	21	2.7	21	1	US-10-605-498-72	Sequence 72, Appl
c	99	21	2.7	21	1	US-10-605-498-73	Sequence 73, Appl
c	100	21	2.7	21	1	US-10-605-498-74	Sequence 74, Appl
c	101	21	2.7	21	1	US-10-605-498-75	Sequence 75, Appl
c	102	21	2.7	21	1	US-10-605-498-76	Sequence 76, Appl
c	103	21	2.7	21	1	US-10-605-498-78	Sequence 78, Appl
c	104	21	2.7	21	1	US-10-605-498-79	Sequence 79, Appl
c	105	21	2.7	21	1	US-10-605-498-80	Sequence 80, Appl
c	106	21	2.7	21	1	US-10-605-498-81	Sequence 81, Appl

c 107	20.8	2.7	25	1	US-10-719-900-152006	Sequence 152006,
108	20.8	2.7	25	1	US-10-809-189-92419	Sequence 92419, A
c 109	20.2	2.6	25	1	US-10-719-900-51106	Sequence 51106, A
110	20.2	2.6	25	1	US-10-719-900-72371	Sequence 72371, A
c 111	20.2	2.6	25	1	US-10-719-900-147040	Sequence 147040,
112	20.2	2.6	25	1	US-10-719-900-248861	Sequence 248861,
113	20.2	2.6	25	1	US-10-719-900-347106	Sequence 347106,
114	20.2	2.6	25	1	US-10-719-900-376561	Sequence 376561,
115	20.2	2.6	25	1	US-10-719-900-415444	Sequence 415444,
c 116	20.2	2.6	25	1	US-10-719-900-472173	Sequence 472173,
117	20.2	2.6	25	1	US-10-719-900-581985	Sequence 581985,
118	20.2	2.6	25	1	US-10-719-900-592387	Sequence 592387,
119	20.2	2.6	25	1	US-10-719-900-611646	Sequence 611646,
c 120	20.2	2.6	25	1	US-10-719-900-685015	Sequence 685015,
c 121	20.2	2.6	25	1	US-10-719-900-685016	Sequence 685016,
c 122	20.2	2.6	25	1	US-10-719-900-819345	Sequence 819345,
123	20.2	2.6	25	1	US-10-719-900-830335	Sequence 830335,
124	20.2	2.6	25	1	US-10-809-189-92432	Sequence 92432, A
125	20.2	2.6	25	1	US-10-719-956-364445	Sequence 364445,
126	20.2	2.6	25	1	US-10-719-956-435352	Sequence 435352,
c 127	20	2.6	20	1	US-10-605-498-82	Sequence 82, Appl
128	20	2.6	20	1	US-10-713-808-13	Sequence 13, Appl
129	19	2.5	19	1	US-10-605-498-87	Sequence 87, Appl
130	19	2.5	19	1	US-10-605-498-90	Sequence 90, Appl
131	18.4	2.4	21	1	US-10-472-779-1	Sequence 1, Appli
c 132	18	2.4	18	1	US-10-605-498-77	Sequence 77, Appl
133	17.8	2.3	21	1	US-10-605-498-89	Sequence 89, Appl
c 134	17.8	2.3	22	1	US-10-472-779-2	Sequence 2, Appli
135	17	2.2	17	1	US-10-339-793-168	Sequence 168, App
136	16.8	2.2	21	1	US-10-751-736-34691	Sequence 34691, A
137	15.8	2.1	19	1	US-09-990-613-0	Sequence 0, Appli
138	15.8	2.1	19	1	US-10-605-498-83	Sequence 83, Appl
139	15.8	2.1	21	1	US-10-605-498-7	Sequence 7, Appli
140	15.4	2.0	17	1	US-09-866-108-10667	Sequence 10667, A
c 141	15.4	2.0	17	1	US-10-211-689-82	Sequence 82, Appl
142	15.4	2.0	17	1	US-10-723-361-10667	Sequence 10667, A
143	15.4	2.0	19	1	US-10-844-072-10	Sequence 10, Appl
c 144	15.4	2.0	19	1	US-10-844-072-133	Sequence 133, App
145	15.4	2.0	19	1	US-10-922-340-10	Sequence 10, Appl
c 146	15.4	2.0	19	1	US-10-922-340-133	Sequence 133, App
c 147	14.8	1.9	18	1	US-10-450-472-50	Sequence 50, Appl
c 148	14.4	1.9	16	1	US-10-179-940-466	Sequence 466, App
149	14.4	1.9	17	1	US-09-866-108-10666	Sequence 10666, A
150	14.4	1.9	17	1	US-09-866-108-10668	Sequence 10668, A
c 151	14.4	1.9	17	1	US-10-060-830-218	Sequence 218, App
c 152	14.4	1.9	17	1	US-10-060-830-219	Sequence 219, App
153	14.4	1.9	17	1	US-10-156-306-5028	Sequence 5028, Ap
c 154	14.4	1.9	17	1	US-10-238-700-2848	Sequence 2848, Ap
155	14.4	1.9	17	1	US-10-723-361-10666	Sequence 10666, A
156	14.4	1.9	17	1	US-10-723-361-10668	Sequence 10668, A
157	14.4	1.9	17	1	US-10-498-462-2203	Sequence 2203, Ap
158	14.4	1.9	17	1	US-10-498-462-2204	Sequence 2204, Ap
c 159	14.4	1.9	17	1	US-10-724-270-1527	Sequence 1527, Ap
c 160	14.4	1.9	18	1	US-10-349-143-6095	Sequence 6095, Ap
161	14.4	1.9	18	1	US-10-702-817-27	Sequence 27, Appl
c 162	14	1.8	17	1	US-09-818-875-4230	Sequence 4230, Ap
163	14	1.8	17	1	US-09-818-875-4231	Sequence 4231, Ap
164	14	1.8	17	1	US-09-780-533A-765	Sequence 765, App
165	14	1.8	17	1	US-09-780-533A-1791	Sequence 1791, Ap
c 166	14	1.8	17	1	US-10-209-787-4230	Sequence 4230, Ap
167	14	1.8	17	1	US-10-209-787-4231	Sequence 4231, Ap
c 168	14	1.8	17	1	US-10-261-185-4230	Sequence 4230, Ap
169	14	1.8	17	1	US-10-261-185-4231	Sequence 4231, Ap
c 170	14	1.8	17	1	US-10-681-074-4230	Sequence 4230, Ap
171	14	1.8	17	1	US-10-681-074-4231	Sequence 4231, Ap
c 172	13.8	1.8	17	1	US-09-866-108-2329	Sequence 2329, Ap
c 173	13.8	1.8	17	1	US-09-866-108-2330	Sequence 2330, Ap
c 174	13.8	1.8	17	1	US-09-866-108-2331	Sequence 2331, Ap
175	13.8	1.8	17	1	US-09-866-108-10669	Sequence 10669, A
176	13.8	1.8	17	1	US-09-866-108-10670	Sequence 10670, A
c 177	13.8	1.8	17	1	US-09-864-785-1425	Sequence 1425, Ap
178	13.8	1.8	17	1	US-09-825-805-772	Sequence 772, App
179	13.8	1.8	17	1	US-09-780-533A-2414	Sequence 2414, Ap
180	13.8	1.8	17	1	US-09-927-046-1306	Sequence 1306, Ap
c 181	13.8	1.8	17	1	US-09-927-046-1904	Sequence 1904, Ap
c 182	13.8	1.8	17	1	US-09-927-046-1905	Sequence 1905, Ap
183	13.8	1.8	17	1	US-09-740-332-4378	Sequence 4378, Ap
184	13.8	1.8	17	1	US-09-817-879-4378	Sequence 4378, Ap
c 185	13.8	1.8	17	1	US-10-060-756A-170	Sequence 170, App
186	13.8	1.8	17	1	US-10-163-552-650	Sequence 650, App
187	13.8	1.8	17	1	US-10-156-306-5029	Sequence 5029, Ap
188	13.8	1.8	17	1	US-10-238-700-484	Sequence 484, App
189	13.8	1.8	17	1	US-10-061-201-1223	Sequence 1223, Ap
c 190	13.8	1.8	17	1	US-10-382-248-80	Sequence 80, Appl
c 191	13.8	1.8	17	1	US-10-676-154-599	Sequence 599, App
c 192	13.8	1.8	17	1	US-10-712-672-332	Sequence 332, App
193	13.8	1.8	17	1	US-10-669-841-6971	Sequence 6971, Ap
c 194	13.8	1.8	17	1	US-10-723-361-2329	Sequence 2329, Ap
c 195	13.8	1.8	17	1	US-10-723-361-2330	Sequence 2330, Ap
c 196	13.8	1.8	17	1	US-10-723-361-2331	Sequence 2331, Ap
197	13.8	1.8	17	1	US-10-723-361-10669	Sequence 10669, A
198	13.8	1.8	17	1	US-10-723-361-10670	Sequence 10670, A
199	13.8	1.8	17	1	US-10-494-343-325	Sequence 325, App
c 200	13.8	1.8	17	1	US-10-498-462-1759	Sequence 1759, Ap
c 201	13.8	1.8	17	1	US-10-498-462-1760	Sequence 1760, Ap
202	13.8	1.8	17	1	US-10-724-270-484	Sequence 484, App
203	13.8	1.8	17	1	US-10-724-270-5305	Sequence 5305, Ap
c 204	13.8	1.8	17	1	US-10-890-776A-170	Sequence 170, App
205	13.4	1.8	16	1	US-10-712-672-1489	Sequence 1489, Ap
c 206	13	1.7	15	1	US-09-918-728B-11	Sequence 11, Appl
207	13	1.7	16	1	US-10-712-672-1490	Sequence 1490, Ap
208	13	1.7	21	1	US-10-605-498-50	Sequence 50, Appl
209	12.8	1.7	16	1	US-09-829-855-10	Sequence 10, Appl
210	12.8	1.7	16	1	US-09-829-855-110	Sequence 110, App
211	12.8	1.7	16	1	US-10-455-013-17	Sequence 17, Appl
212	12.8	1.7	16	1	US-10-455-013-29	Sequence 29, Appl
c 213	12.8	1.7	16	1	US-10-179-940-539	Sequence 539, App
214	12.8	1.7	16	1	US-10-627-250-17	Sequence 17, Appl
215	12.8	1.7	16	1	US-10-627-250-29	Sequence 29, Appl
216	12.8	1.7	16	1	US-10-712-672-1775	Sequence 1775, Ap
217	12.8	1.7	16	1	US-10-607-077A-10	Sequence 10, Appl
218	12.8	1.7	16	1	US-10-607-077A-110	Sequence 110, App
c 219	12.8	1.7	16	1	US-10-776-934-107	Sequence 107, App
c 220	12.8	1.7	16	1	US-10-776-934-568	Sequence 568, App
c 221	12.8	1.7	16	1	US-10-776-934-569	Sequence 569, App
c 222	12.8	1.7	16	1	US-10-776-934-570	Sequence 570, App
c 223	12.8	1.7	16	1	US-10-776-934-571	Sequence 571, App
c 224	12.8	1.7	16	1	US-10-730-771-330	Sequence 330, App

ALIGNMENTS

```
RESULT 1
US-10-719-900-265359
; Sequence 265359, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 265359
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-265359

  Query Match             3.1%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 17;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy        417 ATGGCTACATCTCCCGGTGCTTCAC 441
              ||||||||||||| ||||||||||
Db          1 ATGGCTACATCTCTCGGTGCTTCAC 25


RESULT 2
US-10-719-900-475563/c
; Sequence 475563, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 475563
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-475563

  Query Match             3.1%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 17;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        405 GGCAGGACGAGCATGGCTACATCTC 429
              |||||||||| ||||||||||||||
Db         25 GGCAGGACGAACATGGCTACATCTC 1


RESULT 3
US-10-719-900-618137
; Sequence 618137, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 618137
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-618137

  Query Match             3.1%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 17;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        309 GGCGCGTGTCCCTGGATGTCAACCA 333
              |||||||||||||||| ||||||||
Db          1 GGCGCGTGTCCCTGGACGTCAACCA 25


RESULT 4
US-10-719-900-657749/c
; Sequence 657749, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 657749
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-657749

  Query Match             3.1%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 17;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        308 TGGCGCGTGTCCCTGGATGTCAACC 332
              |||||||||||||||| |||||||
Db         25 TGGCGCGTGTCCCTGGACGTCAACC 1


RESULT 5
US-10-719-900-858223/c
; Sequence 858223, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 858223
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-858223

  Query Match             3.1%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 17;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        362 ACCAAGGATGGCGTGGTGGAGATCA 386
              |||||||| ||||||||||||||||
Db         25 ACCAAGGAAGGCGTGGTGGAGATCA 1


RESULT 6
US-10-840-038-4/c
; Sequence 4, Application US/10840038
; Publication No. US20050009137A1
; GENERAL INFORMATION:
;  APPLICANT: Adams, John
;  APPLICANT:  Chen, Hong
;  TITLE OF INVENTION: An Intracellular Estradiol Binding Protein, a Polynucleotide
;  TITLE OF INVENTION:  Encoding the Same and Cell Lines Overexpressing the Same
;  FILE REFERENCE: 81476-302961
;  CURRENT APPLICATION NUMBER: US/10/840,038
;  CURRENT FILING DATE:  2004-05-06
;  PRIOR APPLICATION NUMBER: US 60/468,717
;  PRIOR FILING DATE: 2003-05-07
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer
US-10-840-038-4
```

```
  Query Match             3.0%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 16;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         38 CGCGTCCCCTTCTCGCTCCTGCG 60
              |||||||||||||||||||||||
Db         23 CGCGTCCCCTTCTCGCTCCTGCG 1


RESULT 7
US-10-719-900-152005/c
; Sequence 152005, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 152005
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-152005

  Query Match             2.9%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 22;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        406 GCAGGACGAGCATGGCTACATCTC 429
              ||||||||| ||||||||||||||
Db         25 GCAGGACGAACATGGCTACATCTC 2


RESULT 8
US-10-719-900-653170
; Sequence 653170, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 653170
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-653170

  Query Match             2.9%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 22;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        376 GGTGGAGATCACCGGCAAGCACGA 399
              ||||||||||| ||||||||||||
Db          1 GGTGGAGATCACAGGCAAGCACGA 24


RESULT 9
US-10-719-900-653171
; Sequence 653171, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 653171
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-653171

  Query Match             2.9%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 22;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        376 GGTGGAGATCACCGGCAAGCACGA 399
              ||||||||||| ||||||||||||
Db          1 GGTGGAGATCACTGGCAAGCACGA 24


RESULT 10
US-10-719-900-855205
; Sequence 855205, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 855205
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-855205

  Query Match             2.9%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 22;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        502 TGAGGGCACACTGACCGTGGAGGC 525
              ||||||||||| ||||||||||||
Db          1 TGAGGGCACACTAACCGTGGAGGC 24


RESULT 11
US-10-719-900-855206
; Sequence 855206, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 855206
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-855206

  Query Match             2.9%;  Score 22.4;  DB 1;  Length 25;
```

```
  Best Local Similarity   95.8%;  Pred. No. 22;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        502 TGAGGGCACACTGACCGTGGAGGC 525
              |||||||||||| ||||||||||
Db          1 TGAGGGCACACTTACCGTGGAGGC 24


RESULT 12
US-10-840-038-5
; Sequence 5, Application US/10840038
; Publication No. US20050009137A1
; GENERAL INFORMATION:
;  APPLICANT: Adams, John
;  APPLICANT:  Chen, Hong
;  TITLE OF INVENTION: An Intracellular Estradiol Binding Protein, a Polynucleotide
;  TITLE OF INVENTION:  Encoding the Same and Cell Lines Overexpressing the Same
;  FILE REFERENCE: 81476-302961
;  CURRENT APPLICATION NUMBER: US/10/840,038
;  CURRENT FILING DATE:  2004-05-06
;  PRIOR APPLICATION NUMBER: US 60/468,717
;  PRIOR FILING DATE: 2003-05-07
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer
US-10-840-038-5

  Query Match             2.9%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         38 CGCGTCCCCTTCTCGCTCCTGC 59
              ||||||||||||||||||||||
Db          1 CGCGTCCCCTTCTCGCTCCTGC 22


RESULT 13
US-10-719-900-51105/c
; Sequence 51105, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 51105
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-51105

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 26;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        414 AGCATGGCTACATCTCCCGGTGCTT 438
              | |||||||||||||| ||||||||
Db         25 AACATGGCTACATCTCTCGGTGCTT 1


RESULT 14
US-10-719-900-248862
; Sequence 248862, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 248862
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-248862

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 26;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        425 ATCTCCCGGTGCTTCACGCGGAAAT 449
              ||||| |||||||||||| |||||||
Db          1 ATCTCTCGGTGCTTCACCCGGAAAT 25


RESULT 15
US-10-719-900-265360
; Sequence 265360, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 265360
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-265360

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 26;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        417 ATGGCTACATCTCCCGGTGCTTCAC 441
              |||||||||||| ' ||||||||||
Db          1 ATGGCTACATCTGTCGGTGCTTCAC 25


RESULT 16
US-10-719-900-376560
; Sequence 376560, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 376560
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
```

US-10-719-900-376560

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        429 CCCGGTGCTTCACGCGGAAATACAC 453
              | |||||||||||| ||||||||||
Db          1 CTCGGTGCTTCACCCGGAAATACAC 25
```

RESULT 17
US-10-719-900-415441
; Sequence 415441, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 415441
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-415441

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        413 GAGCATGGCTACATCTCCCGGTGCT 437
              || |||||||||||||| |||||||
Db          1 GAACATGGCTACATCTCTCGGTGCT 25
```

RESULT 18
US-10-719-900-472172/c
; Sequence 472172, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 472172
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-472172

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        407 CAGGACGAGCATGGCTACATCTCCC 431
              |||||||| ||||||||||||||| |
Db         25 CAGGACGAACATGGCTACATCTCTC 1
```

RESULT 19
US-10-719-900-475562/c
; Sequence 475562, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 475562
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-475562

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        405 GGCAGGACGAGCATGGCTACATCTC 429
              |||||||||| | ||||||||||||
Db         25 GGCAGGACGAACTTGGCTACATCTC 1
```

RESULT 20
US-10-719-900-592386
; Sequence 592386, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 592386
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-592386

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        409 GGACGAGCATGGCTACATCTCCCGG 433
              |||||| |||||||||||||| |||
Db          1 GGACGAACATGGCTACATCTCTCGG 25
```

RESULT 21
US-10-719-900-618136
; Sequence 618136, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 618136
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-618136

```
  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 26;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        309 GGCGCGTGTCCCTGGATGTCAACCA 333
              ||||||||||||| ||| ||||||||
Db          1 GGCGCGTGTCCCAGGACGTCAACCA 25


RESULT 22
US-10-719-900-657748/c
; Sequence 657748, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 657748
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-657748

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 26;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        308 TGGCGCGTGTCCCTGGATGTCAACC 332
              ||||||||||||| |||| |||||||
Db         25 TGGCGCGTGTCCGTGGACGTCAACC 1


RESULT 23
US-10-719-900-830334
; Sequence 830334, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 830334
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-830334

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 26;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        428 TCCCGGTGCTTCACGCGGAAATACA 452
              || |||||||||||| ||||||||||
Db          1 TCTCGGTGCTTCACCCGGAAATACA 25


RESULT 24
US-10-719-900-858224/c
; Sequence 858224, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 858224
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-858224

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 26;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        362 ACCAAGGATGGCGTGGTGGAGATCA 386
              |·|||||| ||| |||||||||||||
Db         25 ACCAAGGAAGGCCTGGTGGAGATCA 1


RESULT 25
US-10-719-956-435353
; Sequence 435353, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427;836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 435353
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-435353

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 26;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        261 GGCAACTCAGCAGCGGGGTCTCGGA 285
              |||||||||||||||| ||||| ||
Db          1 GGCAACTCAGCAGCGGTGTCTCAGA 25


RESULT 26
US-09-911-904-63
; Sequence 63, Application US/09911904
; Publication No. US20030096234A1
; GENERAL INFORMATION:
;  APPLICANT: Farr, Spencer B.
;  APPLICANT:  Pickett, Gavin G.
;  APPLICANT:  Neft, Robin Eileen
;  APPLICANT:  Dunn, II, Robert Thomas
;  TITLE OF INVENTION: CANINE TOXICITY GENES
;  FILE REFERENCE: 400742000200
;  CURRENT APPLICATION NUMBER: US/09/911,904
;  CURRENT FILING DATE:  2002-04-09
;  PRIOR APPLICATION NUMBER: US 60/220,057
;  PRIOR FILING DATE: 2000-07-21
;  NUMBER OF SEQ ID NOS: 386
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 63
;   LENGTH: 23
;   TYPE: DNA
```

```
;   ORGANISM: Canis familiaris
US-09-911-904-63

  Query Match             2.8%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 25;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         73 GGACCCCTTCCGCGACTGGTACC 95
              |||||| ||||||||||||||||
Db          1 GGACCCTTTCCGCGACTGGTACC 23


RESULT 27
US-10-605-498-1/c
; Sequence 1, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-1

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 GGCACGAGGAGCAGAGTCAGC 21
              |||||||||||||||||||||
Db         21 GGCACGAGGAGCAGAGTCAGC 1


RESULT 28
US-10-605-498-2/c
; Sequence 2, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-2

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         11 GCAGAGTCAGCCAGCATGACC 31
              |||||||||||||||||||||
Db         21 GCAGAGTCAGCCAGCATGACC 1


RESULT 29
US-10-605-498-3/c
; Sequence 3, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-3

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         21 CCAGCATGACCGAGCGCCGCG 41
              |||||||||||||||||||||
Db         21 CCAGCATGACCGAGCGCCGCG 1


RESULT 30
US-10-605-498-4/c
; Sequence 4, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-4

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         31 CGAGCGCCGCGTCCCCTTCTC 51
              |||||||||||||||||||||
Db         21 CGAGCGCCGCGTCCCCTTCTC 1
```

```
RESULT 31
US-10-605-498-5/c
; Sequence 5, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-5

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         41 GTCCCCTTCTCGCTCCTGCGG 61
              |||||||||||||||||||||
Db         21 GTCCCCTTCTCGCTCCTGCGG 1


RESULT 32
US-10-605-498-6/c
; Sequence 6, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-6

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 CGCTCCTGCGGGGCCCCAGCT 71
              |||||||||||||||||||||
Db         21 CGCTCCTGCGGGGCCCCAGCT 1


RESULT 33
US-10-605-498-7/c
; Sequence 7, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-7

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         61 GGGCCCCAGCTGGGACCCCTT 81
              |||||||||||||||||||||
Db         21 GGGCCCCAGCTGGGACCCCTT 1


RESULT 34
US-10-605-498-8/c
; Sequence 8, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-8

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         71 TGGGACCCCTTCCGCGACTGG 91
              |||||||||||||||||||||
Db         21 TGGGACCCCTTCCGCGACTGG 1


RESULT 35
US-10-605-498-9/c
; Sequence 9, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
```

```
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-9

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         81 TCCGCGACTGGTACCCGCATA 101
               |||||||||||||||||||||
Db         21 TCCGCGACTGGTACCCGCATA 1


RESULT 36
US-10-605-498-10/c
; Sequence 10, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-10

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         91 GTACCCGCATAGCCGCCTCTT 111
               |||||||||||||||||||||
Db         21 GTACCCGCATAGCCGCCTCTT 1


RESULT 37
US-10-605-498-11/c
; Sequence 11, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-11

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        101 AGCCGCCTCTTCGACCAGGCC 121
              |||||||||||||||||||||
Db         21 AGCCGCCTCTTCGACCAGGCC 1


RESULT 38
US-10-605-498-12/c
; Sequence 12, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-12

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        111 TCGACCAGGCCTTCGGGCTGC 131
              |||||||||||||||||||||
Db         21 TCGACCAGGCCTTCGGGCTGC 1


RESULT 39
US-10-605-498-13/c
; Sequence 13, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
```

```
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-13

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        121 CTTCGGGCTGCCCCGGCTGCC 141
              |||||||||||||||||||||
Db         21 CTTCGGGCTGCCCCGGCTGCC 1


RESULT 40
US-10-605-498-14/c
; Sequence 14, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-14

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        131 CCCCGGCTGCCGGAGGAGTGG 151
              |||||||||||||||||||||
Db         21 CCCCGGCTGCCGGAGGAGTGG 1


RESULT 41
US-10-605-498-15/c
; Sequence 15, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-15

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        141 CGGAGGAGTGGTCGCAGTGGT 161
              |||||||||||||||||||||
Db         21 CGGAGGAGTGGTCGCAGTGGT 1


RESULT 42
US-10-605-498-16/c
; Sequence 16, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-16

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        151 GTCGCAGTGGTTAGGCGGCAG 171
              |||||||||||||||||||||
Db         21 GTCGCAGTGGTTAGGCGGCAG 1


RESULT 43
US-10-605-498-17/c
; Sequence 17, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-17

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        161 TTAGGCGGCAGCAGCTGGCCA 181
              ||||||||||||||||||||
Db         21 TTAGGCGGCAGCAGCTGGCCA 1


RESULT 44
US-10-605-498-18/c
; Sequence 18, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-18

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        171 GCAGCTGGCCAGGCTACGTGC 191
              ||||||||||||||||||||
Db         21 GCAGCTGGCCAGGCTACGTGC 1


RESULT 45
US-10-605-498-19/c
; Sequence 19, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-19

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        181 AGGCTACGTGCGCCCCCTGCC 201
              ||||||||||||||||||||
Db         21 AGGCTACGTGCGCCCCCTGCC 1


RESULT 46
US-10-605-498-20/c
; Sequence 20, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-20

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        191 CGCCCCCTGCCCCCCGCCGCC 211
              ||||||||||||||||||||
Db         21 CGCCCCCTGCCCCCCGCCGCC 1


RESULT 47
US-10-605-498-21/c
; Sequence 21, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 21
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-21

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        201 CCCCCGCCGCCATCGAGAGCC 221
              ||||||||||||||||||||
Db         21 CCCCCGCCGCCATCGAGAGCC 1


RESULT 48
US-10-605-498-22/c
; Sequence 22, Application US/10605498
; Publication No. US20040127441A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-22

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        211 CATCGAGAGCCCCGCAGTGGC 231
              |||||||||||||||||||||
Db         21 CATCGAGAGCCCCGCAGTGGC 1


RESULT 49
US-10-605-498-23/c
; Sequence 23, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-23

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        221 CCCGCAGTGGCCGCGCCCGCC 241
              |||||||||||||||||||||
Db         21 CCCGCAGTGGCCGCGCCCGCC 1


RESULT 50
US-10-605-498-24/c
; Sequence 24, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-24

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        231 CCGCGCCCGCCTACAGCCGCG 251
              |||||||||||||||||||||
Db         21 CCGCGCCCGCCTACAGCCGCG 1


RESULT 51
US-10-605-498-25/c
; Sequence 25, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-25

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        241 CTACAGCCGCGCGCTCAGCCG 261
              |||||||||||||||||||||
Db         21 CTACAGCCGCGCGCTCAGCCG 1


RESULT 52
US-10-605-498-26/c
; Sequence 26, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
```

```
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-605-498-26

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        251 GCGCTCAGCCGGCAACTCAGC 271
              |||||||||||||||||||||
Db         21 GCGCTCAGCCGGCAACTCAGC 1


RESULT 53
US-10-605-498-27/c
; Sequence 27, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 27
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-605-498-27

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        261 GGCAACTCAGCAGCGGGGTCT 281
              |||||||||||||||||||||
Db         21 GGCAACTCAGCAGCGGGGTCT 1


RESULT 54
US-10-605-498-28/c
; Sequence 28, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-605-498-28

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        271 CAGCGGGGTCTCGGAGATCCG 291
              |||||||||||||||||||||
Db         21 CAGCGGGGTCTCGGAGATCCG 1


RESULT 55
US-10-605-498-29/c
; Sequence 29, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-605-498-29

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        281 TCGGAGATCCGGCACACTGCG 301
              |||||||||||||||||||||
Db         21 TCGGAGATCCGGCACACTGCG 1


RESULT 56
US-10-605-498-30/c
; Sequence 30, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 30
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-605-498-30
```

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 291 GGCACACTGCGGACCGCTGGC 311
||||||||||||||||||||
Db 21 GGCACACTGCGGACCGCTGGC 1

RESULT 57
US-10-605-498-31/c
; Sequence 31, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-31

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 301 GGACCGCTGGCGCGTGTCCCT 321
||||||||||||||||||||
Db 21 GGACCGCTGGCGCGTGTCCCT 1

RESULT 58
US-10-605-498-32/c
; Sequence 32, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-32

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 311 CGCGTGTCCCTGGATGTCAAC 331
||||||||||||||||||||
Db 21 CGCGTGTCCCTGGATGTCAAC 1

RESULT 59
US-10-605-498-33/c
; Sequence 33, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-33

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 321 TGGATGTCAACCACTTCGCCC 341
||||||||||||||||||||
Db 21 TGGATGTCAACCACTTCGCCC 1

RESULT 60
US-10-605-498-34/c
; Sequence 34, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-34

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 331 CCACTTCGCCCCGGACGAGCT 351
||||||||||||||||||||
Db 21 CCACTTCGCCCCGGACGAGCT 1

```
RESULT 61
US-10-605-498-35/c
; Sequence 35, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 35
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-35

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        341 CCGGACGAGCTGACGGTCAAG 361
              |||||||||||||||||||||
Db         21 CCGGACGAGCTGACGGTCAAG 1


RESULT 62
US-10-605-498-36/c
; Sequence 36, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-36

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGACCAAGGATG 371
              |||||||||||||||||||||
Db         21 TGACGGTCAAGACCAAGGATG 1


RESULT 63
US-10-605-498-37/c
; Sequence 37, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-37

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        361 GACCAAGGATGGCGTGGTGGA 381
              |||||||||||||||||||||
Db         21 GACCAAGGATGGCGTGGTGGA 1


RESULT 64
US-10-605-498-38/c
; Sequence 38, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-38

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        371 GGCGTGGTGGAGATCACCGGC 391
              |||||||||||||||||||||
Db         21 GGCGTGGTGGAGATCACCGGC 1


RESULT 65
US-10-605-498-39/c
; Sequence 39, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
```

```
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-39

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        381 AGATCACCGGCAAGCACGAGG 401
              |||||||||||||||||||||
Db         21 AGATCACCGGCAAGCACGAGG 1


RESULT 66
US-10-605-498-40/c
; Sequence 40, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-40

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        391 CAAGCACGAGGAGCGGCAGGA 411
              |||||||||||||||||||||
Db         21 CAAGCACGAGGAGCGGCAGGA 1


RESULT 67
US-10-605-498-41/c
; Sequence 41, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 41
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-41

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        401 GAGCGGCAGGACGAGCATGGC 421
              |||||||||||||||||||||
Db         21 GAGCGGCAGGACGAGCATGGC 1


RESULT 68
US-10-605-498-42/c
; Sequence 42, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-42

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        411 ACGAGCATGGCTACATCTCCC 431
              |||||||||||||||||||||
Db         21 ACGAGCATGGCTACATCTCCC 1


RESULT 69
US-10-605-498-43/c
; Sequence 43, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43
```

```
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-43

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        421 CTACATCTCCCGGTGCTTCAC 441
              |||||||||||||||||||||
Db         21 CTACATCTCCCGGTGCTTCAC 1


RESULT 70
US-10-605-498-44/c
; Sequence 44, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-44

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        431 CGGTGCTTCACGCGGAAATAC 451
              |||||||||||||||||||||
Db         21 CGGTGCTTCACGCGGAAATAC 1


RESULT 71
US-10-605-498-45/c
; Sequence 45, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-45

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        441 CGCGGAAATACACGCTGCCCC 461
              |||||||||||||||||||||
Db         21 CGCGGAAATACACGCTGCCCC 1


RESULT 72
US-10-605-498-46/c
; Sequence 46, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 46
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-46

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        451 CACGCTGCCCCCCGGTGTGGA 471
              |||||||||||||||||||||
Db         21 CACGCTGCCCCCCGGTGTGGA 1


RESULT 73
US-10-605-498-47/c
; Sequence 47, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 47
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-47

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        461 CCCGGTGTGGACCCCACCCAA 481
```

```
                    ||||||||||||||||||||
Db         21 CCCGGTGTGGACCCCACCCAA 1


RESULT 74
US-10-605-498-48/c
; Sequence 48, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 48
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-48

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        471 ACCCCACCCAAGTTTCCTCCT 491
                ||||||||||||||||||||
Db         21 ACCCCACCCAAGTTTCCTCCT 1


RESULT 75
US-10-605-498-49/c
; Sequence 49, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-49

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        481 AGTTTCCTCCTCCCTGTCCCC 501
                ||||||||||||||||||||
Db         21 AGTTTCCTCCTCCCTGTCCCC 1


RESULT 76
US-10-605-498-50/c
; Sequence 50, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-50

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        491 TCCCTGTCCCCTGAGGGCACA 511
                ||||||||||||||||||||
Db         21 TCCCTGTCCCCTGAGGGCACA 1


RESULT 77
US-10-605-498-51/c
; Sequence 51, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 51
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-51

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        501 CTGAGGGCACACTGACCGTGG 521
                ||||||||||||||||||||
Db         21 CTGAGGGCACACTGACCGTGG 1


RESULT 78
US-10-605-498-52/c
; Sequence 52, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
```

```
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 52
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-52

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        511 ACTGACCGTGGAGGCCCCCAT 531
              |||||||||||||||||||||
Db         21 ACTGACCGTGGAGGCCCCCAT 1


RESULT 79
US-10-605-498-53/c
; Sequence 53, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 53
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-53

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        521 GAGGCCCCCATGCCCAAGCTA 541
              |||||||||||||||||||||
Db         21 GAGGCCCCCATGCCCAAGCTA 1


RESULT 80
US-10-605-498-54/c
; Sequence 54, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 54
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-54

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        531 TGCCCAAGCTAGCCACGCAGT 551
              |||||||||||||||||||||
Db         21 TGCCCAAGCTAGCCACGCAGT 1


RESULT 81
US-10-605-498-55/c
; Sequence 55, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 55
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-55

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCAACGAGAT 561
              |||||||||||||||||||||
Db         21 AGCCACGCAGTCCAACGAGAT 1


RESULT 82
US-10-605-498-56/c
; Sequence 56, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
```

```
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-56

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCATCCCA 571
              |||||||||||||||||||||
Db         21 TCCAACGAGATCACCATCCCA 1


RESULT 83
US-10-605-498-57/c
; Sequence 57, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 57
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-57

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 TCACCATCCCAGTCACCTTCG 581
              |||||||||||||||||||||
Db         21 TCACCATCCCAGTCACCTTCG 1


RESULT 84
US-10-605-498-58/c
; Sequence 58, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 58
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-58

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        571 AGTCACCTTCGAGTCGCGGGC 591
              |||||||||||||||||||||
Db         21 AGTCACCTTCGAGTCGCGGGC 1


RESULT 85
US-10-605-498-59/c
; Sequence 59, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 59
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-59

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        581 GAGTCGCGGGCCCAGCTTGGG 601
              |||||||||||||||||||||
Db         21 GAGTCGCGGGCCCAGCTTGGG 1


RESULT 86
US-10-605-498-60/c
; Sequence 60, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-60

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        591 CCCAGCTTGGGGGCCCAGAAG 611
              |||||||||||||||||||||
Db         21 CCCAGCTTGGGGGCCCAGAAG 1


RESULT 87
US-10-605-498-61/c
; Sequence 61, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 61
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-61

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        601 GGGCCCAGAAGCTGCAAAATC 621
              |||||||||||||||||||||
Db         21 GGGCCCAGAAGCTGCAAAATC 1


RESULT 88
US-10-605-498-62/c
; Sequence 62, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 62
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-62

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        611 GCTGCAAAATCCGATGAGACT 631
              |||||||||||||||||||||
Db         21 GCTGCAAAATCCGATGAGACT 1


RESULT 89
US-10-605-498-63/c
; Sequence 63, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 63
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-63

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        621 CCGATGAGACTGCCGCCAAGT 641
              |||||||||||||||||||||
Db         21 CCGATGAGACTGCCGCCAAGT 1


RESULT 90
US-10-605-498-64/c
; Sequence 64, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 64
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-64

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAG 651
              |||||||||||||||||||||
Db         21 TGCCGCCAAGTAAAGCCTTAG 1


RESULT 91
US-10-605-498-65/c
```

```
; Sequence 65, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 65
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-65

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        641 TAAAGCCTTAGCCCGGATGCC 661
              |||||||||||||||||||||
Db         21 TAAAGCCTTAGCCCGGATGCC 1


RESULT 92
US-10-605-498-66/c
; Sequence 66, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 66
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-66

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        651 GCCCGGATGCCCACCCCTGCT 671
              |||||||||||||||||||||
Db         21 GCCCGGATGCCCACCCCTGCT 1


RESULT 93
US-10-605-498-67/c
; Sequence 67, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 67
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-67

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        661 CCACCCCTGCTGCCGCCACTG 681
              |||||||||||||||||||||
Db         21 CCACCCCTGCTGCCGCCACTG 1


RESULT 94
US-10-605-498-68/c
; Sequence 68, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 68
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-68

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        671 TGCCGCCACTGGCTGTGCCTC 691
              |||||||||||||||||||||
Db         21 TGCCGCCACTGGCTGTGCCTC 1


RESULT 95
US-10-605-498-69/c
; Sequence 69, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
```

```
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-69

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        681 GGCTGTGCCTCCCCCGCCACC 701
              |||||||||||||||||||||
Db         21 GGCTGTGCCTCCCCCGCCACC 1


RESULT 96
US-10-605-498-70/c
; Sequence 70, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 70
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-70

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        691 CCCCCGCCACCTGTGTGTTCT 711
              |||||||||||||||||||||
Db         21 CCCCCGCCACCTGTGTGTTCT 1


RESULT 97
US-10-605-498-71/c
; Sequence 71, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 71
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-71

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGATACAT 721
              |||||||||||||||||||||
Db         21 CTGTGTGTTCTTTTGATACAT 1


RESULT 98
US-10-605-498-72/c
; Sequence 72, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 72
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-72

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        711 TTTTGATACATTTATCTTCTG 731
              |||||||||||||||||||||
Db         21 TTTTGATACATTTATCTTCTG 1


RESULT 99
US-10-605-498-73/c
; Sequence 73, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
;   LENGTH: 21
;   TYPE: DNA
```

```
;   ORGANISM: Homo sapiens
US-10-605-498-73

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        721 TTTATCTTCTGTTTTTCTCAA 741
              |||||||||||||||||||||
Db         21 TTTATCTTCTGTTTTTCTCAA 1


RESULT 100
US-10-605-498-74/c
; Sequence 74, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 74
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-74

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        731 GTTTTTCTCAAATAAAGTTCA 751
              |||||||||||||||||||||
Db         21 GTTTTTCTCAAATAAAGTTCA 1


RESULT 101
US-10-605-498-75/c
; Sequence 75, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 75
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-75

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        741 AATAAAGTTCAAAGCAACCAC 761
              |||||||||||||||||||||
Db         21 AATAAAGTTCAAAGCAACCAC 1


RESULT 102
US-10-605-498-76/c
; Sequence 76, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 76
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-76

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        744 AAAGTTCAAAGCAACCACCTG 764
              |||||||||||||||||||||
Db         21 AAAGTTCAAAGCAACCACCTG 1


RESULT 103
US-10-605-498-78/c
; Sequence 78, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 78
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-78

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        365 AAGGATGGCGTGGTGGAGATC 385
              |||||||||||||||||||||
Db         21 AAGGATGGCGTGGTGGAGATC 1
```

```
RESULT 104
US-10-605-498-79/c
; Sequence 79, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 79
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-79

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        265 ACTCAGCAGCGGGGTCTCGGA 285
              |||||||||||||||||||||
Db         21 ACTCAGCAGCGGGGTCTCGGA 1


RESULT 105
US-10-605-498-80/c
; Sequence 80, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 80
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-80

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        264 AACTCAGCAGCGGGGTCTCGG 284
              |||||||||||||||||||||
Db         21 AACTCAGCAGCGGGGTCTCGG 1


RESULT 106
US-10-605-498-81/c
; Sequence 81, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 81
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-81

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCCCC 46
              |||||||||||||||||||||
Db         21 ATGACCGAGCGCCGCGTCCCC 1


RESULT 107
US-10-719-900-152006/c
; Sequence 152006, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 152006
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-152006

  Query Match             2.7%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 34;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        406 GCAGGACGAGCATGGCTACATCTC 429
              ||||||||| || ||||||||||||
Db         25 GCAGGACGAACAAGGCTACATCTC 2


RESULT 108
US-10-809-189-92419
; Sequence 92419, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
```

```
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92419
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-92419

  Query Match             2.7%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 34;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        499 CCCTGAGGGCACACTGACCGTGGA 522
              |||||||||||||||  |||||||
Db          2 CCCTGAGGGCACACTTTCCGTGGA 25


RESULT 109
US-10-719-900-51106/c
; Sequence 51106, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 51106
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-51106

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        414 AGCATGGCTACATCTCCCGGTGCTT 438
              | ||||||||||| ||| ||||||||
Db         25 AACATGGCTACAACTCTCGGTGCTT 1


RESULT 110
US-10-719-900-72371
; Sequence 72371, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 72371
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-72371

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        447 AATACACGCTGCCCCCCGGTGTGGA 471
              |||||||||| || || ||||||||
Db          1 AATACACGCTCCCTCCAGGTGTGGA 25


RESULT 111
US-10-719-900-147040/c
; Sequence 147040, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 147040
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-147040

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        257 AGCCGGCAACTCAGCAGCGGGGTCT 281
              | ||| || ||||||||||||||||
Db         25 AACCGACAGCTCAGCAGCGGGGTCT 1


RESULT 112
US-10-719-900-248861
; Sequence 248861, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 248861
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-248861

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        425 ATCTCCCGGTGCTTCACGCGGAAAT 449
              ||||| |||||| |||| |||||||
Db          1 ATCTCTCGGTGCATCACCCGGAAAT 25


RESULT 113
US-10-719-900-347106
; Sequence 347106, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
```

```
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 347106
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-347106

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        132 CCCGGCTGCCGGAGGAGTGGTCGCA 156
              ||||| |||| || ||||||||||
Db          1 CCCGGTTGCCCGATGAGTGGTCGCA 25


RESULT 114
US-10-719-900-376561
; Sequence 376561, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 376561
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-376561

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        429 CCCGGTGCTTCACGCGGAAATACAC 453
              | ||||||||||  ||||||||||
Db          1 CTCGGTGCTTCAGCCGGAAATACAC 25


RESULT 115
US-10-719-900-415444
; Sequence 415444, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 415444
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-415444

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        413 GAGCATGGCTACATCTCCCGGTGCT 437
              || ||||||||| |||| |||||||
Db          1 GAACATGGCTACTTCTCTCGGTGCT 25


RESULT 116
US-10-719-900-472173/c
; Sequence 472173, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 472173
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-472173

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        407 CAGGACGAGCATGGCTACATCTCCC 431
              |||||||| ||| ||||||||||  |
Db         25 CAGGACGAACATCGCTACATCTCTC 1


RESULT 117
US-10-719-900-581985
; Sequence 581985, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 581985
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-581985

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        444 GGAAATACACGCTGCCCCCCGGTGT 468
              |||||||||||||| || || |||||
Db          1 GGAAATACACGCTCCCTCCAGGTGT 25


RESULT 118
US-10-719-900-592387
; Sequence 592387, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
```

```
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 592387
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-592387

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        409 GGACGAGCATGGCTACATCTCCCGG 433
              ||||||| ||||| |||||||| |||
Db          1 GGACGAACATGGGTACATCTCTCGG 25


RESULT 119
US-10-719-900-611646
; Sequence 611646, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 611646
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-611646

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        405 GGCAGGACGAGCATGGCTACATCTC 429
              ||||||| || ||||||||||| ||
Db          1 GGCAGGATGACCATGGCTACATTTC 25


RESULT 120
US-10-719-900-685015/c
; Sequence 685015, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 685015
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-685015

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        448 ATACACGCTGCCCCCCGGTGTGGAC 472
              ||||||||| || || |||||||||
Db         25 ATACACGCTCCCTCCAGGTGTGGAC 1


RESULT 121
US-10-719-900-685016/c
; Sequence 685016, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 685016
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-685016

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        448 ATACACGCTGCCCCCCGGTGTGGAC 472
              ||||||||| || || |||||||||
Db         25 ATACACGCTCCCACCAGGTGTGGAC 1


RESULT 122
US-10-719-900-819345/c
; Sequence 819345, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 819345
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-819345

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        324 ATGTCAACCACTTCGCCCCGGACGA 348
              | |||||||||||||| ||||| ||
Db         25 ACGTCAACCACTTCGCTCCGGAGGA 1


RESULT 123
US-10-719-900-830335
; Sequence 830335, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
```

```
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 830335
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-830335

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        428 TCCCGGTGCTTCACGCGGAAATACA 452
              || |||||||||  | ||||||||||
Db          1 TCTCGGTGCTTCTCCCGGAAATACA 25


RESULT 124
US-10-809-189-92432
; Sequence 92432, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92432
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-92432

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        375 TGGTGGAGATCACCGGCAAGCACGA 399
              | || |||||||| ||||||||||
Db          1 TTGTTGAGATCACTGGCAAGCACGA 25


RESULT 125
US-10-719-956-364445
; Sequence 364445, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 364445
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-364445

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        410 GACGAGCATGGCTACATCTCCCGGT 434
              || || ||||||||||||||| ||||
Db          1 GATGAACATGGCTACATCTCTCGGT 25


RESULT 126
US-10-719-956-435352
; Sequence 435352, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 435352
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-435352

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 40;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        261 GGCAACTCAGCAGCGGGGTCTCGGA 285
              |||||||||||| ||| ||||| ||
Db          1 GGCAACTCAGCACCGGTGTCTCAGA 25


RESULT 127
US-10-605-498-82/c
; Sequence 82, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 82
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-82

  Query Match             2.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 29;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCCC 45
              ||||||||||||||||||||
Db         20 ATGACCGAGCGCCGCGTCCC 1


RESULT 128
US-10-713-808-13
```

```
; Sequence 13, Application US/10713808
; Publication No. US20040265845A1
; GENERAL INFORMATION:
;  APPLICANT: University of Southern California
;  APPLICANT:  Hoon, Dave S. B.
;  APPLICANT:  Takeuchi, Hiroya
;  TITLE OF INVENTION: Detection of Micro Metastasis of Melanoma and Breast Cancer in
;  TITLE OF INVENTION:  Paraffin-Embedded Tumor Draining Lymph Nodes by Multimarker
;  TITLE OF INVENTION:  Quantitative RT-PCR
;  FILE REFERENCE: 89212.0014
;  CURRENT APPLICATION NUMBER: US/10/713,808
;  CURRENT FILING DATE:  2003-11-14
;  PRIOR APPLICATION NUMBER: US 60/426,216
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-713-808-13

  Query Match             2.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 29;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        399 AGGAGCGGCAGGACGAGCAT 418
              ||||||||||||||||||||
Db          1 AGGAGCGGCAGGACGAGCAT 20


RESULT 129
US-10-605-498-87
; Sequence 87, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 87
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-605-498-87

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 35;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        556 CGAGATCACCATCCCAGTC 574
              |||||:|||||:|||||:|
Db          1 CGAGAUCACCAUCCCAGUC 19


RESULT 130
US-10-605-498-90
; Sequence 90, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 90
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-605-498-90

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 35;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCC 44
              |:|||||||||||||:||
Db          1 AUGACCGAGCGCCGCGUCC 19


RESULT 131
US-10-472-779-1
; Sequence 1, Application US/10472779
; Publication No. US20040097539A1
; GENERAL INFORMATION:
;  APPLICANT: TERASHITA, Zen-ichi
;  APPLICANT:  NARUO, Ken-ichi
;  APPLICANT:  UCHIKAWA, Osamu
;  APPLICANT:  NAKANISHI, Atsushi
;  TITLE OF INVENTION: HSP inducing agent
;  FILE REFERENCE: 2890 US0P
;  CURRENT APPLICATION NUMBER: US/10/472,779
;  CURRENT FILING DATE:  2003-09-24
;  PRIOR APPLICATION NUMBER: PCT/JP02/02946
;  PRIOR FILING DATE: 2002-03-27
;  PRIOR APPLICATION NUMBER: JP 2001-92704
;  PRIOR FILING DATE: 2001-03-28
;  NUMBER OF SEQ ID NOS: 3
; SEQ ID NO 1
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer for amplifying HSP27 gene
US-10-472-779-1

  Query Match             2.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 49;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        359 AAGACCAAGGATGGCGTGGT 378
              |||||||||| ||||||||
Db          2 AAGACCAAGGAAGGCGTGGT 21


RESULT 132
US-10-605-498-77/c
; Sequence 77, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
```

```
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 77
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-77

  Query Match             2.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        226 AGTGGCCGCGCCCGCCTA 243
              ||||||||||||||||||
Db         18 AGTGGCCGCGCCCGCCTA 1


RESULT 133
US-10-605-498-89
; Sequence 89, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 89
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-605-498-89

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 57;
  Matches   16;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        576 CCTTCGAGTCGCGGGCCCAGC 596
              ||::|| |:|||||||| ||
Db          1 CCUUCGUGUCGCGGGCCCUGC 21


RESULT 134
US-10-472-779-2/c
; Sequence 2, Application US/10472779
; Publication No. US20040097539A1
; GENERAL INFORMATION:
;  APPLICANT: TERASHITA, Zen-ichi
;  APPLICANT:  NARUO, Ken-ichi
;  APPLICANT:  UCHIKAWA, Osamu
;  APPLICANT:  NAKANISHI, Atsushi
;  TITLE OF INVENTION: HSP inducing agent
;  FILE REFERENCE: 2890 US0P
;  CURRENT APPLICATION NUMBER: US/10/472,779
;  CURRENT FILING DATE:  2003-09-24
;  PRIOR APPLICATION NUMBER: PCT/JP02/02946
;  PRIOR FILING DATE: 2002-03-27
;  PRIOR APPLICATION NUMBER: JP 2001-92704
;  PRIOR FILING DATE: 2001-03-28
;  NUMBER OF SEQ ID NOS: 3
; SEQ ID NO 2
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer for amplifying HSP27 gene
US-10-472-779-2

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 62;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        413 GAGCATGGCTACATCTCCCGG 433
              || |||||||||||||| |||
Db         21 GAACATGGCTACATCTCTCGG 1


RESULT 135
US-10-339-793-168
; Sequence 168, Application US/10339793
; Publication No. US20030180764A1
; GENERAL INFORMATION:
;  APPLICANT: Lynx Therapeutics, Inc.
;  APPLICANT:  Shang, Jin
;  APPLICANT:  Bowen, Benjamin
;  TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
;  FILE REFERENCE: 37-000310US
;  CURRENT APPLICATION NUMBER: US/10/339,793
;  CURRENT FILING DATE:  2003-01-08
;  NUMBER OF SEQ ID NOS: 443
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 168
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-339-793-168

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 136
US-10-751-736-34691
; Sequence 34691, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34691
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-34691
```

```
  Query Match             2.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 75;
  Matches   15;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       170 AGCAGCTGGCCAGGCTACGT 189
             || |||:|||||||:|| :
Db         2 AGGAGCUGGCCAGGCUACUU 21


RESULT 137
US-09-990-613-0
; Sequence 0, Application US/09990613
; Publication No. US20030096219A1
; GENERAL INFORMATION:
;  APPLICANT: Wu, Reen
;  APPLICANT:  Chen, Yin
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE
;  TITLE OF INVENTION:  ANALYSIS OF MUCIN GENE EXPRESSION AND IDENTIFICATION OF
;  TITLE OF INVENTION:  DRUGS HAVING THE ABILITY TO INHIBIT MUCIN GENE EXPRESSION
;  FILE REFERENCE: UC072.001A
;  CURRENT APPLICATION NUMBER: US/09/990,613
;  CURRENT FILING DATE:  2001-11-21
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-990-613-0

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 83;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       403 GCGGCAGGACGAGCATGGC 421
             ||||||  ||||||||||||
Db         1 GCGGCACCACGAGCATGGC 19


RESULT 138
US-10-605-498-83
; Sequence 83, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 83
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-605-498-83

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 83;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       266 CTCAGCAGCGGGGTCTCGG 284
             |:| || ||||||:|:|||
Db         1 CUCUGCUGCGGGGUCUCGG 19


RESULT 139
US-10-605-498-7
; Sequence 7, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-7

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 97;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        60 GGGGCCCCAGCTGGGACCC 78
             |||| |||||||||| |||
Db         3 GGGGTCCCAGCTGGGGCCC 21


RESULT 140
US-09-866-108-10667
; Sequence 10667, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10667
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108-10667

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 141
US-10-211-689-82/c
; Sequence 82, Application US/10211689
; Publication No. US20030232347A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John II
;  APPLICANT:  Anderson, David W.
;  APPLICANT:  Boldog, Ferenc L.
;  APPLICANT:  Burgess, Catherine E.
;  APPLICANT:  Casman, Stacie J.
;  APPLICANT:  Edinger, Shlomit R.
;  APPLICANT:  Gangolli, Esha A.
;  APPLICANT:  Gorman, Linda
;  APPLICANT:  Guo, Xiaojia (Sasha)
;  APPLICANT:  Khramstov, Nikolai V.
;  APPLICANT:  Lepley, Denise M.
;  APPLICANT:  MacDougall, John R.
;  APPLICANT:  Pena, Carol A.
;  APPLICANT:  Peyman, John A.
;  APPLICANT:  Patturajan, Meera
;  APPLICANT:  Rieger, Daniel K.
;  APPLICANT:  Shimkets, Richard A.
;  APPLICANT:  Smithson, Glennda
;  APPLICANT:  Spytek, Kimberly A.
;  APPLICANT:  Vernet, Corine A. M.
;  APPLICANT:  Voss, Edward Z.
;  APPLICANT:  Zhong, Mei
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
;  FILE REFERENCE: 21402-416B
;  CURRENT APPLICATION NUMBER: US/10/211,689
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: 60/311751
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: 60/310,802
;  PRIOR FILING DATE: 2001-08-08
;  PRIOR APPLICATION NUMBER: 60/310,795
;  PRIOR FILING DATE: 2001-08-08
;  PRIOR APPLICATION NUMBER: 60/311,292
;  PRIOR FILING DATE: 2001-08-09
;  PRIOR APPLICATION NUMBER: 60/361,159
;  PRIOR FILING DATE: 2002-02-28
;  PRIOR APPLICATION NUMBER: 60/373,050
;  PRIOR FILING DATE: 2002-04-16
;  PRIOR APPLICATION NUMBER: 60/380,970
;  PRIOR FILING DATE: 2002-05-15
;  PRIOR APPLICATION NUMBER: 60/311,979
;  PRIOR FILING DATE: 2001-08-13
;  PRIOR APPLICATION NUMBER: 60/381,030
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/323,944
;  PRIOR FILING DATE: 2001-09-21
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 132
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 82
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artifical Sequence:  Primer/Probe
US-10-211-689-82

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        399 AGGAGCGGCAGGACGAG 415
              |||||| ||||||||||
Db         17 AGGAGCAGCAGGACGAG 1


RESULT 142
US-10-723-361-10667
; Sequence 10667, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10667
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-723-361-10667

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
```

```
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 143
US-10-844-072-10
; Sequence 10, Application US/10844072
; Publication No. US20050159376A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Vaish, Narendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of 5-Alpha Reductase and
;  TITLE OF INVENTION:  Androgen Receptor Gene Expression Using Short Interfering Nuclei
;  TITLE OF INVENTION:  Acid (siNA)
;  FILE REFERENCE: 400/157 (MBHB04-428)
;  CURRENT APPLICATION NUMBER: US/10/844,072
;  CURRENT FILING DATE:  2004-05-12
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 718
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 10
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-844-072-10

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 92;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        228 TGGCCGCGCCCGCCTAC 244
              :||||||||  ||||:||
Db          1 UGGCCGCGCUCGCCUAC 17


RESULT 144
US-10-844-072-133/c
; Sequence 133, Application US/10844072
; Publication No. US20050159376A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Vaish, Narendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of 5-Alpha Reductase and
;  TITLE OF INVENTION:  Androgen Receptor Gene Expression Using Short Interfering Nuclei
;  TITLE OF INVENTION:  Acid (siNA)
;  FILE REFERENCE: 400/157 (MBHB04-428)
;  CURRENT APPLICATION NUMBER: US/10/844,072
;  CURRENT FILING DATE:  2004-05-12
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 718
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 133
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-844-072-133

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 92;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        228 TGGCCGCGCCCGCCTAC 244
              |||||||| |||||||
Db         19 TGGCCGCGCTCGCCTAC 3


RESULT 145
US-10-922-340-10
; Sequence 10, Application US/10922340
; Publication No. US20050170371A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Vaish, Narendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of 5-Alpha Reductase and
;  TITLE OF INVENTION:  Androgen Receptor Gene Expression Using Short Interfering Nuclei
;  TITLE OF INVENTION:  Acid (siNA)
;  FILE REFERENCE: 400/222 (04-428-A)
;  CURRENT APPLICATION NUMBER: US/10/922,340
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: US 10/884,072
;  PRIOR FILING DATE: 2004-05-12
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: PCT/US04/13456
;  PRIOR FILING DATE: 2004-04-30
;  PRIOR APPLICATION NUMBER: US 10/780,447
;  PRIOR FILING DATE: 2004-02-13
;  PRIOR APPLICATION NUMBER: US 60/292,217
;  PRIOR FILING DATE: 2001-05-18
;  PRIOR APPLICATION NUMBER: US 60/362,016
;  PRIOR FILING DATE: 2002-03-06
;  PRIOR APPLICATION NUMBER: US 60/306,883
;  PRIOR FILING DATE: 2001-07-20
;  PRIOR APPLICATION NUMBER: US 60/311,865
;  PRIOR FILING DATE: 2001-08-13
;  PRIOR APPLICATION NUMBER: US 10/727,780
;  PRIOR FILING DATE: 2003-12-03
;  Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
;  NUMBER OF SEQ ID NOS: 750
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 10
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-922-340-10

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 92;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        228 TGGCCGCGCCCGCCTAC 244
              :||||||| ||||:||
Db          1 UGGCCGCGCUCGCCUAC 17


RESULT 146
US-10-922-340-133/c
; Sequence 133, Application US/10922340
; Publication No. US20050170371A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Vaish, Narendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of 5-Alpha Reductase and
;  TITLE OF INVENTION:  Androgen Receptor Gene Expression Using Short Interfering Nuclei
;  TITLE OF INVENTION:  Acid (siNA)
;  FILE REFERENCE: 400/222 (04-428-A)
;  CURRENT APPLICATION NUMBER: US/10/922,340
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: US 10/884,072
;  PRIOR FILING DATE: 2004-05-12
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: PCT/US04/13456
;  PRIOR FILING DATE: 2004-04-30
;  PRIOR APPLICATION NUMBER: US 10/780,447
;  PRIOR FILING DATE: 2004-02-13
;  PRIOR APPLICATION NUMBER: US 60/292,217
;  PRIOR FILING DATE: 2001-05-18
;  PRIOR APPLICATION NUMBER: US 60/362,016
;  PRIOR FILING DATE: 2002-03-06
;  PRIOR APPLICATION NUMBER: US 60/306,883
;  PRIOR FILING DATE: 2001-07-20
;  PRIOR APPLICATION NUMBER: US 60/311,865
;  PRIOR FILING DATE: 2001-08-13
;  PRIOR APPLICATION NUMBER: US 10/727,780
;  PRIOR FILING DATE: 2003-12-03
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 750
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 133
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-922-340-133

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 92;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        228 TGGCCGCGCCCGCCTAC 244
              ||||||||| |||||||
Db         19 TGGCCGCGCTCGCCTAC 3


RESULT 147
US-10-450-472-50/c
; Sequence 50, Application US/10450472
; Publication No. US20040132094A1
; GENERAL INFORMATION:
;  APPLICANT: Borean Pharma A/S
;  TITLE OF INVENTION: Combinatorial libraries of proteins having the scaffold structure
;  TITLE OF INVENTION:  of C-type lectin-like domains
;  FILE REFERENCE: BOR00003/WO
;  CURRENT APPLICATION NUMBER: US/10/450,472
;  CURRENT FILING DATE:  2003-12-08
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-10-450-472-50

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 99;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         86 GACTGGTACCCGCATAGC 103
              ||| |||||||||| ||
Db         18 GACCGGTACCCGCATCGC 1


RESULT 148
US-10-179-940-466/c
; Sequence 466, Application US/10179940
; Publication No. US20040018618A1
;  GENERAL INFORMATION:
;       APPLICANT: Abrams, Mark A.
;                  Bauer, S. C.
;                  Braford-Goldberg, Sarah R.
;                  Caparon, Maire H.
;                  Easton, Alan M.
;                  Klein, Barbara K.
;                  McKearn, John P.
;                  Olins, Peter O.
;                  Paik, Kumnan
;                  Polazzi, Joseph O.
;       TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
;       NUMBER OF SEQUENCES: 549
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Carol M. Nielsen, Gardere Wynne Sewell LLP,
;            STREET: 1601 Elm Street, Suite 3000
;            CITY: Dallas
;            STATE: Texas
;            COUNTRY: USA
;            ZIP: 75201-4761
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/179,940
;            FILING DATE: 19-Jun-2002
;            CLASSIFICATION: Unknown
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 07/981044
;            FILING DATE: 24-NOV-1992
;            APPLICATION NUMBER: PCT/US93/11198
;            FILING DATE: 22-NOV-1993
;            APPLICATION NUMBER: US 08/411796
;            FILING DATE: 09-APR-1995
;            APPLICATION NUMBER: US 08/559390
;            FILING DATE: 15-NOV-1995
;       ATTORNEY/AGENT INFORMATION:
```

```
;             NAME: Carol M. Nielsen
;             REGISTRATION NUMBER: 37,676
;             REFERENCE/DOCKET NUMBER: 126181-1056 (C2713/1)
;       TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (713)276-5383
;             TELEFAX: (713)276-5555
;   INFORMATION FOR SEQ ID NO: 466:
;       SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;       MOLECULE TYPE: DNA (synthetic)
;       SEQUENCE DESCRIPTION: SEQ ID NO: 466:
US-10-179-940-466

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 91;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 149
US-09-866-108-10666
; Sequence 10666, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10666
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-10666

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 150
US-09-866-108-10668
; Sequence 10668, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10668
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-10668

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy          13 AGAGTCAGCCAGCATG 28
               |||| ||||||||||||
Db           1 AGAGCCAGCCAGCATG 16


RESULT 151
US-10-060-830-218/c
; Sequence 218, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
;  FILE REFERENCE: PB0169
;  CURRENT APPLICATION NUMBER: US/10/060,830
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 218
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-830-218

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          11 GCAGAGTCAGCCAGCA 26
               |||||||||||| |||
Db          17 GCAGAGTCAGCCTGCA 2


RESULT 152
US-10-060-830-219/c
; Sequence 219, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
;  FILE REFERENCE: PB0169
;  CURRENT APPLICATION NUMBER: US/10/060,830
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 219
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-830-219

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          11 GCAGAGTCAGCCAGCA 26
               |||||||||||| |||
Db          16 GCAGAGTCAGCCTGCA 1


RESULT 153
US-10-156-306-5028
; Sequence 5028, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5028
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-5028

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         193 CCCCCTGCCCCCCGCC 208
               |||| :||||||||||
Db           1 CCCCUUGCCCCCCGCC 16


RESULT 154
US-10-238-700-2848/c
; Sequence 2848, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2848
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-2848

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
```

```
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        227 GTGGCCGCGCCCGCCT 242
              ||||||||| ||||||
Db         16 GTGGCCGCGGCCGCCT 1


RESULT 155
US-10-723-361-10666
; Sequence 10666, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10666
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-723-361-10666

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 156
US-10-723-361-10668
; Sequence 10668, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10668
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-723-361-10668

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 157
US-10-498-462-2203
; Sequence 2203, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
;  APPLICANT: Guo, Jinjiao
;  TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
;  FILE REFERENCE: PB01102
;  CURRENT APPLICATION NUMBER: US/10/498,462
;  CURRENT FILING DATE:  2004-06-10
;  PRIOR APPLICATION NUMBER: US 60/339,764
;  PRIOR FILING DATE: 2001-12-10
;  PRIOR APPLICATION NUMBER: PCT/US02/37506
;  PRIOR FILING DATE: 2002-11-22
;  NUMBER OF SEQ ID NOS: 3320
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2203
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-498-462-2203

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              ||| ||||||||||||
Db          2 CTGAGGGGCCCCAGCT 17
```

```
RESULT 158
US-10-498-462-2204
; Sequence 2204, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
;  APPLICANT: Guo, Jinjiao
;  TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
;  FILE REFERENCE: PB01102
;  CURRENT APPLICATION NUMBER: US/10/498,462
;  CURRENT FILING DATE:  2004-06-10
;  PRIOR APPLICATION NUMBER: US 60/339,764
;  PRIOR FILING DATE: 2001-12-10
;  PRIOR APPLICATION NUMBER: PCT/US02/37506
;  PRIOR FILING DATE: 2002-11-22
;  NUMBER OF SEQ ID NOS: 3320
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2204
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-498-462-2204

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
                ||| ||||||||||||
Db          1 CTGAGGGGCCCCAGCT 16


RESULT 159
US-10-724-270-1527/c
; Sequence 1527, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  TITLE OF INVENTION:  RAS, HER2 and HIV
;  FILE REFERENCE: 400/046-US  (MBHB02-326-A)
;  CURRENT APPLICATION NUMBER: US/10/724,270
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: PCT/US02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 10/238,700
;  PRIOR FILING DATE: 2002-09-10
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2002-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 6810
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1527
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-724-270-1527

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        227 GTGGCCGCGCCCGCCT 242
              ||||||||| ||||||
Db         16 GTGGCCGCGGCCGCCT 1


RESULT 160
US-10-349-143-6095/c
; Sequence 6095, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6095
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-8894 for SEQ 2161,
US-10-349-143-6095

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGA 716
              |||||||||||| |||
Db         18 CTGTGTGTTCTTCTGA 3


RESULT 161
US-10-702-817-27
; Sequence 27, Application US/10702817
; Publication No. US20040147471A1
; GENERAL INFORMATION:
;  APPLICANT: Hong Zhang
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1 EXPRESSION
;  FILE REFERENCE: ISPH-0797
;  CURRENT APPLICATION NUMBER: US/10/702,817
;  CURRENT FILING DATE:  2003-11-06
;  PRIOR APPLICATION NUMBER: US 09/106,038
;  PRIOR FILING DATE: 1998-06-26
;  PRIOR APPLICATION NUMBER: PCT/US99/13763
;  PRIOR FILING DATE: 1999-06-17
;  PRIOR APPLICATION NUMBER: 09/695,451
;  PRIOR FILING DATE: 2000-10-24
;  NUMBER OF SEQ ID NOS: 247
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 27
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
```

```
US-10-702-817-27

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || |||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 162
US-09-818-875-4230/c
; Sequence 4230, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4230
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-4230

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         15 AGCCACGCAGTCCA 2


RESULT 163
US-09-818-875-4231
; Sequence 4231, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4231
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-4231

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          3 AGCCACGCAGTCCA 16


RESULT 164
US-09-780-533A-765
; Sequence 765, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 765
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-765

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        164 GGCGGCAGCAGCTG 177
              |||||||||||:|
Db          3 GGCGGCAGCAGCUG 16


RESULT 165
US-09-780-533A-1791
; Sequence 1791, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1791
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1791

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 1.1e+02;
```

```
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        164 GGCGGCAGCAGCTG 177
              ||||||||||||:|
Db          2 GGCGGCAGCAGCUG 15


RESULT 166
US-10-209-787-4230/c
; Sequence 4230, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4230
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-4230

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         15 AGCCACGCAGTCCA 2


RESULT 167
US-10-209-787-4231
; Sequence 4231, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4231
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-4231

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          3 AGCCACGCAGTCCA 16


RESULT 168
US-10-261-185-4230/c
; Sequence 4230, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4230
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-4230

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         15 AGCCACGCAGTCCA 2


RESULT 169
US-10-261-185-4231
; Sequence 4231, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
```

```
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4231
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-4231

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          3 AGCCACGCAGTCCA 16


RESULT 170
US-10-681-074-4230/c
; Sequence 4230, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4230
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-4230

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         15 AGCCACGCAGTCCA 2


RESULT 171
US-10-681-074-4231
; Sequence 4231, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4231
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-4231

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          3 AGCCACGCAGTCCA 16


RESULT 172
US-09-866-108-2329/c
; Sequence 2329, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2329
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-2329

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
```

```
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 173
US-09-866-108-2330/c
; Sequence 2330, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2330
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-2330

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 174
US-09-866-108-2331/c
; Sequence 2331, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2331
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-2331

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              |||||| ||| ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 175
US-09-866-108-10669
; Sequence 10669, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
```

```
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10669
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-10669

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              ||| |||||||||||  |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 176
US-09-866-108-10670
; Sequence 10670, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10670
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-10670

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||| ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 177
US-09-864-785-1425/c
; Sequence 1425, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Draper, Ken
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of NF-Kappa B
;  FILE REFERENCE: 400/022 (MBHB00-812-D)
;  CURRENT APPLICATION NUMBER: US/09/864,785
;  CURRENT FILING DATE:  2001-05-23
;  NUMBER OF SEQ ID NOS: 3929
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1425
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-864-785-1425

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         62 GGCCCCAGCTGGGACCC 78
              || |||||||| |||||
Db         17 GGGCCCAGCTGCGACCC 1


RESULT 178
US-09-825-805-772
; Sequence 772, Application US/09825805
```

```
; Publication No. US20030004122A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-F (400/009)
;  CURRENT APPLICATION NUMBER: US/09/825,805
;  CURRENT FILING DATE:  2001-09-27
;  PRIOR APPLICATION NUMBER: 09/578,223
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 09/476,387
;  PRIOR FILING DATE: 1999-12-30
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1558
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 772
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-825-805-772

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 179
US-09-780-533A-2414
; Sequence 2414, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2414
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2414

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        462 CCGGTGTGGACCCCACC 478
              || |:|:||||||| ||
Db          1 CCCGUGUGGACCCCGCC 17


RESULT 180
US-09-927-046-1306
; Sequence 1306, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1306
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1306

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        506 GGCACACTGACCGTGGA 522
              |||||| :|| ||:|||
Db          1 GGCACAGUGAUCGUGGA 17


RESULT 181
US-09-927-046-1904/c
; Sequence 1904, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1904
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1904

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        423 ACATCTCCCGGTGCTTC 439
              ||||||||| ||| |||
Db         17 ACATCTCCCTGTGATTC 1


RESULT 182
```

```
US-09-927-046-1905/c
; Sequence 1905, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1905
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1905

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        422 TACATCTCCCGGTGCTT 438
              ||||||||||  ||| ||
Db         17 TACATCTCCCTGTGATT 1


RESULT 183
US-09-740-332-4378
; Sequence 4378, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4378
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4378

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCCC 693
              | |:||| |:|||:|||
Db          1 CCCUGGCAGUGCCUCCC 17


RESULT 184
US-09-817-879-4378
; Sequence 4378, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4378
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-4378

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCCC 693
              | |:||| |:|||:|||
Db          1 CCCUGGCAGUGCCUCCC 17


RESULT 185
US-10-060-756A-170/c
; Sequence 170, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 170
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-170

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        295 CACTGCGGACCGCTGGC 311
              ||||||| ||| ||||
Db         17 CACTGCGGCCCGGTGGC 1


RESULT 186
US-10-163-552-650
; Sequence 650, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
;  TITLE OF INVENTION:  HER2
;  FILE REFERENCE: MBHB01-1653-A (400/014)
;  CURRENT APPLICATION NUMBER: US/10/163,552
;  CURRENT FILING DATE:  2002-06-06
;  NUMBER OF SEQ ID NOS: 1997
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 650
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-163-552-650

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 187
US-10-156-306-5029
; Sequence 5029, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5029
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-5029

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        194 CCCCTGCCCCCCGCCGC 210
              ||| :|||||||||| |
Db          1 CCCUUGCCCCCCGCCCC 17


RESULT 188
US-10-238-700-484
; Sequence 484, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 484
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-484

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 1.2e+02;
  Matches    6;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 TTCTTTTGATACATTTA 724
              : |::::||:| |:::|
Db          1 UCCUUUUGAUAAAUUUA 17


RESULT 189
US-10-061-201-1223
; Sequence 1223, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1223
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-1223

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        557 GAGATCACCATCCCAGT 573
              ||||||| || ||||||
Db          1 GAGATCAGCACCCCAGT 17


RESULT 190
US-10-382-248-80/c
; Sequence 80, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, et al.
;  TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
;  FILE REFERENCE: 21402-568C
;  CURRENT APPLICATION NUMBER: US/10/382,248
;  CURRENT FILING DATE:  2003-03-05
;  PRIOR APPLICATION NUMBER: 60/366,928
;  PRIOR FILING DATE: 2002-03-22
;  PRIOR APPLICATION NUMBER: 60/361,974
;  PRIOR FILING DATE: 2002-03-06
;  PRIOR APPLICATION NUMBER: 60/365,477
```

```
;  PRIOR FILING DATE: 2002-03-19
;  PRIOR APPLICATION NUMBER: 60/401,661
;  PRIOR FILING DATE: 2002-08-06
;  NUMBER OF SEQ ID NOS: 82
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 80
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artifical Sequence:  Primer/Probe
US-10-382-248-80

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        664 CCCCTGCTGCCGCCACT 680
              ||||| |||| ||||||
Db         17 CCCCTTCTGCAGCCACT 1


RESULT 191
US-10-676-154-599/c
; Sequence 599, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/676,154
;  CURRENT FILING DATE:  2003-09-29
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 599
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-10-676-154-599

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 AGTTCAAAGCAACCACC 762
              ||| |||||||| ||||
Db         17 AGTACAAAGCAAACACC 1


RESULT 192
US-10-712-672-332/c
; Sequence 332, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 332
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-332

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        254 CTCAGCCGGCAACTCAG 270
              |||||||||  ||||||
Db         17 CTCAGCCGGACACTCAG 1


RESULT 193
US-10-669-841-6971
; Sequence 6971, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6971
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6971
```

```
  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCCC 693
              | |:||| |:|||:|||
Db          1 CCCUGGCAGUGCCUCCC 17


RESULT 194
US-10-723-361-2329/c
; Sequence 2329, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2329
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-2329

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 195
US-10-723-361-2330/c
; Sequence 2330, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2330
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-2330

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 196
US-10-723-361-2331/c
; Sequence 2331, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2331
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-723-361-2331

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              ||||||  ||| ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 197
US-10-723-361-10669
; Sequence 10669, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10669
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-723-361-10669

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              ||| |||||||||| |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 198
US-10-723-361-10670
; Sequence 10670, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10670
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-723-361-10670

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||| ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 199
US-10-494-343-325
; Sequence 325, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  APPLICANT:  Phan, Thuymy
;  TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
;  FILE REFERENCE: PB0184
;  CURRENT APPLICATION NUMBER: US/10/494,343
;  CURRENT FILING DATE:  2004-04-30
;  PRIOR APPLICATION NUMBER: US to be assigned
```

```
;  PRIOR FILING DATE: to be assigned
;  PRIOR APPLICATION NUMBER: PCT/US2002/035129
;  PRIOR FILING DATE: 2002-11-01
;  PRIOR APPLICATION NUMBER: US 60/334,773
;  PRIOR FILING DATE: 2001-11-01
;  NUMBER OF SEQ ID NOS: 870
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 325
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-494-343-325

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        243 ACAGCCGCGCGCTCAGC 259
              ||| |||| ||||||||
Db          1 ACATCCGCTCGCTCAGC 17


RESULT 200
US-10-498-462-1759/c
; Sequence 1759, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
;  APPLICANT: Guo, Jinjiao
;  TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
;  FILE REFERENCE: PB01102
;  CURRENT APPLICATION NUMBER: US/10/498,462
;  CURRENT FILING DATE:  2004-06-10
;  PRIOR APPLICATION NUMBER: US 60/339,764
;  PRIOR FILING DATE: 2001-12-10
;  PRIOR APPLICATION NUMBER: PCT/US02/37506
;  PRIOR FILING DATE: 2002-11-22
;  NUMBER OF SEQ ID NOS: 3320
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1759
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-498-462-1759

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        520 GGAGGCCCCCATGCCCA 536
              ||||||| |||| |||||
Db         17 GGAGGCACCCAGGCCCA 1


RESULT 201
US-10-498-462-1760/c
; Sequence 1760, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
;  APPLICANT: Guo, Jinjiao
;  TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
;  FILE REFERENCE: PB01102
;  CURRENT APPLICATION NUMBER: US/10/498,462
;  CURRENT FILING DATE:  2004-06-10
;  PRIOR APPLICATION NUMBER: US 60/339,764
;  PRIOR FILING DATE: 2001-12-10
;  PRIOR APPLICATION NUMBER: PCT/US02/37506
;  PRIOR FILING DATE: 2002-11-22
;  NUMBER OF SEQ ID NOS: 3320
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1760
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-498-462-1760

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        519 TGGAGGCCCCCATGCCC 535
              ||||||| |||| ||||
Db         17 TGGAGGCACCCAGGCCC 1


RESULT 202
US-10-724-270-484
; Sequence 484, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  TITLE OF INVENTION:  RAS, HER2 and HIV
;  FILE REFERENCE: 400/046-US  (MBHB02-326-A)
;  CURRENT APPLICATION NUMBER: US/10/724,270
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: PCT/US02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 10/238,700
;  PRIOR FILING DATE: 2002-09-10
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2002-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 6810
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 484
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-724-270-484

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 1.2e+02;
  Matches    6;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 TTCTTTTGATACATTTA 724
              : |::::||:| |:::|
Db          1 UCCUUUUGAUAAAUUUA 17


RESULT 203
US-10-724-270-5305
; Sequence 5305, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  TITLE OF INVENTION:  RAS, HER2 and HIV
;  FILE REFERENCE: 400/046-US  (MBHB02-326-A)
;  CURRENT APPLICATION NUMBER: US/10/724,270
;  CURRENT FILING DATE:  2003-11-26
```

```
;  PRIOR APPLICATION NUMBER: PCT/US02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 10/238,700
;  PRIOR FILING DATE: 2002-09-10
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2002-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 6810
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5305
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-724-270-5305

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 204
US-10-890-776A-170/c
; Sequence 170, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/890,776A
;  CURRENT FILING DATE:  2004-07-14
;  PRIOR APPLICATION NUMBER: US 10/060,756
;  PRIOR FILING DATE: 2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4809
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 170
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-890-776A-170

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        295 CACTGCGGACCGCTGGC 311
              ||||||| ||| ||||
Db         17 CACTGCGGCCCGGTGGC 1


RESULT 205
US-10-712-672-1489
; Sequence 1489, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1489
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-1489

  Query Match             1.8%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        197 CTGCCCCCCGCCGCC 211
              | ||||||||||||||
Db          2 CCGCCCCCCGCCGCC 16


RESULT 206
US-09-918-728B-11/c
; Sequence 11, Application US/09918728B
; Publication No. US20030105308A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleoside Triphosphates and Their Incorporation into Oligonucleo
;  FILE REFERENCE: MBHB00-831-H (400/033)
;  CURRENT APPLICATION NUMBER: US/09/918,728B
;  CURRENT FILING DATE:  2002-04-03
;  NUMBER OF SEQ ID NOS: 127
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 11
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-918-728B-11

  Query Match             1.7%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        685 GTGCCTCCCCCGC 697
              |||||||||||||
Db         15 GTGCCTCCCCCGC 3
```

```
RESULT 207
US-10-712-672-1490
; Sequence 1490, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1490
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-1490

  Query Match             1.7%;  Score 13;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        199 GCCCCCCGCCGCC 211
              |||||||||||||
Db          1 GCCCCCCGCCGCC 13


RESULT 208
US-10-605-498-50
; Sequence 50, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-50

  Query Match             1.7%;  Score 13;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy        495 TGTCCCCTGAGGGCACACTGA 515
              ||| |||| |||| |||  ||
Db          1 TGTGCCCTCAGGGGACAGGGA 21


RESULT 209
US-09-829-855-10
; Sequence 10, Application US/09829855
; Patent No. US20020065609A1
; GENERAL INFORMATION:
;  APPLICANT: Matthew, Ashby N.
;  TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;  FILE REFERENCE: ASHBY-1
;  CURRENT APPLICATION NUMBER: US/09/829,855
;  CURRENT FILING DATE:  2001-04-10
;  PRIOR APPLICATION NUMBER: US 60/196063
;  PRIOR FILING DATE: 2000-04-10
;  PRIOR APPLICATION NUMBER: US 60/196258
;  PRIOR FILING DATE: 2000-04-11
;  NUMBER OF SEQ ID NOS: 244
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: unknown
;   FEATURE:
;   OTHER INFORMATION: unidentified soil organism
US-09-829-855-10

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        525 CCCCCATGCCCAAGCT 540
              ||||| |||| |||||
Db          1 CCCCCGTGCCGAAGCT 16


RESULT 210
US-09-829-855-110
; Sequence 110, Application US/09829855
; Patent No. US20020065609A1
; GENERAL INFORMATION:
;  APPLICANT: Matthew, Ashby N.
;  TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;  FILE REFERENCE: ASHBY-1
;  CURRENT APPLICATION NUMBER: US/09/829,855
;  CURRENT FILING DATE:  2001-04-10
;  PRIOR APPLICATION NUMBER: US 60/196063
;  PRIOR FILING DATE: 2000-04-10
;  PRIOR APPLICATION NUMBER: US 60/196258
;  PRIOR FILING DATE: 2000-04-11
;  NUMBER OF SEQ ID NOS: 244
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 110
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: unknown
;   FEATURE:
;   OTHER INFORMATION: unidentified soil organism
US-09-829-855-110

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              |||||| ||| |||||
Db          1 CTGCGGTGCCGCAGCT 16


RESULT 211
US-10-455-013-17
; Sequence 17, Application US/10455013
; Publication No. US20040010810A1
; GENERAL INFORMATION:
;  APPLICANT: KUCHERLAPATI, RAJU
;  APPLICANT:  JAKOBOVITS, AYA
;  APPLICANT:  KLAPHOLZ, SUE
```

```
;  APPLICANT:  BRENNER, DANIEL G.
;  APPLICANT:  CAPON, DANIEL J.
;  TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
;  FILE REFERENCE: CELL 4.6 CON 2
;  CURRENT APPLICATION NUMBER: US/10/455,013
;  CURRENT FILING DATE:  2003-06-04
;  PRIOR APPLICATION NUMBER: 09/019,523
;  PRIOR FILING DATE: 1998-02-05
;  PRIOR APPLICATION NUMBER: 08/234,145
;  PRIOR FILING DATE: 1994-04-28
;  PRIOR APPLICATION NUMBER: 08/112,848
;  PRIOR FILING DATE: 1993-08-27
;  PRIOR APPLICATION NUMBER: 08/031,801
;  PRIOR FILING DATE: 1993-03-15
;  PRIOR APPLICATION NUMBER: 07/919,297
;  PRIOR FILING DATE: 1992-07-24
;  PRIOR APPLICATION NUMBER: 07/610,515
;  PRIOR FILING DATE: 1990-11-08
;  PRIOR APPLICATION NUMBER: 07/466,008
;  PRIOR FILING DATE: 1990-01-12
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-455-013-17

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 212
US-10-455-013-29
; Sequence 29, Application US/10455013
; Publication No. US20040010810A1
; GENERAL INFORMATION:
;  APPLICANT: KUCHERLAPATI, RAJU
;  APPLICANT:  JAKOBOVITS, AYA
;  APPLICANT:  KLAPHOLZ, SUE
;  APPLICANT:  BRENNER, DANIEL G.
;  APPLICANT:  CAPON, DANIEL J.
;  TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
;  FILE REFERENCE: CELL 4.6 CON 2
;  CURRENT APPLICATION NUMBER: US/10/455,013
;  CURRENT FILING DATE:  2003-06-04
;  PRIOR APPLICATION NUMBER: 09/019,523
;  PRIOR FILING DATE: 1998-02-05
;  PRIOR APPLICATION NUMBER: 08/234,145
;  PRIOR FILING DATE: 1994-04-28
;  PRIOR APPLICATION NUMBER: 08/112,848
;  PRIOR FILING DATE: 1993-08-27
;  PRIOR APPLICATION NUMBER: 08/031,801
;  PRIOR FILING DATE: 1993-03-15
;  PRIOR APPLICATION NUMBER: 07/919,297
;  PRIOR FILING DATE: 1992-07-24
;  PRIOR APPLICATION NUMBER: 07/610,515
;  PRIOR FILING DATE: 1990-11-08
;  PRIOR APPLICATION NUMBER: 07/466,008
;  PRIOR FILING DATE: 1990-01-12
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-455-013-29

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 213
US-10-179-940-539/c
; Sequence 539, Application US/10179940
; Publication No. US20040018618A1
;  GENERAL INFORMATION:
;       APPLICANT: Abrams, Mark A.
;                  Bauer, S. C.
;                  Braford-Goldberg, Sarah R.
;                  Caparon, Maire H.
;                  Easton, Alan M.
;                  Klein, Barbara K.
;                  McKearn, John P.
;                  Olins, Peter O.
;                  Paik, Kumnan
;                  Polazzi, Joseph O.
;       TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
;       NUMBER OF SEQUENCES: 549
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Carol M. Nielsen, Gardere Wynne Sewell LLP,
;            STREET: 1601 Elm Street, Suite 3000
;            CITY: Dallas
;            STATE: Texas
;            COUNTRY: USA
;            ZIP: 75201-4761
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/179,940
;            FILING DATE: 19-Jun-2002
;            CLASSIFICATION: Unknown
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 07/981044
;            FILING DATE: 24-NOV-1992
;            APPLICATION NUMBER: PCT/US93/11198
;            FILING DATE: 22-NOV-1993
;            APPLICATION NUMBER: US 08/411796
;            FILING DATE: 09-APR-1995
;            APPLICATION NUMBER: US 08/559390
;            FILING DATE: 15-NOV-1995
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Carol M. Nielsen
;            REGISTRATION NUMBER: 37,676
;            REFERENCE/DOCKET NUMBER: 126181-1056 (C2713/1)
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (713)276-5383
;            TELEFAX: (713)276-5555
;   INFORMATION FOR SEQ ID NO: 539:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA (synthetic)
;       SEQUENCE DESCRIPTION: SEQ ID NO: 539:
US-10-179-940-539
```

```
  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| |||||||||  ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 214
US-10-627-250-17
; Sequence 17, Application US/10627250
; Publication No. US20040093622A1
; GENERAL INFORMATION:
;  APPLICANT: KUCHERLAPATI, RAJU
;  APPLICANT:  JAKOBOVITS, AYA
;  APPLICANT:  KLAPHOLZ, SUE
;  APPLICANT:  BRENNER, DANIEL G.
;  APPLICANT:  CAPON, DANIEL J.
;  TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
;  FILE REFERENCE: CELL 4.4 CPA RCE
;  CURRENT APPLICATION NUMBER: US/10/627,250
;  CURRENT FILING DATE:  2003-07-24
;  PRIOR APPLICATION NUMBER: US/08/031,801
;  PRIOR FILING DATE: 2003-01-10
;  PRIOR APPLICATION NUMBER: 07/919,297
;  PRIOR FILING DATE: 1992-07-24
;  PRIOR APPLICATION NUMBER: PCT/US91/00245
;  PRIOR FILING DATE: 1991-01-11
;  PRIOR APPLICATION NUMBER: 07/610,515
;  PRIOR FILING DATE: 1990-11-08
;  PRIOR APPLICATION NUMBER: 07/466,008
;  PRIOR FILING DATE: 1990-01-12
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-627-250-17

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 215
US-10-627-250-29
; Sequence 29, Application US/10627250
; Publication No. US20040093622A1
; GENERAL INFORMATION:
;  APPLICANT: KUCHERLAPATI, RAJU
;  APPLICANT:  JAKOBOVITS, AYA
;  APPLICANT:  KLAPHOLZ, SUE
;  APPLICANT:  BRENNER, DANIEL G.
;  APPLICANT:  CAPON, DANIEL J.
;  TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
;  FILE REFERENCE: CELL 4.4 CPA RCE
;  CURRENT APPLICATION NUMBER: US/10/627,250
;  CURRENT FILING DATE:  2003-07-24
;  PRIOR APPLICATION NUMBER: US/08/031,801
;  PRIOR FILING DATE: 2003-01-10
;  PRIOR APPLICATION NUMBER: 07/919,297
;  PRIOR FILING DATE: 1992-07-24
;  PRIOR APPLICATION NUMBER: PCT/US91/00245
;  PRIOR FILING DATE: 1991-01-11
;  PRIOR APPLICATION NUMBER: 07/610,515
;  PRIOR FILING DATE: 1990-11-08
;  PRIOR APPLICATION NUMBER: 07/466,008
;  PRIOR FILING DATE: 1990-01-12
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: polylinker
US-10-627-250-29

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 216
US-10-712-672-1775
; Sequence 1775, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1775
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-1775

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   68.8%;  Pred. No. 1.4e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCC 692
              || :|||:|:||| ||
Db          1 CAGUGGCUGUGCCACC 16


RESULT 217
US-10-607-077A-10
; Sequence 10, Application US/10607077A
; Publication No. US20040110183A1
; GENERAL INFORMATION:
;  APPLICANT: Ashby, Matthew
;  TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;  FILE REFERENCE: ASHBY/1 DIV
;  CURRENT APPLICATION NUMBER: US/10/607,077A
;  CURRENT FILING DATE:  2003-06-25
;  PRIOR APPLICATION NUMBER: US 09/829855
;  PRIOR FILING DATE: 2001-04-10
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/11609
;  PRIOR FILING DATE: 2001-04-10
;  PRIOR APPLICATION NUMBER: US 60/196063
;  PRIOR FILING DATE: 2000-04-10
;  PRIOR APPLICATION NUMBER: US 60/196258
;  PRIOR FILING DATE: 2000-04-11
;  NUMBER OF SEQ ID NOS: 244
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: ribosomal DNA sequence tag isolated from
;   OTHER INFORMATION: microbes in soil sample collected
;   OTHER INFORMATION: in Wyoming, USA
US-10-607-077A-10

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        525 CCCCCATGCCCAAGCT 540
              ||||| |||| |||||
Db          1 CCCCCGTGCCGAAGCT 16


RESULT 218
US-10-607-077A-110
; Sequence 110, Application US/10607077A
; Publication No. US20040110183A1
; GENERAL INFORMATION:
;  APPLICANT: Ashby, Matthew
;  TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;  FILE REFERENCE: ASHBY/1 DIV
;  CURRENT APPLICATION NUMBER: US/10/607,077A
;  CURRENT FILING DATE:  2003-06-25
;  PRIOR APPLICATION NUMBER: US 09/829855
;  PRIOR FILING DATE: 2001-04-10
;  PRIOR APPLICATION NUMBER: PCT/US01/11609
;  PRIOR FILING DATE: 2001-04-10
;  PRIOR APPLICATION NUMBER: US 60/196063
;  PRIOR FILING DATE: 2000-04-10
;  PRIOR APPLICATION NUMBER: US 60/196258
;  PRIOR FILING DATE: 2000-04-11
;  NUMBER OF SEQ ID NOS: 244
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 110
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: ribosomal DNA sequence tag isolated from
;   OTHER INFORMATION: microbes in soil sample collected
;   OTHER INFORMATION: in Wyoming, USA
US-10-607-077A-110

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              |||||| ||| |||||
Db          1 CTGCGGTGCCGCAGCT 16


RESULT 219
US-10-776-934-107/c
; Sequence 107, Application US/10776934
; Publication No. US20050014712A1
; GENERAL INFORMATION:
;  APPLICANT: HANSEN, BO
;  APPLICANT:  THRUE, CHARLOTTE ALBAEK
;  APPLICANT:  WESTERGAARD, MAJKEN
;  APPLICANT:  PETERSEN, KAMILLE DUMONG
;  APPLICANT:  WISSENBACH, MARGIT
;  TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
;  FILE REFERENCE: 58610(71432)
;  CURRENT APPLICATION NUMBER: US/10/776,934
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: 60/446,372
;  PRIOR FILING DATE: 2003-02-10
;  PRIOR APPLICATION NUMBER: 60/523,591
;  PRIOR FILING DATE: 2003-11-19
;  NUMBER OF SEQ ID NOS: 741
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 107
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-776-934-107

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        161 TTAGGCGGCAGCAGCT 176
              || || ||||||||||
Db         16 TTTGGAGGCAGCAGCT 1


RESULT 220
US-10-776-934-568/c
; Sequence 568, Application US/10776934
; Publication No. US20050014712A1
; GENERAL INFORMATION:
;  APPLICANT: HANSEN, BO
;  APPLICANT:  THRUE, CHARLOTTE ALBAEK
;  APPLICANT:  WESTERGAARD, MAJKEN
;  APPLICANT:  PETERSEN, KAMILLE DUMONG
;  APPLICANT:  WISSENBACH, MARGIT
;  TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
;  FILE REFERENCE: 58610(71432)
;  CURRENT APPLICATION NUMBER: US/10/776,934
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: 60/446,372
;  PRIOR FILING DATE: 2003-02-10
;  PRIOR APPLICATION NUMBER: 60/523,591
;  PRIOR FILING DATE: 2003-11-19
;  NUMBER OF SEQ ID NOS: 741
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 568
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: beta-D-oxy-LNA modified base
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (13)..(16)
;   OTHER INFORMATION: beta-D-oxy-LNA modified base
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(16)
;   OTHER INFORMATION: phosphorthioate linkage
US-10-776-934-568

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy        161 TTAGGCGGCAGCAGCT 176
              || || ||||||||||
Db         16 TTTGGAGGCAGCAGCT 1


RESULT 221
US-10-776-934-569/c
; Sequence 569, Application US/10776934
; Publication No. US20050014712A1
; GENERAL INFORMATION:
;  APPLICANT: HANSEN, BO
;  APPLICANT:  THRUE, CHARLOTTE ALBAEK
;  APPLICANT:  WESTERGAARD, MAJKEN
;  APPLICANT:  PETERSEN, KAMILLE DUMONG
;  APPLICANT:  WISSENBACH, MARGIT
;  TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
;  FILE REFERENCE: 58610(71432)
;  CURRENT APPLICATION NUMBER: US/10/776,934
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: 60/446,372
;  PRIOR FILING DATE: 2003-02-10
;  PRIOR APPLICATION NUMBER: 60/523,591
;  PRIOR FILING DATE: 2003-11-19
;  NUMBER OF SEQ ID NOS: 741
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 569
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: beta-D-oxy-LNA modified base
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (13)..(15)
;   OTHER INFORMATION: beta-D-oxy-LNA modified base
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(16)
;   OTHER INFORMATION: phosphorthioate linkage
US-10-776-934-569

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        161 TTAGGCGGCAGCAGCT 176
              || || ||||||||||
Db         16 TTTGGAGGCAGCAGCT 1


RESULT 222
US-10-776-934-570/c
; Sequence 570, Application US/10776934
; Publication No. US20050014712A1
; GENERAL INFORMATION:
;  APPLICANT: HANSEN, BO
;  APPLICANT:  THRUE, CHARLOTTE ALBAEK
;  APPLICANT:  WESTERGAARD, MAJKEN
;  APPLICANT:  PETERSEN, KAMILLE DUMONG
;  APPLICANT:  WISSENBACH, MARGIT
;  TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
;  FILE REFERENCE: 58610(71432)
;  CURRENT APPLICATION NUMBER: US/10/776,934
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: 60/446,372
;  PRIOR FILING DATE: 2003-02-10
;  PRIOR APPLICATION NUMBER: 60/523,591
;  PRIOR FILING DATE: 2003-11-19
;  NUMBER OF SEQ ID NOS: 741
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 570
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: beta-D-oxy-LNA modified base
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (13)..(16)
;   OTHER INFORMATION: beta-D-oxy-LNA modified base
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (5)..(13)
;   OTHER INFORMATION: phosphorthioate linkage
US-10-776-934-570

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        161 TTAGGCGGCAGCAGCT 176
              || || ||||||||||
Db         16 TTTGGAGGCAGCAGCT 1


RESULT 223
US-10-776-934-571/c
; Sequence 571, Application US/10776934
; Publication No. US20050014712A1
; GENERAL INFORMATION:
;  APPLICANT: HANSEN, BO
;  APPLICANT:  THRUE, CHARLOTTE ALBAEK
;  APPLICANT:  WESTERGAARD, MAJKEN
;  APPLICANT:  PETERSEN, KAMILLE DUMONG
;  APPLICANT:  WISSENBACH, MARGIT
;  TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
;  FILE REFERENCE: 58610(71432)
;  CURRENT APPLICATION NUMBER: US/10/776,934
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: 60/446,372
;  PRIOR FILING DATE: 2003-02-10
;  PRIOR APPLICATION NUMBER: 60/523,591
;  PRIOR FILING DATE: 2003-11-19
;  NUMBER OF SEQ ID NOS: 741
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 571
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(16)
;   OTHER INFORMATION: phosphorthioate linkage
US-10-776-934-571

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        161 TTAGGCGGCAGCAGCT 176
              || || ||||||||||
Db         16 TTTGGAGGCAGCAGCT 1


RESULT 224
```

```
US-10-730-771-330/c
; Sequence 330, Application US/10730771
; Publication No. US20050074787A1
; GENERAL INFORMATION:
;  APPLICANT: Fan, Jian-Bing
;  APPLICANT:  Hirschhorn, Joel N.
;  APPLICANT:  Huang, Xiaohua
;  APPLICANT:  Kaplan, Paul
;  APPLICANT:  Lander, Eric S.
;  APPLICANT:  Lockhart, David J.
;  APPLICANT:  Ryder, Thomas
;  APPLICANT:  Sklar, Pamela
;  TITLE OF INVENTION: UNIVERSAL ARRAYS
;  FILE REFERENCE: 2825.1016-007
;  CURRENT APPLICATION NUMBER: US/10/730,771
;  CURRENT FILING DATE:  2003-12-08
;  PRIOR APPLICATION NUMBER: US 60/126,473
;  PRIOR FILING DATE: 1999-03-26
;  PRIOR APPLICATION NUMBER: US 60/140,359
;  PRIOR FILING DATE: 1999-06-23
;  PRIOR APPLICATION NUMBER: US 09/536,841
;  PRIOR FILING DATE: 2000-03-27
;  NUMBER OF SEQ ID NOS: 590
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 330
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Template sequence
US-10-730-771-330

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        464 GGTGTGGACCCCACCC 479
              |||| |||||||| ||
Db         16 GGTGAGGACCCCAGCC 1


Search completed: October 18, 2005, 09:44:31
Job time : 3 secs
```